<SEC-DOCUMENT>0000950170-22-016653.txt : 20220811
<SEC-HEADER>0000950170-22-016653.hdr.sgml : 20220811
<ACCEPTANCE-DATETIME>20220811075116
ACCESSION NUMBER:		0000950170-22-016653
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220811
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		221153733

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>wve-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-08-10T21:50:02.9023+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:wve="http://www.wavelifesciences.com/20220630" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_4327803f-9dc9-412c-9468-f676ddf59a28" name="dei:EntityCentralIndexKey" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811">0001631574</ix:nonNumeric><ix:nonNumeric id="F_509b5245-22eb-41f0-8890-375558e8677a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_43f567f4-79fa-4ca0-b106-8941f9b60bef" format="ixt-sec:durwordsen">one year</ix:nonNumeric><ix:nonNumeric id="F_6243545a-3891-47ea-af88-6bb9a7295e61" name="dei:DocumentFiscalPeriodFocus" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811">Q2</ix:nonNumeric><ix:nonNumeric id="F_9aecef43-a584-460c-903d-ced10cc55cad" name="dei:AmendmentFlag" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811">false</ix:nonNumeric><ix:nonNumeric id="F_5d565705-e9c6-4ee7-b392-a931aba94ef5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_c246e5aa-1caf-4481-813a-25d44affd480" format="ixt-sec:durwordsen">one year</ix:nonNumeric><ix:nonNumeric id="F_ad82f3d7-5fc0-4e08-9151-d51206c45b48" name="dei:CurrentFiscalYearEndDate" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811">--12-31</ix:nonNumeric><ix:nonNumeric id="F_a5e01550-cacf-493f-b2e4-2fd75161a30b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_c246e5aa-1caf-4481-813a-25d44affd480" format="ixt-sec:durwordsen">five years</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="wve-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_c58d23cc-a8ef-4814-b890-7cbfec7e1771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66fb8ad3-5567-4c36-8044-b37768f732bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e653c3aa-a802-452a-a708-c1562dbdcb0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19feb3a5-3147-4251-b597-cc5dddc3d03a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f4a66c5-19f5-4662-8e71-93adf30b20fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_283fda3f-a748-40e5-99e9-66dde6ca0cdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4792f081-460e-4ad6-ad8e-325ac9c41dc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d37d597-867b-4964-81ad-9b451a752961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_796c0529-ff6d-4304-8565-b6a278d71641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91887c61-e0ae-4ede-a7ee-64cb872cecda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_523d0df5-7bb1-4976-bcb4-802b05e28667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa7afc38-e09a-44cc-a44e-37a4604bf525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6850af8e-74cf-4159-a423-9e97ac830052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5673c773-6fb6-4577-b5dc-9d23f17ed1bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d3dbb2e-67a6-4144-9218-06e8e22db676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1d7d11c-4b6d-425d-8b75-248ebc031db1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee5e5857-7ec2-4544-8afb-0fae4befe31c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1014ad06-e986-48e5-9503-e639ae78d329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd854128-fccf-4ea5-8af5-094c2a679228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03b94d45-2ab0-4b85-a75d-2f64e83735c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c51ff68-df14-498e-96bb-034965c4e819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4f51145-90ba-40be-9cc2-4a963f92d5b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_810483b6-169c-4003-93e7-2b51cb18d965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_784d98d4-9d33-43ca-b470-1ebb4a0f75cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9134dba-b1a5-4e84-a5c5-72ab5e1405b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0b1b09a-bb0a-4062-85c6-f57ca2210290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02dff14e-65b3-4f3f-9d30-e7af11da66b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4026c365-b133-428c-860d-0c091ee9904f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_961bdd6a-40fc-47c3-ab35-05fb69ac44f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57758a2d-e69c-4d16-9b5f-18555ad23a37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4659dc79-f8b5-4b14-9d07-60ba055803c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf5de431-1632-48b6-aedc-f9c9b3179fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfd509f5-3b0d-4cf5-8cf2-e980ca43764a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c78b4d1-3c37-4274-9f6c-17419b1da82b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e54eb887-4c39-4a17-9604-14097e88cd22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a886904f-adbf-4df1-86db-69f767bee50f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e77d8791-33a3-4c78-aabb-020626bd3fa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30e4d424-87c1-4f5b-a3af-aa203267d79e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01de9b35-d2c7-4f8d-8e10-25a3ffd4f38d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_300b72ac-22b8-4e84-94fc-953ae4a01ce2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_945817ec-c317-4c4d-a941-a9c2cff299de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a341f84-a6ac-41b9-8129-462814cf0ca3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TwoThousandNineteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23abe5e8-775e-492f-9f77-0932a3bf81ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ced6e426-01fc-4c9a-8e66-3dc75c3ec32c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab7d096-c25e-41c2-b352-560599442f0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43f567f4-79fa-4ca0-b106-8941f9b60bef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07ca4716-43a0-42c3-9c43-358b926374da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef54c2d3-5966-4fb3-9eab-f71b3501eec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4adfc1c-840e-441f-bcba-dc515437a1cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d00af1e-f5b9-4394-9bce-63d6f9517de8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f6202df-7ac9-4cd7-83f2-84cbea74e158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25c8d8eb-2dcd-4e58-b29e-a48f2a155cda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f8aaf6a-e030-415e-9d69-aa20d78441ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dc48f65-6d35-4fbe-879e-ed161cf3817c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43b01130-d745-405b-ab3a-510bbb1b2ba5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d44fe466-a23b-42b0-a391-c7dc4d72b912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb037edf-f54b-49db-aac5-3c4357081877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cca9fe41-22fb-4a90-a590-df2e6385179a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f97ce547-93fe-4c54-993a-2fa742897bf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7001869b-47df-4996-89c7-c6dba52a5dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed04036d-ee72-4713-80e6-728911c04be0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97a6000b-e222-4ea3-90d8-088983fa43f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33eafbee-95ba-4008-99b5-86a8a72a242d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ab93180-6144-478f-bf7a-66924176752d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e77fe91-cadf-496b-983c-b01aa60a825d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94d9d100-4484-4e3c-afe1-66999eb32fe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d44b7aa-b23e-472d-a764-81880eb67e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:June2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1e9f65b-ff19-4e3b-9b8b-906b8aa85797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_045adef5-17c5-408e-8baf-d0886f47c57e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:June2022OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c0260b0-d65e-4e5c-ba7f-4ad60a49c91c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b12dd15a-4910-42a5-a1bb-da412b6b9efd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60d55580-0910-42b0-bf64-b485a7374a06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebdb90e8-1c88-4029-9519-649704459478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ea32a82-226e-4e27-8b47-3c751c13dd45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e7cfd1c-3deb-421d-9921-03ae52489936"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c168803d-75ea-450b-8676-2d3cdeeebce0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9b91c5d-dde1-4b7e-9177-b5db41d9bd22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_291b8373-572b-4238-84ea-3e812d9288e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8af245fc-0b06-427d-8e69-217279fe30bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e23b1234-bfa8-4df5-ab78-74d94722218e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddda2744-95b7-4f48-9a57-fe82f59fa3f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d59e805-fcfa-4e3d-8eb1-a7b22fa54655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c246e5aa-1caf-4481-813a-25d44affd480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_031e56ef-ccf2-4828-ab59-1d84613c2255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0288e0e-5b52-4d7c-8564-10340131751a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a786b8-47b1-48cd-a1ab-330c03ba03cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_016f1df7-e574-4d0c-b997-10712c56dbcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f7e7315-a48c-4091-b867-d0e4ab143762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29fd470b-d8b0-4187-9842-129afee626da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35f5ee7d-7f63-4f91-a5c1-961b0904b483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d985ba9-a3f1-4988-8ba2-a12fd859afa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1cd1092-e3ce-42d0-85a8-ee118d1d1baa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TwoThousandNineteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e525306-9d10-4441-8453-95cbed2392b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b4431b2-3b0c-4c57-a400-5e339022d24b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34ff48ca-a39d-487f-903e-584d7f5d9888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3514b40a-9f70-4ea1-8a06-949d2fd1a5a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97a77020-f99d-4117-95e5-bea4e51831d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c059f602-3f2f-41ce-ba29-88681a96cc00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b138242-bd72-42e8-ada7-ec20e596c5d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_081e46bc-e848-4d63-ad8f-3f60872500c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63319f7d-b0a5-431e-b212-d9dd4cc84b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e543347d-565b-47d5-877c-37bddba8c561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_beb23801-7f60-437a-8667-465087c2ce57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a42041d6-7ac3-495f-9b06-c6682bfdc55a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Target"><xbrli:measure>wve:Target</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91391e59-23cc-47eb-8e3b-2fa62b37302b" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8fafca2-a1fb-4382-86be-fbbbcae2f916" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_439fb97a-99d5-488f-9fd9-091ddc889c34" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4dcf7a26-c9fd-48eb-bfc6-6858e0370bb5" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43222bc8-0f49-4576-a21b-0b72f3f1c12d" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from ______ to ______</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6da6cc97-56d2-4405-acae-13590ba5a3f9" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-37627</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46887322-6a45-4437-8799-d521f9b34855" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.501%;"></td>
    <td style="width:22.503%;"></td>
    <td style="width:34.997%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f47388af-bc53-4c1d-84b2-807206671b9d" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Singapore</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82a1e0ee-8026-41e9-ad36-c41c26c05d9c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">00-0000000</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34898983-a47a-467d-beea-da338a9048dd" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7 Straits View #12-00</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bca717dd-7f1c-403b-b343-2cbd0b097938" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Marina One</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06b68b01-bb61-4ab8-a419-59edc901b56c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">East Tower</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df8a9bde-fb9b-4fd1-9c75-b40ea5a52508" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Singapore</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_def9a177-3593-413c-aa6d-b007bf0a2009" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">018936</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f5615fe-3f89-4c9b-a477-291c30e48afa" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">+65</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81521edf-fd38-482f-8c72-513f3b4195fb" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6236 3388</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:34.561%;"></td>
    <td style="width:32.678%;"></td>
    <td style="width:32.761%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Trading symbol</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.100in;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_093808cf-ee60-442b-a061-e83dcf496547" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">$0 Par Value Ordinary Shares</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b996e608-0a7d-4fa0-a646-03b31b95c947" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">WVE</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.00625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18f54e2c-0203-49d3-9475-9d5490b2b80e" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_237d363b-ef0a-4850-a4a7-104bd149a29a" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31e545e6-92f4-4521-9d9a-9034c2289abf" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x2018;&#x2018;large accelerated filer,&#x2019;&#x2019; &#x2018;&#x2018;accelerated filer,&#x2019;&#x2019; &#x2018;&#x2018;smaller reporting company,&#x2019;&#x2019; and &#x2018;&#x2018;emerging growth company&#x2019;&#x2019; in Rule 12b-2 of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.844%;"></td>
    <td style="width:4.156%;"></td>
    <td style="width:41.66%;"></td>
    <td style="width:29.202%;"></td>
    <td style="width:4.137%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5fe59d9b-dbc4-4abb-8137-e19fbfc0aa7a" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83ba7d4d-e026-42a4-b62a-bc0e45536185" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45e52ad9-0f8f-4f52-aa76-9f06d2c07822" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c90554b4-e510-49d5-b9c7-642889d524f8" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">    No  &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The number of outstanding ordinary shares of the registrant as of August 3, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_00823d3c-cc21-4536-90b5-4e8e9705fd4b" contextRef="C_5673c773-6fb6-4577-b5dc-9d23f17ed1bf" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,820,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"><br />.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">QUARTERLY REPORT ON FORM 10-Q</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90.631%;"></td>
    <td style="width:0.993%;"></td>
    <td style="width:8.377%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i_financial_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#unaudited_consolidated_statements_series"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.453in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited_condensed_consolidate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upon Senior Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.201in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 6. Exhibits</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, references to &#x201c;Wave,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us&#x201d; or similar terms refer to Wave Life Sciences Ltd. and our wholly-owned subsidiaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), that relate to future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. In some cases, forward-looking statements are identified by the words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;future,&#x201d; &#x201c;goals,&#x201d; &#x201c;intend,&#x201d; &#x201c;likely,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;ongoing,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;strategy,&#x201d; &#x201c;target,&#x201d; &#x201c;will&#x201d; and &#x201c;would&#x201d; or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements, other than statements of historical fact, about, among other things: </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to fund our future operations; our financial position, revenues, costs, expenses, uses of cash and capital requirements; our need for additional financing or the period for which our existing cash resources will be sufficient to meet our operating requirements; the success, progress, number, scope, cost, duration, timing or results of our research and development activities, preclinical studies and clinical trials, including the timing for initiation or completion of or availability of results from any preclinical studies and clinical trials or for submission, review or approval of any regulatory filing; the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates; the potential benefits that may be derived from any of our product candidates; our strategies, prospects, plans, goals, expectations, forecasts or objectives; the success of our collaborations with third parties; any payment that our collaboration partners may make to us; our ability to identify and develop new product candidates; our intellectual property position; our commercialization, marketing and manufacturing capabilities and strategy; our ability to develop sales and marketing capabilities; our ability to identify, recruit and retain key personnel; our financial performance; developments and projections relating to our competitors in the industry; our liquidity and working capital requirements; the expected impact of new accounting standards;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and our expectations regarding the impact of COVID-19 and variants thereof on our business, including on our research and development activities, preclinical studies and clinical trials, supply of drug product, and workforce.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance or achievements expressed or implied by any forward-looking statement to differ. These risks, uncertainties and other factors include, among other things, our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the severity and duration of the COVID-19 pandemic; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the COVID-19 pandemic, and variants thereof, may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials; any other impacts on our business as a result of or related to the COVID-19 pandemic</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, as well as other risks and uncertainties under the caption &#x201c;Risk Factors&#x201d; contained in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Each forward-looking statement contained in this report is based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as representations or warranties by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. We caution you not to place undue reliance on any forward-looking statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition, any forward-looking statement in this report represents our views only as of the date of this report and should not be relied upon as representing our views as of any subsequent date. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. and Wave Life Sciences Pte. Ltd. names, the Wave Life Sciences mark, PRISM and the other registered and pending trademarks, trade names and service marks of Wave Life Sciences Ltd. appearing in this Form 10-Q are the property of Wave Life Sciences Ltd. This Form 10-Q also contains additional trade names, trademarks and service marks belonging to Wave Life Sciences Ltd. and to other companies. We do not intend our use or display of other parties&#x2019; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Solely for convenience, the trademarks and trade names in this Form 10-Q are referred to without the &#174; and &#153; symbols, but such reference should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="part_i_financial_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART I - FINANCI</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AL INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Financi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">al Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TED BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.296%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.211%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.211%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_93485a0c-f330-45a6-8d78-e734744a1178" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33d07bb2-39a8-499f-accc-c7db4ccddceb" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7a2d376b-d219-469b-88fa-bdfa683212e8" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eb9ba2d3-7bf0-4bd7-97ba-d4a883820362" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b2808a37-a6c8-4538-a7ed-73cacfcedfdf" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a711c581-a0a0-4eac-9519-65931e5cc15c" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33de5aa9-a5c0-481d-b786-7c624b5b2cce" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,416</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_314f747d-e0c5-4548-a608-a9373cbc031a" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_832198f7-edcb-4082-ad0c-e6c4f8b7ffbf" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Long-term assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1240e86a-3d4f-4808-9a7c-438e6798f061" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e01d9807-63de-4e48-b22f-aa0462433e10" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_429661ad-4aa5-431c-b663-312e61c349ba" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a963f058-a70e-462f-8c06-f17622e368ce" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,378</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b2bb2d07-f89d-4c5f-9b76-6059dec53139" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_129f7f51-a11c-424a-90b1-3ca17edea9a0" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c0b65cd8-0b9f-46fb-adce-2ca1c1637c32" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3">955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be0c7a66-4109-487b-acb4-745a2fcc54c3" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3">148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39dbb4db-8626-4ffc-a70d-5cd7bc96489f" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,205</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_96f10658-4c91-4930-9279-13162fe9d34b" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_44e1a5be-c55b-4a2f-b56b-0433db323059" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_84d52910-391f-4fb3-be69-75032e3c0471" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Liabilities, Series A preferred shares and shareholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32c38d72-3b3a-4412-86aa-19ddf9c7f070" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e332dc41-5aa1-4690-a428-e25ff5a2bda8" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78fcbd7f-b92c-47d1-847f-ff5184b02202" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5b596c36-91d3-449e-91ef-ac29206644b2" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc312ca5-ddef-4969-bbba-61910fcee8cf" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8490b0d1-cf8a-432e-91f8-4030306ee5c3" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Current portion of operating lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b78b9e2-aaed-44fe-a473-580543959bc8" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4ba2a02-7f6a-437e-b002-da175ddf4609" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c8764a36-142f-4434-ac74-ee43d14883ea" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6fb56387-7c3e-43d2-95c1-9e8c7e4fa4d7" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,201</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Long-term liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b7869e60-bb9c-4d75-9e22-2a8edb563bde" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bdb48894-5fb8-432e-a99d-6d45816bb452" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_de0ba408-bbee-498b-b578-232147108a0a" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6a93f1c0-c838-4852-88b0-a8a01fa96c01" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a05da4b4-9c10-4ba6-b129-7c3ab5768ced" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,416</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bb6b7870-9720-498c-b8f8-7acdcc1de67a" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a05fdff8-98b7-4450-af1f-803c18c20499" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc48a26c-fdcc-4c83-9ca1-dac2b8913ae4" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Series A preferred shares, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_104b2845-37a0-4f7b-a0a3-dccaccc450b2" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2bd68fc9-a054-422c-b158-638795ec00ca" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_baaa62b3-1c42-4575-bac8-c230dec4e1a6" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9b270da4-5f7a-427a-8473-59c43bd3522d" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dec0b1c6-04be-49c4-abef-069a73d3ccfc" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fca8ae8b-ab82-49ea-ad6b-e66011228325" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding at June 30, 2022 and December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_797223ab-f210-4234-80e3-d9b0049e2bab" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_56cf89b8-5704-4d1b-a8c3-9fc2f8ac6f97" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Shareholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Ordinary shares, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_514b3427-a02b-4880-bcfe-7292b2fa3be3" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1a02a818-40a8-41aa-ab93-94a778c13efd" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CommonStockNoParValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_58a98c9a-7958-41a7-b0b7-95740b805e68" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8c5448e3-161e-4e07-884d-479cffe4ae91" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,724,658</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9b98bb16-0f1e-42c5-ab00-e99510de93c5" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_98d8bcec-8d4a-489a-8048-0f40b9e26524" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,841,116</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding at June 30, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c1d1dad8-0e3a-4750-8c48-bad4dcc9a228" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">802,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_624821f0-d762-490b-94e2-87e46eff56df" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">749,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e0d3096-d3b1-4e66-aeab-072ee7f31ada" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc1dd841-0120-44ee-910d-6fbfdb596534" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9108bbfb-11b1-4203-b071-6f99f1cb12eb" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_19bb061e-0325-4089-885a-0b46d5dc313f" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_db001beb-4319-43a6-baf3-13d03443ae06" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">884,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c1c4562-185e-462b-bd87-04855b72982a" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">805,514</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total shareholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d51f996f-93fe-43fe-8887-8f1efebc8d15" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec40d80f-d250-4aa6-865a-3fbe966339ad" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total liabilities, Series A preferred shares and shareholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7f10d144-49fe-4150-be37-82c5a8cc8f3d" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_992a9be7-6852-4ead-ac03-52cd81ef5c41" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_operat"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.246%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.735%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.93%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.735%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.606%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.93%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_12359bfd-b302-4712-9ba3-25e51af6b736" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3db106bf-6169-427e-9b97-211d55db0ccb" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_06ec458b-ebbb-4547-9bc6-7fc72f5a812a" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b84696e4-be41-401e-ab20-590ccfed185e" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9efeed5b-7c6e-4519-adc4-9a95d057f88e" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_33864c02-41e0-4868-b322-f373d9079f9a" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_14b8ec0f-036c-4e5b-955d-1c93c3786589" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_50499918-e21d-4126-aff3-72fb82438f0f" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_339d4db3-479b-4838-b647-f51e1b64f975" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a8dcfde5-a17b-42a4-a438-6c0a4894f951" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e36ecf38-29ee-45ea-ba67-224c2b430714" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_953b3d7e-d804-425f-bed8-fc9073564bcb" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,047</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_515d6d39-e709-4a68-bac8-ba8149ae34ee" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_856ce140-2564-4ac2-b6e4-7aeab916c92c" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8dd8c4dc-eaca-4dce-9f51-fae26f73e701" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,383</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b295373-0944-40d0-b1d0-ae8e96931098" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_08895d9b-4fa4-4f53-8001-f55ae384d79b" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6dd23e2f-bba7-439c-b2d1-19e8ba17ab94" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,828</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_62feaccd-54dd-452a-b957-bfedb5cd4f19" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3e0042be-7592-47b0-bec0-004487e2a2e4" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">83,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other income, net:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dividend income and interest income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b98fe50b-4998-42d9-8b8b-677ae00cfd8d" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1b428cef-edd7-4a6c-ab57-7564d085405e" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3152fe91-f7e2-4c84-8996-9fb022b00866" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c9bd9fa1-5d2c-4a3a-ab88-e54d339dbb23" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b793dc3-63b4-4f58-8b09-0309ac37ef57" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">744</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc6fd739-6c19-40bb-ba19-433f29c84912" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b71eb404-07aa-4499-907e-9111aabd7eb0" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd73f878-0f90-4e9e-86b0-24ff0f0e5c23" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,050</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_124c182f-05ed-4db4-9f85-695b5e7c0d70" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">868</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57cd71e1-dbc4-4e2f-b912-84257e2fd566" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f1dcf36c-5431-4980-8fc2-c005388713b8" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b7b3e83-7f7c-4358-b81a-d3f039fbb06b" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_006e865e-e517-45a8-ba04-bc483126c523" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a501b4c-cae7-44f1-a372-75eda822d79b" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d6d126d8-d1da-4209-919b-e6ed1af44e8b" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4a9ea51e-7455-4c0f-b633-884e65b52d50" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_afac9fb4-4c4d-40f6-8903-41141401191c" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7c4af975-151e-4501-a1c0-4d74a5ccf809" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_badb4151-4229-4df2-8441-789175ec5931" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ad1710ca-42eb-49d5-96c0-a8f2125c2362" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share attributable to ordinary <br />&#160;&#160;&#160;shareholders&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1469d839-22f7-432a-96ce-5331b0283402" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_da8a6e43-46ef-44f1-835a-fffc4ec963aa" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e676249e-1ca7-4049-a7bd-75db56c9648c" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_7c4fbce9-8366-4f4c-971e-287164fef443" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.78</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4af11e5-be49-468e-a905-0db6f2051b86" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_6d59f1ec-3dc1-4232-a65f-71735d8775ce" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.25</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_05b10637-4466-4f70-8273-fd925114de8c" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_f5b1c711-cc68-4d86-9a62-eef991aaeaaf" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.65</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Weighted-average ordinary shares used in <br />&#160;&#160;&#160;computing net loss per share attributable to <br />&#160;&#160;&#160;ordinary shareholders&#x2014;basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_940a0658-7c93-4654-9b0c-5e0fd1c141a6" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_babfe233-8cd2-4a67-850e-a1c6ca4794a3" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">66,479,293</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8af7b87a-a284-4dac-8de3-612ad1d76f37" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_14782a72-e94a-41ae-891c-1dea6fe425c6" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">49,973,185</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af2e481b-950d-4d8f-95ce-ca14c8acc5b8" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d5bd1b36-6096-46cb-ad92-52c0bb079c19" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">63,514,426</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_81a4b312-c0b7-4357-b481-63d387e91ab5" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_241b1293-c93e-49b9-8a41-773edb03ed44" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">49,220,140</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45fb3cde-8ae2-44e5-8692-f53e636c024b" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a232793a-660b-4f88-8f3e-04f8648ad2bb" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_259c8bd6-c64f-4a04-b303-d876dfa6ca51" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df52f769-78cd-4169-92b7-97aabc03a6f7" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Foreign currency translation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_631d4764-253f-46e1-879e-56f7979b02c1" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bb8ac357-be8b-407f-8928-223e6b0070d7" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7b37ed3e-eeeb-4be1-ae5d-5e51283d175e" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0bb60635-e750-4670-9124-fb80edd4044f" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_57a081e6-a41e-433e-9316-e1c040c0cfc5" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c196ebe1-be3d-4e13-9e83-3040ea83b7da" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c4119a0-b5e5-43f7-bd3d-587b7ad6f723" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="unaudited_consolidated_statements_series"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED STATEMENTS OF SERIES </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">A PREFERRED SHARES AND SHAREHOLDERS&#x2019; EQUITY (DEFICIT)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.454%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.643000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.76%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.959%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.476%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.76%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.76%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.539%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.6%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.76%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Series A<br />Preferred Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Ordinary Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-In-</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total<br />Shareholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b2f5a1ea-f7f1-48f7-bf7a-0b965232b151" contextRef="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77fccdf3-1f74-464d-83f8-01e564c2c4f9" contextRef="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bb910586-c5a8-4db2-9530-f048208a00b0" contextRef="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,778,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d02069bc-4cb9-463a-8d8e-b68c37a0dce7" contextRef="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">694,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b6943aae-39fd-450d-8d36-f74e591e7d72" contextRef="C_d44fe466-a23b-42b0-a391-c7dc4d72b912" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,573</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a5cb987-bd69-4277-941c-fc6f27d03c2d" contextRef="C_f97ce547-93fe-4c54-993a-2fa742897bf2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3bd9e9c8-61a1-4105-9eb5-770b49ff6e9d" contextRef="C_d4adfc1c-840e-441f-bcba-dc515437a1cd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">683,269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f59fd156-7ee0-416d-9767-65deffcce174" contextRef="C_ed04036d-ee72-4713-80e6-728911c04be0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_736159cc-23e9-4cea-bea9-623827facefd" contextRef="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">844,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3b6c7515-f152-4fdc-970f-43a1f4e5c62c" contextRef="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ab5dbc67-6455-42eb-844a-64826fa50fb4" contextRef="C_25c8d8eb-2dcd-4e58-b29e-a48f2a155cda" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_288945d0-56d0-465b-88dd-8080ee15ad99" contextRef="C_60d55580-0910-42b0-bf64-b485a7374a06" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8925fd80-28d6-4792-87ea-87d5dbaa90ac" contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7d2d613b-3b12-48cc-ba28-11ea558acfcf" contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">155,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6a36d288-1c2f-463a-a87b-891b5fa157a5" contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fe13eca6-831b-42d7-844b-6373f33b33bc" contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ecbcf2d9-1e48-4b77-b59d-b4086808a6c7" contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5be9b06a-26db-46d6-843a-cf6b490bd627" contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">44,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_722f1754-d4b4-4557-a848-bb34f1b95248" contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3">336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_23b2b490-bfa4-4130-8099-048a929039aa" contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3">336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0d9f7bfa-800f-45c7-9ba0-3cca2ea76f38" contextRef="C_a42041d6-7ac3-495f-9b06-c6682bfdc55a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1e053349-11ac-4ba4-8c43-ac371ba7b96b" contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc675127-5c80-4be8-8900-e3bc7cacfcc3" contextRef="C_8f7e7315-a48c-4091-b867-d0e4ab143762" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,464</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0e4401c9-7b91-4f5e-a2da-eb4dc10aa066" contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,464</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0b04bd10-f501-4d7a-8e86-c6242517dd08" contextRef="C_19feb3a5-3147-4251-b597-cc5dddc3d03a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b02e6453-e534-499a-974c-ce3375bab36c" contextRef="C_19feb3a5-3147-4251-b597-cc5dddc3d03a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e4ff92ee-ba4a-4881-bc4e-ed71ad2039f6" contextRef="C_91887c61-e0ae-4ede-a7ee-64cb872cecda" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,854,651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_323ae07a-8f7c-4577-9c5a-df2bc7ca84ec" contextRef="C_91887c61-e0ae-4ede-a7ee-64cb872cecda" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">702,649</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fd902ad3-59f5-4838-9125-3699ebe8b3ca" contextRef="C_ddda2744-95b7-4f48-9a57-fe82f59fa3f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f3ea24a4-198e-4fe7-a0eb-fb258827bdb9" contextRef="C_aa7afc38-e09a-44cc-a44e-37a4604bf525" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_56aaf661-a618-41da-921a-8efff1edb105" contextRef="C_ebdb90e8-1c88-4029-9519-649704459478" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">725,733</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a3bfd9ed-44e6-4654-a281-9a81f0bbdb2c" contextRef="C_2f8aaf6a-e030-415e-9d69-aa20d78441ac" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0c71c75-9d44-47f0-87a3-4299fb654fb9" contextRef="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">718,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2b12cec6-c88b-4bc7-8543-8e568397e269" contextRef="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_78755490-4f15-492c-b3cb-9127587aa38a" contextRef="C_e77d8791-33a3-4c78-aabb-020626bd3fa3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_35013dd4-4b9c-43d2-b114-170f9eaa4ff3" contextRef="C_97a77020-f99d-4117-95e5-bea4e51831d4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e2e04bf6-c4dd-4a54-b5e9-5597fafaa565" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f554fb87-6ff1-4162-ab6e-86697e5134ab" contextRef="C_2ab93180-6144-478f-bf7a-66924176752d" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7947bfad-e71c-4ac6-b3ea-568d4191f072" contextRef="C_e653c3aa-a802-452a-a708-c1562dbdcb0b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_af21391d-7f15-45e8-afea-daa0f182a7c5" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4b35c08e-7abf-4b3b-b1be-22b3c7127580" contextRef="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d4ba1748-a140-4334-93f3-044267b21b71" contextRef="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f42474be-8dfc-488f-9151-54b92f45a9f7" contextRef="C_291b8373-572b-4238-84ea-3e812d9288e9" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">50,576,466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_477ab014-c343-403c-a53b-74364ffd1e61" contextRef="C_291b8373-572b-4238-84ea-3e812d9288e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">707,714</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_18c80f69-258e-4b9a-8093-e76159f66a28" contextRef="C_43b01130-d745-405b-ab3a-510bbb1b2ba5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8bc3d538-bd8e-4ae7-94de-b9a147421e16" contextRef="C_4792f081-460e-4ad6-ad8e-325ac9c41dc6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fe627eed-1b0a-4efb-a4ec-62cb56e48b37" contextRef="C_7e77fe91-cadf-496b-983c-b01aa60a825d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">764,499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bdcefc59-caf9-42ca-a2a9-e2ed13e735de" contextRef="C_e543347d-565b-47d5-877c-37bddba8c561" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS&#x2019; EQUITY (DEFICIT) CONTINUED</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.567%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.161%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.724%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.96%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.896%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.724%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.724%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.503%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.564%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.057%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.723999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Series A<br />Preferred Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Ordinary Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Additional<br />Paid-In-</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total<br />Shareholders&#x2019;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a6703c8c-24ea-4480-a859-7d7ab145a106" contextRef="C_29fd470b-d8b0-4187-9842-129afee626da" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_91efc457-1fc4-4585-82eb-4ee72662c334" contextRef="C_29fd470b-d8b0-4187-9842-129afee626da" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8516083c-2347-4d57-8024-dacde6bb70db" contextRef="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,841,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_76b2be44-bf42-414b-99d6-c3c2bd0d2959" contextRef="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">749,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c93cd9d-97ab-4d64-a915-4c5a8055ae31" contextRef="C_35f5ee7d-7f63-4f91-a5c1-961b0904b483" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_bf54e795-a9e3-4584-be28-50781d37588a" contextRef="C_02dff14e-65b3-4f3f-9d30-e7af11da66b7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8109851f-c4bf-4165-94e8-1efeb34f1c9b" contextRef="C_784d98d4-9d33-43ca-b470-1ebb4a0f75cd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">805,514</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ec7baddc-6357-42d9-976b-2d9b1113db90" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;pursuant to the at-the-market <br />&#160;&#160;&#160;equity program, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1063ac0c-afe7-420e-b81a-4313393aa6d1" contextRef="C_016f1df7-e574-4d0c-b997-10712c56dbcb" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">458,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_921053c2-7643-4944-9303-bfbff67dc8a7" contextRef="C_016f1df7-e574-4d0c-b997-10712c56dbcb" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77ea727b-9f47-4a20-8419-e7504ec28471" contextRef="C_9d44b7aa-b23e-472d-a764-81880eb67e69" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_129685f7-d975-4139-b99e-f19212743d6b" contextRef="C_0c78b4d1-3c37-4274-9f6c-17419b1da82b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,971</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_69a39dd2-73bb-41b9-b297-6475398a6ea8" contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,971</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e66215bc-9c8b-427d-b9ef-e37b4668781e" contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">468,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Option exercises</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e1e56f1a-ba16-4083-b2d4-fccaa45cf131" contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fa1ac1eb-e3bd-40ea-be66-3449bb040a61" contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_47e626fb-92a3-4d22-ae09-07f080fd773e" contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares <br />&#160;&#160;&#160;under the ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fa2cb6f0-fa57-4c9b-aae7-c3435cc11562" contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39e0ae5f-5bd7-43eb-9fc8-a6fc11d28810" contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c6c09c77-0792-4566-b0ed-80e587c47706" contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_868d6ee1-2bf1-4d9c-bbad-2267ef32c494" contextRef="C_23abe5e8-775e-492f-9f77-0932a3bf81ba" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d78531b9-5e11-4d6d-8124-b1bc5cf72186" contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ee7cf1f9-ca0c-4666-b3fd-cc80e69d8e48" contextRef="C_081e46bc-e848-4d63-ad8f-3f60872500c5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1e67367c-f1ba-45ef-bd24-67b40270b0b2" contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at March 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aa2d5512-4a49-4211-8aaf-b69f785e1eca" contextRef="C_beb23801-7f60-437a-8667-465087c2ce57" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7946a57c-6e88-4bf1-a6c7-6c256d7299ea" contextRef="C_beb23801-7f60-437a-8667-465087c2ce57" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_426e4e44-8939-43dc-a057-dc3537606a61" contextRef="C_cb037edf-f54b-49db-aac5-3c4357081877" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">60,859,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_32f265d1-8aa1-49dc-9218-06acc03db678" contextRef="C_cb037edf-f54b-49db-aac5-3c4357081877" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">751,229</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ba9a1d8-200c-49d7-adfc-69bdbf3ef9cd" contextRef="C_e9134dba-b1a5-4e84-a5c5-72ab5e1405b9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f6ba635e-e022-4680-9450-6b329ba1c7fd" contextRef="C_9d3dbb2e-67a6-4144-9218-06e8e22db676" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_77256c48-895d-4f43-bed5-ecf12421f36c" contextRef="C_ee5e5857-7ec2-4544-8afb-0fae4befe31c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">843,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c51375a8-583b-467b-9bc7-6cece4633b2a" contextRef="C_4d00af1e-f5b9-4394-9bce-63d6f9517de8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of ordinary shares, <br />&#160;&#160;&#160;net of offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d347e15-abc0-43a4-86c8-97e3e7a2088a" contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">25,464,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_acd97a10-beff-4771-bdba-f09b06330ce9" contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2d1cc638-ad30-4a1b-8653-d31f80520c07" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Issuance of pre-funded warrants, <br />&#160;&#160;&#160;net of offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_79bc1ad5-5a00-4af1-9183-5b8dd0f5e6b8" contextRef="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b8852e0d-876b-4295-a805-a0530db631f0" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3e00bd34-e7a1-43bd-b30c-0a1faa0eeebb" contextRef="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2432e811-fec9-4d55-a379-ffa9c5276b0f" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Vesting of RSUs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8c90fec-7a3d-40dc-9080-b2efecc78ea1" contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a" name="wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">400,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd6e6301-7c1b-40fe-8286-8254d0b99cc2" contextRef="C_0d59e805-fcfa-4e3d-8eb1-a7b22fa54655" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3bf40ad9-278c-4e48-8acb-9f2667669ca8" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f5151126-9230-4903-aaf7-61ad2aea4345" contextRef="C_bfd509f5-3b0d-4cf5-8cf2-e980ca43764a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_02ee4a71-24bc-424b-bfe0-b59bee07c01f" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Balance at June 30, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_40190fe8-e8b3-4656-b1ad-1027b70b184b" contextRef="C_7e7cfd1c-3deb-421d-9921-03ae52489936" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_724684aa-1788-498c-9a3f-346d2ac4970e" contextRef="C_7e7cfd1c-3deb-421d-9921-03ae52489936" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1b04596b-da38-440d-9d78-dcedafb935cd" contextRef="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,724,658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_783fa48e-e04f-4142-b7dc-572454969fac" contextRef="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">802,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f00c5ca7-a14c-43c3-b368-2162ca9878ae" contextRef="C_e1e9f65b-ff19-4e3b-9b8b-906b8aa85797" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">113,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a6bf9f92-a9b1-4bd7-8cc8-ae89d4a88a4b" contextRef="C_3a341f84-a6ac-41b9-8129-462814cf0ca3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9c5308bf-e429-4736-af12-0200b4b4c9e3" contextRef="C_6c51ff68-df14-498e-96bb-034965c4e819" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">884,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_219b930b-2c35-4461-b4ba-599bf055f58a" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">UNAUDITED CONSOLIDATED S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TATEMENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.432%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.045%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.642%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.24%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_56cef9c0-cfbe-4ee9-a038-a6cfc52795eb" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">79,110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0676b932-f523-4d70-8cd3-243a88dcd88d" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">81,230</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="8" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_17d7555a-4a0d-4c2d-b86c-56cffad27006" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="wve:AmortizationOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce14ea9f-e64a-4334-b32a-3400435b861c" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="wve:AmortizationOfRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Depreciation of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9c108c05-d408-4feb-a151-302fa490182e" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1a36168a-7b2a-45b6-98bb-15de6da83c20" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ffc3467b-bcb4-4cc2-b65c-8b91debc427c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aa5131ff-bc04-42df-90fd-8bb51f53c91d" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d533d19e-bca8-44fb-a0a7-439c653e74c5" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f4efb914-f647-4469-bda0-5017f2d3d87c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_34723028-47fe-4a70-a870-f669708b93ad" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,246</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0354eac2-4ddd-4634-9f4a-26448595c26b" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7af13b2d-ef31-4277-82bc-1ec95bf90f40" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_30a23a83-1a22-4b1e-b925-3f24ed7911c9" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,264</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dec78fe9-892a-4595-98fe-33c235faf7b6" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,251</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b25bd41f-e9e7-4eb6-9d4a-763f41a485f3" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_846746e2-6c4a-4328-a144-0298f0828098" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cfa4914f-daba-4801-b402-86a310839646" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,855</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_98b3c8f2-177b-412f-b64c-79785fae4aba" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_07e87d23-cffd-4b9e-ac2f-414003144ca9" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="wve:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,399</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1bd60e59-ef31-4cc2-a4dc-119ad718e8e4" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="wve:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,792</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2e3ac30b-3b1d-41bb-891b-81ba8f2bd729" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_133137c3-6a16-41e1-b8e0-6deeef0727ee" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-">135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_627f3e11-01fe-4d66-a419-e4bc53ecd6b7" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">68,695</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c178cf73-2263-49cb-9ddd-a73e8aae0eb2" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53,776</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eda97b56-1b00-4b2a-a032-2ac1b4087e84" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_06866750-4b1e-4ffd-9091-123b03cc0063" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the sale of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_be53243b-53c0-4e06-beea-0f31653c6e35" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Purchase of short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_aff05a45-2465-4cb7-b5ab-2b5c7196f31c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the maturity of short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_91b3ab2f-7679-4ccb-bb8d-7aa6c10987a2" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_320887c0-85a5-482a-9e32-471a529a0bc8" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">25,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2a415347-7c58-48b1-aa1f-5c7d93f27429" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">447</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of ordinary shares, net of offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_224869a4-4f4c-4078-9b53-25cc801ca10e" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,464</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance pre-funded warrants, net of offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8b418d70-0dbe-4403-918f-b5f92bf4b0fd" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from issuance of ordinary shares pursuant to the <br />&#160;&#160;&#160;at-the-market equity program, net of offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9539e342-69b8-4686-8c73-c5e31c0dd2ae" contextRef="C_c58d23cc-a8ef-4814-b890-7cbfec7e1771" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ecb63e3f-686c-46ff-a7c1-69a9a010ff04" contextRef="C_0d985ba9-a3f1-4988-8ba2-a12fd859afa1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the exercise of share options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c3b549b9-e0e9-480d-9454-f302bb0e0be4" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ae298310-7439-425e-863c-c32725938fd0" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the ESPP</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fc27b866-1e52-44ad-9f86-6512bf0cc12b" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f28fb4c0-91c7-43db-9ac4-e1e250f788d7" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0f95000-f897-418e-9e91-1e0989e87a96" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_c22aaa02-cf39-49d7-8e6e-df1b76a8ddf6" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e63f7159-3d0f-432f-8508-bf9fc585f048" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5e5c185e-bfa0-4167-83fd-05358e39fc99" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b8e6348d-d9da-44ad-85b7-ab09b819c632" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4940093a-f7c8-4bca-9858-84302016a874" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_56db904b-f9ff-4125-afd9-8a41b9050eb5" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3249287c-cc40-4f2c-a5e2-ba70e411bef1" contextRef="C_ed04036d-ee72-4713-80e6-728911c04be0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">188,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6d627e82-2b28-4035-9453-5e17b7dbf63a" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7cbc0092-7a17-4230-8846-5fe9091d0aa9" contextRef="C_e543347d-565b-47d5-877c-37bddba8c561" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Increase in operating lease right-of-use assets and <br />&#160;&#160;&#160;lease liabilities related to lease extension</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_981fb250-e9cf-4b26-b6c7-ca152e2b57c6" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Offering costs in accounts payable at period end</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8e202096-70d2-4285-b491-978a8ce47964" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="wve:OfferingCostsInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">311</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5227bae1-7c88-4834-bbf1-84a96160561f" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="wve:OfferingCostsInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of the unaudited consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited_condensed_consolidate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notes to Unaudited Con</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">solidated Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48c2fd7a-cb17-40c8-a300-337c6f7e85b6" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. THE COMPANY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. (together with its subsidiaries, &#x201c;Wave&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. PRISM, Wave&#x2019;s proprietary discovery and drug development platform, enables the precise design, optimization and production of novel stereopure oligonucleotides. Wave has built a genetic toolkit comprised of multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage learnings and optimizations from the PRISM platform and allow Wave to design built-for-purpose molecules to optimally address disease biology.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#x201c;Wave USA&#x201d;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#x201c;Wave Japan&#x201d;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#x201c;Wave Ireland&#x201d;) was formed as a wholly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#x201c;Wave UK&#x201d;) was formed as a wholly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#x2019;s differentiated neurology portfolio, as well as exploring other therapeutic areas of interest, building the Company&#x2019;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#x2019;s intellectual property, and assuring adequate capital to support these activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has not generated any product revenue and has incurred recurring net losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash, cash equivalents and short-term investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8eef1d96-0259-4d35-8017-b86fe8da4802" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">148.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#x2019;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#x2019;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#x2019;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development efforts will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and in U.S. dollars.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50afd398-d7b7-42d6-a782-e12aa98de83f" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2. SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2022, as amended (the &#x201c;2021 Annual Report on Form 10-K&#x201d;), have had no material changes during the six months ended June 30, 2022, except as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a225325-0660-43d5-8514-d6ab2d1c7412" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#x2014;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#x2014;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70910f88-7e55-4ed2-b9df-11c88b3ba252" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2c698fb-ab44-422c-9453-c6a1e587fc79" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all time deposits with original maturities of more than three months from the date of purchase to be short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53a6c166-efe1-4730-aa97-4b68b3e3cd9b" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9e3637a-40e5-41bb-91e1-e74786590e68" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of June 30, 2022, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, and June 30, 2022 and 2021, the consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39525fb4-4c27-4d36-8e9b-2f438eeabd63" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c8feed8-a573-4e8e-ab7d-59bc876e9dfe" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the Company&#x2019;s financial assets that are measured at fair value on a recurring basis:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.514%;"></td>
        <td style="width:1.224%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.611%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.224%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.686%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.224%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.668%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.224%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.622%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ce24dcec-a46d-4901-a354-0e5c6256e393" contextRef="C_c168803d-75ea-450b-8676-2d3cdeeebce0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15feb769-7b76-4525-b23b-0f67788665c7" contextRef="C_c059f602-3f2f-41ce-ba29-88681a96cc00" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9faad500-3569-4885-be7a-e1e8c7c836fd" contextRef="C_7f4a66c5-19f5-4662-8e71-93adf30b20fb" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dbdb5042-2d7b-4bd2-8ac5-4c5722613159" contextRef="C_d1d7d11c-4b6d-425d-8b75-248ebc031db1" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e8865d8e-886b-4e36-aa71-68fee7dcc384" contextRef="C_ef54c2d3-5966-4fb3-9eab-f71b3501eec9" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c630b86-5144-4158-81e4-b1946b112ad7" contextRef="C_18a786b8-47b1-48cd-a1ab-330c03ba03cb" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_13dd0643-61c2-4981-a6dc-2c4b1af3d291" contextRef="C_c168803d-75ea-450b-8676-2d3cdeeebce0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_844bf528-9e48-4389-a935-060321b35516" contextRef="C_c059f602-3f2f-41ce-ba29-88681a96cc00" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cc6abc8d-001b-44c3-8937-1ee1764caafa" contextRef="C_3514b40a-9f70-4ea1-8a06-949d2fd1a5a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_15a5cf20-0958-4137-bc67-d1f3a83df97b" contextRef="C_07ca4716-43a0-42c3-9c43-358b926374da" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150,564</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_83f947d8-d56d-4858-9585-baa057639273" contextRef="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150,564</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d57b0ec1-44f9-41ae-b1eb-ef662643c5e9" contextRef="C_ced6e426-01fc-4c9a-8e66-3dc75c3ec32c" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3d543454-fe4e-4915-ab03-658c04c198bc" contextRef="C_9d37d597-867b-4964-81ad-9b451a752961" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_4d444dd6-8b6c-41d5-a0da-cb8554d00f2a" contextRef="C_07ca4716-43a0-42c3-9c43-358b926374da" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e7243953-b5a8-4114-941d-8fdaae070ec8" contextRef="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">here have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2b08407a-d57f-4364-9aa9-643db9148eb4" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="wve:FairValueAssetsLevel1ToLevel2TransferAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_12dba31c-794c-4606-a160-2798b255bfcc" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="wve:FairValueAssetsLevel2ToLevel1TransferAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the three months ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash are Level 1 assets which are comprised of funds held in checking and money market accounts. Short-term investments are Level 2 assets which are comprised of time deposits with original maturities of more than three months. The Company determined that the fair value of its short-term investments is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_36cd73fe-bf83-45bf-b4ee-bc4daf2e964e" contextRef="C_796c0529-ff6d-4304-8565-b6a278d71641" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, which approximates the carrying value of the term deposits. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f407babe-5c57-4661-9fdd-9fea89f7c45f" contextRef="C_8af245fc-0b06-427d-8e69-217279fe30bd" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> short-term investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021, as the term deposits that constitute the Company&#x2019;s short-term investments were purchased during the six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0673a4ae-dc48-46ee-9e28-db9036be0681" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4. SHARE-BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) was approved by the Company&#x2019;s shareholders and went into effect on August 10, 2021. The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#x201c;2014 Plan&#x201d;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_09dabe86-a84b-467e-8d9f-e96dabb0c56a" contextRef="C_810483b6-169c-4003-93e7-2b51cb18d965" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,450,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the Company&#x2019;s board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#x201c;RSUs&#x201d;), and performance awards to eligible employees and directors of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options generally vest over periods of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5d565705-e9c6-4ee7-b392-a931aba94ef5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_716882be-180c-4125-a8b9-0de934576943" contextRef="C_eab7d096-c25e-41c2-b352-560599442f0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and any options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a5e01550-cacf-493f-b2e4-2fd75161a30b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f13a43b3-ed19-40c8-a51a-673dff2c0888" contextRef="C_eab7d096-c25e-41c2-b352-560599442f0f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_509b5245-22eb-41f0-8890-375558e8677a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b6c62cc-c23a-40f6-a696-cf87fdd75652" contextRef="C_b0b1b09a-bb0a-4062-85c6-f57ca2210290" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the compensation committee of the Company&#x2019;s board of directors approved an amendment and restatement of the Company&#x2019;s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021, the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. This modification did not result in any incremental expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company determined that a performance-based RSU milestone was achieved and consequently </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_f0667403-c26c-4925-ac78-fec301c8e68b" contextRef="C_30e4d424-87c1-4f5b-a3af-aa203267d79e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding performance-based RSUs vested, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6321b680-b8bf-4d6f-85f4-c2c45a41c186" contextRef="C_283fda3f-a748-40e5-99e9-66dde6ca0cdf" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">384,646</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares. During the three months ended June 30, 2022, the Company recorded share-based compensation expense of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7af0ecae-62fc-4843-8a1a-64cb12b3b1e7" contextRef="C_300b72ac-22b8-4e84-94fc-953ae4a01ce2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents all of the expense related to the achievement of this performance-based RSU milestone. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company did not recognize any expense related to the other performance-based RSU milestones, as the remaining milestones were not considered probable of achievement as of June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_45c2934a-f84f-458f-accc-d8226a09f88a" contextRef="C_9dc48f65-6d35-4fbe-879e-ed161cf3817c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,037,175</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dbc93518-5ca5-43f4-a66d-1f124cb17650" contextRef="C_1ea32a82-226e-4e27-8b47-3c751c13dd45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">55,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> time-based RSUs to employees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9d1f95ac-991f-408c-8f23-97e549f64549" contextRef="C_810483b6-169c-4003-93e7-2b51cb18d965" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,561,172</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares remained available for future grant under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) allows all full-time and certain part-time employees to purchase the Company&#x2019;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning on or about January 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and July 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> every year. Shares are purchased at a price equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8ab49731-b9c6-4aca-af52-bb2ddafe46d0" contextRef="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31" name="wve:SharePurchasePriceAtEqualToFairMarketValuePercentage" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s ordinary shares on the first business day or the last business day of an offering period. During the six months ended June 30, 2022, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc94687b-c29b-4c75-a64a-57b49dd4f4ee" contextRef="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,534</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares were issued under the ESPP. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ace7586f-bc4e-43a6-bb85-a41c8108002b" contextRef="C_f1cd1092-e3ce-42d0-85a8-ee118d1d1baa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">804,940</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares available for issuance under the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00e7e446-2025-42bd-b17c-576bda0638b7" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5. COLLABORATION AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Collaboration and Equity Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54c28199-4ed7-444e-b1e2-044efee90305" contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9" name="wve:CollaborationAndLicenseAgreementMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">February 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA and Wave UK entered into a global strategic collaboration (the &#x201c;Takeda Collaboration&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#x201c;CNS&#x201d;). The Takeda Collaboration provides the Company with at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_79dcfd2a-554e-4537-afc2-2b139e7bd732" contextRef="C_4659dc79-f8b5-4b14-9d07-60ba055803c3" name="wve:CollaborationAgreementCommittedCash" unitRef="U_USD" scale="6" decimals="-5">230.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#x2019;s CNS development programs in (1) Huntington&#x2019;s disease (&#x201c;HD&#x201d;); (2) amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal dementia (&#x201c;FTD&#x201d;); and (3) the Company&#x2019;s discovery-stage program targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATXN3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of spinocerebellar ataxia 3 (&#x201c;SCA3&#x201d;) (collectively, &#x201c;Category 1 Programs&#x201d;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease (collectively, &#x201c;Category 2 Programs&#x201d;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_df92d8e9-4b99-47e8-ba88-0e448a5f1f0d" contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9" name="wve:CollaborationAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5">110.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as an upfront payment. Takeda also agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a5355777-b669-4a6a-b1af-a4e609cd1e1d" contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2314d658-6f07-4bbc-b95c-4ee997f0fb04" contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9" name="wve:CollaborationAndLicenseAgreementResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceed that amount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with Wave USA and Wave UK&#x2019;s entry into the collaboration and license agreement with Takeda (the &#x201c;Takeda Collaboration Agreement&#x201d;), the Company entered into a share purchase agreement with Takeda (the &#x201c;Takeda Equity Agreement,&#x201d; and together with the Takeda Collaboration Agreement, the &#x201c;Takeda Agreements&#x201d;) pursuant to which it agreed to sell to Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31ad37bb-2c33-469c-9917-bfa0fe03abd9" contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,096,892</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_dc2ba5bc-7768-4765-b859-2af0cbbb8d44" contextRef="C_03b94d45-2ab0-4b85-a75d-2f64e83735c8" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">54.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d96c334-cc29-4be1-a872-b249d54eaf37" contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0" name="wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">April 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e33eaf50-1c49-4071-920f-13c20156f82d" contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company did not incur any material costs in connection with the issuance of shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b0d9574d-4d38-4d1e-8493-b77ac8b1f04e" contextRef="C_63319f7d-b0a5-431e-b212-d9dd4cc84b72" name="wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0d937173-b393-486c-880e-db15abc558f7" contextRef="C_5b138242-bd72-42e8-ada7-ec20e596c5d9" name="wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba0cac1b-4aa0-412a-a207-12de45c4827f" contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37" name="wve:CollaborationAndLicenseAgreementResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#x201c;Category 2 Research Term&#x201d;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b710d5ff-bdf5-4993-94d1-5d8a03ec199d" contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37" name="wve:MaximumTargetsForPreclinicalPrograms" unitRef="U_Target" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> targets at </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f130593b-df0c-4275-ae16-d9bb4321524e" contextRef="C_34ff48ca-a39d-487f-903e-584d7f5d9888" name="wve:OptionToReachMaximumTargetsForPreclinicalPrograms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any one time</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#x201c;IND&#x201d;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#x2019;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_31c72243-632d-4221-979d-93d44d1fed32" contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#x2019;s global commercial sales of products from each Category 2 Program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The term of the Takeda Collaboration Agreement commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1f4a408-ca66-407a-93a0-cd48b5a0e020" contextRef="C_6850af8e-74cf-4159-a423-9e97ac830052" name="wve:CollaborationAgreementCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">April 2, 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Takeda may terminate the Takeda Collaboration Agreement for convenience on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a52e5615-da51-44e0-96d6-52aa437b1cd0" contextRef="C_6850af8e-74cf-4159-a423-9e97ac830052" name="wve:MaximumTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> days&#x2019; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Takeda Collaboration is managed by a joint steering committee (&#x201c;JSC&#x201d;) in which both parties are represented equally. The JSC is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and should therefore be combined into a single performance obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a135f479-947d-4cfa-83cf-bb790db534a4" contextRef="C_57758a2d-e69c-4d16-9b5f-18555ad23a37" name="wve:UpFrontConsiderationReceived" unitRef="U_USD" scale="6" decimals="-5">110.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million upfront consideration received and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5a7f243a-0f74-410a-b06f-7efa913e9045" contextRef="C_57758a2d-e69c-4d16-9b5f-18555ad23a37" name="wve:FundReceivableForResearchAndPreclinicalActivities" unitRef="U_USD" scale="6" decimals="-5">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation is being recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The transfer of control for these performance obligations occurs over time and, in management&#x2019;s judgment, this input method is the best measure of progress towards satisfying the performance obligations. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31bcebe0-63b9-43e1-b71a-b2981dbc9e76" contextRef="C_e54eb887-4c39-4a17-9604-14097e88cd22" name="wve:CollaborationAndLicenseAgreementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">October 15, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#x201c;Amendment&#x201d;), which discontinued the Category 2 component of the Takeda Collaboration. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5c469e72-ab1e-4582-b117-2a7038917994" contextRef="C_cd854128-fccf-4ea5-8af5-094c2a679228" name="wve:CollaborationBudgetedResearchAndPreclinicalExpenses" unitRef="U_USD" scale="6" decimals="-5">22.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as full payment for reimbursable Category 2 Program collaboration-budgeted research and preclinical expenses. The Category 1 Programs under the Takeda Collaboration Agreement remain in effect and are unchanged by the Amendment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Through June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had recognized revenue of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_eea4df53-19b4-4347-821f-a62ec809a68f" contextRef="C_d0288e0e-5b52-4d7c-8564-10340131751a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">79.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as collaboration revenue under the Takeda Collaboration Agreement. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_39630a7f-42b4-4096-b686-207fd3b66211" contextRef="C_c9b91c5d-dde1-4b7e-9177-b5db41d9bd22" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6c1c7178-8cfd-46fa-ada2-d007d70f6b62" contextRef="C_031e56ef-ccf2-4828-ab59-1d84613c2255" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively. During the three and six months ended June 30, 2021, the Company recognized revenue of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a733a49a-3bae-4c81-8689-8d108010baf9" contextRef="C_c4f51145-90ba-40be-9cc2-4a963f92d5b2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_dd0c2ea8-781d-4a95-9262-5dfd35e96a1f" contextRef="C_8f6202df-7ac9-4cd7-83f2-84cbea74e158" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a4bb2ff0-fba8-410c-a5b4-e15f60b7dbf2" contextRef="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8a5027af-6b62-46cb-a235-706e501734b0" contextRef="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million was included in current liabilities. The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022 is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_91e30464-72cf-4e44-808f-bf570dd0499d" contextRef="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5">112.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef0b53c2-50db-4ae2-b67f-ade1e6ab0158" contextRef="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each Category 1 Program option upon Takeda&#x2019;s exercise of such option, or immediately as each option expires unexercised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div><ix:nonNumeric id="F_fcc6d25a-1729-4838-bf5d-e997606a44b4" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6. SHAREHOLDERS&#x2019; EQUITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">June 2022 Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1033f259-3cc4-4072-b21e-8088360d8740" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" continuedAt="F_1033f259-3cc4-4072-b21e-8088360d8740_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 16, 2022, the Company closed an underwritten offering (the &#x201c;June 2022 Offering&#x201d;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3349e1b6-0385-4d0d-939e-93f99ea2ea9c" contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">25,464,483</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#x2019;s ordinary shares at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e76350b9-de30-417f-87c4-fbecfc504154" contextRef="C_045adef5-17c5-408e-8baf-d0886f47c57e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a2f3cafd-ba8a-41c2-ab2f-f249a80da45e" contextRef="C_97a6000b-e222-4ea3-90d8-088983fa43f3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,093,656</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#x2019;s ordinary shares at an offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_cd6c11f9-64db-46aa-b5cf-0ff640edf5c7" contextRef="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">2.1499</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_9436f3ff-211f-4df1-9e90-2fa0d0c3b5b6" contextRef="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders&#x2019; equity within additional paid-in capital. The gross proceeds to the Company were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3133c29d-7a97-4224-836e-44ea96c56ca0" contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0" name="wve:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">70.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">before deducting underwriting discounts and commissions and other offering expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The net proceeds of the June 2022 Offering were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_ef172ce1-20cd-4666-baeb-d3c1d9ae1fce" contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. </span></ix:nonNumeric></span><span style=""></span></p><div><ix:continuation id="F_1033f259-3cc4-4072-b21e-8088360d8740_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5cb029ae-0d43-4679-a5de-dbb8488b582d" contextRef="C_1b4431b2-3b0c-4c57-a400-5e339022d24b" name="wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">19.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the number of ordinary shares outstanding or more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_257402f6-7f35-4f61-a824-641d07244041" contextRef="C_961bdd6a-40fc-47c3-ab35-05fb69ac44f8" name="wve:MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">19.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the combined voting power of the Company&#x2019;s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:continuation></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b3ef020-c56d-44f0-bf1d-a2864004da91" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7. NET LOSS PER ORDINARY SHARE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the two-class method to calculate its basic and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_1c919322-bd2e-4d95-b987-73c491c4d5d7" contextRef="C_1014ad06-e986-48e5-9503-e639ae78d329" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,093,656</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> vested and exercisable Pre-Funded Warrants outstanding to purchase ordinary shares for the exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_654fe300-237e-49fa-b8f4-9251d5d28300" contextRef="C_1014ad06-e986-48e5-9503-e639ae78d329" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73d2db2b-76d7-4a24-a933-2ecba6ea5ffd" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following ordinary share equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.963%;"></td>
        <td style="width:1.658%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.787999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.658%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.934%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_598340f5-dcce-4cd7-bb98-315966b09ac2" contextRef="C_945817ec-c317-4c4d-a941-a9c2cff299de" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,526,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_fb4e675c-6485-4110-9ed0-7bd9e26d3d8a" contextRef="C_523d0df5-7bb1-4976-bcb4-802b05e28667" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,584,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_2ea7c7cf-ff5b-4baf-885a-bef2c133eecd" contextRef="C_5e525306-9d10-4441-8453-95cbed2392b8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">979,850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_6817708a-9a10-4dd0-8e06-6c10dec83b9a" contextRef="C_01de9b35-d2c7-4f8d-8e10-25a3ffd4f38d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,027,019</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Series A preferred shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_716e3a88-b576-4483-9b4a-1388f0b08126" contextRef="C_4026c365-b133-428c-860d-0c091ee9904f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_8127d533-2f30-400f-94c9-390c36b86906" contextRef="C_bf5de431-1632-48b6-aedc-f9c9b3179fc4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,901,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, for the periods presented, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not participate in losses.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b5300a8-cbeb-4b11-984b-f51a6f325798" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8. INCOME TAXES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_82e41168-af16-4225-ac09-456c48921553" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_06f7c32e-c3b4-4121-82bf-aab1e3026994" contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f12e1e98-bcac-438e-8a2f-4a482075bf5a" contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6087d0ff-405c-4c6e-8a37-a6d8874a962f" contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> income tax provision. The Company maintained a full valuation allowance for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022 and 2021 in all jurisdictions due to uncertainty regarding future taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s utilization of its net operating loss carryforwards and general business credit carryforwards in the United States may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company is evaluating whether an ownership change occurred during 2022. Should an ownership change have occurred or occur in the future, the Company&#x2019;s ability to utilize its net operating losses and general business credit carryforwards may be limited.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2840a548-618c-4891-9b6d-bcec0270874d" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="wve:GeographicDataDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9. GEOGRAPHIC DATA</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#x2019;s long-lived assets were located in the United States as of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ed69e8c-9c11-438f-9694-12a3b7395698" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10. RELATED PARTIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following related party transaction for the periods presented in the accompanying consolidated financial statements:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#x2019;s founders and a member of the Company&#x2019;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2162d753-0af7-49d4-b20d-33480afcc7a6" contextRef="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619" name="wve:AgreementTerminationNoticePeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> days&#x2019; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_d37c123c-2e65-47e6-ba33-6203af9db7f3" contextRef="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="U_USD" scale="3" decimals="-3">13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month, plus reimbursement for certain expenses. </span></div></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f89f8768-79a1-4893-aa6c-a9a3f0f8678c" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77d87470-9f60-4584-863d-b5b38401f117" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.889%;"></td>
        <td style="width:2.123%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.123%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.647%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b69065f9-1dd4-4a07-8dd3-c4f4ff18e76a" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e0991216-b8aa-46c3-b102-e86e6c7b4007" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_3cf64ad0-b283-4e15-9ccd-6f27b551fdd9" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,473</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_a04cfbde-f076-478c-93e3-93c355e0ba1c" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,571</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_95b3ae12-ac2a-4f33-b400-c9d8abf09bcf" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="wve:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,038</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_0594de7a-cc08-422b-aaac-0ea50257f2a0" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="wve:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_b1f47295-0cf8-4b09-982e-91c269c3ff25" contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,085</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_afe1e480-a8fe-4565-933e-792ee4635f09" contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58626c81-144d-4d8e-871a-3c563d339b9a" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Lease Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into lease arrangements for its facilities. A summary of the arrangements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lexington</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On September 26, 2016, and as amended on December 31, 2016, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d396df6-786f-47d0-bfee-26105ed2de52" contextRef="C_b12dd15a-4910-42a5-a1bb-da412b6b9efd" name="wve:LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11dc2734-5248-4ea3-aa2e-8e4b4116776c" contextRef="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10 year and 9-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> lease , which includes two successive </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f42a80a3-b501-41ac-8f5d-b3321b3b74ed" contextRef="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal options</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, for its facility in Lexington, Massachusetts (the &#x201c;Lexington Lease&#x201d;), which the Company uses primarily for its current good manufacturing practices (&#x201c;cGMP&#x201d;) manufacturing, as well as for additional laboratory and office space. Throughout the term of the Lexington Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Lexington Lease, the Company had restricted cash of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_47eea367-98ca-429a-b798-ea8858069a69" contextRef="C_9c0260b0-d65e-4e5c-ba7f-4ad60a49c91c" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_c181bb63-8bc1-4994-88f7-970d3a1f45e2" contextRef="C_94d9d100-4484-4e3c-afe1-66999eb32fe3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in a separate bank account as of June 30, 2022 and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cambridge</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2015, the Company entered into a lease agreement for an office and laboratory facility in Cambridge, Massachusetts (the &#x201c;Cambridge Lease&#x201d;), which commenced in October 2015 with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a635b5da-20b8-49c9-acef-e1c926703450" contextRef="C_33eafbee-95ba-4008-99b5-86a8a72a242d" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> years with a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0862d0a1-bb5d-4e6c-9722-266b95c6c7ac" contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78b02981-5077-4283-b406-fb168cd38027" contextRef="C_33eafbee-95ba-4008-99b5-86a8a72a242d" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bf8bf15-1ed9-4a50-9371-a30f389feb6e" contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> the lease.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  Throughout the term of the Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Cambridge Lease, the Company had restricted cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_7e066c3f-a8cf-4069-8769-6abbfd738b98" contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_ea391a7a-c532-42fd-bca2-c037cc5c3efd" contextRef="C_e23b1234-bfa8-4df5-ab78-74d94722218e" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in a separate bank account as of June 30, 2022 and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company exercised its option under the Cambridge Lease to lease additional office and laboratory space at the adjoining facility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The combined space constitutes the entire building located at 733 Concord Avenue. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d33988f-7cb6-4d1b-9f36-c9ad8c1bb3f2" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The lease for the additional space commenced on October 1, 2021, with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0da04961-ce67-4ebc-8ab7-a42386104094" contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the &#x201c;Additional Cambridge Lease&#x201d;).</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> On the commencement date of the Additional Cambridge Lease, the Company recorded a right-of-use asset and corresponding operating lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_194b496e-4758-4268-b9b2-71484c782274" contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_20a78be9-9fa9-4b0f-9af3-df376cad8841" contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and began recognizing straight-line rent expense under ASC 842. Throughout the term of the Additional Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company notified the landlord of its intention to exercise the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8634b4ea-be0c-4d30-9067-e97edf3a0d73" contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal option under the Cambridge Lease to extend the lease term through March 2028 (the &#x201c;Cambridge Lease Extension&#x201d;). In June 2022, the Company calculated an incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_e370a311-c340-4996-a203-169257a2a1e3" contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd" name="wve:IncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">10.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and remeasured the right-of-use asset and the lease liabilities related to the Cambridge Lease Extension. As of June 30, 2022, the Company recorded an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><ix:nonFraction id="F_5d6457ca-b2ad-41c0-b4c4-8b84e615b296" contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_ba226b92-f14a-4ca9-9031-f243c254c0cd" contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million of operating right-of-use asset and corresponding operating lease liabilities relating to the Cambridge Lease Extension. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f0b7ef6-94fb-4a07-8f78-9218de61eea2" contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.</span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Management&#x2019;s Discussion and Analysis of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Financial Condition and Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2022, as amended (the &#x201c;2021 Annual Report on Form 10-K&#x201d;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Quarterly Report on Form 10-Q</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">or the &#x201c;Risk Factor&#x201d; section of our 2021 Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM&#153;, our proprietary discovery and drug development platform that enables the precise design, optimization and production of novel stereopure oligonucleotides, we aspire to develop best-in-class medicines that target the transcriptome to treat genetically defined diseases with a high degree of unmet need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are developing oligonucleotides that target ribonucleic acid (&#x201c;RNA&#x201d;) and harness existing cellular machinery to either reduce the expression of disease-promoting RNA or proteins, restore the production of functional proteins, or modulate protein expression. By intervening at the RNA level, we have the potential to address diseases that have historically been difficult to treat with small molecules or biologics, while retaining the ability to titrate dose, modulate duration of effect, and avoid risk of permanent off-target genetic changes and other challenges associated with DNA editing or gene therapy approaches. Oligonucleotides have additional advantages as a therapeutic class, including the ability to access multiple tissue types and the ability to modulate the frequency of dosing to ensure broad distribution within tissues over time. Oligonucleotides also have well-established manufacturing processes and validated test methods based on decades of improvements, as well as established regulatory, access and reimbursement pathways.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our approach is based on the scientific insight that the biological machinery necessary to address genetic diseases already exists in human cells and can be controlled with the right tools. We have built a genetic toolkit comprised of multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage learnings and optimizations from our PRISM platform and allow us to design built-for-purpose molecules to optimally address disease biology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our A-to-I(G) RNA base editing oligonucleotides (&#x201c;AIMers&#x201d;) represent our newest therapeutic modality. AIMers are designed to edit single base mutations on RNA transcripts, thereby avoiding permanent changes to the genome that occur with DNA-targeting approaches. Rather than using an exogenous editing enzyme, AIMers recruit proteins that exist in the body, called &#x201c;ADAR&#x201d; (adenosine deaminases acting on RNA) enzymes, which naturally possess the ability to change an adenine (A) to an inosine (I), which cells read as guanine (G). This approach enables simplified delivery and avoids the risk of irreversible off-target effects with DNA-targeting approaches. AIMers are short in length, fully chemically modified, and use novel chemistry, including proprietary PN backbone modifications and control of stereochemistry, which make them distinct from other ADAR-mediated editing approaches.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55497064_0.jpg" alt="img55497064_0.jpg" style="width:624px;height:276px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our PRISM platform is built on the recognition that a significant opportunity exists to tune the pharmacological properties of oligonucleotide therapeutics by leveraging three key features of these molecules: sequence, chemistry, and stereochemistry. Our unique ability to control stereochemistry, which is a reality of chemically modified oligonucleotides, provides the resolution necessary to optimize pharmacological profiles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PRISM enables us to design stereopure oligonucleotides, which are comprised of molecules with atoms precisely and purposefully arranged in three-dimensional orientations at each linkage. These differ from the mixture-based oligonucleotides currently on the market or in development by others. Additionally, to mitigate pharmacological risks and potential manufacturing challenges, our approach focuses on designing short, chemically modified oligonucleotides without the need for complex delivery vehicles or engineered exogenous enzymes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our work in developing stereopure oligonucleotides has enabled the continued evolution of PRISM and our drug discovery process of selecting genetically defined targets, identifying a sequence and applying the therapeutic modality we determine is best suited for the disease biology. We use our PRISM platform engine to screen candidates and optimize the pharmacologic profile based on predefined design principles, which reflect a deep understanding of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacological properties. Through continued exploration of these interactions using iterative analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> outcomes and machine learning-driven predictive modeling, we also continue to refine our design principles that we deploy across subsequent programs. We continue to invest in PRISM to further evolve and apply the expanding capabilities and promise of our unique platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, we publicly introduced our novel PN backbone chemistry modifications, which have been shown preclinically to increase potency, distribution, and durability of effect across various modalities. PN chemistry has been incorporated into all our current clinical, preclinical, and discovery-stage programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have a robust and diverse pipeline of PN-modified, stereopure oligonucleotides, including our clinical silencing and splicing programs, as well as our AIMers. With RNA base editing, our initial focus is on using N-acetyl galactosamine (&#x201c;GalNAc&#x201d;)-conjugated AIMers to treat hepatic diseases. Our lead programs are designed to treat genetic diseases within the central nervous system (&#x201c;CNS&#x201d;), including amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;), frontotemporal dementia (&#x201c;FTD&#x201d;), Huntington&#x2019;s disease (&#x201c;HD&#x201d;), Duchenne muscular dystrophy (&#x201c;DMD&#x201d;), and alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;). These programs include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WVE-004 (silencing), our C9orf72-targeted variant selective antisense oligonucleotide for the treatment of C9orf72-associated ALS and FTD,</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WVE-003 (silencing), our SNP3-targeted antisense oligonucleotide for the treatment of HD, which is designed to selectively lower mutant HTT protein levels, while leaving wild-type HTT protein levels relatively intact, </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WVE-N531 (splicing), our exon 53 exon-skipping oligonucleotide for the treatment of DMD, and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WVE-006 (RNA editing), our GalNAc-conjugated SERPINA1 AIMer for the treatment of AATD.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">When we built Wave, we recognized the growing momentum in RNA therapeutics and anticipated the value in having an internal current good manufacturing practices (&#x201c;cGMP&#x201d;) manufacturing facility. This capability provides us with increased control and visibility of our drug substance supply chain, thereby accelerating transitions from discovery through clinical development, and the continued ability to innovate in oligonucleotide manufacturing. Our team includes experts in oligonucleotide manufacturing that have successfully delivered clinical supply for six global studies at Wave to date. With our existing manufacturing facility, we are evaluating using our additional capacity to support the clinical supply of innovative oligonucleotides for new partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Current Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55497064_1.jpg" alt="img55497064_1.jpg" style="width:720px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional details regarding our lead therapeutic programs are set forth below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Neurology</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WVE-004</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In ALS and FTD, we are advancing WVE-004, which uses our novel PN chemistry and preferentially targets the transcripts containing the hexanucleotide G4C2 expansion in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> gene. In C9 BAC transgenic mice, WVE-004 led to substantial reductions in repeat-containing C9orf72 transcripts and dipeptide repeat (&#x201c;DPR&#x201d;) proteins that are sustained for at least six months, without disrupting total C9orf72 protein expression.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we initiated our FOCUS-C9 trial, which is a global, multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of intrathecal doses of WVE-004 for patients with C9-ALS and/or C9-FTD. Additional objectives include measurement of polyGP proteins in the cerebrospinal fluid (&#x201c;CSF&#x201d;), plasma and CSF pharmacokinetics and exploratory biomarker and clinical endpoints. The FOCUS-C9 trial is designed to be adaptive with dose level and dosing frequency being guided by an independent committee. Preclinical models that have established pharmacologic activity have informed the starting dose for this trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, we announced a positive update to the ongoing FOCUS-C9 trial that was driven by the observation of potent, durable reductions of poly(GP) dipeptide repeat proteins in CSF with low, single doses of WVE-004. Poly(GP) is a key C9-ALS/C9-FTD disease biomarker that, when reduced in CSF, indicates WVE-004&#x2019;s engagement of target in the brain and spinal cord. Poly(GP) is also a DPR protein translated from both sense and antisense transcripts of the C9orf72 repeat expansions responsible for the pathophysiology of disease.</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Reductions in poly(GP) were observed across all active treatment groups (10 mg, n=2 patients; 30 mg, n=4 patients; 60 mg, n=3 patients), reaching statistical significance versus placebo (n=3 patients) after single 30 mg doses, with a 34% reduction in poly(GP) at day 85 (p=0.011). At the time of analysis, none of the patients dosed with 60 mg had reached day 85. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img55497064_2.jpg" alt="img55497064_2.jpg" style="width:394px;height:338px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As the poly(GP) reduction in the 30 mg single dose cohort does not appear to have plateaued, we are extending the observation period from approximately three months (85 days) to approximately six months to identify the maximum reduction of poly(GP) and duration of effect of low single doses. Based on the durability and potency observed in the 30 mg cohort, FOCUS-C9 has been adapted to include additional patients receiving 20 mg and 30 mg single doses of WVE-004.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional exploratory assessments included monitoring of CSF neurofilament light chain (&#x201c;NfL&#x201d;) and clinical outcome measures. CSF NfL elevations were observed in some patients in the 30 mg and 60 mg single dose cohorts with no meaningful changes in clinical outcome measures, although the dataset and duration were not sufficient to assess clinical effects. Exploratory assessments will continue throughout the single and multidose phases of the FOCUS-C9 trial.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adverse events were balanced across treatment groups, including placebo, and were mostly mild to moderate in intensity. Four patients (including one on placebo) experienced severe and/or serious adverse events; three were reported by the investigators to be related to ALS or administration, and one was reported by the investigator to be related to study drug. There were no treatment-associated elevations in CSF white blood cell counts or protein and no other notable laboratory abnormalities were observed.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect to share additional single and multidose data from the FOCUS-C9 clinical trial in the second half of 2022. We expect to use these data to optimize dose level and frequency, as well as enable discussions with regulatory authorities regarding the next phase of development later in 2022. Planning is underway for expected initiation of an open-label extension clinical trial in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WVE-003</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In HD, we are currently advancing WVE-003, a stereopure antisense oligonucleotide designed to selectively target an undisclosed single nucleotide polymorphism (&#x201c;SNP&#x201d;), &#x201c;mHTT SNP3&#x201d;, associated with the disease-causing mutant huntingtin (&#x201c;mHTT&#x201d;) mRNA transcript within the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HTT </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">gene. WVE-003 incorporates our novel PN chemistry, as well as learnings from our first-generation HD programs. Targeting mRNA with SNP3 allows us to lower expression of transcript from the mutant allele, while leaving the healthy transcript relatively intact, thereby preserving wild-type (healthy) huntingtin (&#x201c;wtHTT&#x201d;) protein, which is important for neuronal function. Our allele-selective approach may also enable us to address the pre-manifest, or asymptomatic, HD patient population in the future. In preclinical studies, WVE-003 showed dose-dependent and selective reduction of mHTT mRNA </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and potent and durable knockdown of mHTT mRNA and protein </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. A pharmacokinetic-pharmacodynamic (&#x201c;PK-PD&#x201d;) model for WVE-003 based on preclinical data predicts that WVE-003 may attain sufficient concentrations to engage mHTT transcript in both the cortex and striatum and decrease expression of the mHTT protein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The SELECT-HD trial is a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial to assess the safety and tolerability of intrathecally administered WVE-003 for patients with early manifest HD. Additional objectives include measurement of mHTT and wtHTT protein and exploratory pharmacokinetic, pharmacodynamic, clinical and magnetic resonance imaging (&#x201c;MRI&#x201d;) endpoints. The SELECT-HD trial is designed to be adaptive, with dose level and dosing frequency being guided by an independent committee. Preclinical models that have established pharmacologic activity have informed the starting dose for this trial. In September 2021, we announced the initiation of dosing in the SELECT-HD trial. We expect to share clinical data in the second half of 2022 to provide further insight into the clinical effects of PN chemistry and enable decision making for WVE-003.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WVE-N531</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">: In DMD, we are advancing WVE-N531, which is designed to target exon 53 within the dystrophin gene. WVE-N531 is designed to cause the cellular splicing machinery to skip over this exon during pre-mRNA processing, which restores the dystrophin mRNA reading frame and enables production of truncated, but functional dystrophin protein. Exon-skipping produces dystrophin from the endogenous dystrophin gene (not micro or mini dystrophin expressed from a vector), under the control of native gene-regulatory elements, resulting in normal temporospatial expression. WVE-N531 is both our first splicing candidate and our first systemically administered candidate incorporating PN chemistry to be assessed in the clinic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, we announced the initiation of dosing in an open-label clinical trial evaluating WVE-N531 as a treatment for boys with DMD who are amenable to exon 53 skipping. We expect to share clinical data, including muscle biopsies, in the fourth quarter of 2022 to provide further insight into the clinical effects of PN chemistry and enable decision making for WVE-N531.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Hepatic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are initially focused on developing AIMers (A-to-I(G) RNA base editing oligonucleotides), which use our novel PN chemistry, to address genetic hepatic diseases. Our AIMers are relatively short and stable (fully chemically modified), which enables us to leverage clinically-proven GalNAc-mediated delivery to hepatocytes with subcutaneous dosing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WVE-006:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> In AATD, we are currently advancing WVE-006, our first AIMer (RNA editing) candidate that uses GalNAc-conjugation and endogenous ADAR enzymes to correct the SERPINA1 Z mutation, which is the most common cause of AATD. ADAR editing may provide an ideal approach for increasing circulating levels of wild-type AAT protein and reducing aggregation in the liver, thus simultaneously addressing both the lung and liver manifestations of the disease. We selected WVE-006 as our AATD AIMer development candidate, our IND-enabling activities are underway, and we expect to submit clinical trial applications in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Continuing Impacts of COVID-19</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We continue to closely monitor developments related to COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020. In response to this global pandemic, we have concentrated our efforts on the health and safety of our employees and patients, while maintaining business continuity and honoring our commitment to deliver life-changing treatments for people battling devastating diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our on-site activities continue with protocols for safely accessing and working within our facilities, including a mandatory COVID-19 vaccination policy that we implemented in October 2021. While we continue to conduct research and development activities, including our ongoing clinical trials, the COVID-19 pandemic has impacted, and may continue to impact, certain of our early-stage discovery efforts and clinical trials. We are working with our clinical investigators, research and development vendors, and supply chain vendors to continually assess and take steps to mitigate the potential impact of COVID-19 on our manufacturing operations and research and development activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We will continue to closely monitor the COVID-19 situation as we evolve our business continuity plans. Given the global risks and uncertainties associated with COVID-19, our business, results of operations, and prospects could be materially adversely affected. For additional information, see &#x201c;Item 1A. Risk Factors&#x201d; in the 2021 Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have never been profitable, and since our inception, we have incurred significant operating losses. Our net loss was $41.3 million and $38.8 million for the three months ended June 30, 2022 and 2021, respectively. Our net loss was $79.1 million and $81.2 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, we had an accumulated deficit of $884.6 million and $805.5 million, respectively. We expect to incur significant expenses and operating losses for the foreseeable future.</span><span style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any product revenue since our inception and do not expect to generate any revenue from the sale of products for the foreseeable future. Under the revenue recognition standard, we recognize collaboration revenue under the Takeda Collaboration Agreement (as defined in Note 5 in the notes to the unaudited consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, &#x201c;Note 5&#x201d;), which became effective in April 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, which include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">compensation-related expenses, including employee salaries, bonuses, share-based compensation expense and other related benefits expenses for personnel in our research and development organization;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with third parties, including contract research organizations (&#x201c;CROs&#x201d;) that conduct research, preclinical and clinical activities on our behalf, as well as contract manufacturing organizations (&#x201c;CMOs&#x201d;) that manufacture drug product for use in our preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred related to our internal manufacturing of drug substance for use in our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">expenses related to compliance with regulatory requirements;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">expenses related to third-party consultants;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">research and development supplies and services expenses; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">facility-related expenses, including rent, maintenance and other general operating expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We recognize research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our primary research and development focus since inception has been the development of our proprietary discovery and drug development platform, PRISM. We are using PRISM, which includes our novel PN backbone chemistry modifications, to design, develop and commercialize a broad pipeline of nucleic acid therapeutic candidates that target RNA using silencing, splicing, and ADAR editing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses consist primarily of expenses related to our CROs, CMOs, consultants, other external vendors and fees paid to global regulatory agencies to conduct our clinical trials, in addition to compensation-related expenses, internal manufacturing expenses, facility-related expenses and other general operating expenses. These expenses are incurred in connection with research and development efforts and our preclinical studies and clinical trials. We track certain external expenses on a program-by-program basis. However, we do not allocate compensation-related expenses, internal manufacturing expenses, equipment repairs and maintenance expense, facility-related expenses or other operating expenses to specific programs. These expenses, which are not allocated on a program-by-program basis, are included in the &#x201c;PRISM and other research and development expenses&#x201d; category along with other external expenses related to our discovery and development programs, as well as platform development and identification of potential drug discovery candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur significant research and development expenses in the foreseeable future as we continue to manage our existing clinical trials, initiate additional clinical trials for certain product candidates, pursue later stages of clinical development for certain product candidates, maintain our manufacturing capabilities and continue to discover and develop additional product candidates in multiple therapeutic areas.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of compensation-related expenses, including salaries, bonuses, share-based compensation and other related benefits costs for personnel in our executive, finance, corporate, legal and administrative functions, as well as compensation-related expenses for our board of directors. General and administrative expenses also include legal fees; expenses associated with being a public company; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; other operating costs; and facility-related expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other income, net consists primarily of refundable tax credits from tax authorities. We recognize refundable tax credits when there is reasonable assurance that we will comply with the requirements of the refundable tax credit and that the refundable tax credit will be received.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are a Singapore multi-national company subject to taxation in the United States and various other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our significant accounting policies, judgments and estimates are described in Note 2 in the notes to the audited consolidated financial statements included in the 2021 Annual Report on Form 10-K, as well as in Note 2 in the notes to the unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q. We believe that our revenue recognition policy, particularly (a) assessing the number of performance obligations; (b) determining the transaction price; (c) allocating the transaction price to the performance obligations in the contract; and (d) determining the pattern over which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in our analysis of contracts with CROs and CMOs to estimate the contract expense, involve a greater degree of judgment, and therefore we consider them to be our critical accounting policies. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the three months ended June 30, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.824%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.372%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.828%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">375</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,776</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2,401</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,733</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31,635</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,902</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12,806</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,969</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,837</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,539</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,604</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(65</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(42,164</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(39,828</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2,336</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">868</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,062</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(194</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(41,296</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(38,766</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2,530</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(41,296</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(38,766</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(2,530</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the three months ended June 30, 2022 and 2021 was $0.4 million and $2.8 million, respectively, and was primarily earned under the Takeda Collaboration Agreement. The decrease in revenue is driven by an increase in the expected future research and development services under the Takeda Collaboration Agreement based on the revenue recognition standard, as well as the discontinuation of the Category 2 component in the third quarter of 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:53.255%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.773%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.636%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.884%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ALS and FTD program</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,348</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,381</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(33</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HD programs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,253</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,911</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(5,658</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DMD programs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">392</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">356</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AATD program</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,541</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,538</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PRISM and other research and development expenses (1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">23,199</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20,984</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29,733</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31,635</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,902</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.0925;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Includes expenses related to discovery and development programs, identification of potential drug discovery candidates, compensation, internal manufacturing, equipment repairs and maintenance, facilities and other operating expenses, which are not allocated to specific programs. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $29.7 million for the three months ended June 30, 2022, compared to approximately $31.6 million for the three months ended June 30, 2021. The decrease of $1.9 million was due to the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.0925;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a decrease of less than $0.1 million in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $5.7 million in external expenses related to our HD programs, driven by decreased external expenses related to our discontinued WVE-120101 and WVE-120102 programs, partially offset by continuing external expenses for our WVE-003 (PN-modified silencing oligonucleotide) program; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of less than $0.1 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide); </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of $1.5 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of $2.2 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, primarily due to increases in compensation-related expenses, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">including the share-based compensation expense related to the achievement of a performance-based RSU milestone, offset by decreases in other external research and development expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $12.8 million for the three months ended June 30, 2022, as compared to $11.0 million for the three months ended June 30, 2021. The increase of $1.8 million is primarily driven by increases in compensation-related expenses, including the share-based compensation expense related to the achievement of a performance-based RSU milestone, offset by decreases in other external general and administrative expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other income, net for the three months ended June 30, 2022 and 2021, was $0.9 million and $1.1 million, respectively. Other income, net for both periods primarily consisted of income related to refundable tax credits from tax authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Provision</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended June 30, 2022 and 2021, we recorded no income tax provision. We maintained a full valuation allowance for the three months ended June 30, 2022 and 2021 in all jurisdictions due to uncertainty regarding future taxable income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the six months ended June 30, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.824%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.372%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.828%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,125</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,776</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(651</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">57,203</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65,028</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(7,825</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,180</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">21,047</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,133</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">82,383</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">86,075</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(3,692</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(80,258</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(83,299</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,041</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,148</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,069</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(921</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(79,110</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(81,230</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,120</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Income tax provision</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(79,110</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(81,230</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,120</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the six months ended June 30, 2022 and 2021 was $2.1 million and $2.8 million, respectively, and was primarily earned under the Takeda Collaboration Agreement. The decrease in revenue is driven by the discontinuation of the Category 2 component in the third quarter of 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.255%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.773%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.636%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.884%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ALS and FTD program</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,087</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,821</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(1,734</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">HD programs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,446</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,361</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(11,915</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DMD programs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">817</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">156</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">661</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">AATD program</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,852</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,849</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PRISM and other research and development expenses (1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">46,001</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">42,687</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,314</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">57,203</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65,028</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(7,825</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.0925;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Includes expenses related to discovery and development programs, identification of potential drug discovery candidates, compensation, internal manufacturing, equipment repairs and maintenance, facilities and other operating expenses, which are not allocated to specific programs. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $57.2 million for the six months ended June 30, 2022, compared to $65.0 million for the six months ended June 30, 2021. The decrease of $7.8 million was due to the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $1.7 million in external expenses related to our ALS and FTD program, WVE-004 (PN-modified silencing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a decrease of $11.9 million in external expenses related to our HD programs, driven by decreased external expenses related to our discontinued WVE-120101 and WVE-120102 programs, partially offset by continuing external expenses for our WVE-003 (PN-modified silencing oligonucleotide) program; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of $0.7 million in external expenses related to our DMD programs, including WVE-N531 (PN-modified splicing oligonucleotide); </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of $1.8 million in external expenses related to our AATD program, WVE-006 (PN-modified RNA editing oligonucleotide); and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">an increase of $3.3 million in internal and external research and development expenses that are not allocated on a program-by-program basis and are related to other discovery and development programs, including PRISM and the identification of potential drug discovery candidates, primarily due to increases in compensation-related expenses, including the share-based compensation expense related to the achievement of a performance-based RSU milestone. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $25.2 million for the six months ended June 30, 2022, as compared to approximately $21.0 million for the six months ended June 30, 2021. The increase of $4.1 million was primarily due to increases in compensation-related expenses, including the share-based compensation expense related to the achievement of a performance-based RSU milestone, as well as increases in professional services expenses and other general and administrative operating expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Other income, net for the six months ended June 30, 2022 and 2021, was $1.1 million and $2.1 million, respectively. Other income, net for both periods primarily consisted of income related to refundable tax credits from tax authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Provision</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022 and 2021, we recorded no income tax provision. We maintained a full valuation allowance for the six months ended June 30, 2022 and 2021 in all jurisdictions due to uncertainty regarding future taxable income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any product revenue and have incurred recurring net losses. To date, we have primarily funded our operations through public and other registered offerings of our ordinary shares, collaborations with third parties and private placements of debt and equity securities. Through June 30, 2022, we have received an aggregate of approximately $1,021.2 million in net proceeds from these transactions, consisting of $630.9 million in net proceeds from public and other registered offerings of our ordinary shares, $301.0 million from our collaborations and $89.3 million in net proceeds from private placements of our debt and equity securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 16, 2022, we closed an underwritten offering (the &#x201c;June 2022 Offering&#x201d;), in which we issued and sold 25,464,483 ordinary shares and Pre-Funded Warrants to purchase up to 7,093,656 ordinary shares. The net proceeds of the June 2022 Offering were approximately $65.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022, we had cash, cash equivalents and short-term investments totaling $148.2 million, restricted cash of $3.7 million for our leased premises in Cambridge, Massachusetts and Lexington, Massachusetts, and an accumulated deficit of $884.6 million. Our operating lease commitments as of June 30, 2022 total approximately $50.6 million, of which $3.6 million is related to payments in 2022 and $47.0 million is related to payments beyond 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations for at least the next twelve months. We have based this expectation on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. In addition, we may elect to raise additional funds before we need them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if we expect we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate significant revenue from product sales, if ever, we expect to continue to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. In May 2019, we filed a shelf registration statement on Form S-3ASR with the SEC pursuant to which we registered for sale an indeterminate amount of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine. Our shelf registration statement on Form S-3ASR also included a prospectus covering up to an aggregate of $250.0 million in ordinary shares that we may issue and sell from time to time, through Jefferies LLC (&#x201c;Jefferies&#x201d;) acting as our sales agent, pursuant to the open market sales agreement that we entered into with Jefferies in May 2019, as amended in March 2020 and March 2022 (the &#x201c;Sales Agreement&#x201d;), for our &#x201c;at-the-market&#x201d; equity program. Since we no longer qualified as a &#x201c;well-known seasoned issuer&#x201d; at the time of the filing of our Annual Report on Form 10-K for the year ended December 31, 2019, we previously amended the shelf registration statement to register for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, including the $250.0 million in ordinary shares that we may issue and sell from time to time pursuant to our &#x201c;at-the-market&#x201d; equity program. This registration statement, which we refer to as the &#x201c;2019 Form S-3,&#x201d; remained effective until our 2022 Form S-3 (as defined below) was declared effective on May 4, 2022, after which time we may no longer offer or sell any securities under the 2019 Form S-3. During the six months ended June 30, 2022, the Company sold 458,092 ordinary shares under its at-the-market equity program for aggregate net proceeds of $1.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On March 3, 2022, we filed a new universal shelf registration on Form S-3 with the SEC, which was declared effective by the SEC on May 4, 2022, pursuant to which we registered for sale up to $500.0 million of any combination of our ordinary shares, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which we refer to as the &#x201c;2022 Form S-3.&#x201d; The 2022 Form S-3 includes a prospectus covering up to approximately $132.0 million in ordinary shares that have not yet been issued or sold under our Sales Agreement with Jefferies. As of August 10, 2022, we have $430.0 million in securities available for issuance under the 2022 Form S-3, including approximately $132.0 million in ordinary shares available for issuance under our at-the-market equity program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flow activity:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.898%;"></td>
    <td style="width:1.549%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.306%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.549%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.698%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(68,695</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(53,776</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(25,594</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(447</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">67,116</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,686</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(228</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(120</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(27,401</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(40,657</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, operating activities used $68.7 million of cash, primarily due to our net loss of $79.1 million, offset by $10.9 million of share-based compensation expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2021, operating activities used $53.8 million of cash, primarily due to our net loss of $81.2 million, offset by a $30.0 million decrease in accounts receivable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, investing activities used $25.6 million of cash, of which $50.0 million related to purchases of short-term investments, $25.0 million of which was subsequently sold and $0.6 million related to purchases and sales of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2021, investing activities used $0.4 million of cash, related to purchases of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, net cash provided by financing activities was $67.1 million, which was primarily due to the net proceeds from the June 2022 Offering, which was comprised of sales of ordinary shares and Pre-Funded Warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2021, net cash provided by financing activities was $13.7 million, which was primarily due to the net proceeds from sales of ordinary shares under our at-the-market equity program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur significant expenses in connection with our ongoing research and development activities and our internal cGMP manufacturing activities. Furthermore, we anticipate that our expenses will continue to vary if and as we:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">continue to conduct our clinical trials evaluating our product candidates in patients;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">conduct research and preclinical development of discovery targets and advance additional programs into clinical development; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">file clinical trial applications with global regulatory agencies and conduct clinical trials for our programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">evaluate next steps for our programs in rare, inherited eye diseases;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">make strategic investments in continuing to innovate our research and development platform, PRISM, and in optimizing our manufacturing processes and formulations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">maintain our manufacturing capabilities through our internal facility and our CMOs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">maintain our intellectual property portfolio and consider the acquisition of complementary intellectual property;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">seek and obtain regulatory approvals for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">respond to the impacts of the COVID-19 global pandemic on our business; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">establish and build capabilities to market, distribute and sell our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with the development of drug candidates and because the extent to which we may enter into collaborations with third parties for development of product candidates is unknown, we are unable to estimate the amounts of future capital outlays and operating expenses associated with completing the research and development for our therapeutic programs. Our future capital requirements for our therapeutic programs will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the progress, results and costs of conducting research and continued preclinical and clinical development for our therapeutic programs and future potential pipeline candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the number and characteristics of product candidates and programs that we pursue;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the cost of manufacturing clinical supplies of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">whether and to what extent milestone events are achieved under our collaboration with Takeda or any potential future licensee or collaborator;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the impacts of the COVID-19 global pandemic on our business;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of our product candidates, to the extent any are approved for commercial sale, and the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological and market developments; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Adequate additional funds may not be available to us on acceptable terms when we need them, or at all. We do not currently have any committed external source of funds, except for possible future payments from Takeda under the Takeda Collaboration Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our shareholders. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our shareholders&#x2019; ownership interests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign exchange rates, as well as, to a lesser extent, inflation and capital market risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to interest rate risk in the ordinary course of our business. Our cash and cash equivalents are held in readily available checking and money market accounts. Our short-term investments are comprised of term deposits which have fixed interest rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Exchange Rate Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, we have not hedged our foreign currency exposure. For the three and six months ended June 30, 2022 and 2021, changes in foreign currency exchange rates did not have a material impact on our business, financial condition, results of operations or cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We do not believe that inflation had a material effect on our business, financial condition, results of operations or cash flows for the three and six months ended June 30, 2022 and 2021. If the global inflationary trends continue, we expect appreciable increases in clinical trial, labor, and other operating costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capital Market Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We currently have no product revenues and depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our share price, including impacts of the COVID-19 pandemic on the capital markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2022. The term &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2022, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="part_ii_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PART II &#x2013; OTHE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Proceedings</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We are not currently a party to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Ri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">sk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In addition to the other information set forth in this Quarterly Report on Form 10-Q, including the risk factor below, you should carefully consider the factors discussed under the caption &#x201c;Risk Factors&#x201d; that appear in Item 1A of our 2021 Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We issued pre-funded warrants as part of our June 2022 financing, which may cause additional dilution to our shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we closed an underwritten offering in which we issued and sold 25,464,483 ordinary shares and, to RA Capital Management, L.P. in lieu of additional ordinary shares, pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 7,093,656 ordinary shares at an exercise price of $0.0001 per share. The Pre-Funded Warrants contain a so-called &#x201c;blocker&#x201d; provision which provides that they are only exercisable upon receipt of shareholder approval or if such exercise would not cause the aggregate number of ordinary shares or the combined voting power of total securities, in each case, beneficially owned by the holder (together with its affiliates) to exceed 19.99% of the number of ordinary shares or total securities, respectively, outstanding immediately after giving effect to the exercise. To the extent the Pre-Funded Warrants above are exercised, additional ordinary shares will be issued and such issuance would dilute existing shareholders and increase the number of shares eligible for resale in the public market.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sales of Equit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">y Securities and Use of Proceeds</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">We did not repurchase any of our equity securities during the three months ended June 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults Upon</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Senior Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ety Disclosures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The information set forth in this paragraph is included herein for the purpose of providing the disclosure required under &#x201c;Item 1.01 - Entry into a Material Definitive Agreement&#x201d; of Form 8-K. On August 8, 2022, Wave Life Sciences USA, Inc. (the &#x201c;Subsidiary&#x201d;), a wholly-owned subsidiary of Wave Life Sciences Ltd. (and together with the Subsidiary, the &#x201c;Company&#x201d;), entered into the Second Amendment to its lease with CPI/King 733 Concord Owner, LLC (the &#x201c;Second Lease Amendment&#x201d;), which, among other things, extended the term of the lease at 733 Concord Avenue, Cambridge, Massachusetts, which serves as the Company&#x2019;s U.S. headquarters. The Second Lease Amendment amends the lease agreement dated as of April 6, 2015, between the Subsidiary and King 733 Concord LLC, an affiliate of King Street Properties Investments, LLC (the &#x201c;Original Lease&#x201d;), as amended by the First Amendment to the Original Lease dated December 9, 2020. Under the Second Lease Amendment, the lease term with respect to the approximately 30,893 square feet of space leased under the Original Lease (the &#x201c;Original Premises&#x201d;) was extended for an additional period of five years commencing on April 1, 2023, and expiring as of March 31, 2028. During the extension period, the Company has agreed to pay an average base rent for the Original Premises of approximately $3.3 million per year, plus certain costs and expenses, including a proportionate share of applicable taxes, operating expenses and utilities. In addition, the Company received a tenant improvement allowance of up to $0.9 million. The foregoing description of the Second Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Lease Amendment, a copy of which is attached as an exhibit this Quarterly Report on Form 10-Q.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 6. E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">xhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.875%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:47.732%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:7.003%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:13.041%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:9.044%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:9.897%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Filed</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">with this</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Report</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Incorporated by</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Reference herein</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">from Form or</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Schedule</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Filing</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">SEC</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">File/Reg.</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1631574/000119312522173529/d364213dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Form 8-K</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Exhibit 4.1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">06/14/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-37627</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="wve-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment (to Lease) by and between Wave Life Sciences USA, Inc. and CPI/King 733 Concord Owner, LLC, dated as of August 8, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="wve-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="wve-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">32*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="wve-ex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Section 1350 Certifications of Principal Executive Officer and Principal Financial Officer</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Instance Document &#x2013; The instance document does not appear in the interactive data file because its Inline XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">X</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(*) The certifications attached as Exhibit 32 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Wave Life Sciences Ltd. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:46.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES LTD.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date: August 11, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date: August 11, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>wve-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">733 CONCORD AVENUE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CAMBRIDGE, MASSACHUSETTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SECOND AMENDMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:46.221%;"></td>
    <td style="width:53.779%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXECUTION DATE:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">August 8, 2022</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LANDLORD:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CPI/King 733 Concord Owner, LLC, a Delaware limited liability company (as successor-in-interest to King 733 Concord LLC, a Delaware limited liability company)</font></p></td>
   </tr>
   <tr style="height:31.7pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TENANT:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences USA, Inc., a Delaware corporation</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXISTING<br>PREMISES:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Approximately 44,019 rentable square feet of space, in the aggregate, consisting of: (i) approximately 30,893 rentable square feet of space in the Building (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and (ii) approximately 13,126 rentable square feet of space on the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;min-width:fit-content;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">) floor of the Building (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ROFO Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), both, as more particularly described in the Existing Lease (as defined below).</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">DATE OF EXISTING LEASE:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">April 6, 2015</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:36.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT EXPIRATION DATE OF ORIGINAL PREMISES:</font></p><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXTENDED EXPIRATION DATE FOR ORIGINAL PREMISES:</font></p><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXPIRATION DATE FOR ROFO PREMISES:</font></p><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">PRIOR AMENDMENTS/SUPPLEMENTS TO LEASE:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2023</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2028</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2026</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Commencement Letter dated October 1, 2015<br>Letter Agreement dated September 28, 2016<br>First Amendment dated December 9, 2020 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)<br>Term Commencement Letter dated September 30, 2021</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Tenant desires to extend the Term of the Lease with respect to the Original Premises for an additional period; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Landlord is willing to extend the Term of the Lease with respect to the Original Premises for an additional period, upon the terms and conditions hereinafter set forth.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, the Existing Lease, as previously amended, is hereby further amended by this Second Amendment (the Existing Lease, as previously amended, and as further amended by this Second Amendment, shall hereafter be referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Any capitalized terms used herein shall have the same definition as set forth in the Existing Lease, except to the extent otherwise set forth in this Second Amendment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Extension of Term of Lease With Respect to the Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Term of the Lease with respect to the Original Premises is hereby extended for an additional period (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Extension Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) commencing as of April 1, 2023 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Extension Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and expiring as of March 31, 2028 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Extended Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the parties hereby acknowledging and agreeing that the Expiration Date with respect to the ROFO Premises is September 30, 2026.  The Original Premises Extension Term shall be on all of the terms and conditions of the Lease immediately preceding the Original Premises Extension Term, except as expressly set forth in this Second Amendment.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Condition of Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Tenant hereby accepts the Original Premises in their &#x201c;as is&#x201d;, &#x201c;where is&#x201d; condition on the Original Premises Extension Date, with all faults, and without representations or warranties from Landlord of any kind whatsoever.  Except for Landlord&#x2019;s Original Premises Contribution (as hereinafter defined) and Landlord&#x2019;s continuing maintenance and repair obligations expressly set forth in the Lease, Tenant acknowledges and agrees that Landlord has no obligation to perform any work or to provide any other concession with respect to the Original Premises for the Original Premises Extension Term.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Base Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. From and after the Original Premises Extension Date and continuing through the Original Premises Extended Expiration Date, Tenant shall pay Base Rent with respect to the Original Premises as follows:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:76.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.405%;"></td>
    <td style="width:27.873%;"></td>
    <td style="width:32.722%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Period of Time</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Annual Base Rent</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Monthly Base Rent</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4/1/2023-3/31/2024:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$3,151,086.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$262,590.50</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4/1/2024-3/31/2025:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$3,245,618.58</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$270,468.20</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4/1/2025-3/31/2026:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$3,342,987.14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$278,582.25</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4/1/2026-3/31/2027:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$3,443,276.75</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$286,939.72</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4/1/2027-3/31/2028:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$3,546,575.05</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$295,547.91</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additional Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. During the Original Premises Extension Term, Tenant shall continue to pay to Landlord with respect to the Original Premises (i) Tenant&#x2019;s Share of Operating Costs in accordance with the provisions of Section 5.2(c) of the Lease, (ii) Tenant&#x2019;s Share of Taxes in accordance with the provisions of Section 5.3(c) of the Lease and (iii) the cost of all utility services consumed in the Original Premises (including, without limitation, electricity, gas and water) in accordance with the provisions of Section 9 of the Lease.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Original Premises Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Amount</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Landlord shall provide to Tenant a tenant improvement allowance with respect to the Original Premises equal to up to Nine Hundred Twenty-Six Thousand Seven Hundred Ninety and 00/100 Dollars ($926,790.00) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Original Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to be used by Tenant solely for costs incurred by Tenant for work (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Work</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to be performed by Tenant in the Original Premises and/or the ROFO Premises.  For the purposes hereof, Landlord&#x2019;s Original Premises Contribution shall not include: (i) the cost of any of Tenant&#x2019;s Property (as defined in Section 14.1(b) of the Lease), including without limitation telecommunications and computer equipment and all associated wiring and cabling and trade fixtures, (ii) the cost of any fixtures or Alterations (as defined in Section 11 of the Lease) that will be removed at the end of the Term, (iii) any fees paid to Tenant, any Affiliated Entity or Successor (as both terms are defined in Section 13.7 of the Lease), and (iv) any so-called &#x201c;soft costs.&#x201d;  Tenant&#x2019;s Work shall be performed in accordance with the provisions of the Lease (including, without limitation, Section 11 thereof).  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Requisitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  Landlord shall pay Landlord&#x2019;s Proportion (hereinafter defined) of the cost shown on each requisition (hereinafter defined) submitted by Tenant to Landlord within thirty (30) days of submission thereof by Tenant to Landlord until the entirety of Landlord&#x2019;s Original Premises Contribution has been exhausted.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Proportion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall be a fraction, the numerator of which is Landlord&#x2019;s Original Premises Contribution and the denominator of which is the total contract price for Tenant&#x2019;s Work for the Original Premises (as evidenced by reasonably detailed documentation delivered to Landlord with the requisition first submitted by Tenant).  A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">requisition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean AIA Documents G-702 and G-703 duly executed and certified by Tenant&#x2019;s architect and general contractor (accompanied by, without limitation, invoices from Tenant&#x2019;s contractors, vendors, service providers and consultants (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Contractors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and partial lien waivers and subordinations of lien, as specified in M.G.L. Chapter 254, Section 32 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Lien Waivers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) with respect to the prior month&#x2019;s requisition, and such other documentation as Landlord or any Mortgagee may reasonably request) showing in reasonable detail the costs of the item in question or of the improvements installed to date in the Original Premises, accompanied by certifications executed by an officer of Tenant that the amount of the requisition in question does not exceed the cost of the items, services and work covered by such requisition.  Landlord shall have the right, upon reasonable advance notice to Tenant, to inspect Tenant&#x2019;s books and records relating to each requisition in order to verify the amount thereof.  Tenant shall submit requisition(s) no more often than monthly. Landlord shall have no obligation to pay any portion of Landlord&#x2019;s Original Premises Contribution with respect to any requisition submitted after April 1, 2025.  Tenant shall not be entitled to any unused portion of Landlord&#x2019;s Original Premises Contribution. Landlord&#x2019;s obligation to pay any portion of Landlord&#x2019;s Original Premises Contribution shall be conditioned upon there existing no default by Tenant in its obligations under the Lease which is continuing beyond any applicable notice and cure period at the time that Landlord would otherwise be required to make such payment. Landlord&#x2019;s obligation to pay the final ten percent (10%) of Landlord&#x2019;s Original Premises Contribution shall be subject to simultaneous delivery of all Lien Waivers relating to items, services and work performed in connection with Tenant&#x2019;s Work.</font></div></div>
  <div style="text-indent:3.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notice Addresses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  For all purposes of the Lease, the suite number for notice addresses for Landlord as set forth in Section 24 of the Lease, as amended by Section 3 of the First Amendment, has been changed to Suite 2400.</font></div></div>
  <div style="text-indent:3.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  The parties hereby acknowledge that Landlord is currently holding a Letter of Credit in the amount of $1,000,000.00 as the Security Amount pursuant to Section 7 of the Lease. The parties hereby further acknowledge that Landlord shall continue to hold said Letter of Credit during the Extension Term pursuant to and in accordance with said Section 7 of the Lease, except that the provisions of Section 7.6 of the Lease shall have no further applicability with respect to the Security Amount.</font></div></div>
  <div style="text-indent:3.333%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Notice of Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.  In accordance with Section 25.16 of the Existing Lease, at Tenant&#x2019;s option, each of the parties shall join in the execution, in recordable form and substantially similar to the form attached as Exhibit 10 to the Existing Lease, of a statutory notice of lease and/or written declaration, or an amendment to any existing notice and/or declaration, reflecting Tenant&#x2019;s extension of the Term of the Lease, which notice of lease may be recorded by Tenant with the Middlesex South Registry of Deeds and/or filed with the Registry District of the Land Court, as appropriate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. Tenant and Landlord each warrants and represents that it has dealt with no broker in connection with the consummation of this Second Amendment, other than Colliers International (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Tenant and Landlord each agrees to defend, indemnify and save the other harmless from and against any claims arising in breach of the representation and warranty set forth in the immediately preceding sentence. Landlord shall pay a brokerage commission to the Broker pursuant to a separate agreement between Landlord and the Broker. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">C.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Deleted/Inapplicable Lease Provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.   Section 1.2 of the Lease (Extension Term) is hereby deleted in its entirety and is of no further force or effect.  Section 3 and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Lease shall have no applicability with respect to this Second Amendment.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">D.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Ratification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. In all other respects, except as expressly modified herein, the Lease is hereby ratified and confirmed.  The submission of drafts of this document for examination and negotiation does not constitute an offer, or a reservation of or option for any of the terms and conditions set forth in this Second Amendment, and this Second Amendment shall not be binding upon Landlord or Tenant unless and until Landlord shall have executed and delivered a fully executed copy of this Second Amendment to Tenant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">E.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Conflict</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. In the event that any of the provisions of the Existing Lease are inconsistent with this Second Amendment or the state of facts contemplated hereby, the provisions of this Second Amendment shall control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">F.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. This Second Amendment may be executed in any number of counterparts and by each of the undersigned on separate counterparts, which counterparts taken together shall constitute one and the same instrument.  This Second Amendment may be executed by electronic signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature.  Without limitation, in addition to electronically produced signatures, &#x201c;electronic signature&#x201d; shall include faxed versions of an original signature or electronically scanned and transmitted versions (e.g., via pdf) of an original signature.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page Follows]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EXECUTED as of the date first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">LANDLORD:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CPI/KING 733 CONCORD OWNER, LLC,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">a Delaware limited liability company</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Thomas Ragno</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">__________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">     Name: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thomas Ragno</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">     Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Authorized Signatory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">__________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">TENANT:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WAVE LIFE SCIENCES USA, INC.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br>a Delaware corporation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">_____________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">     Name: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">___________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">     Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">___________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>wve-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I, Paul B. Bolno, M.D., MBA, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Wave Life Sciences Ltd.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:    August 11, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.488%;"></td>
    <td style="width:2.512%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>wve-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 302</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I, Kyle Moran, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Wave Life Sciences Ltd.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:    August 11, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.488%;"></td>
    <td style="width:2.512%;"></td>
    <td style="width:90.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2075000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>wve-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS UNDER SECTION 906</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Wave Life Sciences Ltd. (the &#x201c;Company&#x201d;), does hereby certify, to such officer&#x2019;s knowledge, that:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Quarterly Report for the quarter ended June 30, 2022 (the &#x201c;Form 10-Q&#x201d;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;min-width:fit-content;"></font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.898%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:39.1%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:   August 11, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Paul B. Bolno, M.D., MBA</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:59.898%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:39.1%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Dated:   August 11, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kyle Moran</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img55497064_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55497064_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $4 G # 2(  A$! Q$!_\0
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MYD@_WY"YSZ!:_4;]M?XVCX&_L]^(]7MI_)UO4$_LK2^<-]HF!&\?[B;W_P"
MBOPXQCC)/N>IK['A_"W<L3+T7ZGSF;UM%17JPHHHK[<^8LPHHHH"S"BBB@+,
M*]N^'/[+.I^._AK;>.K_ ,5:/X2T"\OI=/M)]2@NIP\D?WVE:")U@0$8WR$#
M],^(U]%?L_\ [6=K\ ?#MO!8>&=4O-:@EGF:6#Q)-;:;?EP0@N[+8R2; <94
MH2%&3Q7#C'75/_9U=W\OU_X)UX94^?\ >[?,Y_2/V;9M8\)W^N1:Y)!'9^#[
MKQ8WVC362*=8+A86A@DW_O%);/F@ <8V\YKF;O\ 9U^)^GVN@W%UX%UJVAUZ
M>.UTQYK?9]IFD7='&,GY68<@-C(KO;7]K!K7P:-$'AI/._X0R^\)?:$N0J!K
MF]%U]H6/9@*I&WR\\C^+M7=^(/\ @H _B+6-#UF?P7-!JMOK&G:QJ4=OJJK9
MWDEIC&V/R-ZEL#EW?:!@"N%5,P@_@3^[Y;'5R862WL>"ZM^SQ\3M"\0Z)H5_
MX$UNVUG6C(-.LFMB9+KR_P#6;0"?N]3G&!R>*U[O]FSQCI>BWW]I:)K%AXH@
MU>RTB+0GT_(F>Z7,)^T!]JLQ.%3!SZBO1/#_ .VU<^'Y?#FSPHEU!IU_K\]W
M'-J# W5OJDF^2)'"[HGCXQ(,YQT&:R/#/[4'A[P'I\&E>&? MU8Z-;^)]'\2
M0V][K;7<H-B/FB:1HAGS#W  7LIJW4QS5N17^7?U[?\ #H2IX5?://M6_9T^
M*&@Z[HFBZAX#URUU;6WDCTVT>VR]TT?^L"X.,J.3G&!STYK"^('PM\6_"G4;
M6P\8>'[SP]>W4/VB"&]4!I(]Q7>,$\9!'X5])_"K]LK3;?QMX;BU[3AHNAPZ
MYK^IW^H232W)$.IJ^856--ZE"5 D7/KM[5YY^UM\2/ WCG6O VD?#R2ZN?#?
MA3P[%H\=U=B0&5A([G;Y@#L & W, 2<\"JHU\7*LJ=6%EK=].O6_H14HT%3<
MX2U_X8\'HHHKUSSK,**** LPHHHH"S"GV]O+=3QP01--/*PCCB099V)PJ@=R
M20/QIE?4W_!.7X*_\+8_:%L=4O(/-T3PF@U:XW#*O/DBVC/_  ,%\>D1KFQ%
M>.&I2JRZ(WHTG6J1@NI^H?[+OP<C^!'P/\+^$=BB_M[83ZA(O_+2[D^>8Y[@
M,=H]E%>JNP7 />@9[]:\R_:*^('_  KWX8ZC=02>7J5Z/L-GZ^8X(+#_ '5W
M-^ K\HC&IBZZBM92?YGVF*Q%++L+.O4TC33?W'QQ^T%X^_X6%\4-3O(I/,T^
MS/V&SYR#&A(+#_>;<?RKS>EP!P.@XHK]DH4HX>E&E#9(_C''8JIC\34Q57XI
MMM_,2BEI*W.(**6B@!**6DH WO O@V_^('BJQT'33&EW=EMK3,0BJJEF)P">
M #P!DUNZE\(=6_M:/3M E3Q5<>2T\L6GPRQR6ZJP4^9'*JLO)&#CFL#P;K]M
MX8\06^HW=C)J$40;$4-T]K(K$8#I(G*L#R*]@L/V@-*UR354\06=TE@GAVXT
MNW26[:>\O'DD1RLEP$X^Z0#MP/QKR,54Q=.IS48WC;RW_-_AZGUV58?*L1AG
M#%SY:CEOKM;TLNNKYGV2Z\)I7P;U6XL=7DU,3Z1>:;?V=A+826QDF8W!PK*
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M[9G['OB?]JK6/#OV3QK9^'M"T>&0I8S6#SM)<.?FE+"11]U54#''S>M?./\
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M\$B2PR*'22-@RNI&001P01WH_L' ?R?BP]C3['F'_"FKK_H*0_\ ?D_XT?\
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MP,+.$HA*RF578G)4 ;37O>O?MB?"3PO=:7;:MXK.G37]M;7F+C3;M19Q7&!
MUX?*Q:;R1@3[#7M"L&4$'(/>@#XW\1ZE\3K'Q=\3;;PK)XE\1ZU):ZI+8:@R
MZA;6^F8D0P6PM9U%I,^PNL,MNVYBF6'S$U1M_P#A,U^&NHS-XX\0G3EURU=;
M4:1XC61HQ!*LUNURRM?(COY<F^/*(Z;/NN5K[7HH X_X07VHZI\+_#%UJVE:
MEHFI2V$33Z?J]R;F[@;;]V65@&=O4L WJ <BNPHHH **** "BBB@ HHHH \[
M\=?"Z\\5>-='UZQU:&PCBT^ZT;4[.XM#,MY97#Q/(L;"1#%*#",/\P^8Y4\5
MA_"OX%ZGX#U[2-0UGQ2OB*/0-"_X1O1(8M/6T,-F7B9FG8.WFS$6\*EE"+A"
M0@+&O8** /GWQ9^RO=^(OB]XZ\66WC%].T/QUX>'A_7]#.G++)(JV\L,4L%P
M7'E%?-W$%&SC'&>//=#_ &"=;@TG6[/7/B<NMO>?#AOAO9R1Z"EL+.T$FZ*4
MA9CYC*!@@D%B<Y'2OL2B@#Q.?]G!IO%WP4UT>(&1OAKIEWIPA%K_ ,A'S[)+
M7?NW_N]NS=C#9SCWH^%/[,MA\/\ ]ER#X)ZKJLNO:5_9=[I5SJ$47V62:*Y>
M5F*KN;80)B!R?NY]J]LHH ^0=)_8)U+^Q=9L_$/Q+EUZX_X02X^'N@S)HL=J
MNFZ=(NW?*JR$W$H 49R@(!XR<UZCX3_9O;PO\5/ GC/_ (2%KG_A%_!(\'?8
MOLNW[2 \3?:"^_Y?]4/DP>O7BO;:* /!/BG\+?&?C;XR7LNAZK#X<T+4/![:
M->ZI/8"[+%[ERT<(\U-DH1B0S*Z\\J<5L77[.&G7'@?QIX535+BVT_7FLFM)
M(T!DL#:6UM# ?F)$A#6D;G(&<D>]>Q;03G'-+0!X-<?L[^)+RZN?$ESXTLY/
M'\NL66JKJ":,5T]5M8);>.#[+YY<J4N)B6\W=N<$$!0M4]#_ &2[30?B!J?B
M"&;09X;Z]OM2\ZZT+?J=O<72R>8(KKSPH0/*[#,9<*Q3=CFOH6B@#PFS_9A-
MKX.U_0?^$C9QJVC:)I)N/LG^J_L]-OF;=_/F>F1M]370_'GPMXG\43?#UO";
MP6VH:;XF2^EO+JW^T0VT(LKR,O)$)(RZEI$7"L#\X/:O5:3 ZXH \H^'?P,D
M\">(-*UN;7FU74(8-6-^YM1"MW=7]W#<RRJH8^6BM#M5/FX(RQ(R>)C_ &0G
MO?#T7AG6/%TE[X8TK1[_ $;0+:WT]8;FSCN@JF2>4NPG>-555PB C)8,3FOH
MZB@#PBZ_9]\5ZU-K>KZSXYLKKQ/=S:/=65U:Z'Y-K;2:=+++&'A,[-(LAE;<
M-ZD9^4CC$.F_LY^)M#U&/Q%8>.;0>,X]7U'43?7&B[K*2*]C@66!K<3!AM-M
M$RN) ?EYSDU[[10!XQJ?P)US5+_Q()/%=L=,U^YTW4[J$Z7B9;ZT:US(D@EP
M(I%M0/+*DJ7)#$#!IQ?LWZ@NJ16\OBQ9/"5CJ>I:UIFDC3E$\%Y>I<*_FW'F
M?O(HS=SLJA%/S*&9@O/N=% 'F_@CX0GP?KWA?4?[5-V-$\*Q^&?*,&WSMC1-
MY^=QVY\K[O/7KQ7I%%% %2/_ )"D_P#UQC_]">K=5(_^0I/_ -<8_P#T)ZMT
M %>5_M(? \_M ?#C_A&HM;?PY?0:A::I9:FML+D0W%O*)(]T19=ZDC!&X=:]
M4HH ^/\ XO?L)^(_BS-XSGE^*BZ;+XWT/3-,\2+'X>CD2[GLF#1SPYFS"C<Y
MC!8\_>KT^Q_9J-GK'QSOO^$@+_\ "S[:&W,?V3']F^78&TW9W_O<YW_P],>]
M>XT4 ?/_ ,)?V53\+O'W@?Q-_P )*=3/AGX?P>!/LQLA']H$<RR?:=V\[<[<
M>7@]?O5S7QH_8CG^*7C/QUJ>E^/KCPOH?Q MK&U\6:4NEQ7;WBVG$1MYG<?9
MV*_*?E<=3C-?4M% 'RWXZ_8AC\90?%:"'Q:VGP>.=0T"]2/[!YGV!=,6)5CS
MY@\SS!$/F^7;GH:]/^.OA;Q1XFN/AVWA.2"UU'3?$RWTMY=6WVF&VA^P7L9>
M2,21EU+2HF%8'+@]J]5I-HSG'- 'E/PT^!TO@#Q#9:U<:ZVK7XM=26^<VPA%
MS=7MY'=RS* Q$:!DVK'S@$98D9/&6_[)<\V@Q^'=3\8/>>']*T/4=!\/PP:<
ML-Q90W:A#)/)O83O&BJBX6,$9+ DY'T510!\Z>,OV4[GQ[XDM/$NNZCX7UG7
MY=.ATS5#JGAIKFTE2*25DDMXC<AH7VRLK!GD1N#M&*[+P[\"?^$?\>6GB1=9
M,WV?5M6U/[+]GVAOMJQ+Y>[=_!Y0YQSGH,5ZS10!XQXD^$^I>'?V4]?^'^D2
MOKFJIX?N["U=8UC:XE='VX4M@'+ <G'O4%O\ ];UK6H_$7B?Q9#J.O\ V[29
M]UEI?V6WCMK"666. 1F5VW.\\I:0L>H 4 8/MO6@#' H \9U[]G^_P!7\7:M
M<0>*!:>$M;UNQ\1:IHIL \\MW:>1L$5SO'EQ.;2W+*49OD;:R[CC#TO]EO4;
M>33=,O?&*W7A'2;?5[2PTV'3!%=)#?HZL)+CS"':,.P4B-<C&X$\U]!T4 ?/
M$?[,/B*_BFGUKQ[#=:M#IFDV&F7=CHJVZ6DFG79NK>9XVF?S2S[0ZY4$9V[<
MC'91_"_QA-XL\/\ B>_\6Z9/K%K:W6FZDL.BO';W5G-+%($A4W!:*13",.S.
M#N.5Z8]5HH ^<Y?V3;^/P]_PC]EXS%KH>IZ%IN@^(8FTP/->PV:%%>W?S +=
MI(V*-E9 !@KAN3VL/P-:.2U8ZT3Y'C.;Q<!]GZ^8LH^S_>XQYN=_MTYKU>B@
M!!T%+110 53_ .8N?^N'_LU7*I_\Q<_]</\ V:@"Y1110!P?Q ^'6H>)_%7@
M_P 1Z-K$.DZIX>GG.V[LS=0W%O.@2:,J)$*MA5*N"<$<JP.*Y#X<_L[WG@?Q
M%X:FO/% U;0/"4-Y;^'=.6P$,T"7! )N)MY\XI&/+7:L8P26#'D7_C/XZ\2Z
M#XS\#>'/#VLZ+X>77AJ!N=2UJT:Y6$00JZ[$$L0+$L<Y;& ?2O/O"?Q\\>>-
M-*CUR!-(M;#3?"$'B>^L+>REGGU*3SKV-HK9S(HCCE6T5D8JY'F+PU 'I"_
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M*3-&: %HI*,T +1244 58_\ D*3_ /7&/_T)ZMU4C_Y"D_\ UQC_ /0GJW0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M/_F+G_KA_P"S5<JG_P Q<_\ 7#_V:@"Y1110!P_C[X/>&_B;X@\.:EXCL8-7
MAT3[3Y6G7UO%<6LQF15)D1U.2NT%2,8R:ZRUT>PL;C[1;V-M!/Y*6WFQ0JK>
M4A)2/(&=J[FPO09..M7** .<L/AOX2TO3=5T^R\+Z+9V&K%FU"UM]/A2*\+
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M^ZDMFETR!-J-)C&[!)8KW[?05U_PX^,%E>:MIGAJTT<:?8^6(8&\S+%@"22
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MBX6?]?\ !'Q_\A2?_KC'_P"A/5NJD?\ R%)_^N,?_H3U;KW#D"BBB@ HHHH
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M%I:]7UWZD2Q%6<>64M#ROP3\ ]+\$ZOX7U&SG076C6<]K--':I&]^9 !YDC
MYRN#CKUKU2BBNG#X6CA(<E"/*O\ @)?DD95*DZCO-W94C_Y"D_\ UQC_ /0G
MJQ-,MO"\C_=12QQZ 9JO'_R%)_\ KC'_ .A/1JQQIEW_ -<7_P#0376M78PF
M^6+:/'/^&Q/AQ_S]:C_X O1_PV)\./\ GZU'_P  7KX0ZY/N:-IK])_U=P?>
M7WK_ "/YK?B+G-[<L/\ P%__ "1]W_\ #8GPX_Y^M1_\ 7I?^&P_AQWO-04=
MR;%\#WKX.I:/]7<'WE]Z_P @7B-G'\L/N?\ \D?I"^_XB:\FY6/A;39$F3<,
M+J-R,.C8[PQY5@>C/[)SW? %?+/[)?Q3DN[%?#E].6%OB&,,>@/^J(_(H?HG
MK7TYJDA72[QAD$0N0?\ @)KX/'866"JNE+H?O.19M2SS"1Q-/1O1KLSS?X@>
M,]!U!H_L5^T&O:7*9;*]2!G1).C1L1]Z-Q\K =CD<J"-6U^,V@-;1-<-/%.5
M!DC2)F56QR V!D ]\#->$K]T4OX5\F\=5OHD?LT>'<);5R^]?Y'O7_"Y?#7_
M #VN?_ =JH:[\8M-ETN>/1[GR=1D 2*:\@?RHB2 9&P"3M!+;>Y &1G(\2:1
M(\%W5 W +,!GZ4N590P8,K#(93D$>HI?7JW9#_U=P?>7WK_(^F?".CV6@Z';
MVMC(UQ"P,S74C!GN9'.YYG;NSL2Q/OQ@<5Q7Q$^/G@WP#K,V@^(EO!.\ <I]
MB:2*6-P1UZ,.H(]C7DWPC^-6IZ?^T!-\.;QC<Z3?Z?%<V#$_-;3+#O=1ZHR@
MG'8CWKK?VMOAI_PEO@==?LXM^I:&&E;:.7MS_K%_X#PWX&OI,IJX;'5E&JVH
MWY7;HS\MXPPF9Y#A95,*DYJ*J1NKJ4'\UKO\T9?@_P#:E\#>&+>?2Y-2O[C2
M;=Q_9KM9R&6.$_\ +%\]0G16SDKM!Y!)Z+_AL3X<?\_6H_\ @"]?"'7IS1C\
M:_1O]7<'WE]Z_P C^<?^(C9S_+#_ ,!?_P D?=__  V)\./^?K4?_ %ZZ9/'
MT7Q2T738O!]S<);:FKM=:HJ%&LH%;8X&>D['Y5';E_X0#^=->U?LT_$VX\(>
M)#ICRL+.Y;S4C[,P&'7'J5&1[I[UP8WA^E3HN>';YEW_ .&/;R;Q"Q=;%QI9
MA&/)+2\4TT_O=S[:N)=-\"^%Y'@M'ATS3+8L+>TC+LL:+T51R3C\37CVL?M6
M?"SQ%I5SI]])?W-E=1F.2-K%\,I]/0]P1R" 17N4,T5W LD962&105;J&4C_
M  K\]?V@OAL?AK\1[VS@3;I5Y_I=B<<"-CRG_ 6R/IBO"RG"8;&5)4:]T]U;
M\>A]WQ=G&99+AZ>,P*C*%[2NF[7V>C6C_P CZ+\*_M:^#=+TL6>JZK?7\MNY
MCBO/L3[[B$8V-(,<28X;'!(W#&<#:_X;$^''_/UJ/_@"]?"&T^E&.,U]9_J[
M@^\OO7^1^4?\1&SG^6'_ ("__DC[O_X;$^''_/UJ/_@"]=/X!^/_ (/^)&I3
M6.CW5Q]HB57/VFW:(')P ">I)[5^=%>I? IF2;Q"RDJPAM\%>H/F'FN>OP]A
M8TVX2=].OGZ';@_$3-)UDJT(..K=DT]$WO=_D?H4K!NE5?\ F+G_ *X?^S51
M\&74U[X5TJXN',D\MLC.[=6..IJ]_P Q<_\ 7#_V:OS^<7"3B^A_0M"JJ]*-
M6.TDG]^I<HHHJ#8**** "N&^)7BK5]%:PL-$1#>W6YVD90VQ5QV/ Y/4^E)\
M4/$%UH*:85>>#3I9&%S/;\., ;5SV!.>G7%</?VVL370U73=1-^)8E 2\.X[
M,Y"ACVY^M92E;0I(]$\$^)KZ_1++6A"FHX+(\)^651C/'8C-=/?7'V2SGGQN
M,<;/CUP":\AM]:U&UN+*YM=.==0CR&6X&(4###'=GGU&/2HU^(FI:Y=7>D)J
M,4MN8V$LYA"2'G!6/!QCWQD5*J)+4?*<1I_CYUDU&[OT:YOKJ3SO,!&"<8"G
MT '3%>=>-/AQJGQ,\*ZC'I<BV^JP/]ILK@L%V7 !('/9@2I[8:O<KG3K&UL!
M$NGI+#&,+"D08_Y]ZY#0;S_A%[.]^WVUQ#(\@:.+RSAN/7I6=.M.C456&Z=P
MJ4XUJ;ISV:L?(OP)_:&UKX<Z#)X"U+3M1N;JUNW2UM[2$27,+DGS("I]&!(Q
MZGVKZ(TSQEKVHZ1;:C,FI:8MPNX0W\'ER)R1\P(KYL_:@O;"[\?1>(M,1-,U
MI9A%=/;2%'>1$5UE '(90R OD9...":]2\!?M8V/B#PO#I'BV"9=:E7[/]OA
M0-#.2/ED<9RASUP",\\9KZ?'1PV:X=X_ 13DG^\5]4^NG9[W_P"">)3P^89#
M7I8/-4X0JQO1;6DX^3[K:V_X'T/<W45EI?GW$AEB159FQG<>,''KDTEQ_JW)
MX7:26/3&.M<OH)G\56JQ7<@.FVZJ (^!*<<9/< <\57TO28]7U.YF"2)HZ,5
MCA:1B)"./7IWKXQGTB'>"XC'H\K9^5YF*_08%:<W>D_LK[!&Z6$OV>-CN\MU
MWH"?3G(_.LR'6]VH2:==JL5VO*LA^208SQZ'VK.1:)I*HS50\6:^VDQQQV[(
M;ISDAAG:OKCWJAX?U>XU@2O<2Q+Y?RB-!@MGN>>GTK)HNYNZ9K5]X?OX[W3K
ME[6Y3HZ'J/0CN/8U](_"OXA?\)]H\\DT*P7]HRQSI&<JV1E6'H#@\>QKYKTW
M1[WQ#K5AI.GHC7M[)Y:&4D(@ +,[8YP "<#K7T]\._AY8_#W2Y;>WE>ZN[@J
M]S=R<&5@,# '"J.<#W[UV813O?H<]7EMYG64445ZARA1110 4444 %%%% !1
M110!GZ_H&G^*-'N]*U:SAU#3;N,Q3VMP@9)%/4$5\Q>(/V>?&WPOTS5].^'T
ML'BCPGJ4UO/+H>J3;+RV\B1'189F.&4",* W0>O6OJVD(S79A\54P]U'6+W3
MV_KS1YN,P%+&).=U);-:-7W^7D]#Y)U_6?B-XP?QE:6?PCU:SNO$4]C*)-0N
MX8X+<VXC^\^?F!,?;L:O:W^R7=?%1M1\0?%'7I3K^I2Q".U\/,8K73\ *I7<
M#YC[0%W,.F>M?4^P5%>6WVJUDA#F,L.''\)[&M*V.G.E*G2BH75M+WM9*UVW
M9:+8QPF6K#XB.(G4E.47S*]K)IMWLDDW=O>Y\87FE^*_A#XK\0>#K3POK&J^
M DT=)4\5/'YRE5C+RI(>HD4[L%>O]WI7*ZK^T=X'\5&'4]#%Q=Z?X@FCL(/L
M4+LB2H 67E1R2PPHYYK[7F:ZM]0N(;E(TMPBF&1<G>>=V?3'I[URND^$]*T/
M6+R2+3;.TLU87%KY4*QQ1,0?,**!M!SR2.>:\[$YO3>&]F\.E5BH)2N[>[NY
M+JW:/5):Z';A\EPSQKQ-6I-TYN3E!-*[DI:IN+Y=9-NWW'SWX#^'/BOXL:YX
MQTCXHZ'J>A:3"@AMIK5VM_M<9=@ DJL3P@&2O]X].E'B'X$^)?A)_;A^'\\6
MI:%J^GRZ?/HVHN6>&)PW^J;.1AG9O0DG/6OHAI);;4M.N+2=Y]-O PE:9RPS
M@E6&>F?RJY+IEF\GGF%'?^\W(KYJ&?8[#Q5+GYJ:^R]8_=\EJM=-SV,;E.7X
MZI*M3H*C*5G>&CO9)N[OO:[3NO(^/-8\;^,/%UM\0;E-#G\/)IGAH:*UO<>5
M)$_E$&1II& *AA*6&W;A5!RV:N:7X+G^(VHZ=XF^(<R);+:6ZV^@V$;>4$52
MR"3/WB-[<GU-?3.O>"?#VM7B76HZ+;:A<';&7EA\P,!]T.O1E';<#BO//%7@
M&Y&K6VF>'+F?0+!<S&%A]HLF(Z[8B<Q]<8C9>O2N'$Y].--PPL%2;5KJ]TK*
MZ3;;5[;K4QP^0TW-2Q4Y54M;.R3?1M)*]K]=/(37;ZPU/1X+/2[69XK<J?)A
MBVK'&O8_ATK2N-EY;Q2(I1&"LH88('! KGM#\1S^#[B[TC7]*FMW60RC4-/#
M7-O)'@88@#S$ ]U('K6+J'BZYOK>.UTR6.2!3L2>SD$GFCM@C/Y5^,YE1G)M
M+;>Y^DX644=3%H*ZSK%G;0Q(+F:9$215&1SW]1C.?:M+Q)^SCK7P]U[4O$7P
MFN;. :A;36UWX9U3/V1TE(+_ &=Q_J26 ..F0.<<56^%][JFG^-/#UM)!$\[
M;D9"=S.A&&;/\+*.>^:^F0N[K7Z7X:RE@\)B*T)7YY6:>L6HK3\WKNCX[BS#
MT\;5I4ZBMRJZ:=I)O_AO1GR=8>(/B)IEYI=LWP?UM[JQ\,MX<REW 8'),>)1
M)G 7$?3WK3\+?LU^(?B-)X?NOBO-9Q:7HMC#86?AC2F)CDCCVX^U2 _/DHK%
M!QD#GU^@_%7B>'PS;P@027VHWC^19:? 0);F3!.T9X"@ LS'A5!)K(M_!FJZ
M]MN/$NM7"EN?[+T69[6UC_V3(N)93[EE!_N"OV5YC-+]S!0?=7O\KMV^1\!#
M)X7_ ']251=G9+YI)7VZZ>1V%K;Q6=M%!!$D,,2A$CC4*J*!@  = !VJ6N0/
MPKT*-2;1M2TZ?M<6FIW"./?[Y!^C BJ4VL:Q\/9 ^M7/]M>&R=K:L\:QW-CS
M@&X"@*\?K(H4KU92,L/)/?VT.\HI%8, 000><BEH&%%%% %2/_D*3_\ 7&/_
M -">O%M4\.?'U=0O)F\<^ SH'FNYM?\ A&+K[1]FR3L\S[9MW[.-VW&><=J]
MIC_Y"D__ %QC_P#0GIFN?\@>^_Z]Y/\ T$U4=T9U/@EZ'Y1:Q/>Q6O\ Q*[=
M9KF1]J^<V$C')W-Z_AU-4'L]>7)BOHS+C^)/D)^;MGCHGYFMQ2-JG/4>M&1Z
MBOVF=-5'=L_BBGBG17+&*^:O<QK/Q-$9#::@GV+4DQO@ZJV>C(?XE/Z=ZE;Q
M)9?;8+.-GGNICQ%&N2HP#N;T&".M6=2TJQUB%8KZVAND4Y42#D?0]11I>CV&
MCQM'8VL5JK#YMB\M]3U-"56]KJWXE.6$DN;E?-VZ??O\OQ.P\$>*E\"ZA-XB
MG:5;"Q3;.D&/,E+G"1IGC=N 8>FPFOK/1?VN/"_BN.'2[+1/&.JS70%I_:UC
MX8O)=-$C* 6:Y">6J@GYB3A<'/2OA'XCWDB7%EX8M5:22S<27*1\F2\< ;!C
MJ44A/]XOZU^B_P !?A(WPE^"]OH#KNUBY@DN[\C^*YD7E1[*-J#_ ':^%X@E
M"I%3ZWT]#]T\/:=7#U94K>[9.3[.^B^7^9\R?$/Q%KT7B#3="TRZCT&RN(#+
M+K,J!B\GS!;:'(VASMW'.25SM'>L>\T_Q/X7>*YT[Q,?M#2X2QUB4RPWC%EQ
M%R-RL5WX*'.0."!7J.I:+9:M;K::I8V][''*LOD7<*R*DB'Y6PP.&4]#U%9&
MD_#OPWHDD<EII4/FQ[=DD[-.Z[69E(,A8@@L<'J,XZ5^61^J*BG*,G4OWT:_
M-/R_$_L.:QTZ_P"[J1C2:_EO*_WV:>_EYWT\AT?Q!8>)KACXON[BV\21/&;C
M2[]%MS;,I5%9(F.W!6X==RC#A23TQ70_#3Q!YGB\:1X9D?4/#4<6Z]EV[K:Q
M*1A(H(6#;%/R\HH]SBO2M>\)Z)XI6)=9TBQU41?<^V6Z2E?H2,BKUC8VNE6<
M=I96T-G:QC"0V\81%^BCBM:V98FM"5.32C*UTDEM:VR6UE^1E0RG"X>K&O%R
M<U?><FM=]'IK>]NCU6IY#)X^LOAO^V1H>KWVF:WJT,>GJ/L^@Z7-J%P2;1@,
M11*6QR.<=,U].Q?M=^$]2E6TN?!?Q%L[:;Y);C4O!5_;VT:'AFEDDC"H@'4L
M<8KP_P"'%NMU^VKIE]:W$=U%:V[V%V(3EK6X6R),4@[$@Y!Z'##JI ],_;*^
M*'V#2K/P78S[9[X"YORK<K"#\B'_ 'F&?HOO7?P[A9XJI*C%6;F_NTU^X^)\
M3,VI97AZ.,G)2Y:$$E_>O)<OW_@?&OB2YOK[Q!>#0[5=.TCS6>)IFWOL+95!
MZ;5/7U%9+MXATW%P FH6Z_ZVWZ2%><E#GJ/3O71[A@<TFX>HK]W]BM^9W/X%
M6->L7"-NNF_]?@9=GXGTV^@$L,Y92,X*X8<,<$=C\C<'VK4\'ZT-<UY(])G:
M-[242&_(Q%$5.YFW=]H4L<=A67?>%]&U.Y^T76GV\LQ^\^,%OKCK^-7?$EY%
MX7\&K:6R+!<ZNIB2.,;1%9JWSD =/,<;?]U']:QJSJ4X^\T=>%HX6O42IJ6F
MKOTM^;>RVWN?6?PU_;:\(-I/]E+H/C76+RU&]HM$\,W6HB&-B=H9X$8#H<>@
M('45S?[27QK\-?%+P7IOV+PYXDTS6+2\9H8_$.C3Z7-Y>SY]B3JK.K'8,@8R
M.O!K9_87^&D7@GP'J?Q%UIOLLFIQ,MN\G BL8SN9S_OL"?HB^M>&_%;X@W'Q
M,\=:EKT[,L4K^7:PL?\ 50+PB_7')]V-?'9?@U5S*52F_=AK?S[??N?L/$&;
MO"<-TL-6BO:559+?W5K?[K)=K^1YE'#KUUF2>6.S+'*P0\^6/0MGDXHCURZT
M>80ZV(Q#(RK#?1+A,G'RN,_*>>#T.*WLCUILT<5Q$\4JI+&XPR.,@CW%?;^R
MY?>C+4_$OKD9VA5@N7R5FO1_Y[]3-N/$VG6MOY\L^V/'''+<*< =SAAP*]/^
M$^DQ>,/#7BBRN)M1TR*\MK;<]C<M:W47[PL,2(<H>.<=N*\PL?"VC:;<BXMM
M.MXIAR'QDK],]/PKVCX'M^Z\1G.?DM__ $)ZSJJ4H6J6MIMZHZ,/.A3JIX:]
MTI.[_P +['O_ ,/OV4-%MM-\/ZJOC_XG/)"L-R+:7QM?-;L5PVUH]^TH<8*X
MP1Q7OR\:L?\ KA_[-5#P2NWPCHX_Z=8__016A_S%S_UP_P#9J_(*VE627=G]
MAX*3EA:3?\L?R1<HHHK$[0HHI* (;RV@O+66&XC2:!UPZ2 %2/>O)=+6WLKS
M4]-M'::RM)S]GFZJ5/)4-WVG(K=\=ZI##XEM=/OI!]EEMU>&-ON&3>0<^^,8
MSQ6/K.KVNA6C/.RIM'[N%>&8]@!7/4E=V+B9OBGQ%!HMHZ%MUU(A\N,>_&X^
M@K,\&:-':Z.EQ+"IN)F+AG4;@O;Z>OXT_3+[2]1LUU+498'O%R'$N/W8SPJK
MZ5IV&O6&K;EM;A7<?P'*M^1K!ED[5Y'\</VDO"GP*CA&NQ:A?2N(WDATZ)',
M".S*C/N9?O%6PHR3M)QCFO5=2O[;2K&XO;VXCM+2WC:6:>9@J1H!DL2>@%?(
M_P 4_"?PN_:B^(6@Z_X?\8+?ZKI-S':ZGI<*L(Y(HO,<2RQR!2NS+@-@AL[:
M^MX9R["8W&<^9PF\/%/F<$WK]E-KX;[7[VOH>=F6,6!PTZ_5=._DO4SOBGX=
M\'?%KQ8NOVEG<PVT\$3LRYMVN!M!_>(1E3@X['BN/^*'A7PIHEG:7^G:]:V_
MB+Y&N-$AC<*L9X1E;;@.,<C/(Y'3GU'PG=:=8Z[<7)97M[=V^S?;$#"0$G:Q
M4<'C]37I+?%/X;6<:6^M7VAV.H,H:2UEM@3_ +)^X>".:]*,J>5XJV PDU%/
M5I?'_B]W7\.Y^<T<5CN),'&><9E">GN0E/F]BF]H>_:.EKZ7V39YM\#OBH^H
M^'W\,7'R7+@I:O& NUSV)Z!6_0\=Z]ET6&^T#3F@N[=ID#%D^S$.5SU!'UKY
M&\97>B^'/B)=W_A:_BN]%:<31_92=L:.?F09 Q@\CZ"OJ+P?\3M/\0:-:R3R
MD7"KY4TP7*&0=3QZC!_&OGL]R^.%JQK48N,*BNDU:SZKY'UW#>92QE">'KR4
MJE%\K:=TUTE\S:GURS6(N[21C^ZT3AORQ7 ^)-0-[JPU"TBE\J$)B1HR 2.>
M:](6^@O%S!<1S#K\C@U6N"-C;B-O?/2OE=C[,\>U*\>^O);A^&E;<0#P/:LV
M3(4]0?UKU7^P=-683QVL6_/#+R/RZ5F7TD,GB*UC0*TT<4AEXZ*0, _C4N0'
M5?LT65SXJ\?#4I;J**+1;8XMUSOE:0% 3[  Y]\5]8"OE?X8^,M#^&&M:GJV
MH6EP5NX4A:6T0-Y0#$EBF02#D<CTZ5ZWJW[2'@#2]/CN5UM;]I "EM9QL\IS
MZ@@;?^!$5Z&'G!0U9S5(R<MCTZBO(]-_:=\'WIVW$>J::P;:WVFR8A??*;AB
MO5+"^@U.S@N[69+BVG0212QME74C((/I75&<9_"[F+BUN6****L04444 %%%
M% !1110 4444 %%%% ";::T2OPRAAZ$9I]% &=)X=TV08:SCVXV[0,#'IBO'
M/$DS>%?&=QI]G<-:Z:\D;M&O1%8 D#T'TKW2O,_B%X4#^)-,UA7Q')*D<ZL.
M%V@D-G\,?E7C9E1BZ#E&.JU.S#3M42;.._X2*>U\3.T]Q)>6$0:-7A 9<-RI
M..,]LFKTNL2W6OBT9&M(XHC(RNRD2YP!@CL!D]:L:#/C4]<E(WPS3 QM",I(
M ".#T)Y&:L747R[$M8T9F&"Q78#G&6/M7YUBO>5DMSZ:CW.*\7WUHGE/<P74
M)1CY%]!C*M[<YQ]>M<?JMGX9O;A-3,[6&MA,?VC9!K:=L_W@!M<'_:#"OI"3
MX9Z)J6B_9+^$WTDBG-T7.03_ !)S@8SQ61X6^$9TG5[>YU.:VU**R!%J3%\Y
M[!FSP"!Z=^:YJ_"N/E*FHO26[3^%>=]_EN73S?#J,FUJMO,\H^%.E>++/Q:G
MB$67_"1Z?:JZO-"HM;HHRD;5C<B-_7AD)].@KZ!\/^.-&\07$EI;79AU)!F3
M3KQ&@NDXSS$X#8]P"/0UOA169KWA?2?$UJL&JZ?!?1IRAE7+1G^\C=5/NI!K
M]*R;*H9/AOJ\9<VK;=K:ORZ'S.-Q<L;5]K)6Z'.^'F35O%FO^(;D,R6<ITBR
M.TD11Q[3.PQT+RY!/I"E=A:WUO> F">.;'7RV!Q]:XOX;QMH>D:QH]O'-<3:
M?J]VF)YR[E9)#.A9V)8Y29>3D\5)KG@S5O$\FZ>ZLM'4'(DL(/,NO^_S8 _!
M:]TX#0\>?$[PE\+])&I>+O$VD^&;$Y"SZM>1VZN1U"[R-QY' R>:\"T'XO\
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M6?(Y]5_UBDY8V*Z6LMK=KW/RM_X4)^U%_P!"U=_GIO\ C1_PH3]J/_H6KO\
M\IO^-?JG]NBH^W1U[?\ :E?R_'_,^'_U7P7G^'^1^5G_  H3]J/_ *%J[_\
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MFC)8F3=J2B$R7+A#&NQ4(([=#[5ZV->M@,?.3[+7S!\1+36[[XF?#V"SCO\
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M>PXKIZ6BMTDM$9[[A1113$%%%% !1110 4444 )M!XH Q2T4 %%%% !1110
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M3=H%.KAJU/:S<[6N>Y@L-]3P\:'->U]=MW?;YA11161W!1110 53_P"8N?\
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MV >.!SS7H6*,"EKY&,5'9'Z$VWN%%%%4(**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img55497064_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55497064_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &  X0# 2(  A$! Q$!_\0
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M<-D>^.:R=96=-<\079AFA2/7TC.L),^ZR7Y2?W8ZJ?7IS72L.F[7,75>]CZ
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MO-*X2.-2SL>@ Y)I]9VO_P#(MZI_UZ2_^@&FE=V$W97,K_A87A$C_D/V6/\
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MDW]MV'_/63_OR_\ A1_;5A_SUD_[\O\ X5 "<GFER?6CE"Y-_;5A_P ]9/\
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M?VM:>LW_ 'X?_"K47^I3_=%/J1E+^UK3UF_[\/\ X4?VM:>LW_?A_P#"KM%
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MO/6_^@3I_P#WT_\ C1_PO/6_^@3I_P#WT_\ C1]1K]@^MT>YZM_:-I_SV_\
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M^@3I_P#WT_\ C1]1K]@^MT>YZM_:-I_SV_\ '3_A1_:-I_SV_P#'3_A7E/\
MPO/6_P#H$Z?_ -]/_C1_PO/6_P#H$Z?_ -]/_C1]1K]@^MT>YZJ-1M,?Z[O_
M '3_ (4O]HVG_/;_ ,=/^%>4#XY:V/\ F$Z?_P!]/_C2_P#"\];_ .@3I_\
MWT_^-'U&OV_$/K='N>K?VC:?\]O_ !T_X4?VC:?\]O\ QT_X5Y3_ ,+SUO\
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M_A0=1M,?Z[_QUO\ "N@HHY@L1P$-;QL#D%00:DIL?^K7Z4ZI&%%%% !1110
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MK=6B"*<@!>W)/YUG:YXGU/Q ]O\ ;)(XXK9"D,%M&(HXP>N%%*%*LI)W_/\
MX 2J4G%JQU%AH.G>&O!]]K6OZ.;^_COOL(M))2J0D $EBO7_ /55SPU9^%-=
MCU34(=(L5O%:);?2[R_,<87 W.K=3DY^GXUR.A>,-7\/6]Q;6CPRVMP=TEO=
M1"6-CZX/>K4/CS5H=3N-1^S:9)<3;,&2S4B+8,+L'\-.5*J[Z_B_NL$:E-6_
MR.KD\/Z+I/Q3D\--9Q2:;JEN%59 '>VD9204;J,$?D:\PN(3;W,T!.3%(R$^
MN#C^E=1X?\516OB>Z\2ZT\]YJ2QLULH0;6E(V@L<_*H'8#^5<K)(TLCRR'+N
MQ9CZDG)K2C&47:79?>9U91DM.[^X[CX>_$*?PG="SO2\NCRM\Z=3 3_$OMZC
M^M?1<,T=Q!'-$P:.10ZL.X(R#7C7PS^&?F^3KVO0?)P]K:./O>CN/3T'XFO:
M*\G'2IRJ>YOU/2PD9J'O?(****XCJ"BBB@ HHHH *.U%':@!L?\ JU^E.IL?
M^K7Z4Z@ HHHH **YF_\ B'X3TO4);"]UJ"&ZB8H\3*V01U'3G\*Z2.1)8DD0
M[D<!E/J#0 ZBL[1]<L-=BNI=/F,J6MS):RDH5Q(APPYZ_6M&@ HK.?7+!/$,
M>A-*PU"2V-TL>PX,8;:3NQCKVK1H **** "BBB@ HHHH **** "BB@@$$$9!
M[4 1?:8/^>T?_?0JC>:=HNH3K/>6MC<2J,!Y55CC.<9/:K7]GV7_ #Z6_P#W
M['^%5#+H0ENXB^G>99J'N4RF85(R"X_A& 3S0!*EKI4=\UZD5JMTPVF8!=V.
MF,_A4:Z;HB/<NMI8AKE2LY"+^\!ZAO4'OZU-;P:9=VT=Q;0VDT$JAXY(U5E=
M3T((X(J7^S[+_GTM_P#OV/\ "@!H%B)TG'V?S40QH_&Y5."5!].!Q["H6M-)
M;3FTYH+,V3 JUN57RR"<D%>G)YI&_L9;J6U(LOM,47G/"%4NJ?WBO7''6DTX
MZ1JMA%?64-O+;3#*/Y.,C..A /:@!UE::5IH<645K;A\;O+P,XZ5;^TP?\]H
M_P#OH4S^S[+_ )]+?_OV/\*K[-(^W?8=EE]K\OS?(PF_9G&[;UQGC- %O[3!
M_P ]H_\ OH4?:8/^>T?_ 'T*9_9]E_SZ6_\ W['^%,EM-/@A>66VMDC12S,8
MUP .2>E $WVF#_GM'_WT*/M,'_/:/_OH53T_^R-5T^"^LH;::UG0/%((@ RG
MH1D59_L^R_Y]+?\ []C_  H ?]I@_P">T?\ WT*/M,'_ #VC_P"^A6)#K/AB
MXDC2&2TD:2Z>R4+#G]\OWDZ<$>_%;']GV7_/I;_]^Q_A0 _[3!_SVC_[Z%'V
MF#_GM'_WT*9_9]E_SZ6__?L?X4?V?9?\^EO_ -^Q_A0 _P"TP?\ /:/_ +Z%
M'VF#_GM'_P!]"F?V?9?\^EO_ -^Q_A1_9]E_SZ6__?L?X4 /^TP?\]H_^^A1
M]I@_Y[1_]]"F?V?9?\^EO_W['^%']GV7_/I;_P#?L?X4 /\ M,'_ #VC_P"^
MA1]I@_Y[1_\ ?0IG]GV7_/I;_P#?L?X4?V?9?\^EO_W['^% #_M,'_/:/_OH
M4?:8/^>T?_?0IG]GV7_/I;_]^Q_A1_9]E_SZ6_\ W['^% #GN(/+;]]'T_O"
ME%Q!@?OH_P#OH5$]A9B-O]$M^G_/,?X4HT^RP/\ 1+?_ +]+_A0!)]I@_P">
MT?\ WT*Q=7\,^%]>E$VJ:=8W,H_Y:, &/U(Y-:_]GV7_ #Z6_P#W['^%8NK:
M]X2T*41:G>:;;2G_ )9N%+?D!D54>:_N[BE:VI>TK2]$T. P:7;6=I&>HB !
M;ZGJ?QJ_]I@_Y[1_]]"LS2KOP]K<!GTN33[N,=3"%;'U'4?C6A_9]E_SZ6__
M '['^%*5[Z[@K6T'_:8/^>T?_?0H^TP?\]H_^^A3/[/LO^?2W_[]C_"C^S[+
M_GTM_P#OV/\ "D,?]I@_Y[1_]]"C[3!_SVC_ .^A3/[/LO\ GTM_^_8_PH_L
M^R_Y]+?_ +]C_"@!_P!I@_Y[1_\ ?0H^TP?\]H_^^A3/[/LO^?2W_P"_8_PH
M_L^R_P"?2W_[]C_"@!_VF#_GM'_WT*/M,'_/:/\ [Z%,_L^R_P"?2W_[]C_"
MC^S[+_GTM_\ OV/\* '_ &F#_GM'_P!]"C[3!_SVC_[Z%,_L^R_Y]+?_ +]C
M_"C^S[+_ )]+?_OV/\* .8\5^"]#\87MO/J-Y/&UO&43R)E4$$Y.<@^E8'_"
MFO"7_00U#_P(C_\ B:M>/?&=MX*U"SMTT&UNQ<Q,^2P3;@X_NG/6N2_X71#_
M -"E:?\ ?\?_ !%=]*&*<$Z>WJCDJ2PZD^?<Z/\ X4UX2_Z"&H?^!$?_ ,31
M_P *:\)?]!#4/_ B/_XFN<_X71#_ -"E:?\ ?\?_ !%'_"Z(?^A2M/\ O^/_
M (BM/9XWO^*,^?"?TF='_P *:\)?]!#4/_ B/_XFC_A37A+_ *"&H?\ @1'_
M /$USG_"Z(?^A2M/^_X_^(H_X71#_P!"E:?]_P ?_$4>SQO?\4'/A/Z3.C_X
M4UX2_P"@AJ'_ ($1_P#Q-'_"FO"7_00U#_P(C_\ B:YS_A=$/_0I6G_?\?\
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M !%+_P +HA_Z%*T_[_C_ .(H]GC>_P"*#GPG])G1_P#"FO"7_00U#_P(C_\
MB:/^%->$O^@AJ'_@1'_\37.?\+HA_P"A2M/^_P"/_B*/^%T0_P#0I6G_ '_'
M_P 11[/&]_Q0<^$_I,Z/_A37A+_H(:A_X$1__$T?\*:\)?\ 00U#_P "(_\
MXFN<_P"%T0_]"E:?]_Q_\11_PNB'_H4K3_O^/_B*/9XWO^*#GPG])G1_\*:\
M)?\ 00U#_P "(_\ XFC_ (4UX2_Z"&H?^!$?_P 37.?\+HA_Z%*T_P"_X_\
MB*/^%T0_]"E:?]_Q_P#$4>SQO?\ %!SX3^DSH_\ A37A+_H(:A_X$1__ !-'
M_"FO"7_00U#_ ,"(_P#XFN<_X71#_P!"E:?]_P ?_$4?\+HA_P"A2M/^_P"/
M_B*/9XWO^*#GPG])G1_\*:\)?]!#4/\ P(C_ /B:/^%->$O^@AJ'_@1'_P#$
MUSG_  NB'_H4K3_O^/\ XBC_ (71#_T*5I_W_'_Q%'L\;W_%!SX3^DSH_P#A
M37A+_H(:A_X$1_\ Q-'_  IKPE_T$-0_\"(__B:YS_A=$/\ T*5I_P!_Q_\
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M/\*/[/LO^?2W_P"_8_PH ?\ :8/^>T?_ 'T*/M,'_/:/_OH4S^S[+_GTM_\
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M_P =?^0WH_\ U[2?^A"O**^AP?\  B>)BOXS"BBBNHYPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H/2BB@#V+1?"GAV_MM$\1W-A!'I/
M]FM]L3)VM<!P@R,YR26_(57O/#OA_P (_P!G0ZOI=O.U[K,L>^7.5M02HQST
M&5.:\_C\5:M%X6D\.),@TZ23S&79\V<AL;O3(I/$/BG5?%$MM)JDJ.UM'Y<?
MEIM '<_7WKB5"KS:RTU^[H=GMJ?+HM?ZN=KJ7@^P\+Z7K$FH6:2RW.J)::9Y
MF?EB)#%A_P !)'U%6_'>C:#IK7NFZ78^'TNR8HX85N'%V&?;_"?E[YY/2N$U
MKQCK/B!=/&H3QN+#F$*F.>.6]3\HJWJ_C_6=<M;B"^ATUO/4*\JVBB3 ]&ZC
MI0J-:\7)^NOH#JTK-)&WX6^'5W!XGBB\3Z?LM1;RSK#YRGSBF/E^4G^\*V-+
M\*^'O%$GA74X]+33X;Y[A;FTBE8K)Y88C!//\/..U>9:/K-_H.J1:CI\YCN8
ML@$C<"#U!!Z@UK7?CWQ!=ZE87QNHX9+ DVZ01!(TS][Y>AR.#3J4JTI74OT[
M]/N)A4I)6:_K3J='K%IX=/AK3/%$.@10)'J,EK/8QS,%G0;L<]CP.GO2>--'
MT1?!-EJ^E6%BLS71BDGTV9GA5<'Y6W<[NG;UK!N_B%X@O+VRNGFMD-D[20Q1
MVZK'N8$$E>Y()_.JNN>,M8U^QBL;M[>*TB?S!!;0B)"WJ0.IZT1I54XOMYO[
MARJTVG_D:6A6UOIWP_UG7Y+6&XNI)TL;8S('$61EGP1C..AKJO#F@^&M0\/Z
M<-,L-(U74&CW7EO>WC17!?&2J < =?:N'T37+&'PSJ^@:HDQM[LK-;RPJ&,4
MR]"02.".#5BU^(OB"SM(((39![>(117!M$,J*!@8;Z45*=25^7OW\@A4A&U^
MQV5AH.@67@O3+N_T_0H+V:6:.4ZK.\>2KL-H*YR1T_"N3\0Z;IUO\/\ 0M3M
M[6&&ZNKJX622,GYE#-M'/8#&*@LOB#KEEID.GA+"X@A+,GVJU$K98DDDGN23
M19_$'6K'3H[!(=-EMHW=T6:T5]I9BQQGIR32C2JQ=]]>_34;J4FK>7;T.PT[
M1_#EKX%T"_NK3P^MS=QR&235)Y(S(5;^';G/O^%9$T'A_P +^$]&U&Z\/1:I
M=:OOF9I966.% >$7'?!'Y&LF'XC:Y#916?D:9+!"6,:RV:MLW$DXSTY-0:9X
M]UW2;$V4+VLMJ)#*D5Q;K(L;$DG;GIR3Q25&KK?OW?F#JT]+=NQU'AB;PWK&
MFZ],WA"Q4:;:M<1;Y79GY.%8URMWX9UC4].N/$MGHT5KI#*90L4R[8U7@X!.
M[J#VJK;^*M5MI-7D22(OJR,ET6C'(.<X].M8O.,9./K6T*4HR;3_ #?J92J1
MDDG_ )'M:^ ?#S_$#3D\W2TM'M SZ27;S9&V,=P'UP>O:L%HO#VA>#M+U&Z\
M-6VHR75_/!)N=E?:KL!MQWP *Y0^-]:/B6W\0;X/M]O#Y*'ROEVX*\CZ$U9T
M[XB:]IEC%9VXL6BBD>6,RVP=D9F+$@GIR36'L*VEW?;K;O\ \ V]M2N[*V_3
MT.E30-(T?XH/X::V2;3-5MPJK,@:2W9E)7:QY!!'Y&O,[B$V]U- 3N,4C)GU
MP<?TKIO#_BJ.S\2W7B366N+S4UC8VP"C:TI& 6.>% [ 5R\DC2R/)(<N[%F/
MJ3R:WI1E%^]V7WF-246M.[^X]#^''Q'D\-RII>JR,^D.WR.>3;$]Q_L^H[=1
M7T#%*DT22Q.KQNH964Y# ]"*\,^&GPT.JM%K>MPD6(.ZWMW',_HS?[/MW^G7
MW15"J%4 *!@ #@5Y..=-U/<WZGHX15.3W]N@M%%%<1UA1110 4444 %':BCM
M0 V/_5K]*=38_P#5K]*=0!@P^"O#=OK1UB/1[87_ )AE$Q!.'/5@"< ^X&:>
MG@[P['KQUQ=(M1J18O\ : G.XC!;'3=[XS6W10!@3^"?#=S93V<NDP-!/=M>
MR+EAF=A@OD'()''%/;P=X=?0ET0Z/:_V:K^8L 3 #_WL]=WOG-;E% %+2M)T
M_1-/CL-,M(K6UCR5CB7 R>I]S[UG6W@KPY8ZC/J-EI%K;WLH<&:-.5W?>*CH
MN>^,9K>HH Y+PE\.M!\(VD*V]K'<7J1-"][*GSNI))&.@ZXXZU>L?!/AO3#;
MFRTF"'[-.;F$*3B.0C:6 SQQVZ5OT4 8-IX*\-6&HSZA:Z-:0W4P8/(J8X;[
MV!T7/?&,U8L_#&BZ?+82VFGQ1/81-#:LN?W2-]Y1SWK6HH **** "BBB@ HH
MHH ***0C((/0T +69)H&G2O.[PL6GNH[N3YSS*FW:>O;8O'3BIO[*M/[LO\
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M!_PHK3/^@U>_]^T_PH_X45IG_0:O?^_:?X5S_P#PN+_J7E_\&$G^%'_"XO\
MJ7E_\&$G^%:\N._JQGS83^KG0?\ "BM,_P"@U>_]^T_PH_X45IG_ $&KW_OV
MG^%<_P#\+B_ZEY?_  82?X4?\+B_ZEY?_!A)_A1RX[^K!S83^KG0?\**TS_H
M-7O_ '[3_"C_ (45IG_0:O?^_:?X5S__  N+_J7E_P#!A)_A1_PN+_J7E_\
M!A)_A1RX[^K!S83^KG0?\**TS_H-7O\ W[3_  H_X45IG_0:O?\ OVG^%<__
M ,+B_P"I>7_P82?X4?\ "XO^I>7_ ,&$G^%'+COZL'-A/ZN=!_PHK3/^@U>_
M]^T_PH_X45IG_0:O?^_:?X5S_P#PN+_J7E_\&$G^%'_"XO\ J7E_\&$G^%'+
MCOZL'-A/ZN=!_P **TS_ *#5[_W[3_"C_A16F?\ 0:O?^_:?X5S_ /PN+_J7
ME_\ !A)_A1_PN+_J7E_\&$G^%'+COZL'-A/ZN=!_PHK3/^@U>_\ ?M/\*/\
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M7\IYI_PHK3/^@U>_]^T_PJYI7P5T2PU*&ZN;VYO8XCN\B55",>V<=1[5W_\
M95I_=E_[_/\ XT?V5:?W9?\ O\_^-#Q=9JW,"PU):\I<50JA5   P .U+5+^
MRK3^[+_W^?\ QH_LJT_NR_\ ?Y_\:YC<NT52_LJT_NR_]_G_ ,:/[*M/[LO_
M '^?_&@"[15+^RK3^[+_ -_G_P :/[*M/[LO_?Y_\: +M%4O[*M/[LO_ '^?
M_&C^RK3^[+_W^?\ QH NT52_LJT_NR_]_G_QH.E6F/NR_P#?Y_\ &@"W'_JU
M^E.ID0"PH!T"@4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KP+QQ(L?C75[HRPZQ,9(XHM+N#<P7<.,#_163Y2#G.?SZ<^^US6I^*F
ML/%-II:VJR6C%$N[G?@P22[A"N,<[BI!],KZT >>WS:(WC#Q#_PGC7\<N(O[
M(3=+Q%L'^HV<&3=UQSG\:S/&VH:W?>+KGQ!I%G?SV/A8P(DB2*J%@0\^]2=S
M':0O /3FO4UU?7F\4R:-Y.FX2U6Z\W=)DJSLN,8Z_+G\:@M?%]U=37%H-.5+
MW3HY'U5&D.V A24"G'S;^&'^SUYXH \^^)]]HU^\%[I$L;:Q*()?D:<7I0E"
MOV<#Y,[2<YXZ]Z]LB):%"5925!(;J/K[UR.B>-9M5&D0RV"0WET[I<0B7/E$
M0^:A4XY#*5(/'4^E:.D:Y?76N7&EWEO:[HH!*TEM(6$;%L>6VX#)QSD<?3B@
M#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JV^AI1T
M%))_JV^AI1T% '*?$CQ)-X6\%W5]:G;=R,L$#?W7;O\ @ 3^%?*TLLD\SS32
M-)*Y+.[G)8GN37U+\3?#MQXF\$75I:*7NH66XA0?QLN<K]2"<>]?+#*R.R.I
M5U.&5A@@^A%>K@>7D=MS@Q5^9=C1T'7;[PWK$&IZ?*T<T3 LH/$B]U;U!KZ^
ML+R/4-.M;V+_ %=Q$DJY]& (_G7Q[H^CWFO:M;Z981&2XG8* !PH[L?0#K7V
M!IMDFFZ7:6,9REM"D*D]PH _I6>/Y;KN7A+V?8M4445YQV!1110 4444 %%%
M% !1110!X=\=?^0WH_\ U[2?^A"O**]7^.O_ "&]'_Z]I/\ T(5Y17T.#_@1
M/$Q7\9A11174<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% ':^ /']SX1O!;W!>;2)FS+$.3$?[Z?U'>OHRRO;;4;*&\LYD
MFMYE#1R(<AA7SM\/OA]<>+;L7=V'ATB)OGD'!F(_@7^I[?6OHJTM+>PM(K6T
MA2&WB4*D:# 4"O$S#V?/[N_4];!>TY/>VZ$U%%%>>=H4444 %%%% !1110 V
M/[I^I_G3J;']T_4_SIU !1110 4444 %%%% !1110 4444 %%%% !1110 4=
MJ*.U #8_]6OTIU-C_P!6OTIU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%(1D$9QGN* %KFKSP3IE_%JAN1YEW?R^:+PHOFP$!0FQL<!=HQ
M_P#7K8^PR_\ 00NO_'/_ (FC[#+_ -!"Z_\ '/\ XF@"$:.JZ[)JXN'^T/9+
M:8*C: K,V['KEOI69#X,M;?9)%>7 NGBEBO)\+NO!)DDOQC(;E<=!P..*V?L
M,O\ T$+K_P <_P#B:/L,O_00NO\ QS_XF@#'3P79Q:KI&HQ75Q'-IUH;3Y2
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M^%#_ /4Q'_P#_P#LZZ+QMXT'@J^M;>5;Z[-S&7#)+&FW!QCE#ZUS'_"Z8?\
MH'ZE_P"!,?\ \17H47B^1>SV^1QU5AN=\^_S)?\ A0__ %,1_P# /_[.C_A0
M_P#U,1_\ _\ [.HO^%TP_P#0/U+_ ,"8_P#XBC_A=,/_ $#]2_\  F/_ .(K
M6^._JQG;"?U<E_X4/_U,1_\  /\ ^SH_X4/_ -3$?_ /_P"SJ+_A=,/_ $#]
M2_\  F/_ .(H_P"%TP_] _4O_ F/_P"(HOCOZL%L)_5R7_A0_P#U,1_\ _\
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MY\__ +.E_P"%#_\ 4Q'_ , __LZA'QIA!/\ Q+]2Y_Z>8_\ XBE_X73#_P!
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M_00NO_'/_B: +M%4OL,O_00NO_'/_B:/L,O_ $$+K_QS_P")H NT52^PR_\
M00NO_'/_ (FC[#+_ -!"Z_\ '/\ XF@"[15+[#+_ -!"Z_\ '/\ XFC[#+_T
M$+K_ ,<_^)H NT52^PR_]!"Z_P#'/_B:/L,O_00NO_'/_B: +M%4OL,O_00N
MO_'/_B:/L,O_ $$+K_QS_P")H NT52^PR_\ 00NO_'/_ (FC[#+_ -!"Z_\
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MB["<5+<R_#G@GP_X5!;2K!8YF&&G<EY"/3<>@]ABNAJEY6I?\_5O_P!^#_\
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M -!JR_[]-1_PHK5?^@U9?]^FK6_X7=8_\^MW_P!^$_\ CE'_  NZQ_Y];O\
M[\)_\<H]IC>WY!R83N9/_"BM5_Z#5E_WZ:IK/X%W@O(C>ZS ;8,#((8V#E?0
M$\"M#_A=UC_SZW?_ 'X3_P".4?\ "[K'_GUN_P#OPG_QRCGQO;\@Y<)W/4M.
MTZTTFPAL;&!8;:%=J(HZ?_7]ZM5Y'_PNZQ_Y];O_ +\)_P#'*/\ A=UC_P ^
MMW_WX3_XY7(\+7>KB=*Q%%?:/7**\C_X7=8_\^MW_P!^$_\ CE'_  NZQ_Y]
M;O\ [\)_\<I?5*_\H?6:7\QZY17D?_"[K'_GUN_^_"?_ !RC_A=UC_SZW?\
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M_P _5O\ ]^#_ /%5SFQ=HJEY6I?\_5O_ -^#_P#%4>5J7_/U;_\ ?@__ !5
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M110 4444 %%%% !1110 4444 %%%5]0NOL.FW5WLW^1"\NW.-VT$XS^%"5]
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MZW_@8/\ XBC_ (7PG_0NM_X&#_XBCZE7_E_(/K='N>Q45X[_ ,+X3_H76_\
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MK_WX;_&C_A16H_\ 0<M?^_#?XUZY_:-[_P ^4/\ W_\ _L:/[1O?^?*'_O\
M_P#V-'UZOW_ /JE'L>1_\**U'_H.6O\ WX;_ !H_X45J/_0<M?\ OPW^->N?
MVC>_\^4/_?\ _P#L:/[1O?\ GRA_[_\ _P!C1]>K]_P#ZI1['D?_  HK4?\
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M^?*'_O\ _P#V-'UZOW_ /JE'L>1CX%ZB21_;EKQ_TP;_ !H_X45J/_0<M?\
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MXU<TKX&M%J4,FJ:K%/9H<R0PQE6?VR3P*]0_M&]_Y\H?^_\ _P#8T?VC>_\
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M=0I_BSQ6;>>(;&QU_2]%F\TW>I+*UOM7*XC +9/;@T :M%%% !1110 4444
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M&_PH_P"%)^)?^?G3_P#OXW^%/ZWA_P"8/JU;L>=_:;@R)(;B;S$&$?S#E1Z
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M_";^%O\ H8=-_P# E?\ &C_A-_"W_0PZ;_X$K_C7RM11_9L/YF'U^78^J?\
MA-_"W_0PZ;_X$K_C1_PF_A;_ *&'3?\ P)7_ !KY6HH_LV'\S#Z_+L?4Z^-O
M"P9O^*ATWD_\_"_XT[_A-_"W_0PZ;_X$K_C7RM12_LV'\S#Z_+L?5/\ PF_A
M;_H8=-_\"5_QH_X3?PM_T,.F_P#@2O\ C7RM13_LV'\S#Z_+L?5/_";^%O\
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MNBU#6[BVUC0[>W@AELM1D9&N#)R,1.XVKCG.T<Y[]* -RBBB@ HHHH ****
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M?^ C_P"%'/'N')+L9%%:_P#PBGB/_H :I_X"/_A1_P (IXC_ .@!JG_@(_\
MA1SQ[AR2[%[P'K5OH7BVVNKU]EE(KP7)()&QEQR!R><5Z1:?$7PXFH:E'+<
M6.G"-M'&QL,5B9"!QQR>^.OM7E/_  BGB/\ Z &J?^ C_P"%'_"*>(_^@!JG
M_@(_^%<]6E2J/F;_ !-Z=2I!62.Q^'WBS1[6SO+/Q/-B)+M=1M259LS#)(&
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MX=.:+4)KB2&>R\\7$3NS;5(^ZW.,UYK_ ,(IXC_Z &J?^ C_ .%'_"*>(_\
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M_9J_\_=Y_P!_C1_9J_\ /W>?]_C0!;7[S_7^E.JE_9J_\_=Y_P!_C1_9J_\
M/W>?]_C0!=HJE_9J_P#/W>?]_C1_9J_\_=Y_W^- %VBJ7]FK_P _=Y_W^-']
MFK_S]WG_ '^- %VBJ7]FK_S]WG_?XT?V:O\ S]WG_?XT 7:*I?V:O_/W>?\
M?XT?V:O_ #]WG_?XT 7:*I?V:O\ S]WG_?XT?V:O_/W>?]_C0!=HJE_9J_\
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MLU?^?N\_[_&C^S5_Y^[S_O\ &@"W'_JU^E.JD--4# N[S_O\:/[-7_G[O/\
MO\: +M%4O[-7_G[O/^_QH_LU?^?N\_[_ !H NT52_LU?^?N\_P"_QH_LU?\
MG[O/^_QH NT52_LU?^?N\_[_ !H_LU?^?N\_[_&@"[15+^S5_P"?N\_[_&C^
MS5_Y^[S_ +_&@"[15+^S5_Y^[S_O\:/[-7_G[O/^_P : +M%4O[-7_G[O/\
MO\:?%8B&4/\ :+E\=GE)!_"@"U1110 4444 %(S!5+,0 .I-+534_P#D%W/_
M %S- $OVNV_Y^(O^^Q1]KMO^?B+_ +[%8_E1_P#/-/\ OD5'/#(8L6D5KYQ(
MQYX.WWZ#- &Y]KMO^?B+_OL4?:[;_GXB_P"^Q7G-MXEO9-+TC49]/LA#?WOV
M;RK=7DD _> XR!SE!CZ\UK?\)%I+1(\<4\LC"4F".V+2H(SM<LO;!X_EF@#L
M/M=M_P _$7_?8H^UVW_/Q%_WV*Y!/$&ESO.MK!<72P1K([V]J74*R;UP>^0>
M@_2HT\3Z-*B^6DLDC7 M1#'!O?S"A<# R.5&<YQ0!V?VNV_Y^(O^^Q1]KMO^
M?B+_ +[%<<?$FC^2LB1S2'9)))%';%GA5#M<R+_#@@C^6:F&MZ0T<DJL'CCN
M(K8LD607D"E,>H(=>?>@#J_M=M_S\1?]]BC[7;?\_$7_ 'V*X+3_ !/'>VNG
M3S:>MHMU<30N9U(4",2'<IQSQ'SG '-;&GW]IJ:;X+2=(R@=))K?8LBGH5)Z
MCO\ B* .E^UVW_/Q%_WV*/MEM_S\0_\ ?8K'\J/_ )YI_P!\BM&RMX6M\F&,
MG)_A% $_VRU_Y^8?^^Q1]LM?^?F'_OL4OV:#_GA'_P!\"D:WME4LT,04#))4
M8% !]LM?^?F'_OL4?;+7_GYA_P"^Q7%WGQ.\"V5\;5]0BD<':SPP%T!_W@,?
ME75Z=<Z5JUE'>Z>]M<VTGW9(@"#_ /7]JN4)15VB5*+T3+/VRU_Y^8?^^Q1]
MLM?^?F'_ +[%+]F@_P">$?\ WP*/LT'_ #PC_P"^!4%"?;+7_GYA_P"^Q1]L
MM?\ GYA_[[%+]F@_YX1_]\"C[-!_SPC_ .^!0 GVRU_Y^8?^^Q1]LM?^?F'_
M +[%+]F@_P">$?\ WP*/LT'_ #PC_P"^!0 GVRU_Y^8?^^Q1]LM?^?F'_OL4
MOV:#_GA'_P!\"C[-!_SPC_[X% "?;+7_ )^8?^^Q1]LM?^?F'_OL4OV:#_GA
M'_WP*/LT'_/"/_O@4 )]LM?^?F'_ +[%'VRU_P"?F'_OL4OV:#_GA'_WP*YJ
M^\9>&+&X:!I!.ZG#?9X#(%/U Q51A*3M%7(G4A35YM)>9TGVRU_Y^8?^^Q1]
MLM?^?F'_ +[%4=+U#1]:MS-I[P3*IPP"89#Z$$9'XU?^S0?\\(_^^!2::=F4
MFI*Z$^V6O_/S#_WV*/MEK_S\P_\ ?8I?LT'_ #PC_P"^!1]F@_YX1_\ ? I#
M$^V6O_/S#_WV*/MEK_S\P_\ ?8I?LT'_ #PC_P"^!1]F@_YX1_\ ? H 3[9:
M_P#/S#_WV*/MEK_S\P_]]BE^S0?\\(_^^!1]F@_YX1_]\"@!/MEK_P _,/\
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ML4?;+7_GYA_[[%+]F@_YX1_]\"C[-!_SPC_[X% "?;+7_GYA_P"^Q1]LM?\
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MK-2MO;H$0$Y./>K= !1110!ROQ!U":Q\,%('*-=3+;EU."%();'U"D?C7DH
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M>6DTMG&8[6!X(K?:/+ =E).,=?E_4UH_V5I_G>=]B@\W>LF_RQG<J[5/U )
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4%["UQ931)C<ZD#/2IZ* ,?[)??\\8?^_I_PH^R7W_/&'_OZ?\ "MBB@#'^
MR7W_ #QA_P"_I_PH^R7W_/&'_OZ?\*V** ,?[)??\\8?^_I_PH^R7W_/&+_O
MZ?\ "MBB@#'^R7W_ #QA_P"_I_PIKV-W+&T<EO Z."K*TF0P/4$8K:HH QEL
MKQ$5$MX%50 JB3  '0#BE^R7W_/&'_OZ?\*V** ,?[)??\\8?^_I_P *LP?;
MH8]GV:$\YSYQ_P *OT4 5/-OO^?6+_O]_P#8T>;??\^L7_?[_P"QJW10!4\V
M^_Y]8O\ O]_]C1YM]_SZQ?\ ?[_[&K=% %3S;[_GUB_[_?\ V-'FWW_/K%_W
M^_\ L:MT4 5/-OO^?6+_ +_?_8T>;??\^L7_ '^_^QJW10!4\V^_Y]8O^_W_
M -C1YM]_SZQ?]_O_ +&K=% %3S;[_GUB_P"_W_V-'FWW_/K%_P!_O_L:MT4
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M_2M"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]OI5V[\#7$MK(D#V<<\OV[S9,$&03N63) R<<9^G% ';":(S&$2(90,E-PW
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MMO%)>0*]PS+""X^<KU ^E<9<^!+NX;4 \D4KW/GE+F2X8'$@^ZR!>0.GWB,
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img55497064_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img55497064_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ++ T$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYF4'ZC(IO1V$M=3TVBN4\)?$7P]XT@NGTB:=I+5 \T4L)1E!SCV/0]#7%?\
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MCTKIM<^-GP_U/S=,U70-4NTCD*8>VA(5@<94^9D=.HP:/$WPL\2:/XVD\7^
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MUO?;H$NZWN>AT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0
M449HS0 4444 %%%% !1110 5FZ_HMMXBT&]T>\>5+>[C,<C0D!P#Z$@C/X5I
M44FDU9@G;4Q/"?A>Q\'>'H=%TZ6XEMH6=E:X96<EB2<D #OZ5MT44[W"P444
M4 -D0R1.@=D+*1N7JON/>N3\%?#G1O DE]+ILU[<37I4RRWDBNW&>!M5>Y)K
MKJ*%H[ANK".BR(R.H96&"I&01Z5R7A/X>:7X+U"^N-'O=02WO&+/922(T"G/
M!4;=PQT^]TZYKKJ*%H[ATL%%%% !1110!B>*_#,'BW1)-(NK^^M+:4CS39NJ
M-(O]TEE;CZ>E3^'O#^G^%]#MM(TR(QVMNN!N.68GDLQ[DGFM2BA: ]0HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH 3%&*6B@"GJ@QH]]_U[O_Z":YOX5_\
M),- _P"O;_V8UTNJ_P#('O?^O>3_ -!-<U\*_P#DF&@?]>W_ +,: .PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.2=(I8HVSF0
MD+CV&:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:K_P @>]_Z
M]Y/_ $$US7PK_P"28:!_U[?^S&NEU7_D#WO_ %[R?^@FN:^%?_),- _Z]O\
MV8T =A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.[
M_P"/RR_WV_\ 0:N"J5Y_Q^67^^W_ *":NBDNH!1113 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"'SQ]K,&WD)OS^.*F%4Q_R&&_ZX#_T(U<%)
M %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBF-+&CJK.JLYPH)QD^U #
MZ*3-00W]G<RO%!=0RR)]](Y Q7Z@=* &:K_R![W_ *]Y/_037-?"O_DF&@?]
M>W_LQKI-5(_L>]/;[/)_Z":YOX5_\DQT#_KV_P#9C0!V%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_7 ?^A&KHJD/^0PW_7 ?^A&KHI( HHHI@%%%% !1110 4444 %%%% !1110
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M]O\ T$U=%)=0"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%(?\AAO^N _]"-715(?\AAO^N _]"-7120!1113 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_NG^1IWAO_D6[#_KBO\ *K7P/U.9_P"\+T_4U:***@Z0HHHH **** "BBB@
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M"-:>J_\ (,G_ -VLSP:?^*9MOJW_ *$:M? _D<\_X\?1_H;]% HJ#H"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX7^35U0Z5ROB/_D8M%_Z^%_DU=4.E7+X8G/2_BS^7Y"T445!T!1110 4444
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MKR9^:WD ]CFICKEMC[LF?0BCF069C^(_^1CT7_KX7^35U0Z5R6HR#4-6L+H
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M*GH]S5\R^MNK3)]>E31ZS=)PQ1_J*Z#K44EI;R_?A0_A7'ROHSINC.CUU/\
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M%':01_=A0?A4N,<#I1RL+HYI=-O9N3&V#UWM5A-"E/\ K)47Z#/^%;N#13Y
MNS,CT.!?OR2-^.!5F/3+./&(%/N>:MT4^5"NQBQ(GW45?H*=BEHIV 3%+110
M 4444 %%%% %*[_X_;+_ 'V_]!JX*IWG_'Y9?[[?^@FKHI+J 4444P"BBB@
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M[/J6LBY>2#4+N^1X%B\X.! C29B?8%7[BC@Y8]Z6ZO\ UM_P?/J)WMI_6_\
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MI>E7MOXCU*[EAVP3:99V\;;U.9$,VX8SGC>O/3FJ>SMT_P Y?\#Y"_K\(_\
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M 4444 %%%% !1110 4444 %%%% %*\_X_++_ 'V_]!-715*\_P"/RR_WV_\
M035S.!274!:*,T4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%!H
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M;VAV_C+Q'K-MK6L3_P!C:3$WF6^E1<RRC'!F;]=HX]N]"!G>KTIU-7BESVH
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MBB@ HHHH **** "BBB@ HHHH YCQS(\6@.\;LCKT9#@CD=ZZ1>5'TKF?'O\
MR+LO^>XKIT^X/H*O["?F_P!#G3_?R7DOS8HI:04M0= 4444 %%%% !1110 4
M444 %%%% !1110 4444 %!HH- '*>(_^1BT7_KX7^35U0Z5ROB/_ )&+1?\
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MKZ>*YT62:"1)(I(MR.K9# ]"#7 _"G_D+>)O^N\?\C7+35J4_D:U/]XAZ/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110!RWCW_D79?\ /<5T\?\
MJU^@KF/'O_(NR_Y[BNG3[B_05?\ R[7J_P!#GC_O$O1?FQPHI!2U!T!1110
M4444 %%%% !1110 4444 %%%% !1110 4&B@T <IXC_Y&+1?^OA?Y-75#I7*
M^(_^1BT7_KX7^35U0Z5<OAB<]+^+/Y?D+7S_ /'O_D:M-_Z\?_9VKZ KY_\
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MI: "BBB@"IJO_('O?^O>3_T$US7PK_Y)AH'_ %[?^S&NEU7_ ) ][_U[R?\
MH)KFOA7_ ,DPT#_KV_\ 9C0!V%%%% !1110 4444 %%%% !1110 4AI:* ,#
MQ;HT&L:+(DI*M'\R-C..Q'TKQW0?A[IOBQ-:MX6-G=6C*L<@^922">1Z=*]T
MU7_D&7'^X:\\^%(SJWB;_KO'_P"@FNNC5E&E*W2QY]6A!XJ+[IW^5CQ>[M=:
M\$ZR]E?0-%*,$H>4E7L5(ZBO7O"FD>'/&.F&YT_4KI9T $UO)MW1-CZ<CK@U
MWWB;PMIOBO3&LM2B##K'(OWHV]5/].AKYWUSP]XB^&6OPW<,C!5(\B]B'R/_
M ++9[^QKIA7=:/*G9F5; T>;FG!,]D_X5I'S_P 3)\^\8J#_ (5E/_T%$Q_U
MP/\ \55CP!\3+#Q=$MI=;+75@.8<_+* /O(?Z=:[[(KFEB*]-VD]064X*:NH
MGF9^&M^"=M];D9Z[2.*@;X<ZP&(6:S*]OG8?^RUZG11]=K$O),)V?WGDC^ -
M<1L!+=QZK+Q^HJ,^#?$4!VQ6I8'O',H'ZD5Z_BC%/Z]4[(AY'0Z-KYGB6I:-
MK&FPJ^H6\J1,V 2X9<^^":30]=N=!O3<0@.K+M>-CPP_QKUCQ*H.A7&?[I_E
M7 ?#?1;'6] U1+V$.4OG5'!PR# Z'T]NE=$,4I4WSHX:F4SIUTZ$]=]3L]&\
M8Z9JNV)I/L]P>/+E.,_0]ZZ$$$5Y?K'P_OK/,FGN+J(?P'AQ_0_I5#2_%FL:
M'(+>4M+&AP8)\[E^A/(_6L7A8U%S47\CJIYG6P[Y,9&WFCV 4M<YHWC+2]5V
MQF3[/<'CRY3C)]CT-=%N&*XY0E!VDK'LT:].M'FINZ%HI <TM2:A10#10 44
M44 %%%% !1110 4444 %%%% '+>/?^1=E_SW%=-&04'T%<UX\_Y%Z3_/<55^
M%<LDWPXTJ261Y'/G99V))_?/W-:\O[J_G^AS)_[2UY+\V=E10**R.D**** "
MBBB@ HHHH **** "BBB@ HHHH **** "@T4E '*^(_\ D8M%_P"OA?Y-75#I
M7*^(_P#D8]%_Z^%_DU=4.E7+X8G/2_BS^7Y"U\__ ![_ .1JTW_KQ_\ 9VKW
M\5X!\>_^1JTW_KQ_]G:M\%_%0\3_  SRZR_X_K?_ *ZK_.OM&OBZR_X_K?\
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MN5]BMHWBW2]7"HDODW!_Y8R<'\/6MW/&:\LUGP%J%@3+8G[7$#D*.)!^'?\
M"JVE>,=6T>00SDW$2G#139W+^/4?C1+"QFN:B[BIYK5H2Y,7"WF>N@TM<_HO
MBW2]7Q&DODW!_P"64O!)]O6M_-<<H2@[21[-*M3JQYJ;NA:*3-+FI-0HHHH
M**** "BBB@ HHHH Y?QV#_PCTG'^<BJ7PG_Y)II/UF_]'/6OXS_Y%2^/^RO_
M *$*R/A/_P DTTGZS_\ HYZW_P"7'S_0Y%_O3_PK\V=J****P.L**** "BBB
M@ HHHH **** "BBC- !129I<T %%)FC(H ":0G![U1U#6M.TQ-]Y=QQ>BDY)
M^@')KD=2^(\" KIUJTC=GE^5?R[_ *5K"A4J?"CDKX[#T/CD7_$T\4?B+1B\
MBJ!,K')Z#YJZQ'#KN4A@>017A.H7T^IWTMW<L&ED//H!Z#VKU+P+]I_X1F'[
M1NQN/E[O[G:MZ^']G33;//R_,?K&(G%1LF=,*\ ^/?\ R-6F_P#7C_[.U>_C
MK7@'Q[_Y&K3?^O'_ -G:IP?\5'J8G^&>767_ !_6_P#UU7^=?:-?%UE_Q_6_
M_75?YU]HUOF&\?F983J%%%!KSCL.9\5>.M(\'O;)J?VC-P"4\J/=T]?SKD=2
M^.>@0V$LFGVUU<70X2.1/+4GU+<\5TOC3X?6/C:2T>]O+FW^S!@H@V\Y]<@^
ME<3J/P#LA8R'3-7N?M@YC%R%V$^AVKD5U4E0LN?<PJ>UO[NP:)\=X)IW36],
M-O'C*26I+\^A4_SS74Z1\6O#.LZM;:;:&[^T7#^6F^' S[G-<+H?P&O7FD.N
MZE%%"%^1;)MS$^I+* /R-=9H?P9TC0M;L]4@U._DEM9/,5'V;2?0X7WJZJPV
MMB8.MU/2JH:KJ]OH\5M+<K(8Y[F.V#(!A&=MJELD8&2!^(J_6+XMT^74_">I
M6UN,W)A,D'M*GSH?^^E%<+=M6=25]$+=>)K&S\467A^59_M=W$9$D"?NUQG"
MLV>&8*Y QSL/I5:Y\9Z=:Z^ND20W6XW:61N B^4LSQF14)W9Y ';&2!7*&[C
MUG0]2\;0%6$-W!<6S@#_ %%N '&?^!W _'I6C9Z*?$7@/4;B$HMWJ=W+J-K,
M!P'5\V[]OX8XZ>V_3_@?I?YH5T]OZW_6WWG5:MK=MI$NGPS1S2S7]RMM!'"H
M)+$$ECDC"J 23Z#O659^,+C4K?[38>%=:N;8NZ+*LEHH;:Q4D!IP<9!Z@5F>
M&=2'C3Q)#K@4"UTRR6!8^I2[E :8'W10J_5F%0^"M%O[GPQ#-%XGU:TC:>X(
M@ABM2B?OGZ%X6;\R:-G;^OZZ_,5_Z_K[COD8M&K%"A(!*MC(]CCBL#_A,+,W
MOEBTO#8_:?L9U(!/LXFW;=GWM_WOEW;=N[C-:$VH74&HQ6B:-?W$+8W7J/ (
MTSUW!I _'?"GVS7#/()/A=+IT<@%]_:#6?E\AO/^U9QCKG'S?3GI1U!NR.JU
M#Q=:6%W=1?8[VXM[(J+Z[@5#%:9 /SY8,<*0QV*V >:N>(/$.G^&=!N=9U&4
MK:6Z;CLP6<GHJ\\DG %<NUU!:Z'X[AN) DT=Q.[*W4K)"OED>N>@]QCM6'XN
MM]87PW<)?Z'?SV>G:&T<$L4L!C$[0%9)7#2!_E&5&%/5SSD8EM\M_)/[TW^'
MZZE15Y)>;7W-+\;W/5895G@CE4$*ZA@#UP1FL"#QC:3WD:"QOEL9;@VL.HE$
M\B24$KM&&+@%@5#%0I(X/(SJ:-,\^B64LEO+;NT*YBE*EEX[[21^1-<IXGOK
M>^L],U^PU"2ZCM]1AABTYE BEF\WRVR-HD\Q06(!. 4!*G%7)6G;S_4F+O&_
M6QKWWC&SL;NZC-G>SVMDZQWU]"J&&U8@'#Y8,<!E8E58*#SC!QT6<C(KSR[N
MH(?!WCVTDD"W*372LA^\3-&/*P.IW;E ]3P*WO$44D'PSU6*7_6)H\JOSGD0
MD&HO:',^R?WJ_P"'ZFD8\TDN[:^YK7YG2T5YG!X3T/\ X2+PO&=/A:.[TN=[
MQ6&1>,HA(,X_Y:D%B?GSSSU%5](@BNO['T6^B270CJFI0?9I>8F,<C>1$5/!
M4*'(4\?(/05;T=OZWL0M8J71_P"7_ /5**X?P!;6%IJ_BZWTLK]CBU1414.4
MC(@CW(OH%.1@<#&.U=Q2Z)@][!1110 4444 %0W5M#>6LMM<1K+!,C1R(PR&
M4C!!^H-34AH Y3_A6G@L?\RUIW_?JK-AX%\+:7>Q7MCH5E;W,1S'*D>"I]C6
M;>7E]??%&VTG^TI+.QL[(7HMX\ WCEF7!)ZJN <#N1Z5%J[SZ-\2-&EL]3N9
M%UEWANM-=]T:JD9(F1?X,;0">AS^8M0.X.,>U>=,CR^$I_%QN;D:HLKSHXF8
M*J+(5$>W.-N!TQWKT7K]:Y%_"VJ?9IM&CN[4:)+.9"2K>>J%MQC';&<\YS@T
M ;^IS2KH-U/%.EO+Y#,LKG"H=N<FN)\-S1+KNC"T74+5IK=S=F]=\71VC&W=
MP6S\V>..W-=EJ>F3:K9WNFRM''93P;$="3(K>X/&!Q6;!HNM7=YIS:O<6/D:
M>WF1BU5MTKA2H+9^Z,$\#.: '^*]>;2K.2W72[^\$T$F9+:/<L?&/F/;K^E4
M_A9Q\,M!&>EM_P"S&NCU4?\ $GOO^O>3_P!!-<Y\+/\ DF.@_P#7O_[,: .P
MHHHH **** "BBB@ HHHH **** "BBB@"GJO_ "#+C_<KSSX4_P#(6\3?]=X_
MY&O0]4!.FS@ DE.@KSSX4?\ (6\3?]=X_P"1K>G_  I_(Y*G^\0]'^AZ<*6@
M45@=8&FD4ZB@#S/XA?"JU\1K)J6DK';:KU8=$G]B.S>_YUY;X4\;:Y\.]4ET
MZ\MY6M5<^?8R\%6]4)Z']#7TZ0>,5R?C7P%IGC*RQ./(OHP?)NHQROLWJOM^
M5=5+$)+DJ:HYZE+7FAN;&@^(--\1Z:M_I=RL\!X./O(?[K#L?:M3(-?+,<WB
M?X5^)BI'ER#@J<M!<+_7^8KWWP9XZTKQC8;[5_)NT_UUJY&Y/<?WE]_Y&IJT
M'#WHZQ*IU>;W9;FGXD_Y 5S_ +O]*Y#X0?\ (&U;_L(/_(5U_B/+:'<@ GY3
MT^E<A\(/^0+JW_80?^0I0_@R]492_P!YCZ,]&HHHK ZPHHHH 0CFLG5O#NFZ
MRF+J!?,Q@2KPP_&M<T@!IQDXNZ,ZE*%2/+-71Y5K/@._T\--9DW<(YV@8<?A
MW_"HM'\:ZII9$%QFZA0[2LA^=?;/7\#7K6*Q]7\,Z;K()N8 LN,":/AQ^/?\
M:[8XM37+65SQJN53I2]I@Y<K[=!FC^*=,UA56*<1S'_EE)PWX>OX5M9KRC6/
M VIZ8QEM?]+B'(*##CZCO^%-TCQKJFE,(;G-U$O!24X=?H?\:)82,US47<5/
M-IT9>SQ<+/OT/6@:6L31_%.EZP L$P28CF*3AO\ Z_X5M;A7'*+B[-'M4JL*
ML>:#NA:*3-&:DT%HHHH **** ,'QG_R*=]_NK_Z$*R/A/_R332?K/_Z.>M?Q
MG_R*=]_NK_Z$*R/A/_R332?K/_Z.>NC_ )A_G^AR+_>W_A7YL[6BBBN<ZPHH
MHH **** "BBB@ HI,T9H #0?QJ.>XAMT\R:5(T'5G8 ?K7,:EX]TFSRMNSW<
MF/\ EE]W_OK_  S5PISF_=1A6Q-*BKU)6.JR*K7>H6MC&9+FXCA0=W;%>97_
M (ZUC4',5H!;*W $0W,?Q(_E4%IX3U[69//FC:/=R9;EB"?SYKICA.76K*QY
M<\WYWRX:#D_P.KU'XB:?;EDLHI+EQP&^ZN?K_P#6KE;KQ;K^L.8;=VCS_P L
MK9#G\^M=3IOPZL( &OYGNF_N#Y$_Q/YUUEII]I81"*UMXX4'9% JO:T*?P*[
M\R?JN/Q/\:?*NR/+['P+K%^PEN<6X8\M(=S_ )#_ !KK+#P!I-IA[CS+J3OO
M.%_(5U>VEP:RGBZL]+V.JAE.&I:M7?F</XJBT[3M2TN26&"*UC<&3]V,!0&S
MV]A7865Q!=V4-Q:L&@E0/&P& 5(XKB?B?"PTR*;(V_,OOG8YKIO"G_(I:1_U
MYQ?^@BHFFZ46S>BDJTTEV_(V>]?/_P >_P#D:M-_Z\?_ &=J]_KP#X]_\C5I
MO_7C_P"SM6F#_BHUQ/\ #/+K+_C^M_\ KJO\Z^T:^+K+_C^M_P#KJO\ .OM&
MM\PWC\S+"=0HHHKSCL"BBB@ HHHH **** *T.GV5M8?88+.WBL]I7[.D2K'@
M]1M Q@Y/YU+!!#:V\=O;Q1PP1*$CCC4*J*!@  <  =JDHH AM[2VM$=+:WBA
M5W:1A&@4,['+,<=23R3WK'D\$>$Y9'DD\+Z*\CDLS-I\1+$]23MZUO44 ,AA
MBMX4AAC2.*-0J(B@*H'   Z"JIT;2SJHU4Z;9_VB%VB[\A?.QC&-^,XQQUJ[
M11Y@4KG1M+O;Z"^N]-LY[RW_ -3<2P*TD7.?E8C(Y]*LSP0W5O);W$4<T,JE
M)(Y%#*ZG@@@\$5)11Y!YB*JHH50%4#  & !5%-#TB/5FU5-+LEU)QAKQ;=!,
M>,<OC/3CK5^B@"C<:+I5WJ,&HW.F6<U]  (;F2!6DCP<C:Q&1R3T]:MS0Q7,
M$D$\22PR*4>-U#*RD8((/4$=J?11Y!UN0BSMA+#*+>$20(4B?8,QJ<9"GL#@
M<#T'I6/K?ATZA8+:6!TZW@:5I+BVNM.2YM[C=DDNF5.[=ALAASUS6]10]03L
M8WAOP_'X?LYXP\3S7$OFRF"$0Q A515CCR=BA44 9/3KS6S113;N"5@HHHI
M%%%% !5>]G>UL9[B.![AXHV=88_O2$#(4>YZ58I#VH \V\92P:S#IBWO@C5;
M^Y,'GJ;:58Y[0D\KN# @\=N*K>"[>WTS7D,'@+6[2:X'EOJ-_,)C&G7&YF)
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M_P!"%9'PG_Y)II/UG_\ 1SUT?\P_S_0Y%_O;_P *_-G:T449KG.L**3-&10
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M/?\ R-6F_P#7C_[.U?0%?/\ \>_^1JTW_KQ_]G:JP7\5&F)_AGEUE_Q_6_\
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M6=RRZ';AKW4&A9$3]SL,*E@-V6/./[N>:$#/812T@I: "BBB@"IJO_('O?\
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MNZ_ZY-_(UPOP@_Y NJ_]?[?^@BNZU3_D%W7_ %R;^1KA?A!_R!=5_P"O]O\
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M#)_[ZX8_G1]4O\$DRO;V^)'TOQ6!K'A#2]7W.T7D7!_Y:Q<'/N.]>9:9\?"
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M_P"NJ_SK[1KXNLO^/ZW_ .NJ_P Z^T:WS#>/S,L)U"BBBO..P**** "BBB@
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M&<8'U;<:WEM($NI+I8D$\BA&D Y*CH#],G\Z=;6T-I"(;>)8HP20JC R3DT
M<_XLT&?5+.2XBUO4K 06\F8K61527C/S9!STQVZU4^%AS\,M!/K;_P#LQKI=
M5_Y ][_U[R?^@FN:^%?_ "3#0/\ KV_]F- '84444 %%%% !1110 4444 %%
M%% !1110 R7_ %;?[IK%\(?\BY!_O/\ ^A&MJ7_5-]#6+X0_Y%R#_>?_ -"-
M:+^&SFE_O$?1_H;M%(*6LSI"BBB@ HHHH **** *>J?\@NZ_ZY-_(UPOP@_Y
M NJ_]?[?^@BNZU3_ )!=U_UR;^1KA?A!_P @75?^O]O_ $$5T0_@R]4<DO\
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MT %%%% %35?^0/>_]>\G_H)KFOA7_P DPT#_ *]O_9C72ZK_ ,@>]_Z]Y/\
MT$US7PK_ .28:!_U[?\ LQH ["BBB@ HHHH **** "BBB@ HHHH **** &2_
MZI_H:QO"2E?#L 8$$,_!&/XC6V>:15VC   ]JKF]WE,G3O44^R:%%+0**DU"
MBBB@ HHHH **** *>J?\@NZ_ZY-_(UPOP@_Y NJ_]?[?^@BN[U3_ )!5U_UR
M;^1KA/A!_P @75?^O]O_ $$5T0_@R^1R2_WJ/HST4=*6D%+7.=84444 %%%%
M !1110 5AZSXNTC1(K[[1<"6XLH1/+:PD&783U"DC/Y\?B*W*\P^*GAG5_$5
MO/)!I]J;>RA$D,L4;2W<[G_EFH'W5]>O;\*@DY)/84FTKH[^QUO3=1NI;2UO
M(I+F%%>6%6!:,-TW8Z&J&J>,M&TM9PUQ]HFM[B.WGAMRK/&SD!202..1S_6L
MSX?Z!J/AFQDTVYM; 6JJKQ7=NACEF)ZB5?[P]<^E<I\3?!^L^([QKP6%M%%#
M/'!"UI$TUQ.K$ NY&,*H)X]CSCFM5"'M>6^G]?U^)GSR]FY=?Z_K\#U&QU;3
M]3DN8[&\AN&MI/+F$3AMC8S@_P"?7TK*E\::(EQ9PPW(N?M-TUIO@92L4B@D
M[\D8'!]?RIG@O2M0T/2&TN^M-/A2W?;#+9#:)UQ]]E[-Z\G)S^/G/C+P#K7B
M'Q-:7T]E9V?VJ[:'%G TH6, D2SL, YP!T'!]>*480<[-Z=_Z_I!*4E"]M3U
M_3M4L=7M3<Z==Q74 =D\R)MPW X(S5NLCPS!?6NA06VH65C9SPDQ^58_ZHJ#
MPRC'RYZXK7K.22=D:1;:U"BBBI&8/C/_ )%.^_W5_P#0A61\)_\ DFFD_6?_
M -'/6OXS_P"13OO]U?\ T(5D?"?_ ))II/UG_P#1SUT?\P_S_0Y%_O;_ ,*_
M-G:T445SG6%%%% #2*,4ZB@"&2VAG0I-$CH1@JR@@BL.^\!^%=0#?:- L,MG
M+1PB-CGW7!KHJ*:DULR7%/='G=Y\%_"%T<Q075ITX@N"?_0]U<_>? *T89LM
M<FC('W9H0P/X@C%>QTN*UCB*L=F0Z,'T/GJ]^!7B&%B;6^L;E<DJ"61OQR/K
M6%/\,_'&EN)(],F9T/#6TP8_F#FOJ$BC%:K&5.NI#P\.A\MKK7Q"T$KNNM<A
M"@ ";?(H ]FR*OVGQF\961*7$]K=.,@BXM@"/^^-O^37TH4# A@"/0U0N]!T
MF^&+K3;2;.?]9"IZ_A3^LPE\4!>QDOAD>-V?Q]O%P+W0H7&>6AG*X'L"#_.N
MALOCKX>F(6ZLK^V/&3L5AGOT.?TKH[SX6>#;W.[1(8LD',#-'_Z"17.WGP)\
M.3+_ *+>7]LW;#JZ_B",_K3YL-+HT'+676YOV7Q5\&WH!768X<YXG1H_YBNA
MM?$.C7RJUKJEG*&Z;9ER?PS7C][\ ;M238Z[#(#G"SP%2/3D$Y_*N=N_@OXP
MLVWP0VET0>#!< 'Z_/MI>QH2^&0>TJK>)ZU\3Y$_X1R%]ZA3(V#G@_NVQ6_X
M0FBF\(Z48I$<+:QJ2C X.T9%?,&N:)XCT2&*+6;:\@A=OW8E8E,CT.<=Z[_X
M"S7_ /;VIP(7_LT6P:08.T2[AM^A(W_E5U:"5&Z=[&5*7[YNVY[=JNK66B:=
M)J&H2/%:Q??=8GDVCU(4$X]Z^=_BYXETCQ/X@L;K1[O[3#%:^6[>6Z8;>QQA
M@#T(KZ49%D1D=0RL,,I&01[UX#\3?A8^CM+K>@PEM..6GME&3;^Z^J?R^G2,
M&X*?O;FV)4G'38\LMG6.[A=CA5=23[9KZQT+QSX=\37CVNCWSW4J+O8"VE4*
M/=F4 ?G7S1X2\(ZEXPU9;*P3;&N#/<,/DB7U/J?0=Z^H/#'AC3?">D)I^G18
M4<R2M]^5N[,?\XK;'.&B>YEA5+5K8V:KZ@EU)IUTEC(D5VT3""1Q\JO@[2>#
MP#CL:L5RGB_P;-XFGM;JSUV]TBZMT9%DMB?F!(/."#V]:\Y)-V9VW:U1YA?)
MJ^@?$?0KKQ[)'J\DA5;62UD"I$=V Q38N<$@XX_'&*T/B/XSL7\;1Z#K<5T=
M#L"LT\-JJLUU(0&4-EAA!G_/&.DT;X316VN0:OKVO7NN75NP:'S\@ @Y&<LQ
M.#SC(%>C5U2JP3B][7\EY'/&G)\W2]O/U/GCP5XQTR'XNWFI+;W*VVJL;:V1
M47<A>1-NX;L #'8FN_O]!\2Z#XXU?7-#TN'5;?5H!&\37*PM"X &X[NHXZ#U
M]JUM%\!_V/X]U3Q/_:7G?;D=?LWD;=FYE/WMQS]WT'6NRJ:M6+Y>5=+/_+_@
MCA3DN;F[W7^?_ /$;3PU=6UGH_PY>96EN9CJ6L&)LK'"",)GWP/QQVJRGB[Q
M5J'A_6?$^EZE:V6F:5<>1#IILU<2HNW[SGYAPPZ?I7H?A[PK_8VK:OJMU>?;
M;_4IMS2^5L$<8^[&!D\#U[\>E<Y=?"QV_M"SL/$5S9:+J,WG75@MNCEFR"=L
MAY4<#L?QJO:QD_>]?GU_#1>@*GRK3^EK^;U.TT#5!K?A_3]4$?E_:H$E*9SM
M)&2*T:KV%E!INGV]C:IL@MXUBC7/15&!5BN:5G)\NQK&_*K[A1114E!1110
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M'I;X_P#'C0!V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBF^,/^1.UC_KTD_]!-.\*?\ (HZ1_P!>D7_H(K3['S(^V; ZTM HK,L****
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MVL?]>DG_ *":7PG_ ,BEI'_7I%_Z"*O['S(^V;-%%%06%%%% !1110 4444
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M>6[P3QK)$_#*W0U*!@8%4Y>[8R5-JJY]TE]UP%+0**DU"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Q?&'_ ")VL?\ 7I)_Z":7PG_R*6D?]>D7
M_H(IOC#_ )$[6/\ KTD_]!-.\)_\BEI'_7I%_P"@BK^Q\R/MFS1114%A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!4U7_D#WO_7O)_Z":YKX5_\
M),- _P"O;_V8UTNJ_P#('O?^O>3_ -!-<U\*_P#DF&@?]>W_ +,: .PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC8Q:GIMS8S$B*XC:-\
M=<$8I=/LHM.TZWLH<^5!&L:9/. ,"K-)1?2PK:W%HHHH&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .P1UD0.C!D89#*<@BG56L+"VTRQ@LK.(16T""..->BJ.!5F@ HHHH ****
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M$;W(/?D@9'IB@#H%!"C<<GO3J** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K&\2:I/I6GQ/;+%YT\Z0(\QPD98XW-["MFN;\8PS36-IF":XT]9PU[
M# "7>/!XP.2,XR!UH CLM<O8'UBVU%K>>33H1,+B!2JL"K':1D[6&.F>AIOA
MW4M1U*6"2;6M+G!0/-:6Z?O(\C@$[SC'TK.TVV3S]6;2=(F_L9[4*;.=3$L\
MV3G:K<@;>#QSQ4L36VJ:MHW]DZ5/926DN^XD>V,(CCV$&/./FR2.F1QUH [4
M4M(#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>)-0A\-^+8M534M'AGO++R'MM5O3:(ZQN2'238PR#(05QR"#D8.>VHIO>_\
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M &!GG'KS4/\ PC>A?VK_ &I_8NG?VCNW_:_LJ>;NZ9WXSGWS2C[MOZZM_K^
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M@'!Q /%VGMI%M?1PW3RW,YM8K(1@3M.I(:+!(4,NULDMMPI.<<UC:[X<N/\
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M/!&TL8CD*@N@;<%..1GO]:%L)[G*'XA6*V)U%M*U<:8EPUM+>^0A2-Q(8L;
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M:YK2:TM;G19;23S'C+Q2.ZG:0K$$XSR"1QUI.Z>G=_\ I.GX_P!7$]4O1?\
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M%$\CG"HI8GV%>?P:+KEQX;TCPE<Z4\4-A+;K/J+31-#+# ZL-BAM^Y@BC#*
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MS?S_ &956V"R>:0S8*9 4?*1G)&,$DC+5T-<?XYGDMK[PM-#:37<BZMD00E
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M.:-K_P!?=_7<-[$GB34+Q=2T;1=/N_L<VHRR&2Y55:2.*--S; P*[B=JY((
M)XSBLP^)+OP_;^*+?4+HZA)HUJM[#-*JH\L;JQ"OL 7(9&&0!P1QGDVM4MM6
MNCX>\0II/_$PL2QN=.6=&D"2IM=4D)"%E.T\D A3STJJ?#=WX@M_%%QJ%J=/
MDUFU6RAAE97>*-%8!GV$KDL[' )X YSP!JR?]?<-;J_]>O\ 78476M:%>Z!-
MJ&LO?Q:I.+6YAEAB1(9&C9U,110P *[<,7R".<CFUK.K:Y:>-/#]BB6D6DWE
MQ)&[K*7EEQ [@%2@" ,N<AB3@=.1546NM:[>Z!#J&C/81:7.+JYFEFB=)I%C
M9%$01BQ!+;LL$P .,GAWB8ZM+XGT.>S\.ZA=V^FW+S2312VRB0- Z80/*IR"
MXSD#H<9[UI?[_N_JY*V^7XZ_\ [*BJ-U=7T5W81V^FF:"=V%S*9E0VR[20=O
M\>3A<#US5ZI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#4]"TC
M6A$-5TJQOQ%GRQ=6Z2[,]<;@<9P/RJU;V\%I;1VUM#'#!$H2.*-0JHHZ  <
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F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>wve-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-10T21:49:59.7735+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="wve-20220630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:href="wve-20220630.xsd#StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany" xlink:href="wve-20220630.xsd#Role_DisclosureTheCompany" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="wve-20220630.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurements1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="wve-20220630.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="wve-20220630.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:href="wve-20220630.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare" xlink:href="wve-20220630.xsd#Role_DisclosureNetLossPerOrdinaryShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="wve-20220630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData" xlink:href="wve-20220630.xsd#Role_DisclosureGeographicData" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties" xlink:href="wve-20220630.xsd#Role_DisclosureRelatedParties" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="wve-20220630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases" xlink:href="wve-20220630.xsd#DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="wve-20220630.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables" xlink:href="wve-20220630.xsd#Role_DisclosureNetLossPerOrdinaryShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="wve-20220630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" xlink:href="wve-20220630.xsd#DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" xlink:href="wve-20220630.xsd#Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="wve-20220630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_18"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OfferingCostsInAccountsPayable" xlink:label="wve_OfferingCostsInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wve_AmortizationOfRightOfUseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="wve_OfferingCostsInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GeographicDataAbstract" xlink:label="wve_GeographicDataAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GeographicDataDisclosureTextBlock" xlink:label="wve_GeographicDataDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_GeographicDataAbstract" xlink:to="wve_GeographicDataDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_RestrictedCashMember" xlink:label="wve_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="wve_RestrictedCashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:label="wve_FairValueAssetsLevel1ToLevel2TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:label="wve_FairValueAssetsLevel2ToLevel1TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="wve_FairValueAssetsLevel1ToLevel2TransferAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="wve_FairValueAssetsLevel2ToLevel1TransferAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TimeBasedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeSharePurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ResearchLicenseAndOptionAgreementMember" xlink:label="wve_ResearchLicenseAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_PfizerIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_ResearchLicenseAndOptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementUpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryTwoProgramsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommittedCash" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTargetsForPreclinicalPrograms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommencementDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTerminationNoticePeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_UpFrontConsiderationReceived" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityLineItems" xlink:label="wve_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityTable" xlink:label="wve_EquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_June2022OfferingMember" xlink:label="wve_June2022OfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GrossProceedsFromIssuanceOfCommonStock" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" xlink:label="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="wve_EquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_June2022OfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityTable" xlink:to="wve_EquityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="wve_GrossProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="wve_EquityLineItems" xlink:to="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="wve_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_AgreementTerminationNoticePeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="wve_ConsultingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ScientificAdvisorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LexingtonMassachusettsMember" xlink:label="wve_LexingtonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CambridgeMassachusettsMember" xlink:label="wve_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncrementalBorrowingRate" xlink:label="wve_IncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="wve_LexingtonMassachusettsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="wve_CambridgeMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="wve_IncrementalBorrowingRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>wve-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-10T21:50:01.3032+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:label="wve_FairValueAssetsLevel2ToLevel1TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:label="wve_FairValueAssetsLevel1ToLevel2TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OfferingCostsInAccountsPayable" xlink:label="wve_OfferingCostsInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LexingtonMassachusettsMember" xlink:label="wve_LexingtonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ResearchLicenseAndOptionAgreementMember" xlink:label="wve_ResearchLicenseAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityTable" xlink:label="wve_EquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncrementalBorrowingRate" xlink:label="wve_IncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GrossProceedsFromIssuanceOfCommonStock" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityLineItems" xlink:label="wve_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_June2022OfferingMember" xlink:label="wve_June2022OfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GeographicDataDisclosureTextBlock" xlink:label="wve_GeographicDataDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" xlink:label="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_RestrictedCashMember" xlink:label="wve_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CambridgeMassachusettsMember" xlink:label="wve_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GeographicDataAbstract" xlink:label="wve_GeographicDataAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ConsultingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Inputs Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity investment aggregate purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfer Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FairValueAssetsLevel2ToLevel1TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level2 to level1 transfer amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares under ESPP, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNoParValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, No Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, Series A preferred shares and shareholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfer Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FairValueAssetsLevel1ToLevel2TransferAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets level1 to level2 transfer amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ScientificAdvisorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scientific Advisor [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to ordinary shareholders diluted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs in accounts payable at period end</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering costs in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OfferingCostsInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lexington Massachusetts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lexington Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington, Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Share Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of global costs and potential profits sharing ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Global Costs And Potential Profits Sharing Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of global costs and potential profits sharing ratio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category Two Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category Two Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryTwoProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Category two programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ResearchLicenseAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research, License and Option Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ResearchLicenseAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research License And Option Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_ResearchLicenseAndOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research, license and option agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of share options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of ordinary shares, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of ordinary shares, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, committed cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Committed Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementCommittedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement committed cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration and license agreement, deferred revenue current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Professional and Contract Services Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting service expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional and Contract Services Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license agreement month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration-budgeted research and preclinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Budgeted Research And Preclinical Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">collaboration-budgeted research and preclinical expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fund receivable for research and preclinical activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fund Receivable For Research And Preclinical Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fund receivable for research and preclinical activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax benefit (provision)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental borrowing rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchase price at equal to fair market value percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Purchase Price At Equal To Fair Market Value Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share purchase price at equal to fair market value percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued under equity agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front consideration received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Consideration Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_UpFrontConsiderationReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Up-front consideration received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Equity Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AtTheMarketEquityProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at June 30, 2022 and December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Interest and Dividend, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend income and interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, no par value; 86,724,658 and 59,841,116 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In-Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PfizerIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and license agreement, deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of pre-funded warrants , net of offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity/</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the maturity of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of ownership interest in ordinary shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ownership interest in ordinary shares outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_June2022OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June 2022 Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_June2022OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June 2022 Offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In-Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Ordinary Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Share Purchase Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and Share Purchase Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Data Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Geographic Data Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee share purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Share Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum percentage of combined voting power of securities outstanding immediate effect of exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of combined voting power of securities outstanding immediate effect of exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs to Employees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in Operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Inputs Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to reach maximum targets for preclinical programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Reach Maximum Targets For Preclinical Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to reach maximum targets for preclinical programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses related to CROs and CMOs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum targets for preclinical programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Targets For Preclinical Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTargetsForPreclinicalPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum targets for preclinical programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee leasing arrangements operating leases renewal term description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Renewal Term Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time-based RSUs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Time Based Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TimeBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Time-based restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense not yet recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement termination period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_MaximumTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting agreement termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AgreementTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in operating lease right-of-use assets and lease liabilities related to lease extension</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and Share Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Share Purchase Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and share purchase agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment agreement official closure month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Agreement Official Closure Date Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity investment agreement official closure date month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance pre-funded warrants, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge, Massachusetts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of additional lease space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend the lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to ordinary shareholders basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda pharmaceutical company limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Series A preferred shares and shareholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant or Right, Original issuance date, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant or Right, Reason for Issuance, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded warrant exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Exercise Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants (Member)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Funded Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category One Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category One Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CategoryOneProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Category one programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Inputs Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of RSUs, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock award vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_AmortizationOfRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments, at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research term under collaboration and license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Data [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="wve_GeographicDataAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Geographic data.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares granted to employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares excluded from calculation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ConsultingAgreementMember" xlink:to="wve_ConsultingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:to="wve_FairValueAssetsLevel2ToLevel1TransferAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementCommencementDate" xlink:to="wve_CollaborationAgreementCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:to="wve_FairValueAssetsLevel1ToLevel2TransferAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ScientificAdvisorMember" xlink:to="wve_ScientificAdvisorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_OfferingCostsInAccountsPayable" xlink:to="wve_OfferingCostsInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_LexingtonMassachusettsMember" xlink:to="wve_LexingtonMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EmployeeSharePurchasePlanMember" xlink:to="wve_EmployeeSharePurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CategoryTwoProgramsMember" xlink:to="wve_CategoryTwoProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_ResearchLicenseAndOptionAgreementMember" xlink:to="wve_ResearchLicenseAndOptionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementCommittedCash" xlink:to="wve_CollaborationAgreementCommittedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PerformanceBasedRestrictedStockUnitsMember" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementMember" xlink:to="wve_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EquityTable" xlink:to="wve_EquityTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_FundReceivableForResearchAndPreclinicalActivities" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_IncrementalBorrowingRate" xlink:to="wve_IncrementalBorrowingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GrossProceedsFromIssuanceOfCommonStock" xlink:to="wve_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_UpFrontConsiderationReceived" xlink:to="wve_UpFrontConsiderationReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AtTheMarketEquityProgramMember" xlink:to="wve_AtTheMarketEquityProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAgreementUpfrontPayment" xlink:to="wve_CollaborationAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PfizerIncMember" xlink:to="wve_PfizerIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EquityLineItems" xlink:to="wve_EquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_June2022OfferingMember" xlink:to="wve_June2022OfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndSharePurchaseAgreementsAbstract" xlink:to="wve_CollaborationAndSharePurchaseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GeographicDataDisclosureTextBlock" xlink:to="wve_GeographicDataDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" xlink:to="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_MaximumTargetsForPreclinicalPrograms" xlink:to="wve_MaximumTargetsForPreclinicalPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" xlink:to="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TimeBasedRestrictedStockUnitsMember" xlink:to="wve_TimeBasedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_MaximumTerminationNoticePeriod" xlink:to="wve_MaximumTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AgreementTerminationNoticePeriod" xlink:to="wve_AgreementTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndSharePurchaseAgreementsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_RestrictedCashMember" xlink:to="wve_RestrictedCashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CambridgeMassachusettsMember" xlink:to="wve_CambridgeMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementDate" xlink:to="wve_CollaborationAndLicenseAgreementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_PreFundedWarrantsMember" xlink:to="wve_PreFundedWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CategoryOneProgramsMember" xlink:to="wve_CategoryOneProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_AmortizationOfRightOfUseAssets" xlink:to="wve_AmortizationOfRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_CollaborationAndLicenseAgreementResearchTerm" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wve_GeographicDataAbstract" xlink:to="wve_GeographicDataAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>wve-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-10T21:49:59.8135+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:href="wve-20220630.xsd#StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" xlink:href="wve-20220630.xsd#DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" xlink:href="wve-20220630.xsd#Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="wve-20220630.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="wve-20220630.xsd#DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OfferingCostsInAccountsPayable" xlink:label="wve_OfferingCostsInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="wve_AmortizationOfRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="wve_OfferingCostsInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_RestrictedCashMember" xlink:label="wve_RestrictedCashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="wve_RestrictedCashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel1ToLevel2TransferAmount" xlink:label="wve_FairValueAssetsLevel1ToLevel2TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FairValueAssetsLevel2ToLevel1TransferAmount" xlink:label="wve_FairValueAssetsLevel2ToLevel1TransferAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="wve_FairValueAssetsLevel1ToLevel2TransferAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="wve_FairValueAssetsLevel2ToLevel1TransferAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandTwentyOneEquityIncentivePlanMember" xlink:label="wve_TwoThousandTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="wve_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TimeBasedRestrictedStockUnitsMember" xlink:label="wve_TimeBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PerformanceBasedRestrictedStockUnitsMember" xlink:label="wve_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EmployeeSharePurchasePlanMember" xlink:label="wve_EmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" xlink:label="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" xlink:label="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="wve_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TimeBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_PerformanceBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_EmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryOneProgramsMember" xlink:label="wve_CategoryOneProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PfizerIncMember" xlink:label="wve_PfizerIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ResearchLicenseAndOptionAgreementMember" xlink:label="wve_ResearchLicenseAndOptionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementUpfrontPayment" xlink:label="wve_CollaborationAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CategoryTwoProgramsMember" xlink:label="wve_CategoryTwoProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="wve_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMember" xlink:label="wve_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndSharePurchaseAgreementsMember" xlink:label="wve_CollaborationAndSharePurchaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementMonthAndYear" xlink:label="wve_CollaborationAndLicenseAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_FundReceivableForResearchAndPreclinicalActivities" xlink:label="wve_FundReceivableForResearchAndPreclinicalActivities"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementResearchTerm" xlink:label="wve_CollaborationAndLicenseAgreementResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommittedCash" xlink:label="wve_CollaborationAgreementCommittedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" xlink:label="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" xlink:label="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTargetsForPreclinicalPrograms" xlink:label="wve_MaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_OptionToReachMaximumTargetsForPreclinicalPrograms" xlink:label="wve_OptionToReachMaximumTargetsForPreclinicalPrograms"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAgreementCommencementDate" xlink:label="wve_CollaborationAgreementCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MaximumTerminationNoticePeriod" xlink:label="wve_MaximumTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_UpFrontConsiderationReceived" xlink:label="wve_UpFrontConsiderationReceived"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationBudgetedResearchAndPreclinicalExpenses" xlink:label="wve_CollaborationBudgetedResearchAndPreclinicalExpenses"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CollaborationAndLicenseAgreementDate" xlink:label="wve_CollaborationAndLicenseAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryOneProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_PfizerIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_ResearchLicenseAndOptionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="wve_CategoryTwoProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="wve_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="wve_CollaborationAndSharePurchaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_FundReceivableForResearchAndPreclinicalActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommittedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTargetsForPreclinicalPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAgreementCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_MaximumTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_UpFrontConsiderationReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="wve_CollaborationAndLicenseAgreementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityLineItems" xlink:label="wve_EquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_EquityTable" xlink:label="wve_EquityTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AtTheMarketEquityProgramMember" xlink:label="wve_AtTheMarketEquityProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_June2022OfferingMember" xlink:label="wve_June2022OfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_GrossProceedsFromIssuanceOfCommonStock" xlink:label="wve_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" xlink:label="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" xlink:label="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="wve_EquityLineItems" xlink:to="wve_EquityTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_AtTheMarketEquityProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="wve_EquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="wve_EquityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_June2022OfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="wve_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="wve_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="wve_EquityLineItems" xlink:to="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_PreFundedWarrantsMember" xlink:label="wve_PreFundedWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="wve_PreFundedWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AgreementTerminationNoticePeriod" xlink:label="wve_AgreementTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ConsultingAgreementMember" xlink:label="wve_ConsultingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_ScientificAdvisorMember" xlink:label="wve_ScientificAdvisorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="wve_AgreementTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="wve_ConsultingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="wve_ScientificAdvisorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LexingtonMassachusettsMember" xlink:label="wve_LexingtonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_CambridgeMassachusettsMember" xlink:label="wve_CambridgeMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" xlink:label="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncrementalBorrowingRate" xlink:label="wve_IncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="wve_LexingtonMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="wve_CambridgeMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="wve_IncrementalBorrowingRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>wve-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-10T21:49:59.9916+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.wavelifesciences.com/20220630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:wve="http://www.wavelifesciences.com/20220630" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" id="Role_StatementUnauditedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Unaudited Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical" id="Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit" id="StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit">
        <link:definition>100040 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" id="Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Unaudited Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany" id="Role_DisclosureTheCompany">
        <link:definition>100060 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1" id="DisclosureFairValueMeasurements1">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100090 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>100110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare" id="Role_DisclosureNetLossPerOrdinaryShare">
        <link:definition>100120 - Disclosure - Net Loss Per Ordinary Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100130 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData" id="Role_DisclosureGeographicData">
        <link:definition>100140 - Disclosure - Geographic Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100150 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100190 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables" id="Role_DisclosureNetLossPerOrdinaryShareTables">
        <link:definition>100200 - Disclosure - Net Loss Per Ordinary Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100210 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" id="Role_DisclosureTheCompanyAdditionalInformationDetail">
        <link:definition>100220 - Disclosure - The Company - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" id="DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail">
        <link:definition>100230 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetail">
        <link:definition>100250 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" id="DisclosureCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail" id="Role_DisclosureShareholdersEquityAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Shareholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails" id="DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Net Loss Per Ordinary Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail" id="Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail">
        <link:definition>100290 - Disclosure - Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail" id="Role_DisclosureRelatedPartiesAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Related Parties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>100320 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="wve_CollaborationAndSharePurchaseAgreementsAbstract" name="CollaborationAndSharePurchaseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_GeographicDataAbstract" name="GeographicDataAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_AgreementTerminationNoticePeriod" name="AgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_AmortizationOfRightOfUseAssets" name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_CollaborationAgreementCommencementDate" name="CollaborationAgreementCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationAgreementCommittedCash" name="CollaborationAgreementCommittedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_CollaborationAgreementUpfrontPayment" name="CollaborationAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementDate" name="CollaborationAndLicenseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementMonthAndYear" name="CollaborationAndLicenseAgreementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementResearchTerm" name="CollaborationAndLicenseAgreementResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_CollaborationBudgetedResearchAndPreclinicalExpenses" name="CollaborationBudgetedResearchAndPreclinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear" name="EquityInvestmentAgreementOfficialClosureDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_FairValueAssetsLevel1ToLevel2TransferAmount" name="FairValueAssetsLevel1ToLevel2TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_FairValueAssetsLevel2ToLevel1TransferAmount" name="FairValueAssetsLevel2ToLevel1TransferAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_FundReceivableForResearchAndPreclinicalActivities" name="FundReceivableForResearchAndPreclinicalActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_IncrementalBorrowingRate" name="IncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" name="LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_MaximumTargetsForPreclinicalPrograms" name="MaximumTargetsForPreclinicalPrograms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_MaximumTerminationNoticePeriod" name="MaximumTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" name="MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_OfferingCostsInAccountsPayable" name="OfferingCostsInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="wve_OptionToReachMaximumTargetsForPreclinicalPrograms" name="OptionToReachMaximumTargetsForPreclinicalPrograms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" name="PercentageOfGlobalCostsAndPotentialProfitsSharingRatio" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding" name="PercentageOfOwnershipInterestInOrdinarySharesOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_SharePurchasePriceAtEqualToFairMarketValuePercentage" name="SharePurchasePriceAtEqualToFairMarketValuePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="wve_UpFrontConsiderationReceived" name="UpFrontConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="wve_EquityLineItems" name="EquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_AtTheMarketEquityProgramMember" name="AtTheMarketEquityProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CategoryOneProgramsMember" name="CategoryOneProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CategoryTwoProgramsMember" name="CategoryTwoProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_CollaborationAndSharePurchaseAgreementsMember" name="CollaborationAndSharePurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ConsultingAgreementMember" name="ConsultingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_EmployeeSharePurchasePlanMember" name="EmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_June2022OfferingMember" name="June2022OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_LexingtonMassachusettsMember" name="LexingtonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PerformanceBasedRestrictedStockUnitsMember" name="PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PfizerIncMember" name="PfizerIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ResearchLicenseAndOptionAgreementMember" name="ResearchLicenseAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_ScientificAdvisorMember" name="ScientificAdvisorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TimeBasedRestrictedStockUnitsMember" name="TimeBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TwoThousandNineteenEmployeeSharePurchasePlanMember" name="TwoThousandNineteenEmployeeSharePurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_TwoThousandTwentyOneEquityIncentivePlanMember" name="TwoThousandTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_EquityTable" name="EquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="wve_GeographicDataDisclosureTextBlock" name="GeographicDataDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>wve-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-08-10T21:49:59.8698+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:href="wve-20220630.xsd#Role_StatementUnauditedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:href="wve-20220630.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:href="wve-20220630.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssets" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wve_AmortizationOfRightOfUseAssets" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="wve_IncreaseDecreaseInOperatingLeaseLiabilities" order="11" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="12" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AmortizationOfRightOfUseAssets" xlink:label="wve_AmortizationOfRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="wve_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="wve_AccruedExpensesAndOtherCurrentLiabilities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="wve-20220630.xsd#wve_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="wve_AccruedExpensesAndOtherCurrentLiabilities"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533713280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WVE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WAVE LIFE SCIENCES LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">U0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001631574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,820,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Straits View #12-00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Marina One<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">East Tower<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">018936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6236 3388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">$0 Par Value Ordinary Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533774288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,163<span></span>
</td>
<td class="nump">$ 150,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investments</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">5,396<span></span>
</td>
<td class="nump">6,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,555<span></span>
</td>
<td class="nump">5,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">160,114<span></span>
</td>
<td class="nump">162,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">19,808<span></span>
</td>
<td class="nump">22,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">28,791<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">53,205<span></span>
</td>
<td class="nump">44,443<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">213,319<span></span>
</td>
<td class="nump">207,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,168<span></span>
</td>
<td class="nump">7,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,085<span></span>
</td>
<td class="nump">14,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">37,466<span></span>
</td>
<td class="nump">37,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">4,363<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">64,082<span></span>
</td>
<td class="nump">64,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">75,256<span></span>
</td>
<td class="nump">77,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">35,160<span></span>
</td>
<td class="nump">24,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">110,416<span></span>
</td>
<td class="nump">102,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">174,498<span></span>
</td>
<td class="nump">166,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at June 30, 2022 and December 31, 2021</a></td>
<td class="nump">7,874<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value; 86,724,658 and 59,841,116 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">802,449<span></span>
</td>
<td class="nump">749,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">113,169<span></span>
</td>
<td class="nump">87,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(884,624)<span></span>
</td>
<td class="num">(805,514)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">30,947<span></span>
</td>
<td class="nump">32,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, Series A preferred shares and shareholders' equity</a></td>
<td class="nump">$ 213,319<span></span>
</td>
<td class="nump">$ 207,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918532156704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A preferred stock, shares issued</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A preferred stock, shares outstanding</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,724,658<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,724,658<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533856576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="nump">$ 2,776,000<span></span>
</td>
<td class="nump">$ 2,125,000<span></span>
</td>
<td class="nump">$ 2,776,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,733,000<span></span>
</td>
<td class="nump">31,635,000<span></span>
</td>
<td class="nump">57,203,000<span></span>
</td>
<td class="nump">65,028,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,806,000<span></span>
</td>
<td class="nump">10,969,000<span></span>
</td>
<td class="nump">25,180,000<span></span>
</td>
<td class="nump">21,047,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">42,539,000<span></span>
</td>
<td class="nump">42,604,000<span></span>
</td>
<td class="nump">82,383,000<span></span>
</td>
<td class="nump">86,075,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(42,164,000)<span></span>
</td>
<td class="num">(39,828,000)<span></span>
</td>
<td class="num">(80,258,000)<span></span>
</td>
<td class="num">(83,299,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Dividend income and interest income, net</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">744,000<span></span>
</td>
<td class="nump">1,054,000<span></span>
</td>
<td class="nump">998,000<span></span>
</td>
<td class="nump">2,050,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">868,000<span></span>
</td>
<td class="nump">1,062,000<span></span>
</td>
<td class="nump">1,148,000<span></span>
</td>
<td class="nump">2,069,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(41,296,000)<span></span>
</td>
<td class="num">(38,766,000)<span></span>
</td>
<td class="num">(79,110,000)<span></span>
</td>
<td class="num">(81,230,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,296,000)<span></span>
</td>
<td class="num">$ (38,766,000)<span></span>
</td>
<td class="num">$ (79,110,000)<span></span>
</td>
<td class="num">$ (81,230,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders basic</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders diluted.</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (1.25)<span></span>
</td>
<td class="num">$ (1.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic.</a></td>
<td class="nump">66,479,293<span></span>
</td>
<td class="nump">49,973,185<span></span>
</td>
<td class="nump">63,514,426<span></span>
</td>
<td class="nump">49,220,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted</a></td>
<td class="nump">66,479,293<span></span>
</td>
<td class="nump">49,973,185<span></span>
</td>
<td class="nump">63,514,426<span></span>
</td>
<td class="nump">49,220,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,296,000)<span></span>
</td>
<td class="num">$ (38,766,000)<span></span>
</td>
<td class="num">$ (79,110,000)<span></span>
</td>
<td class="num">$ (81,230,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(142,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228,000)<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (41,438,000)<span></span>
</td>
<td class="num">$ (38,766,000)<span></span>
</td>
<td class="num">$ (79,338,000)<span></span>
</td>
<td class="num">$ (81,350,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527238624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-The-Market Equity Program [Member]</div></th>
<th class="th"><div>Series A Preferred Shares [Member]</div></th>
<th class="th"><div>Ordinary Shares [Member]</div></th>
<th class="th">
<div>Ordinary Shares [Member] </div>
<div>At-The-Market Equity Program [Member]</div>
</th>
<th class="th"><div>Additional Paid-In-Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 82,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,573<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="num">$ (683,269)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,778,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">52,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,636<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="num">(725,733)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,854,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">82,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,573<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="num">(683,269)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,778,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">21,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,358<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="num">(764,499)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,576,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">52,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,636<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="num">(725,733)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,854,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">718,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">2,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,766)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">21,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,358<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="num">(764,499)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,576,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,980<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(805,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of ordinary shares under the ESPP</a></td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of ordinary shares under ESPP, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,951<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(843,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,859,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">32,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,980<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(805,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,841,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (79,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">30,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,169<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(884,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,724,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,951<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(843,328)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,859,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Beginning balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">51,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,464,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants , net of offering costs.</a></td>
<td class="nump">14,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Share-based compensation</a></td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,296)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">30,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,169<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="num">$ (884,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,724,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527154800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (79,110)<span></span>
</td>
<td class="num">$ (81,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">3,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10,921<span></span>
</td>
<td class="nump">6,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,946)<span></span>
</td>
<td class="num">(3,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="num">(5,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,776)<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,855)<span></span>
</td>
<td class="num">(2,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,399)<span></span>
</td>
<td class="num">(1,792)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,695)<span></span>
</td>
<td class="num">(53,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from the maturity of short-term investments</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(25,594)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of offering costs</a></td>
<td class="nump">51,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance pre-funded warrants, net of offering costs</a></td>
<td class="nump">14,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of share options</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the ESPP</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">67,116<span></span>
</td>
<td class="nump">13,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of foreign exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(228)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(27,401)<span></span>
</td>
<td class="num">(40,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">154,215<span></span>
</td>
<td class="nump">188,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">126,814<span></span>
</td>
<td class="nump">147,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease right-of-use assets and lease liabilities related to lease extension</a></td>
<td class="nump">12,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_OfferingCostsInAccountsPayable', window );">Offering costs in accounts payable at period end</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of offering costs</a></td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="nump">$ 13,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in Operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_OfferingCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs in accounts payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_OfferingCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918534948976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. THE COMPANY</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Wave Life Sciences Ltd. (together with its subsidiaries, &#8220;Wave&#8221; or the &#8220;Company&#8221;) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. PRISM, Wave&#8217;s proprietary discovery and drug development platform, enables the precise design, optimization and production of novel stereopure oligonucleotides. Wave has built a genetic toolkit comprised of multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage learnings and optimizations from the PRISM platform and allow Wave to design built-for-purpose molecules to optimally address disease biology.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#8220;Wave USA&#8221;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#8220;Wave Japan&#8221;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#8220;Wave Ireland&#8221;) was formed as a wholly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#8220;Wave UK&#8221;) was formed as a wholly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">owned subsidiary of Wave Life Sciences Ltd.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#8217;s differentiated neurology portfolio, as well as exploring other therapeutic areas of interest, building the Company&#8217;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#8217;s intellectual property, and assuring adequate capital to support these activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has not generated any product revenue and has incurred recurring net losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had cash, cash equivalents and short-term investments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">148.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#8217;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#8217;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#8217;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#8217;s research and development efforts will be successful, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and in U.S. dollars.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535801056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2. SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies described in the Company&#8217;s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 3, 2022, as amended (the &#8220;2021 Annual Report on Form 10-K&#8221;), have had no material changes during the six months ended June 30, 2022, except as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all time deposits with original maturities of more than three months from the date of purchase to be short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of June 30, 2022, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the consolidated statements of Series A preferred shares and shareholders&#8217; equity (deficit) for the three months ended March 31, and June 30, 2022 and 2021, the consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535606672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the Company&#8217;s financial assets that are measured at fair value on a recurring basis:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.514%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.668%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.622%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">123,163</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">123,163</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">151,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">126,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">150,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">150,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154,215</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154,215</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">here have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> transfers between fair value levels during the three months ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and restricted cash are Level 1 assets which are comprised of funds held in checking and money market accounts. Short-term investments are Level 2 assets which are comprised of time deposits with original maturities of more than three months. The Company determined that the fair value of its short-term investments is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, which approximates the carrying value of the term deposits. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> short-term investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021, as the term deposits that constitute the Company&#8217;s short-term investments were purchased during the six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535713920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4. SHARE-BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;) was approved by the Company&#8217;s shareholders and went into effect on August 10, 2021. The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#8220;2014 Plan&#8221;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5,450,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the Company&#8217;s board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#8220;RSUs&#8221;), and performance awards to eligible employees and directors of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options generally vest over periods of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5d565705-e9c6-4ee7-b392-a931aba94ef5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, and any options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a5e01550-cacf-493f-b2e4-2fd75161a30b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_509b5245-22eb-41f0-8890-375558e8677a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the compensation committee of the Company&#8217;s board of directors approved an amendment and restatement of the Company&#8217;s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021, the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. This modification did not result in any incremental expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company determined that a performance-based RSU milestone was achieved and consequently </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the outstanding performance-based RSUs vested, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">384,646</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares. During the three months ended June 30, 2022, the Company recorded share-based compensation expense of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, which represents all of the expense related to the achievement of this performance-based RSU milestone. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company did not recognize any expense related to the other performance-based RSU milestones, as the remaining milestones were not considered probable of achievement as of June 30, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2022, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,037,175</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> options and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">55,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> time-based RSUs to employees.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,561,172</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares remained available for future grant under the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan (&#8220;ESPP&#8221;) allows all full-time and certain part-time employees to purchase the Company&#8217;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning on or about January 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and July 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> every year. Shares are purchased at a price equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s ordinary shares on the first business day or the last business day of an offering period. During the six months ended June 30, 2022, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">77,534</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares were issued under the ESPP. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">804,940</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares available for issuance under the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918622755152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5. COLLABORATION AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Collaboration and Equity Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">February 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA and Wave UK entered into a global strategic collaboration (the &#8220;Takeda Collaboration&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#8220;CNS&#8221;). The Takeda Collaboration provides the Company with at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">230.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#8217;s CNS development programs in (1) Huntington&#8217;s disease (&#8220;HD&#8221;); (2) amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal dementia (&#8220;FTD&#8221;); and (3) the Company&#8217;s discovery-stage program targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ATXN3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of spinocerebellar ataxia 3 (&#8220;SCA3&#8221;) (collectively, &#8220;Category 1 Programs&#8221;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#8217;s disease and Parkinson&#8217;s disease (collectively, &#8220;Category 2 Programs&#8221;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">110.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as an upfront payment. Takeda also agreed to fund the Company&#8217;s research and preclinical activities in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceed that amount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Simultaneously with Wave USA and Wave UK&#8217;s entry into the collaboration and license agreement with Takeda (the &#8220;Takeda Collaboration Agreement&#8221;), the Company entered into a share purchase agreement with Takeda (the &#8220;Takeda Equity Agreement,&#8221; and together with the Takeda Collaboration Agreement, the &#8220;Takeda Agreements&#8221;) pursuant to which it agreed to sell to Takeda </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,096,892</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of its ordinary shares at a purchase price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">54.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">April 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company did not incur any material costs in connection with the issuance of shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#8220;Category 2 Research Term&#8221;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> targets at </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">any one time</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#8220;IND&#8221;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#8217;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#8217;s research and preclinical activities in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#8217;s global commercial sales of products from each Category 2 Program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The term of the Takeda Collaboration Agreement commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">April 2, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Takeda may terminate the Takeda Collaboration Agreement for convenience on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#8217;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Takeda Collaboration is managed by a joint steering committee (&#8220;JSC&#8221;) in which both parties are represented equally. The JSC is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and should therefore be combined into a single performance obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">At the outset of the arrangement, the transaction price included the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">110.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million upfront consideration received and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#8217;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation is being recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The transfer of control for these performance obligations occurs over time and, in management&#8217;s judgment, this input method is the best measure of progress towards satisfying the performance obligations. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#8217;s consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">October 15, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#8220;Amendment&#8221;), which discontinued the Category 2 component of the Takeda Collaboration. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">22.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as full payment for reimbursable Category 2 Program collaboration-budgeted research and preclinical expenses. The Category 1 Programs under the Takeda Collaboration Agreement remain in effect and are unchanged by the Amendment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Through June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company had recognized revenue of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">79.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million as collaboration revenue under the Takeda Collaboration Agreement. During the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recognized revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement, respectively. During the three and six months ended June 30, 2021, the Company recognized revenue of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million under the Takeda Collaboration Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">114.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million was included in current liabilities. The aggregate amount of the transaction price allocated to the Company&#8217;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022 is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">112.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million is included in current liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each Category 1 Program option upon Takeda&#8217;s exercise of such option, or immediately as each option expires unexercised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918620804608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6. SHAREHOLDERS&#8217; EQUITY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">June 2022 Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 16, 2022, the Company closed an underwritten offering (the &#8220;June 2022 Offering&#8221;) in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,464,483</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s ordinary shares at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,093,656</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of the Company&#8217;s ordinary shares at an offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2.1499</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders&#8217; equity within additional paid-in capital. The gross proceeds to the Company were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">before deducting underwriting discounts and commissions and other offering expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The net proceeds of the June 2022 Offering were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">65.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. </span></span><span style=""/></p><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the number of ordinary shares outstanding or more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% of the combined voting power of the Company&#8217;s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918532120288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Ordinary Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7. NET LOSS PER ORDINARY SHARE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company applies the two-class method to calculate its basic and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022, there are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7,093,656</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> vested and exercisable Pre-Funded Warrants outstanding to purchase ordinary shares for the exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.0001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following ordinary share equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.963%;"/>
        <td style="width:1.658%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.787999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.658%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.934%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,526,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,584,490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">979,850</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,027,019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Series A preferred shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,901,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,901,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Additionally, for the periods presented, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not participate in losses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535609808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8. INCOME TAXES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">During the three and six months ended June 30, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> income tax provision. The Company maintained a full valuation allowance for the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2022 and 2021 in all jurisdictions due to uncertainty regarding future taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s utilization of its net operating loss carryforwards and general business credit carryforwards in the United States may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. As of June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, the Company is evaluating whether an ownership change occurred during 2022. Should an ownership change have occurred or occur in the future, the Company&#8217;s ability to utilize its net operating losses and general business credit carryforwards may be limited.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535656720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Data<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_GeographicDataAbstract', window );"><strong>Geographic Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_GeographicDataDisclosureTextBlock', window );">Geographic Data</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">9. GEOGRAPHIC DATA</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company&#8217;s long-lived assets were located in the United States as of June 30, 2022 and December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_GeographicDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Geographic data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_GeographicDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_GeographicDataDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Geographic Data Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_GeographicDataDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918532120288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10. RELATED PARTIES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following related party transaction for the periods presented in the accompanying consolidated financial statements:</span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#8217;s founders and a member of the Company&#8217;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> days&#8217; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> thousand per month, plus reimbursement for certain expenses. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535545184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.889%;"/>
        <td style="width:2.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.647%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,574</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,473</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,571</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11,085</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,861</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535596288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12. LEASES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Lease Arrangements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into lease arrangements for its facilities. A summary of the arrangements is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lexington</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On September 26, 2016, and as amended on December 31, 2016, the Company entered into a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10 year and 9-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> lease , which includes two successive </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal options</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, for its facility in Lexington, Massachusetts (the &#8220;Lexington Lease&#8221;), which the Company uses primarily for its current good manufacturing practices (&#8220;cGMP&#8221;) manufacturing, as well as for additional laboratory and office space. Throughout the term of the Lexington Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Lexington Lease, the Company had restricted cash of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in a separate bank account as of June 30, 2022 and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cambridge</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In April 2015, the Company entered into a lease agreement for an office and laboratory facility in Cambridge, Massachusetts (the &#8220;Cambridge Lease&#8221;), which commenced in October 2015 with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> years with a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> the lease.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  Throughout the term of the Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Cambridge Lease, the Company had restricted cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in a separate bank account as of June 30, 2022 and December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company exercised its option under the Cambridge Lease to lease additional office and laboratory space at the adjoining facility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The combined space constitutes the entire building located at 733 Concord Avenue. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The lease for the additional space commenced on October 1, 2021, with a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the &#8220;Additional Cambridge Lease&#8221;).</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> On the commencement date of the Additional Cambridge Lease, the Company recorded a right-of-use asset and corresponding operating lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million and began recognizing straight-line rent expense under ASC 842. Throughout the term of the Additional Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company notified the landlord of its intention to exercise the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> renewal option under the Cambridge Lease to extend the lease term through March 2028 (the &#8220;Cambridge Lease Extension&#8221;). In June 2022, the Company calculated an incremental borrowing rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">% and remeasured the right-of-use asset and the lease liabilities related to the Cambridge Lease Extension. As of June 30, 2022, the Company recorded an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million of operating right-of-use asset and corresponding operating lease liabilities relating to the Cambridge Lease Extension. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533745712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all time deposits with original maturities of more than three months from the date of purchase to be short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unaudited Interim Financial Data</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim consolidated balance sheet as of June 30, 2022, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the consolidated statements of Series A preferred shares and shareholders&#8217; equity (deficit) for the three months ended March 31, and June 30, 2022 and 2021, the consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> or any other interim period or future year or period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535615664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the Company&#8217;s financial assets that are measured at fair value on a recurring basis:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.514%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.668%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.224%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.622%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">123,163</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">123,163</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">151,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">126,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">25,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">150,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">150,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154,215</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154,215</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535642224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following ordinary share equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.963%;"/>
        <td style="width:1.658%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.787999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.658%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.934%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Options to purchase ordinary shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,526,312</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">4,584,490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">979,850</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2,027,019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Series A preferred shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,901,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,901,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535696000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.889%;"/>
        <td style="width:2.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.123%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.647%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,574</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">10,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses related to CROs and CMOs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,473</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3,571</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,038</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">11,085</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">14,861</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/>&#160;</p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533749136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Company - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,163<span></span>
</td>
<td class="nump">$ 150,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short term investments</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents and short-term investments</a></td>
<td class="nump">$ 148,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533983536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Inputs Level 2 [Member] | Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">123,163,000<span></span>
</td>
<td class="nump">150,564,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">151,814,000<span></span>
</td>
<td class="nump">154,215,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Restricted cash</a></td>
<td class="nump">3,651,000<span></span>
</td>
<td class="nump">3,651,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Fair Value Inputs Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">123,163,000<span></span>
</td>
<td class="nump">150,564,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">126,814,000<span></span>
</td>
<td class="nump">154,215,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Fair Value Inputs Level 1 [Member] | Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Restricted cash</a></td>
<td class="nump">3,651,000<span></span>
</td>
<td class="nump">$ 3,651,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Fair Value Inputs Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring [Member] | Fair Value Inputs Level 2 [Member] | Short-Term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611133-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Footnote 11(c)))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=wve_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=wve_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527219328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_FairValueAssetsLevel1ToLevel2TransferAmount', window );">Fair Value Assets Level1 To Level2 Transfer Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_FairValueAssetsLevel2ToLevel1TransferAmount', window );">Fair Value Assets Level2 To Level1 Transfer Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_FairValueAssetsLevel1ToLevel2TransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level1 to level2 transfer amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_FairValueAssetsLevel1ToLevel2TransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_FairValueAssetsLevel2ToLevel1TransferAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets level2 to level1 transfer amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_FairValueAssetsLevel2ToLevel1TransferAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918532020944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,534<span></span>
</td>
<td class="nump">44,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,464,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember', window );">Time-based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-based RSUs [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="nump">384,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wve_TwoThousandNineteenEmployeeSharePurchasePlanMember', window );">2019 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_SharePurchasePriceAtEqualToFairMarketValuePercentage', window );">Share purchase price at equal to fair market value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Minimum [Member] | RSUs to Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Plan [Member] | Maximum [Member] | RSUs to Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement By Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_SharePurchasePriceAtEqualToFairMarketValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchase price at equal to fair market value percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_SharePurchasePriceAtEqualToFairMarketValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_TimeBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wve_TwoThousandNineteenEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wve_TwoThousandNineteenEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wve_TwoThousandTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wve_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527717888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>Target </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 2,776<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">$ 2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Collaboration and license agreement, deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_UpFrontConsiderationReceived', window );">Up-front consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Category One Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio', window );">Percentage of global costs and potential profits sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAgreementUpfrontPayment', window );">Upfront payment under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementMonthAndYear', window );">Collaboration and license agreement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementResearchTerm', window );">Research term under collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAgreementCommencementDate', window );">Collaboration agreement commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  02,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_MaximumTerminationNoticePeriod', window );">Collaboration agreement termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAgreementCommittedCash', window );">Collaboration agreement, committed cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio', window );">Percentage of global costs and potential profits sharing ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementDate', window );">Collaboration and License Agreement Date</a></td>
<td class="text">Oct. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 79,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Collaboration and license agreement, deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Collaboration and license agreement, deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember', window );">Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_FundReceivableForResearchAndPreclinicalActivities', window );">Fund receivable for research and preclinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationAndLicenseAgreementResearchTerm', window );">Research term under collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_MaximumTargetsForPreclinicalPrograms', window );">Maximum targets for preclinical programs | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_OptionToReachMaximumTargetsForPreclinicalPrograms', window );">Option to reach maximum targets for preclinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">any one time<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_CollaborationBudgetedResearchAndPreclinicalExpenses', window );">Collaboration-budgeted research and preclinical expenses</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember', window );">Collaboration and Share Purchase Agreements [Member] | Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued under equity agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear', window );">Equity investment agreement official closure month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementCommittedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement committed cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementCommittedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationAndLicenseAgreementResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationAndLicenseAgreementResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_CollaborationBudgetedResearchAndPreclinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>collaboration-budgeted research and preclinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_CollaborationBudgetedResearchAndPreclinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity investment agreement official closure date month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_FundReceivableForResearchAndPreclinicalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fund receivable for research and preclinical activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_FundReceivableForResearchAndPreclinicalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_MaximumTargetsForPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum targets for preclinical programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_MaximumTargetsForPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_MaximumTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_MaximumTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_OptionToReachMaximumTargetsForPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to reach maximum targets for preclinical programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_OptionToReachMaximumTargetsForPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of global costs and potential profits sharing ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_UpFrontConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_UpFrontConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wve_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wve_CategoryOneProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wve_CategoryOneProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=wve_CategoryTwoProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=wve_CategoryTwoProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=wve_CollaborationAndSharePurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918532024768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant or Right, Original issuance date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 16, 2022, the Company closed an underwritten offering (the &#8220;June 2022 Offering&#8221;) in which the Company issued and sold 25,464,483 of the Company&#8217;s ordinary shares at a price of $2.15 per share and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 7,093,656 of the Company&#8217;s ordinary shares at an offering price of $2.1499 per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders&#8217; equity within additional paid-in capital. The gross proceeds to the Company were $70.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds of the June 2022 Offering were approximately $65.5 million. The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of ordinary shares outstanding or more than 19.99% of the combined voting power of the Company&#8217;s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember', window );">At-The-Market Equity Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="nump">$ 13,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_June2022OfferingMember', window );">June 2022 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="nump">25,464,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of ordinary shares</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">$ 65,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_PreFundedWarrantsMember', window );">Pre Funded Warrants (Member)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 2.1499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre-funded warrant exercise price per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise', window );">Minimum percentage of combined voting power of securities outstanding immediate effect of exercise</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_PreFundedWarrantsMember', window );">Pre Funded Warrants (Member) | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding', window );">Percentage of ownership interest in ordinary shares outstanding</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=wve_PreFundedWarrantsMember', window );">Pre Funded Warrants (Member) | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase price of pre-funded warrants</a></td>
<td class="nump">7,093,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity/</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of combined voting power of securities outstanding immediate effect of exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest in ordinary shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wve_AtTheMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wve_June2022OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wve_June2022OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=wve_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=wve_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918535833824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share (Additional Information) (Details) - Pre Funded Warrants (Member)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrant outstanding | shares</a></td>
<td class="nump">7,093,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price Per Share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=wve_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=wve_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918534283104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from calculation of diluted net loss per share</a></td>
<td class="nump">8,526,312<span></span>
</td>
<td class="nump">4,584,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from calculation of diluted net loss per share</a></td>
<td class="nump">979,850<span></span>
</td>
<td class="nump">2,027,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from calculation of diluted net loss per share</a></td>
<td class="nump">3,901,348<span></span>
</td>
<td class="nump">3,901,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918626237488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527103664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Detail) - Scientific Advisor [Member] - Consulting Agreement [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_AgreementTerminationNoticePeriod', window );">Consulting agreement termination notice period</a></td>
<td class="text">14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting service expenses</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wve_ScientificAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=wve_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=wve_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918533746464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 6,574<span></span>
</td>
<td class="nump">$ 10,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses related to CROs and CMOs</a></td>
<td class="nump">3,473<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 11,085<span></span>
</td>
<td class="nump">$ 14,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139918527200416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 26, 2016</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend description</a></td>
<td class="text">In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Description of additional lease space</a></td>
<td class="text">The lease for the additional space commenced on October 1, 2021, with a term of five years and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the &#8220;Additional Cambridge Lease&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 28,791<span></span>
</td>
<td class="nump">18,378<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=wve_LexingtonMassachusettsMember', window );">Lexington, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription', window );">Renewal options</a></td>
<td class="text">10 year and 9-month lease , which includes two successive five-year renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=wve_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease option to extend description</a></td>
<td class="text">five-year renewal option to extend the lease.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend the lease</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wve_IncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">10.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_IncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_IncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements operating leases renewal term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wve_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=wve_LexingtonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=wve_LexingtonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=wve_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=wve_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>wve-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:wve="http://www.wavelifesciences.com/20220630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wve-20220630.xsd" xlink:type="simple"/>
    <context id="C_c58d23cc-a8ef-4814-b890-7cbfec7e1771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_66fb8ad3-5567-4c36-8044-b37768f732bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_e653c3aa-a802-452a-a708-c1562dbdcb0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_19feb3a5-3147-4251-b597-cc5dddc3d03a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_7f4a66c5-19f5-4662-8e71-93adf30b20fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_283fda3f-a748-40e5-99e9-66dde6ca0cdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_4792f081-460e-4ad6-ad8e-325ac9c41dc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9d37d597-867b-4964-81ad-9b451a752961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_796c0529-ff6d-4304-8565-b6a278d71641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_91887c61-e0ae-4ede-a7ee-64cb872cecda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_523d0df5-7bb1-4976-bcb4-802b05e28667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_aa7afc38-e09a-44cc-a44e-37a4604bf525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_6850af8e-74cf-4159-a423-9e97ac830052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="C_5673c773-6fb6-4577-b5dc-9d23f17ed1bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-08-03</instant>
        </period>
    </context>
    <context id="C_9d3dbb2e-67a6-4144-9218-06e8e22db676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_d1d7d11c-4b6d-425d-8b75-248ebc031db1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ee5e5857-7ec2-4544-8afb-0fae4befe31c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_1014ad06-e986-48e5-9503-e639ae78d329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_bc79ed5e-e97e-43dd-86ab-860fc162b811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_cd854128-fccf-4ea5-8af5-094c2a679228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_03b94d45-2ab0-4b85-a75d-2f64e83735c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndSharePurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_6c51ff68-df14-498e-96bb-034965c4e819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_c4f51145-90ba-40be-9cc2-4a963f92d5b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_810483b6-169c-4003-93e7-2b51cb18d965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_784d98d4-9d33-43ca-b470-1ebb4a0f75cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9134dba-b1a5-4e84-a5c5-72ab5e1405b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_b0b1b09a-bb0a-4062-85c6-f57ca2210290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_02dff14e-65b3-4f3f-9d30-e7af11da66b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4026c365-b133-428c-860d-0c091ee9904f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_961bdd6a-40fc-47c3-ab35-05fb69ac44f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="C_57758a2d-e69c-4d16-9b5f-18555ad23a37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_4659dc79-f8b5-4b14-9d07-60ba055803c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="C_bf5de431-1632-48b6-aedc-f9c9b3179fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_bfd509f5-3b0d-4cf5-8cf2-e980ca43764a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_0c78b4d1-3c37-4274-9f6c-17419b1da82b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_c20e87e3-d498-4147-b0a9-71f5f7748d21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_e54eb887-4c39-4a17-9604-14097e88cd22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">wve:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wve:ScientificAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_a886904f-adbf-4df1-86db-69f767bee50f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_e77d8791-33a3-4c78-aabb-020626bd3fa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_30e4d424-87c1-4f5b-a3af-aa203267d79e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="C_01de9b35-d2c7-4f8d-8e10-25a3ffd4f38d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_300b72ac-22b8-4e84-94fc-953ae4a01ce2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_945817ec-c317-4c4d-a941-a9c2cff299de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_3a341f84-a6ac-41b9-8129-462814cf0ca3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TwoThousandNineteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_23abe5e8-775e-492f-9f77-0932a3bf81ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_ced6e426-01fc-4c9a-8e66-3dc75c3ec32c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_eab7d096-c25e-41c2-b352-560599442f0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="C_43f567f4-79fa-4ca0-b106-8941f9b60bef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_07ca4716-43a0-42c3-9c43-358b926374da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef54c2d3-5966-4fb3-9eab-f71b3501eec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_d4adfc1c-840e-441f-bcba-dc515437a1cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4d00af1e-f5b9-4394-9bce-63d6f9517de8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_8f6202df-7ac9-4cd7-83f2-84cbea74e158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_25c8d8eb-2dcd-4e58-b29e-a48f2a155cda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_2f8aaf6a-e030-415e-9d69-aa20d78441ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="C_9dc48f65-6d35-4fbe-879e-ed161cf3817c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_43b01130-d745-405b-ab3a-510bbb1b2ba5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_d44fe466-a23b-42b0-a391-c7dc4d72b912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-26</instant>
        </period>
    </context>
    <context id="C_cb037edf-f54b-49db-aac5-3c4357081877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_cca9fe41-22fb-4a90-a590-df2e6385179a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_f97ce547-93fe-4c54-993a-2fa742897bf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7001869b-47df-4996-89c7-c6dba52a5dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_ed04036d-ee72-4713-80e6-728911c04be0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_97a6000b-e222-4ea3-90d8-088983fa43f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="C_33eafbee-95ba-4008-99b5-86a8a72a242d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="C_2ab93180-6144-478f-bf7a-66924176752d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_7e77fe91-cadf-496b-983c-b01aa60a825d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_94d9d100-4484-4e3c-afe1-66999eb32fe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9d44b7aa-b23e-472d-a764-81880eb67e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:June2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="C_e1e9f65b-ff19-4e3b-9b8b-906b8aa85797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_045adef5-17c5-408e-8baf-d0886f47c57e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:June2022OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="C_9c0260b0-d65e-4e5c-ba7f-4ad60a49c91c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_b12dd15a-4910-42a5-a1bb-da412b6b9efd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_60d55580-0910-42b0-bf64-b485a7374a06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_ebdb90e8-1c88-4029-9519-649704459478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_1ea32a82-226e-4e27-8b47-3c751c13dd45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TimeBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_7e7cfd1c-3deb-421d-9921-03ae52489936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c168803d-75ea-450b-8676-2d3cdeeebce0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_c9b91c5d-dde1-4b7e-9177-b5db41d9bd22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_291b8373-572b-4238-84ea-3e812d9288e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_8af245fc-0b06-427d-8e69-217279fe30bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e23b1234-bfa8-4df5-ab78-74d94722218e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wve:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ddda2744-95b7-4f48-9a57-fe82f59fa3f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0d59e805-fcfa-4e3d-8eb1-a7b22fa54655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_c246e5aa-1caf-4481-813a-25d44affd480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wve:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_031e56ef-ccf2-4828-ab59-1d84613c2255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_d0288e0e-5b52-4d7c-8564-10340131751a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_18a786b8-47b1-48cd-a1ab-330c03ba03cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">wve:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_016f1df7-e574-4d0c-b997-10712c56dbcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_8f7e7315-a48c-4091-b867-d0e4ab143762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_29fd470b-d8b0-4187-9842-129afee626da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_35f5ee7d-7f63-4f91-a5c1-961b0904b483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d985ba9-a3f1-4988-8ba2-a12fd859afa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f1cd1092-e3ce-42d0-85a8-ee118d1d1baa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wve:TwoThousandNineteenEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_5e525306-9d10-4441-8453-95cbed2392b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_1b4431b2-3b0c-4c57-a400-5e339022d24b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">wve:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_34ff48ca-a39d-487f-903e-584d7f5d9888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryTwoProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_3514b40a-9f70-4ea1-8a06-949d2fd1a5a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_97a77020-f99d-4117-95e5-bea4e51831d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_c059f602-3f2f-41ce-ba29-88681a96cc00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_5b138242-bd72-42e8-ada7-ec20e596c5d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_081e46bc-e848-4d63-ad8f-3f60872500c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_63319f7d-b0a5-431e-b212-d9dd4cc84b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_e543347d-565b-47d5-877c-37bddba8c561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_beb23801-7f60-437a-8667-465087c2ce57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a42041d6-7ac3-495f-9b06-c6682bfdc55a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wve:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">wve:CategoryOneProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">wve:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Target">
        <measure>wve:Target</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_4327803f-9dc9-412c-9468-f676ddf59a28">0001631574</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_43f567f4-79fa-4ca0-b106-8941f9b60bef"
      id="F_509b5245-22eb-41f0-8890-375558e8677a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_6243545a-3891-47ea-af88-6bb9a7295e61">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_9aecef43-a584-460c-903d-ced10cc55cad">false</dei:AmendmentFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c246e5aa-1caf-4481-813a-25d44affd480"
      id="F_5d565705-e9c6-4ee7-b392-a931aba94ef5">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_ad82f3d7-5fc0-4e08-9151-d51206c45b48">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_c246e5aa-1caf-4481-813a-25d44affd480"
      id="F_a5e01550-cacf-493f-b2e4-2fd75161a30b">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:DocumentType
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_91391e59-23cc-47eb-8e3b-2fa62b37302b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_b8fafca2-a1fb-4382-86be-fbbbcae2f916">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_439fb97a-99d5-488f-9fd9-091ddc889c34">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_4dcf7a26-c9fd-48eb-bfc6-6858e0370bb5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_43222bc8-0f49-4576-a21b-0b72f3f1c12d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_6da6cc97-56d2-4405-acae-13590ba5a3f9">001-37627</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_46887322-6a45-4437-8799-d521f9b34855">WAVE LIFE SCIENCES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_f47388af-bc53-4c1d-84b2-807206671b9d">U0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_82a1e0ee-8026-41e9-ad36-c41c26c05d9c">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_34898983-a47a-467d-beea-da338a9048dd">7 Straits View #12-00</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_bca717dd-7f1c-403b-b343-2cbd0b097938">Marina One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_06b68b01-bb61-4ab8-a419-59edc901b56c">East Tower</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_df8a9bde-fb9b-4fd1-9c75-b40ea5a52508">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_def9a177-3593-413c-aa6d-b007bf0a2009">018936</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_4f5615fe-3f89-4c9b-a477-291c30e48afa">+65</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_81521edf-fd38-482f-8c72-513f3b4195fb">6236 3388</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_093808cf-ee60-442b-a061-e83dcf496547">$0 Par Value Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_b996e608-0a7d-4fa0-a646-03b31b95c947">WVE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_18f54e2c-0203-49d3-9475-9d5490b2b80e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_237d363b-ef0a-4850-a4a7-104bd149a29a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_31e545e6-92f4-4521-9d9a-9034c2289abf">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_5fe59d9b-dbc4-4abb-8137-e19fbfc0aa7a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_83ba7d4d-e026-42a4-b62a-bc0e45536185">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_45e52ad9-0f8f-4f52-aa76-9f06d2c07822">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_c90554b4-e510-49d5-b9c7-642889d524f8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_5673c773-6fb6-4577-b5dc-9d23f17ed1bf"
      decimals="INF"
      id="F_00823d3c-cc21-4536-90b5-4e8e9705fd4b"
      unitRef="U_shares">86820111</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_93485a0c-f330-45a6-8d78-e734744a1178"
      unitRef="U_USD">123163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_33d07bb2-39a8-499f-accc-c7db4ccddceb"
      unitRef="U_USD">150564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_7a2d376b-d219-469b-88fa-bdfa683212e8"
      unitRef="U_USD">25000000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_eb9ba2d3-7bf0-4bd7-97ba-d4a883820362"
      unitRef="U_USD">5396000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_b2808a37-a6c8-4538-a7ed-73cacfcedfdf"
      unitRef="U_USD">6584000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_a711c581-a0a0-4eac-9519-65931e5cc15c"
      unitRef="U_USD">6555000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_33de5aa9-a5c0-481d-b786-7c624b5b2cce"
      unitRef="U_USD">5416000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_314f747d-e0c5-4548-a608-a9373cbc031a"
      unitRef="U_USD">160114000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_832198f7-edcb-4082-ad0c-e6c4f8b7ffbf"
      unitRef="U_USD">162564000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_1240e86a-3d4f-4808-9a7c-438e6798f061"
      unitRef="U_USD">19808000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_e01d9807-63de-4e48-b22f-aa0462433e10"
      unitRef="U_USD">22266000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_429661ad-4aa5-431c-b663-312e61c349ba"
      unitRef="U_USD">28791000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_a963f058-a70e-462f-8c06-f17622e368ce"
      unitRef="U_USD">18378000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_b2bb2d07-f89d-4c5f-9b76-6059dec53139"
      unitRef="U_USD">3651000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_129f7f51-a11c-424a-90b1-3ca17edea9a0"
      unitRef="U_USD">3651000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssets
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_c0b65cd8-0b9f-46fb-adce-2ca1c1637c32"
      unitRef="U_USD">955000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_be0c7a66-4109-487b-acb4-745a2fcc54c3"
      unitRef="U_USD">148000</us-gaap:OtherAssets>
    <us-gaap:AssetsNoncurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_39dbb4db-8626-4ffc-a70d-5cd7bc96489f"
      unitRef="U_USD">53205000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_96f10658-4c91-4930-9279-13162fe9d34b"
      unitRef="U_USD">44443000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_44e1a5be-c55b-4a2f-b56b-0433db323059"
      unitRef="U_USD">213319000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_84d52910-391f-4fb3-be69-75032e3c0471"
      unitRef="U_USD">207007000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_32c38d72-3b3a-4412-86aa-19ddf9c7f070"
      unitRef="U_USD">11168000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_e332dc41-5aa1-4690-a428-e25ff5a2bda8"
      unitRef="U_USD">7281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_78fcbd7f-b92c-47d1-847f-ff5184b02202"
      unitRef="U_USD">11085000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_5b596c36-91d3-449e-91ef-ac29206644b2"
      unitRef="U_USD">14861000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_fc312ca5-ddef-4969-bbba-61910fcee8cf"
      unitRef="U_USD">37466000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_8490b0d1-cf8a-432e-91f8-4030306ee5c3"
      unitRef="U_USD">37098000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_0b78b9e2-aaed-44fe-a473-580543959bc8"
      unitRef="U_USD">4363000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_d4ba2a02-7f6a-437e-b002-da175ddf4609"
      unitRef="U_USD">4961000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_c8764a36-142f-4434-ac74-ee43d14883ea"
      unitRef="U_USD">64082000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_6fb56387-7c3e-43d2-95c1-9e8c7e4fa4d7"
      unitRef="U_USD">64201000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_b7869e60-bb9c-4d75-9e22-2a8edb563bde"
      unitRef="U_USD">75256000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_bdb48894-5fb8-432e-a99d-6d45816bb452"
      unitRef="U_USD">77479000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_de0ba408-bbee-498b-b578-232147108a0a"
      unitRef="U_USD">35160000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_6a93f1c0-c838-4852-88b0-a8a01fa96c01"
      unitRef="U_USD">24955000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_a05da4b4-9c10-4ba6-b129-7c3ab5768ced"
      unitRef="U_USD">110416000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_bb6b7870-9720-498c-b8f8-7acdcc1de67a"
      unitRef="U_USD">102434000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_a05fdff8-98b7-4450-af1f-803c18c20499"
      unitRef="U_USD">174498000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_cc48a26c-fdcc-4c83-9ca1-dac2b8913ae4"
      unitRef="U_USD">166635000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_104b2845-37a0-4f7b-a0a3-dccaccc450b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_2bd68fc9-a054-422c-b158-638795ec00ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_baaa62b3-1c42-4575-bac8-c230dec4e1a6"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_9b270da4-5f7a-427a-8473-59c43bd3522d"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_dec0b1c6-04be-49c4-abef-069a73d3ccfc"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_fca8ae8b-ab82-49ea-ad6b-e66011228325"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_797223ab-f210-4234-80e3-d9b0049e2bab"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_56cf89b8-5704-4d1b-a8c3-9fc2f8ac6f97"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockNoParValue
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_514b3427-a02b-4880-bcfe-7292b2fa3be3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_1a02a818-40a8-41aa-ab93-94a778c13efd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_58a98c9a-7958-41a7-b0b7-95740b805e68"
      unitRef="U_shares">86724658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="INF"
      id="F_8c5448e3-161e-4e07-884d-479cffe4ae91"
      unitRef="U_shares">86724658</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_9b98bb16-0f1e-42c5-ab00-e99510de93c5"
      unitRef="U_shares">59841116</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="INF"
      id="F_98d8bcec-8d4a-489a-8048-0f40b9e26524"
      unitRef="U_shares">59841116</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_c1d1dad8-0e3a-4750-8c48-bad4dcc9a228"
      unitRef="U_USD">802449000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_624821f0-d762-490b-94e2-87e46eff56df"
      unitRef="U_USD">749851000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_2e0d3096-d3b1-4e66-aeab-072ee7f31ada"
      unitRef="U_USD">113169000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_dc1dd841-0120-44ee-910d-6fbfdb596534"
      unitRef="U_USD">87980000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_9108bbfb-11b1-4203-b071-6f99f1cb12eb"
      unitRef="U_USD">-47000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_19bb061e-0325-4089-885a-0b46d5dc313f"
      unitRef="U_USD">181000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_db001beb-4319-43a6-baf3-13d03443ae06"
      unitRef="U_USD">-884624000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_5c1c4562-185e-462b-bd87-04855b72982a"
      unitRef="U_USD">-805514000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_d51f996f-93fe-43fe-8887-8f1efebc8d15"
      unitRef="U_USD">30947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_ec40d80f-d250-4aa6-865a-3fbe966339ad"
      unitRef="U_USD">32498000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_7f10d144-49fe-4150-be37-82c5a8cc8f3d"
      unitRef="U_USD">213319000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_992a9be7-6852-4ead-ac03-52cd81ef5c41"
      unitRef="U_USD">207007000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_12359bfd-b302-4712-9ba3-25e51af6b736"
      unitRef="U_USD">375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_3db106bf-6169-427e-9b97-211d55db0ccb"
      unitRef="U_USD">2776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_06ec458b-ebbb-4547-9bc6-7fc72f5a812a"
      unitRef="U_USD">2125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_b84696e4-be41-401e-ab20-590ccfed185e"
      unitRef="U_USD">2776000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_9efeed5b-7c6e-4519-adc4-9a95d057f88e"
      unitRef="U_USD">29733000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_33864c02-41e0-4868-b322-f373d9079f9a"
      unitRef="U_USD">31635000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_14b8ec0f-036c-4e5b-955d-1c93c3786589"
      unitRef="U_USD">57203000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_50499918-e21d-4126-aff3-72fb82438f0f"
      unitRef="U_USD">65028000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_339d4db3-479b-4838-b647-f51e1b64f975"
      unitRef="U_USD">12806000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_a8dcfde5-a17b-42a4-a438-6c0a4894f951"
      unitRef="U_USD">10969000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_e36ecf38-29ee-45ea-ba67-224c2b430714"
      unitRef="U_USD">25180000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_953b3d7e-d804-425f-bed8-fc9073564bcb"
      unitRef="U_USD">21047000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_515d6d39-e709-4a68-bac8-ba8149ae34ee"
      unitRef="U_USD">42539000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_856ce140-2564-4ac2-b6e4-7aeab916c92c"
      unitRef="U_USD">42604000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_8dd8c4dc-eaca-4dce-9f51-fae26f73e701"
      unitRef="U_USD">82383000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_0b295373-0944-40d0-b1d0-ae8e96931098"
      unitRef="U_USD">86075000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_08895d9b-4fa4-4f53-8001-f55ae384d79b"
      unitRef="U_USD">-42164000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_6dd23e2f-bba7-439c-b2d1-19e8ba17ab94"
      unitRef="U_USD">-39828000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_62feaccd-54dd-452a-b957-bfedb5cd4f19"
      unitRef="U_USD">-80258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_3e0042be-7592-47b0-bec0-004487e2a2e4"
      unitRef="U_USD">-83299000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_b98fe50b-4998-42d9-8b8b-677ae00cfd8d"
      unitRef="U_USD">124000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_1b428cef-edd7-4a6c-ab57-7564d085405e"
      unitRef="U_USD">8000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_3152fe91-f7e2-4c84-8996-9fb022b00866"
      unitRef="U_USD">150000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_c9bd9fa1-5d2c-4a3a-ab88-e54d339dbb23"
      unitRef="U_USD">19000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_4b793dc3-63b4-4f58-8b09-0309ac37ef57"
      unitRef="U_USD">744000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_fc6fd739-6c19-40bb-ba19-433f29c84912"
      unitRef="U_USD">1054000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_b71eb404-07aa-4499-907e-9111aabd7eb0"
      unitRef="U_USD">998000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_fd73f878-0f90-4e9e-86b0-24ff0f0e5c23"
      unitRef="U_USD">2050000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_124c182f-05ed-4db4-9f85-695b5e7c0d70"
      unitRef="U_USD">868000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_57cd71e1-dbc4-4e2f-b912-84257e2fd566"
      unitRef="U_USD">1062000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_f1dcf36c-5431-4980-8fc2-c005388713b8"
      unitRef="U_USD">1148000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_0b7b3e83-7f7c-4358-b81a-d3f039fbb06b"
      unitRef="U_USD">2069000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_006e865e-e517-45a8-ba04-bc483126c523"
      unitRef="U_USD">-41296000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_1a501b4c-cae7-44f1-a372-75eda822d79b"
      unitRef="U_USD">-38766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_d6d126d8-d1da-4209-919b-e6ed1af44e8b"
      unitRef="U_USD">-79110000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_4a9ea51e-7455-4c0f-b633-884e65b52d50"
      unitRef="U_USD">-81230000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_afac9fb4-4c4d-40f6-8903-41141401191c"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_7c4af975-151e-4501-a1c0-4d74a5ccf809"
      unitRef="U_USD">-38766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_badb4151-4229-4df2-8441-789175ec5931"
      unitRef="U_USD">-79110000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_ad1710ca-42eb-49d5-96c0-a8f2125c2362"
      unitRef="U_USD">-81230000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="2"
      id="F_1469d839-22f7-432a-96ce-5331b0283402"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="2"
      id="F_da8a6e43-46ef-44f1-835a-fffc4ec963aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="2"
      id="F_e676249e-1ca7-4049-a7bd-75db56c9648c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="2"
      id="F_7c4fbce9-8366-4f4c-971e-287164fef443"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="2"
      id="F_d4af11e5-be49-468e-a905-0db6f2051b86"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="2"
      id="F_6d59f1ec-3dc1-4232-a65f-71735d8775ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="2"
      id="F_05b10637-4466-4f70-8273-fd925114de8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="2"
      id="F_f5b1c711-cc68-4d86-9a62-eef991aaeaaf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="0"
      id="F_940a0658-7c93-4654-9b0c-5e0fd1c141a6"
      unitRef="U_shares">66479293</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="0"
      id="F_babfe233-8cd2-4a67-850e-a1c6ca4794a3"
      unitRef="U_shares">66479293</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="0"
      id="F_8af7b87a-a284-4dac-8de3-612ad1d76f37"
      unitRef="U_shares">49973185</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="0"
      id="F_14782a72-e94a-41ae-891c-1dea6fe425c6"
      unitRef="U_shares">49973185</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="0"
      id="F_af2e481b-950d-4d8f-95ce-ca14c8acc5b8"
      unitRef="U_shares">63514426</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="0"
      id="F_d5bd1b36-6096-46cb-ad92-52c0bb079c19"
      unitRef="U_shares">63514426</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="0"
      id="F_81a4b312-c0b7-4357-b481-63d387e91ab5"
      unitRef="U_shares">49220140</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="0"
      id="F_241b1293-c93e-49b9-8a41-773edb03ed44"
      unitRef="U_shares">49220140</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_45fb3cde-8ae2-44e5-8692-f53e636c024b"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_a232793a-660b-4f88-8f3e-04f8648ad2bb"
      unitRef="U_USD">-38766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_259c8bd6-c64f-4a04-b303-d876dfa6ca51"
      unitRef="U_USD">-79110000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_df52f769-78cd-4169-92b7-97aabc03a6f7"
      unitRef="U_USD">-81230000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_631d4764-253f-46e1-879e-56f7979b02c1"
      unitRef="U_USD">-142000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_bb8ac357-be8b-407f-8928-223e6b0070d7"
      unitRef="U_USD">-228000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_7b37ed3e-eeeb-4be1-ae5d-5e51283d175e"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_0bb60635-e750-4670-9124-fb80edd4044f"
      unitRef="U_USD">-41438000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_57a081e6-a41e-433e-9316-e1c040c0cfc5"
      unitRef="U_USD">-38766000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_c196ebe1-be3d-4e13-9e83-3040ea83b7da"
      unitRef="U_USD">-79338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_6c4119a0-b5e5-43f7-bd3d-587b7ad6f723"
      unitRef="U_USD">-81350000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e"
      decimals="INF"
      id="F_b2f5a1ea-f7f1-48f7-bf7a-0b965232b151"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_883ae04c-9fb0-4b03-a500-16a6a05dcf0e"
      decimals="-3"
      id="F_77fccdf3-1f74-464d-83f8-01e564c2c4f9"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7"
      decimals="INF"
      id="F_bb910586-c5a8-4db2-9530-f048208a00b0"
      unitRef="U_shares">48778678</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8ad75e81-056c-4a85-b15b-c340a1b5a0a7"
      decimals="-3"
      id="F_d02069bc-4cb9-463a-8d8e-b68c37a0dce7"
      unitRef="U_USD">694085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d44fe466-a23b-42b0-a391-c7dc4d72b912"
      decimals="-3"
      id="F_b6943aae-39fd-450d-8d36-f74e591e7d72"
      unitRef="U_USD">71573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f97ce547-93fe-4c54-993a-2fa742897bf2"
      decimals="-3"
      id="F_5a5cb987-bd69-4277-941c-fc6f27d03c2d"
      unitRef="U_USD">389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d4adfc1c-840e-441f-bcba-dc515437a1cd"
      decimals="-3"
      id="F_3bd9e9c8-61a1-4105-9eb5-770b49ff6e9d"
      unitRef="U_USD">-683269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ed04036d-ee72-4713-80e6-728911c04be0"
      decimals="-3"
      id="F_f59fd156-7ee0-416d-9767-65deffcce174"
      unitRef="U_USD">82778000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1"
      decimals="INF"
      id="F_736159cc-23e9-4cea-bea9-623827facefd"
      unitRef="U_shares">844796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f546a55b-be67-4dc5-85d8-21b4aadce6b1"
      decimals="-3"
      id="F_3b6c7515-f152-4fdc-970f-43a1f4e5c62c"
      unitRef="U_USD">8028000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_25c8d8eb-2dcd-4e58-b29e-a48f2a155cda"
      decimals="-3"
      id="F_ab5dbc67-6455-42eb-844a-64826fa50fb4"
      unitRef="U_USD">8028000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_60d55580-0910-42b0-bf64-b485a7374a06"
      decimals="-3"
      id="F_288945d0-56d0-465b-88dd-8080ee15ad99"
      unitRef="U_USD">4063000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"
      decimals="-3"
      id="F_8925fd80-28d6-4792-87ea-87d5dbaa90ac"
      unitRef="U_USD">4063000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"
      decimals="INF"
      id="F_7d2d613b-3b12-48cc-ba28-11ea558acfcf"
      unitRef="U_shares">155184</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"
      decimals="INF"
      id="F_6a36d288-1c2f-463a-a87b-891b5fa157a5"
      unitRef="U_shares">31957</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"
      decimals="-3"
      id="F_fe13eca6-831b-42d7-844b-6373f33b33bc"
      unitRef="U_USD">200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"
      decimals="-3"
      id="F_ecbcf2d9-1e48-4b77-b59d-b4086808a6c7"
      unitRef="U_USD">200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"
      decimals="INF"
      id="F_5be9b06a-26db-46d6-843a-cf6b490bd627"
      unitRef="U_shares">44036</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_cc627f0c-db6c-48e4-a999-c7ed3a4cb13a"
      decimals="-3"
      id="F_722f1754-d4b4-4557-a848-bb34f1b95248"
      unitRef="U_USD">336000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"
      decimals="-3"
      id="F_23b2b490-bfa4-4130-8099-048a929039aa"
      unitRef="U_USD">336000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a42041d6-7ac3-495f-9b06-c6682bfdc55a"
      decimals="-3"
      id="F_0d9f7bfa-800f-45c7-9ba0-3cca2ea76f38"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"
      decimals="-3"
      id="F_1e053349-11ac-4ba4-8c43-ac371ba7b96b"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_8f7e7315-a48c-4091-b867-d0e4ab143762"
      decimals="-3"
      id="F_fc675127-5c80-4be8-8900-e3bc7cacfcc3"
      unitRef="U_USD">-42464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bb84a86b-856a-4bb3-b935-cf1b54f491d0"
      decimals="-3"
      id="F_0e4401c9-7b91-4f5e-a2da-eb4dc10aa066"
      unitRef="U_USD">-42464000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_19feb3a5-3147-4251-b597-cc5dddc3d03a"
      decimals="INF"
      id="F_0b04bd10-f501-4d7a-8e86-c6242517dd08"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_19feb3a5-3147-4251-b597-cc5dddc3d03a"
      decimals="-3"
      id="F_b02e6453-e534-499a-974c-ce3375bab36c"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_91887c61-e0ae-4ede-a7ee-64cb872cecda"
      decimals="INF"
      id="F_e4ff92ee-ba4a-4881-bc4e-ed71ad2039f6"
      unitRef="U_shares">49854651</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_91887c61-e0ae-4ede-a7ee-64cb872cecda"
      decimals="-3"
      id="F_323ae07a-8f7c-4577-9c5a-df2bc7ca84ec"
      unitRef="U_USD">702649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ddda2744-95b7-4f48-9a57-fe82f59fa3f5"
      decimals="-3"
      id="F_fd902ad3-59f5-4838-9125-3699ebe8b3ca"
      unitRef="U_USD">75636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa7afc38-e09a-44cc-a44e-37a4604bf525"
      decimals="-3"
      id="F_f3ea24a4-198e-4fe7-a0eb-fb258827bdb9"
      unitRef="U_USD">269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ebdb90e8-1c88-4029-9519-649704459478"
      decimals="-3"
      id="F_56aaf661-a618-41da-921a-8efff1edb105"
      unitRef="U_USD">-725733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2f8aaf6a-e030-415e-9d69-aa20d78441ac"
      decimals="-3"
      id="F_a3bfd9ed-44e6-4654-a281-9a81f0bbdb2c"
      unitRef="U_USD">52821000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12"
      decimals="0"
      id="F_b0c71c75-9d44-47f0-87a3-4299fb654fb9"
      unitRef="U_shares">718179</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_731bce56-ba7f-4b36-962e-ba0aa20d7d12"
      decimals="-3"
      id="F_2b12cec6-c88b-4bc7-8543-8e568397e269"
      unitRef="U_USD">5065000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e77d8791-33a3-4c78-aabb-020626bd3fa3"
      decimals="-3"
      id="F_78755490-4f15-492c-b3cb-9127587aa38a"
      unitRef="U_USD">5065000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_97a77020-f99d-4117-95e5-bea4e51831d4"
      decimals="-3"
      id="F_35013dd4-4b9c-43d2-b114-170f9eaa4ff3"
      unitRef="U_USD">2722000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_e2e04bf6-c4dd-4a54-b5e9-5597fafaa565"
      unitRef="U_USD">2722000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_2ab93180-6144-478f-bf7a-66924176752d"
      decimals="0"
      id="F_f554fb87-6ff1-4162-ab6e-86697e5134ab"
      unitRef="U_shares">3636</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:NetIncomeLoss
      contextRef="C_e653c3aa-a802-452a-a708-c1562dbdcb0b"
      decimals="-3"
      id="F_7947bfad-e71c-4ac6-b3ea-568d4191f072"
      unitRef="U_USD">-38766000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="-3"
      id="F_af21391d-7f15-45e8-afea-daa0f182a7c5"
      unitRef="U_USD">-38766000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9"
      decimals="INF"
      id="F_4b35c08e-7abf-4b3b-b1be-22b3c7127580"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_a47f01ff-fbcb-4367-a11e-45732a43f9f9"
      decimals="-3"
      id="F_d4ba1748-a140-4334-93f3-044267b21b71"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_291b8373-572b-4238-84ea-3e812d9288e9"
      decimals="0"
      id="F_f42474be-8dfc-488f-9151-54b92f45a9f7"
      unitRef="U_shares">50576466</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_291b8373-572b-4238-84ea-3e812d9288e9"
      decimals="-3"
      id="F_477ab014-c343-403c-a53b-74364ffd1e61"
      unitRef="U_USD">707714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_43b01130-d745-405b-ab3a-510bbb1b2ba5"
      decimals="-3"
      id="F_18c80f69-258e-4b9a-8093-e76159f66a28"
      unitRef="U_USD">78358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4792f081-460e-4ad6-ad8e-325ac9c41dc6"
      decimals="-3"
      id="F_8bc3d538-bd8e-4ae7-94de-b9a147421e16"
      unitRef="U_USD">269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7e77fe91-cadf-496b-983c-b01aa60a825d"
      decimals="-3"
      id="F_fe627eed-1b0a-4efb-a4ec-62cb56e48b37"
      unitRef="U_USD">-764499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e543347d-565b-47d5-877c-37bddba8c561"
      decimals="-3"
      id="F_bdcefc59-caf9-42ca-a2a9-e2ed13e735de"
      unitRef="U_USD">21842000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_29fd470b-d8b0-4187-9842-129afee626da"
      decimals="INF"
      id="F_a6703c8c-24ea-4480-a859-7d7ab145a106"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_29fd470b-d8b0-4187-9842-129afee626da"
      decimals="-3"
      id="F_91efc457-1fc4-4585-82eb-4ee72662c334"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3"
      decimals="INF"
      id="F_8516083c-2347-4d57-8024-dacde6bb70db"
      unitRef="U_shares">59841116</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cde1db94-a6aa-4691-8189-e80d7c8dc0d3"
      decimals="-3"
      id="F_76b2be44-bf42-414b-99d6-c3c2bd0d2959"
      unitRef="U_USD">749851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_35f5ee7d-7f63-4f91-a5c1-961b0904b483"
      decimals="-3"
      id="F_1c93cd9d-97ab-4d64-a915-4c5a8055ae31"
      unitRef="U_USD">87980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_02dff14e-65b3-4f3f-9d30-e7af11da66b7"
      decimals="-3"
      id="F_bf54e795-a9e3-4584-be28-50781d37588a"
      unitRef="U_USD">181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_784d98d4-9d33-43ca-b470-1ebb4a0f75cd"
      decimals="-3"
      id="F_8109851f-c4bf-4165-94e8-1efeb34f1c9b"
      unitRef="U_USD">-805514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_ec7baddc-6357-42d9-976b-2d9b1113db90"
      unitRef="U_USD">32498000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_016f1df7-e574-4d0c-b997-10712c56dbcb"
      decimals="INF"
      id="F_1063ac0c-afe7-420e-b81a-4313393aa6d1"
      unitRef="U_shares">458092</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_016f1df7-e574-4d0c-b997-10712c56dbcb"
      decimals="-3"
      id="F_921053c2-7643-4944-9303-bfbff67dc8a7"
      unitRef="U_USD">1167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9d44b7aa-b23e-472d-a764-81880eb67e69"
      decimals="-3"
      id="F_77ea727b-9f47-4a20-8419-e7504ec28471"
      unitRef="U_USD">1167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_0c78b4d1-3c37-4274-9f6c-17419b1da82b"
      decimals="-3"
      id="F_129685f7-d975-4139-b99e-f19212743d6b"
      unitRef="U_USD">3971000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f"
      decimals="-3"
      id="F_69a39dd2-73bb-41b9-b297-6475398a6ea8"
      unitRef="U_USD">3971000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc"
      decimals="0"
      id="F_e66215bc-9c8b-427d-b9ef-e37b4668781e"
      unitRef="U_shares">468226</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc"
      decimals="0"
      id="F_e1e56f1a-ba16-4083-b2d4-fccaa45cf131"
      unitRef="U_shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc"
      decimals="-3"
      id="F_fa1ac1eb-e3bd-40ea-be66-3449bb040a61"
      unitRef="U_USD">37000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f"
      decimals="-3"
      id="F_47e626fb-92a3-4d22-ae09-07f080fd773e"
      unitRef="U_USD">37000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc"
      decimals="0"
      id="F_fa2cb6f0-fa57-4c9b-aae7-c3435cc11562"
      unitRef="U_shares">77534</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_66fb8ad3-5567-4c36-8044-b37768f732bc"
      decimals="-3"
      id="F_39e0ae5f-5bd7-43eb-9fc8-a6fc11d28810"
      unitRef="U_USD">174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f"
      decimals="-3"
      id="F_c6c09c77-0792-4566-b0ed-80e587c47706"
      unitRef="U_USD">174000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_23abe5e8-775e-492f-9f77-0932a3bf81ba"
      decimals="-3"
      id="F_868d6ee1-2bf1-4d9c-bbad-2267ef32c494"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f"
      decimals="-3"
      id="F_d78531b9-5e11-4d6d-8124-b1bc5cf72186"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_081e46bc-e848-4d63-ad8f-3f60872500c5"
      decimals="-3"
      id="F_ee7cf1f9-ca0c-4666-b3fd-cc80e69d8e48"
      unitRef="U_USD">-37814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a886904f-adbf-4df1-86db-69f767bee50f"
      decimals="-3"
      id="F_1e67367c-f1ba-45ef-bd24-67b40270b0b2"
      unitRef="U_USD">-37814000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_beb23801-7f60-437a-8667-465087c2ce57"
      decimals="INF"
      id="F_aa2d5512-4a49-4211-8aaf-b69f785e1eca"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_beb23801-7f60-437a-8667-465087c2ce57"
      decimals="-3"
      id="F_7946a57c-6e88-4bf1-a6c7-6c256d7299ea"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_cb037edf-f54b-49db-aac5-3c4357081877"
      decimals="0"
      id="F_426e4e44-8939-43dc-a057-dc3537606a61"
      unitRef="U_shares">60859968</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_cb037edf-f54b-49db-aac5-3c4357081877"
      decimals="-3"
      id="F_32f265d1-8aa1-49dc-9218-06acc03db678"
      unitRef="U_USD">751229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e9134dba-b1a5-4e84-a5c5-72ab5e1405b9"
      decimals="-3"
      id="F_8ba9a1d8-200c-49d7-adfc-69bdbf3ef9cd"
      unitRef="U_USD">91951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9d3dbb2e-67a6-4144-9218-06e8e22db676"
      decimals="-3"
      id="F_f6ba635e-e022-4680-9450-6b329ba1c7fd"
      unitRef="U_USD">95000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee5e5857-7ec2-4544-8afb-0fae4befe31c"
      decimals="-3"
      id="F_77256c48-895d-4f43-bed5-ecf12421f36c"
      unitRef="U_USD">-843328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4d00af1e-f5b9-4394-9bce-63d6f9517de8"
      decimals="-3"
      id="F_c51375a8-583b-467b-9bc7-6cece4633b2a"
      unitRef="U_USD">-53000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a"
      decimals="0"
      id="F_6d347e15-abc0-43a4-86c8-97e3e7a2088a"
      unitRef="U_shares">25464483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a"
      decimals="-3"
      id="F_acd97a10-beff-4771-bdba-f09b06330ce9"
      unitRef="U_USD">51220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_2d1cc638-ad30-4a1b-8653-d31f80520c07"
      unitRef="U_USD">51220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85"
      decimals="-3"
      id="F_79bc1ad5-5a00-4af1-9183-5b8dd0f5e6b8"
      unitRef="U_USD">14268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_b8852e0d-876b-4295-a805-a0530db631f0"
      unitRef="U_USD">14268000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_abdaceb1-0e8b-4354-b79f-d1fae57a3d85"
      decimals="-3"
      id="F_3e00bd34-e7a1-43bd-b30c-0a1faa0eeebb"
      unitRef="U_USD">6950000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_2432e811-fec9-4d55-a379-ffa9c5276b0f"
      unitRef="U_USD">6950000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_cca9fe41-22fb-4a90-a590-df2e6385179a"
      decimals="0"
      id="F_e8c90fec-7a3d-40dc-9080-b2efecc78ea1"
      unitRef="U_shares">400207</wve:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0d59e805-fcfa-4e3d-8eb1-a7b22fa54655"
      decimals="-3"
      id="F_cd6e6301-7c1b-40fe-8286-8254d0b99cc2"
      unitRef="U_USD">-142000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_3bf40ad9-278c-4e48-8acb-9f2667669ca8"
      unitRef="U_USD">-142000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_bfd509f5-3b0d-4cf5-8cf2-e980ca43764a"
      decimals="-3"
      id="F_f5151126-9230-4903-aaf7-61ad2aea4345"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="-3"
      id="F_02ee4a71-24bc-424b-bfe0-b59bee07c01f"
      unitRef="U_USD">-41296000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7e7cfd1c-3deb-421d-9921-03ae52489936"
      decimals="INF"
      id="F_40190fe8-e8b3-4656-b1ad-1027b70b184b"
      unitRef="U_shares">3901348</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_7e7cfd1c-3deb-421d-9921-03ae52489936"
      decimals="-3"
      id="F_724684aa-1788-498c-9a3f-346d2ac4970e"
      unitRef="U_USD">7874000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563"
      decimals="INF"
      id="F_1b04596b-da38-440d-9d78-dcedafb935cd"
      unitRef="U_shares">86724658</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c9fa7af9-1b16-4e3b-b760-0fcd67eec563"
      decimals="-3"
      id="F_783fa48e-e04f-4142-b7dc-572454969fac"
      unitRef="U_USD">802449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1e9f65b-ff19-4e3b-9b8b-906b8aa85797"
      decimals="-3"
      id="F_f00c5ca7-a14c-43c3-b368-2162ca9878ae"
      unitRef="U_USD">113169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3a341f84-a6ac-41b9-8129-462814cf0ca3"
      decimals="-3"
      id="F_a6bf9f92-a9b1-4bd7-8cc8-ae89d4a88a4b"
      unitRef="U_USD">-47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6c51ff68-df14-498e-96bb-034965c4e819"
      decimals="-3"
      id="F_9c5308bf-e429-4736-af12-0200b4b4c9e3"
      unitRef="U_USD">-884624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_219b930b-2c35-4461-b4ba-599bf055f58a"
      unitRef="U_USD">30947000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_56cef9c0-cfbe-4ee9-a038-a6cfc52795eb"
      unitRef="U_USD">-79110000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_0676b932-f523-4d70-8cd3-243a88dcd88d"
      unitRef="U_USD">-81230000</us-gaap:ProfitLoss>
    <wve:AmortizationOfRightOfUseAssets
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_17d7555a-4a0d-4c2d-b86c-56cffad27006"
      unitRef="U_USD">1593000</wve:AmortizationOfRightOfUseAssets>
    <wve:AmortizationOfRightOfUseAssets
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_ce14ea9f-e64a-4334-b32a-3400435b861c"
      unitRef="U_USD">1043000</wve:AmortizationOfRightOfUseAssets>
    <us-gaap:Depreciation
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_9c108c05-d408-4feb-a151-302fa490182e"
      unitRef="U_USD">3425000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_1a36168a-7b2a-45b6-98bb-15de6da83c20"
      unitRef="U_USD">3857000</us-gaap:Depreciation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_ffc3467b-bcb4-4cc2-b65c-8b91debc427c"
      unitRef="U_USD">10921000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_aa5131ff-bc04-42df-90fd-8bb51f53c91d"
      unitRef="U_USD">6785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_d533d19e-bca8-44fb-a0a7-439c653e74c5"
      unitRef="U_USD">30000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_f4efb914-f647-4469-bda0-5017f2d3d87c"
      unitRef="U_USD">-1188000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_34723028-47fe-4a70-a870-f669708b93ad"
      unitRef="U_USD">-1246000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_0354eac2-4ddd-4634-9f4a-26448595c26b"
      unitRef="U_USD">1946000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_7af13b2d-ef31-4277-82bc-1ec95bf90f40"
      unitRef="U_USD">3475000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_30a23a83-1a22-4b1e-b925-3f24ed7911c9"
      unitRef="U_USD">3264000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_dec78fe9-892a-4595-98fe-33c235faf7b6"
      unitRef="U_USD">-5251000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_b25bd41f-e9e7-4eb6-9d4a-763f41a485f3"
      unitRef="U_USD">-3776000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_846746e2-6c4a-4328-a144-0298f0828098"
      unitRef="U_USD">-2048000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_cfa4914f-daba-4801-b402-86a310839646"
      unitRef="U_USD">-1855000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_98b3c8f2-177b-412f-b64c-79785fae4aba"
      unitRef="U_USD">-2776000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <wve:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_07e87d23-cffd-4b9e-ac2f-414003144ca9"
      unitRef="U_USD">-2399000</wve:IncreaseDecreaseInOperatingLeaseLiabilities>
    <wve:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_1bd60e59-ef31-4cc2-a4dc-119ad718e8e4"
      unitRef="U_USD">-1792000</wve:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_2e3ac30b-3b1d-41bb-891b-81ba8f2bd729"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_133137c3-6a16-41e1-b8e0-6deeef0727ee"
      unitRef="U_USD">-135000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_627f3e11-01fe-4d66-a419-e4bc53ecd6b7"
      unitRef="U_USD">-68695000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_c178cf73-2263-49cb-9ddd-a73e8aae0eb2"
      unitRef="U_USD">-53776000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_eda97b56-1b00-4b2a-a032-2ac1b4087e84"
      unitRef="U_USD">700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_06866750-4b1e-4ffd-9091-123b03cc0063"
      unitRef="U_USD">447000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_be53243b-53c0-4e06-beea-0f31653c6e35"
      unitRef="U_USD">106000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_aff05a45-2465-4cb7-b5ab-2b5c7196f31c"
      unitRef="U_USD">50000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_91b3ab2f-7679-4ccb-bb8d-7aa6c10987a2"
      unitRef="U_USD">25000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_320887c0-85a5-482a-9e32-471a529a0bc8"
      unitRef="U_USD">-25594000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_2a415347-7c58-48b1-aa1f-5c7d93f27429"
      unitRef="U_USD">-447000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_224869a4-4f4c-4078-9b53-25cc801ca10e"
      unitRef="U_USD">51464000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_8b418d70-0dbe-4403-918f-b5f92bf4b0fd"
      unitRef="U_USD">14336000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c58d23cc-a8ef-4814-b890-7cbfec7e1771"
      decimals="-3"
      id="F_9539e342-69b8-4686-8c73-c5e31c0dd2ae"
      unitRef="U_USD">1105000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0d985ba9-a3f1-4988-8ba2-a12fd859afa1"
      decimals="-3"
      id="F_ecb63e3f-686c-46ff-a7c1-69a9a010ff04"
      unitRef="U_USD">13150000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_c3b549b9-e0e9-480d-9454-f302bb0e0be4"
      unitRef="U_USD">37000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_ae298310-7439-425e-863c-c32725938fd0"
      unitRef="U_USD">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_fc27b866-1e52-44ad-9f86-6512bf0cc12b"
      unitRef="U_USD">174000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_f28fb4c0-91c7-43db-9ac4-e1e250f788d7"
      unitRef="U_USD">336000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_f0f95000-f897-418e-9e91-1e0989e87a96"
      unitRef="U_USD">67116000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_c22aaa02-cf39-49d7-8e6e-df1b76a8ddf6"
      unitRef="U_USD">13686000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_e63f7159-3d0f-432f-8508-bf9fc585f048"
      unitRef="U_USD">-228000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_5e5c185e-bfa0-4167-83fd-05358e39fc99"
      unitRef="U_USD">-120000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_b8e6348d-d9da-44ad-85b7-ab09b819c632"
      unitRef="U_USD">-27401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_4940093a-f7c8-4bca-9858-84302016a874"
      unitRef="U_USD">-40657000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_56db904b-f9ff-4125-afd9-8a41b9050eb5"
      unitRef="U_USD">154215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_ed04036d-ee72-4713-80e6-728911c04be0"
      decimals="-3"
      id="F_3249287c-cc40-4f2c-a5e2-ba70e411bef1"
      unitRef="U_USD">188148000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_6d627e82-2b28-4035-9453-5e17b7dbf63a"
      unitRef="U_USD">126814000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e543347d-565b-47d5-877c-37bddba8c561"
      decimals="-3"
      id="F_7cbc0092-7a17-4230-8846-5fe9091d0aa9"
      unitRef="U_USD">147491000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_981fb250-e9cf-4b26-b6c7-ca152e2b57c6"
      unitRef="U_USD">12006000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <wve:OfferingCostsInAccountsPayable
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="-3"
      id="F_8e202096-70d2-4285-b491-978a8ce47964"
      unitRef="U_USD">311000</wve:OfferingCostsInAccountsPayable>
    <wve:OfferingCostsInAccountsPayable
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="-3"
      id="F_5227bae1-7c88-4834-bbf1-84a96160561f"
      unitRef="U_USD">57000</wve:OfferingCostsInAccountsPayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_48c2fd7a-cb17-40c8-a300-337c6f7e85b6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. THE COMPANY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Wave Life Sciences Ltd. (together with its subsidiaries, &#x201c;Wave&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. PRISM, Wave&#x2019;s proprietary discovery and drug development platform, enables the precise design, optimization and production of novel stereopure oligonucleotides. Wave has built a genetic toolkit comprised of multiple therapeutic modalities, including RNase-H mediated silencing, RNAi, splicing, and RNA base editing, all of which leverage learnings and optimizations from the PRISM platform and allow Wave to design built-for-purpose molecules to optimally address disease biology.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was incorporated in Singapore on July 23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#x201c;Wave USA&#x201d;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#x201c;Wave Japan&#x201d;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September 13, 2012. On May 31, 2016, Wave Life Sciences Ireland Limited (&#x201c;Wave Ireland&#x201d;) was formed as a wholly&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;owned subsidiary of Wave Life Sciences Ltd. On April 3, 2017, Wave Life Sciences UK Limited (&#x201c;Wave UK&#x201d;) was formed as a wholly&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;owned subsidiary of Wave Life Sciences Ltd.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s primary activities since inception have been developing and evolving PRISM to design, develop and commercialize oligonucleotide therapeutics, advancing the Company&#x2019;s differentiated neurology portfolio, as well as exploring other therapeutic areas of interest, building the Company&#x2019;s research, development and manufacturing capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#x2019;s intellectual property, and assuring adequate capital to support these activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has not generated any product revenue and has incurred recurring net losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had cash, cash equivalents and short-term investments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;148.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund its operations for at least the next twelve months. The Company has based this expectation on assumptions that may prove to be incorrect, and the Company may use its available capital resources sooner than it currently expects. If the Company&#x2019;s anticipated operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#x2019;s operations. In addition, the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or future operating plans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#x2019;s therapeutic programs will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#x2019;s research and development efforts will be successful, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and in U.S. dollars.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-5"
      id="F_8eef1d96-0259-4d35-8017-b86fe8da4802"
      unitRef="U_USD">148200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_50afd398-d7b7-42d6-a782-e12aa98de83f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies described in the Company&#x2019;s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 3, 2022, as amended (the &#x201c;2021 Annual Report on Form 10-K&#x201d;), have had no material changes during the six months ended June 30, 2022, except as described below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all time deposits with original maturities of more than three months from the date of purchase to be short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying interim consolidated balance sheet as of June 30, 2022, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, and June 30, 2022 and 2021, the consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; or any other interim period or future year or period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_9a225325-0660-43d5-8514-d6ab2d1c7412">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset. Level 3 includes private investments that are supported by little or no market activity.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_70910f88-7e55-4ed2-b9df-11c88b3ba252">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid securities with original final maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents are comprised of funds in cash and money market accounts.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_a2c698fb-ab44-422c-9453-c6a1e587fc79">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all time deposits with original maturities of more than three months from the date of purchase to be short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_53a6c166-efe1-4730-aa97-4b68b3e3cd9b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash, cash equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents, restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_f9e3637a-40e5-41bb-91e1-e74786590e68">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying interim consolidated balance sheet as of June 30, 2022, the related interim consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the consolidated statements of Series A preferred shares and shareholders&#x2019; equity (deficit) for the three months ended March 31, and June 30, 2022 and 2021, the consolidated statements of cash flows for the six months ended June 30, 2022 and 2021, and the related interim information contained within the notes to the unaudited consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations for the three and six months ended June 30, 2022 and 2021. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; or any other interim period or future year or period.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_39525fb4-4c27-4d36-8e9b-2f438eeabd63">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s financial assets that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.514%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.668%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;123,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;123,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;151,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;126,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;here have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; transfers between fair value levels during the three months ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash are Level 1 assets which are comprised of funds held in checking and money market accounts. Short-term investments are Level 2 assets which are comprised of time deposits with original maturities of more than three months. The Company determined that the fair value of its short-term investments is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which approximates the carrying value of the term deposits. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; short-term investments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021, as the term deposits that constitute the Company&#x2019;s short-term investments were purchased during the six months ended June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_0c8feed8-a573-4e8e-ab7d-59bc876e9dfe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the Company&#x2019;s financial assets that are measured at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.514%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.668%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.224%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.622%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;123,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;123,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;151,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;126,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;150,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;154,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c168803d-75ea-450b-8676-2d3cdeeebce0"
      decimals="-3"
      id="F_ce24dcec-a46d-4901-a354-0e5c6256e393"
      unitRef="U_USD">123163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c059f602-3f2f-41ce-ba29-88681a96cc00"
      decimals="-3"
      id="F_15feb769-7b76-4525-b23b-0f67788665c7"
      unitRef="U_USD">123163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7f4a66c5-19f5-4662-8e71-93adf30b20fb"
      decimals="-3"
      id="F_9faad500-3569-4885-be7a-e1e8c7c836fd"
      unitRef="U_USD">25000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_d1d7d11c-4b6d-425d-8b75-248ebc031db1"
      decimals="-3"
      id="F_dbdb5042-2d7b-4bd2-8ac5-4c5722613159"
      unitRef="U_USD">25000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_ef54c2d3-5966-4fb3-9eab-f71b3501eec9"
      decimals="-3"
      id="F_e8865d8e-886b-4e36-aa71-68fee7dcc384"
      unitRef="U_USD">3651000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_18a786b8-47b1-48cd-a1ab-330c03ba03cb"
      decimals="-3"
      id="F_1c630b86-5144-4158-81e4-b1946b112ad7"
      unitRef="U_USD">3651000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c168803d-75ea-450b-8676-2d3cdeeebce0"
      decimals="-3"
      id="F_13dd0643-61c2-4981-a6dc-2c4b1af3d291"
      unitRef="U_USD">151814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c059f602-3f2f-41ce-ba29-88681a96cc00"
      decimals="-3"
      id="F_844bf528-9e48-4389-a935-060321b35516"
      unitRef="U_USD">126814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3514b40a-9f70-4ea1-8a06-949d2fd1a5a0"
      decimals="-3"
      id="F_cc6abc8d-001b-44c3-8937-1ee1764caafa"
      unitRef="U_USD">25000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_07ca4716-43a0-42c3-9c43-358b926374da"
      decimals="-3"
      id="F_15a5cf20-0958-4137-bc67-d1f3a83df97b"
      unitRef="U_USD">150564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec"
      decimals="-3"
      id="F_83f947d8-d56d-4858-9585-baa057639273"
      unitRef="U_USD">150564000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_ced6e426-01fc-4c9a-8e66-3dc75c3ec32c"
      decimals="-3"
      id="F_d57b0ec1-44f9-41ae-b1eb-ef662643c5e9"
      unitRef="U_USD">3651000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_9d37d597-867b-4964-81ad-9b451a752961"
      decimals="-3"
      id="F_3d543454-fe4e-4915-ab03-658c04c198bc"
      unitRef="U_USD">3651000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_07ca4716-43a0-42c3-9c43-358b926374da"
      decimals="-3"
      id="F_4d444dd6-8b6c-41d5-a0da-cb8554d00f2a"
      unitRef="U_USD">154215000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_852449ae-8e42-4c66-b9c8-f7d6a073e6ec"
      decimals="-3"
      id="F_e7243953-b5a8-4114-941d-8fdaae070ec8"
      unitRef="U_USD">154215000</us-gaap:AssetsFairValueDisclosure>
    <wve:FairValueAssetsLevel1ToLevel2TransferAmount
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="INF"
      id="F_2b08407a-d57f-4364-9aa9-643db9148eb4"
      unitRef="U_USD">0</wve:FairValueAssetsLevel1ToLevel2TransferAmount>
    <wve:FairValueAssetsLevel2ToLevel1TransferAmount
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="INF"
      id="F_12dba31c-794c-4606-a160-2798b255bfcc"
      unitRef="U_USD">0</wve:FairValueAssetsLevel2ToLevel1TransferAmount>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_796c0529-ff6d-4304-8565-b6a278d71641"
      decimals="-5"
      id="F_36cd73fe-bf83-45bf-b4ee-bc4daf2e964e"
      unitRef="U_USD">25000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_8af245fc-0b06-427d-8e69-217279fe30bd"
      decimals="INF"
      id="F_f407babe-5c57-4661-9fdd-9fea89f7c45f"
      unitRef="U_USD">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_0673a4ae-dc48-46ee-9e28-db9036be0681">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;) was approved by the Company&#x2019;s shareholders and went into effect on August 10, 2021. The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#x201c;2014 Plan&#x201d;), such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August 10, 2021. The aggregate number of ordinary shares authorized for issuance of awards under the 2021 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5,450,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares, plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August 10, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2021 Plan authorizes (and the 2014 Plan previously authorized) the Company&#x2019;s board of directors or a committee of the board of directors to, among other things, grant non-qualified share options, restricted awards, which include restricted shares and restricted share units (&#x201c;RSUs&#x201d;), and performance awards to eligible employees and directors of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options generally vest over periods of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_5d565705-e9c6-4ee7-b392-a931aba94ef5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and any options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a5e01550-cacf-493f-b2e4-2fd75161a30b;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the grant date. RSUs can be time-based or performance-based. Time-based RSUs generally vest over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_509b5245-22eb-41f0-8890-375558e8677a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The vesting of performance-based RSUs is contingent on the achievement of certain performance milestones. Any RSUs that are forfeited are available to be granted again.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, the compensation committee of the Company&#x2019;s board of directors approved an amendment and restatement of the Company&#x2019;s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021, the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. This modification did not result in any incremental expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company determined that a performance-based RSU milestone was achieved and consequently &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the outstanding performance-based RSUs vested, which resulted in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;384,646&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares. During the three months ended June 30, 2022, the Company recorded share-based compensation expense of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which represents all of the expense related to the achievement of this performance-based RSU milestone. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did not recognize any expense related to the other performance-based RSU milestones, as the remaining milestones were not considered probable of achievement as of June 30, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the six months ended June 30, 2022, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,037,175&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; options and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;55,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; time-based RSUs to employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,561,172&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares remained available for future grant under the 2021 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Wave Life Sciences Ltd. 2019 Employee Share Purchase Plan (&#x201c;ESPP&#x201d;) allows all full-time and certain part-time employees to purchase the Company&#x2019;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a six-month offering period beginning on or about January 15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and July 15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; every year. Shares are purchased at a price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s ordinary shares on the first business day or the last business day of an offering period. During the six months ended June 30, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;77,534&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares were issued under the ESPP. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;804,940&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares available for issuance under the ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_810483b6-169c-4003-93e7-2b51cb18d965"
      decimals="INF"
      id="F_09dabe86-a84b-467e-8d9f-e96dabb0c56a"
      unitRef="U_shares">5450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_eab7d096-c25e-41c2-b352-560599442f0f"
      id="F_716882be-180c-4125-a8b9-0de934576943">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_eab7d096-c25e-41c2-b352-560599442f0f"
      id="F_f13a43b3-ed19-40c8-a51a-673dff2c0888">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_b0b1b09a-bb0a-4062-85c6-f57ca2210290"
      id="F_1b6c62cc-c23a-40f6-a696-cf87fdd75652">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_30e4d424-87c1-4f5b-a3af-aa203267d79e"
      decimals="2"
      id="F_f0667403-c26c-4925-ac78-fec301c8e68b"
      unitRef="U_pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_283fda3f-a748-40e5-99e9-66dde6ca0cdf"
      decimals="0"
      id="F_6321b680-b8bf-4d6f-85f4-c2c45a41c186"
      unitRef="U_shares">384646</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_300b72ac-22b8-4e84-94fc-953ae4a01ce2"
      decimals="-5"
      id="F_7af0ecae-62fc-4843-8a1a-64cb12b3b1e7"
      unitRef="U_USD">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9dc48f65-6d35-4fbe-879e-ed161cf3817c"
      decimals="0"
      id="F_45c2934a-f84f-458f-accc-d8226a09f88a"
      unitRef="U_shares">2037175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_1ea32a82-226e-4e27-8b47-3c751c13dd45"
      decimals="0"
      id="F_dbc93518-5ca5-43f4-a66d-1f124cb17650"
      unitRef="U_shares">55075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_810483b6-169c-4003-93e7-2b51cb18d965"
      decimals="0"
      id="F_9d1f95ac-991f-408c-8f23-97e549f64549"
      unitRef="U_shares">1561172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <wve:SharePurchasePriceAtEqualToFairMarketValuePercentage
      contextRef="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31"
      decimals="2"
      id="F_8ab49731-b9c6-4aca-af52-bb2ddafe46d0"
      unitRef="U_pure">0.85</wve:SharePurchasePriceAtEqualToFairMarketValuePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_6a9cfb4f-4377-4a77-8409-87f0fab0ae31"
      decimals="INF"
      id="F_dc94687b-c29b-4c75-a64a-57b49dd4f4ee"
      unitRef="U_shares">77534</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f1cd1092-e3ce-42d0-85a8-ee118d1d1baa"
      decimals="INF"
      id="F_ace7586f-bc4e-43a6-bb85-a41c8108002b"
      unitRef="U_shares">804940</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_00e7e446-2025-42bd-b17c-576bda0638b7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. COLLABORATION AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Takeda Collaboration and Equity Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Wave USA and Wave UK entered into a global strategic collaboration (the &#x201c;Takeda Collaboration&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#x201c;CNS&#x201d;). The Takeda Collaboration provides the Company with at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;230.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in committed cash and Takeda with the option to co-develop and co-commercialize the Company&#x2019;s CNS development programs in (1) Huntington&#x2019;s disease (&#x201c;HD&#x201d;); (2) amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal dementia (&#x201c;FTD&#x201d;); and (3) the Company&#x2019;s discovery-stage program targeting &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;ATXN3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the treatment of spinocerebellar ataxia 3 (&#x201c;SCA3&#x201d;) (collectively, &#x201c;Category 1 Programs&#x201d;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple preclinical programs for CNS disorders, including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease (collectively, &#x201c;Category 2 Programs&#x201d;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as an upfront payment. Takeda also agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; research term and to reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceed that amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Simultaneously with Wave USA and Wave UK&#x2019;s entry into the collaboration and license agreement with Takeda (the &#x201c;Takeda Collaboration Agreement&#x201d;), the Company entered into a share purchase agreement with Takeda (the &#x201c;Takeda Equity Agreement,&#x201d; and together with the Takeda Collaboration Agreement, the &#x201c;Takeda Agreements&#x201d;) pursuant to which it agreed to sell to Takeda &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,096,892&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; of its ordinary shares at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;54.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. In &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company closed the Takeda Equity Agreement and received aggregate cash proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company did not incur any material costs in connection with the issuance of shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;With respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive an opt-in payment and will lead manufacturing and joint clinical co-development activities and Takeda will lead joint co-commercial activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the Company will be eligible to receive development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; research term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#x201c;Category 2 Research Term&#x201d;). During that term, the Takeda Collaboration provided that the parties may collaborate on preclinical programs for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; targets at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;any one time&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed upon targets through completion of Investigational New Drug application (&#x201c;IND&#x201d;)-enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such targets, subject to the Company&#x2019;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#x2019;s research and preclinical activities in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to receive tiered high single-digit to mid-teen royalties on Takeda&#x2019;s global commercial sales of products from each Category 2 Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the Takeda Collaboration Agreement commenced on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 2, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, unless terminated earlier, will continue until the date on which: (i) with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii) with respect to each Category 1 Program target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii) with respect to each Category 2 Program target, the date on which royalties are no longer payable with respect to products directed to such target.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Takeda may terminate the Takeda Collaboration Agreement for convenience on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; notice, in its entirety or on a target-by-target basis. Subject to certain exceptions, each party has the right to terminate the Takeda Collaboration Agreement on a target-by-target basis if the other party, or a third party related to such party, challenges the patentability, enforceability or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party, subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a target-by-target basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#x2019;s insolvency. In certain termination circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Takeda Collaboration is managed by a joint steering committee (&#x201c;JSC&#x201d;) in which both parties are represented equally. The JSC is tasked with overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed this arrangement in accordance with ASC Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;) and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term. The Company identified the following material promises under the arrangement: (1) the non-exclusive, royalty-free research and development license for each Category 1 Program; (2) the research and development services for each Category 1 Program through completion of the first proof of mechanism study; (3) the exclusive option to license, co-develop and co-commercialize each Category 1 Program; (4) the right to exclusively license the Category 2 Programs; and (5) the research and preclinical development services of the Category 2 Programs through completion of IND-enabling studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and should therefore be combined into a single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a discount, and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; (2) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; (3) research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; (4) the material right provided for the exclusive option to license, co-develop and co-commercialize HD; (5) the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; (6) the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3; and (7) the research and preclinical development services and right to exclusively license the Category 2 Programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the outset of the arrangement, the transaction price included the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront consideration received and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant financing component. The option exercise fees to license, co-develop and co-commercialize each Category 1 Program that may be received are excluded from the transaction price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations associated with the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for HD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and non-exclusive research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#x2019;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for the exclusive option to license, co-develop and co-commercialize HD; the material right provided for the exclusive option to license, co-develop and co-commercialize ALS and FTD; and the material right provided for the exclusive option to license, co-develop and co-commercialize SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value in excess of the amounts to be paid by Takeda associated with each option represented a material right.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue associated with the research and development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs expected to be incurred to satisfy each Category 1 Program performance obligation. Revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation is being recognized as the research and preclinical development services are provided using an input method, according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The transfer of control for these performance obligations occurs over time and, in management&#x2019;s judgment, this input method is the best measure of progress towards satisfying the performance obligations. The amount allocated to the material right for each Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred revenue on the Company&#x2019;s consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 15, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Wave USA, Wave UK and Takeda entered into the Second Amendment to the Takeda Collaboration Agreement (the &#x201c;Amendment&#x201d;), which discontinued the Category 2 component of the Takeda Collaboration. Pursuant to the Amendment, Takeda agreed to pay the Company an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as full payment for reimbursable Category 2 Program collaboration-budgeted research and preclinical expenses. The Category 1 Programs under the Takeda Collaboration Agreement remain in effect and are unchanged by the Amendment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Through June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had recognized revenue of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;79.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as collaboration revenue under the Takeda Collaboration Agreement. During the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recognized revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Takeda Collaboration Agreement, respectively. During the three and six months ended June 30, 2021, the Company recognized revenue of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Takeda Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included in current liabilities. The aggregate amount of the transaction price allocated to the Company&#x2019;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022 is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;112.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is included in current liabilities. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the research and development services for each Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the deferred revenue that relates to the material right for each Category 1 Program option upon Takeda&#x2019;s exercise of such option, or immediately as each option expires unexercised.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <wve:CollaborationAndLicenseAgreementMonthAndYear
      contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9"
      id="F_54c28199-4ed7-444e-b1e2-044efee90305">2018-02</wve:CollaborationAndLicenseAgreementMonthAndYear>
    <wve:CollaborationAgreementCommittedCash
      contextRef="C_4659dc79-f8b5-4b14-9d07-60ba055803c3"
      decimals="-5"
      id="F_79dcfd2a-554e-4537-afc2-2b139e7bd732"
      unitRef="U_USD">230000000.0</wve:CollaborationAgreementCommittedCash>
    <wve:CollaborationAgreementUpfrontPayment
      contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9"
      decimals="-5"
      id="F_df92d8e9-4b99-47e8-ba88-0e448a5f1f0d"
      unitRef="U_USD">110000000.0</wve:CollaborationAgreementUpfrontPayment>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9"
      decimals="-5"
      id="F_a5355777-b669-4a6a-b1af-a4e609cd1e1d"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAndLicenseAgreementResearchTerm
      contextRef="C_bdcef329-e9c5-4943-9ec6-3283c31a46b9"
      id="F_2314d658-6f07-4bbc-b95c-4ee997f0fb04">P4Y</wve:CollaborationAndLicenseAgreementResearchTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0"
      decimals="INF"
      id="F_31ad37bb-2c33-469c-9917-bfa0fe03abd9"
      unitRef="U_shares">1096892</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_03b94d45-2ab0-4b85-a75d-2f64e83735c8"
      decimals="INF"
      id="F_dc2ba5bc-7768-4765-b859-2af0cbbb8d44"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">54.70</us-gaap:SaleOfStockPricePerShare>
    <wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear
      contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0"
      id="F_3d96c334-cc29-4be1-a872-b249d54eaf37">2018-04</wve:EquityInvestmentAgreementOfficialClosureDateMonthAndYear>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a3afbee9-d6d3-41c7-8c6c-2339ead01cb0"
      decimals="-5"
      id="F_e33eaf50-1c49-4071-920f-13c20156f82d"
      unitRef="U_USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio
      contextRef="C_63319f7d-b0a5-431e-b212-d9dd4cc84b72"
      decimals="2"
      id="F_b0d9574d-4d38-4d1e-8493-b77ac8b1f04e"
      unitRef="U_pure">0.50</wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio>
    <wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio
      contextRef="C_5b138242-bd72-42e8-ada7-ec20e596c5d9"
      decimals="2"
      id="F_0d937173-b393-486c-880e-db15abc558f7"
      unitRef="U_pure">0.50</wve:PercentageOfGlobalCostsAndPotentialProfitsSharingRatio>
    <wve:CollaborationAndLicenseAgreementResearchTerm
      contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37"
      id="F_ba0cac1b-4aa0-412a-a207-12de45c4827f">P4Y</wve:CollaborationAndLicenseAgreementResearchTerm>
    <wve:MaximumTargetsForPreclinicalPrograms
      contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37"
      decimals="INF"
      id="F_b710d5ff-bdf5-4993-94d1-5d8a03ec199d"
      unitRef="U_Target">6</wve:MaximumTargetsForPreclinicalPrograms>
    <wve:OptionToReachMaximumTargetsForPreclinicalPrograms
      contextRef="C_34ff48ca-a39d-487f-903e-584d7f5d9888"
      id="F_f130593b-df0c-4275-ae16-d9bb4321524e">any one time</wve:OptionToReachMaximumTargetsForPreclinicalPrograms>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_2bc28323-c7d6-4bf5-a661-eededfaa4d37"
      decimals="-5"
      id="F_31c72243-632d-4221-979d-93d44d1fed32"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAgreementCommencementDate
      contextRef="C_6850af8e-74cf-4159-a423-9e97ac830052"
      id="F_c1f4a408-ca66-407a-93a0-cd48b5a0e020">2018-04-02</wve:CollaborationAgreementCommencementDate>
    <wve:MaximumTerminationNoticePeriod
      contextRef="C_6850af8e-74cf-4159-a423-9e97ac830052"
      id="F_a52e5615-da51-44e0-96d6-52aa437b1cd0">P180D</wve:MaximumTerminationNoticePeriod>
    <wve:UpFrontConsiderationReceived
      contextRef="C_57758a2d-e69c-4d16-9b5f-18555ad23a37"
      decimals="-5"
      id="F_a135f479-947d-4cfa-83cf-bb790db534a4"
      unitRef="U_USD">110000000.0</wve:UpFrontConsiderationReceived>
    <wve:FundReceivableForResearchAndPreclinicalActivities
      contextRef="C_57758a2d-e69c-4d16-9b5f-18555ad23a37"
      decimals="-5"
      id="F_5a7f243a-0f74-410a-b06f-7efa913e9045"
      unitRef="U_USD">60000000.0</wve:FundReceivableForResearchAndPreclinicalActivities>
    <wve:CollaborationAndLicenseAgreementDate
      contextRef="C_e54eb887-4c39-4a17-9604-14097e88cd22"
      id="F_31bcebe0-63b9-43e1-b71a-b2981dbc9e76">2021-10-15</wve:CollaborationAndLicenseAgreementDate>
    <wve:CollaborationBudgetedResearchAndPreclinicalExpenses
      contextRef="C_cd854128-fccf-4ea5-8af5-094c2a679228"
      decimals="-5"
      id="F_5c469e72-ab1e-4582-b117-2a7038917994"
      unitRef="U_USD">22500000</wve:CollaborationBudgetedResearchAndPreclinicalExpenses>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d0288e0e-5b52-4d7c-8564-10340131751a"
      decimals="-5"
      id="F_eea4df53-19b4-4347-821f-a62ec809a68f"
      unitRef="U_USD">79800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c9b91c5d-dde1-4b7e-9177-b5db41d9bd22"
      decimals="-5"
      id="F_39630a7f-42b4-4096-b686-207fd3b66211"
      unitRef="U_USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_031e56ef-ccf2-4828-ab59-1d84613c2255"
      decimals="-5"
      id="F_6c1c7178-8cfd-46fa-ada2-d007d70f6b62"
      unitRef="U_USD">1900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c4f51145-90ba-40be-9cc2-4a963f92d5b2"
      decimals="-5"
      id="F_a733a49a-3bae-4c81-8689-8d108010baf9"
      unitRef="U_USD">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8f6202df-7ac9-4cd7-83f2-84cbea74e158"
      decimals="-5"
      id="F_dd0c2ea8-781d-4a95-9262-5dfd35e96a1f"
      unitRef="U_USD">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430"
      decimals="-5"
      id="F_a4bb2ff0-fba8-410c-a5b4-e15f60b7dbf2"
      unitRef="U_USD">114200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_4668f4ff-9ea4-49a6-a6c4-f58661d3e430"
      decimals="-5"
      id="F_8a5027af-6b62-46cb-a235-706e501734b0"
      unitRef="U_USD">37100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0"
      decimals="-5"
      id="F_91e30464-72cf-4e44-808f-bf570dd0499d"
      unitRef="U_USD">112700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_1f2a6034-4f7a-4468-90f7-15781d7c05a0"
      decimals="-5"
      id="F_ef0b53c2-50db-4ae2-b67f-ade1e6ab0158"
      unitRef="U_USD">37500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_fcc6d25a-1729-4838-bf5d-e997606a44b4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;June 2022 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 16, 2022, the Company closed an underwritten offering (the &#x201c;June 2022 Offering&#x201d;) in which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;25,464,483&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the Company&#x2019;s ordinary shares at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,093,656&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the Company&#x2019;s ordinary shares at an offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.1499&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders&#x2019; equity within additional paid-in capital. The gross proceeds to the Company were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;before deducting underwriting discounts and commissions and other offering expenses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The net proceeds of the June 2022 Offering were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;65.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of ordinary shares outstanding or more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the combined voting power of the Company&#x2019;s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_1033f259-3cc4-4072-b21e-8088360d8740">On June 16, 2022, the Company closed an underwritten offering (the &#x201c;June 2022 Offering&#x201d;) in which the Company issued and sold 25,464,483 of the Company&#x2019;s ordinary shares at a price of $2.15 per share and pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 7,093,656 of the Company&#x2019;s ordinary shares at an offering price of $2.1499 per Pre-Funded Warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each Pre-Funded Warrant. These Pre-Funded Warrants were recorded as a component of shareholders&#x2019; equity within additional paid-in capital. The gross proceeds to the Company were $70.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds of the June 2022 Offering were approximately $65.5 million. The Pre-Funded Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of ordinary shares outstanding or more than 19.99% of the combined voting power of the Company&#x2019;s securities outstanding immediately after giving effect to such exercise, unless and until shareholder approval is obtained. </us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0"
      decimals="INF"
      id="F_3349e1b6-0385-4d0d-939e-93f99ea2ea9c"
      unitRef="U_shares">25464483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_045adef5-17c5-408e-8baf-d0886f47c57e"
      decimals="2"
      id="F_e76350b9-de30-417f-87c4-fbecfc504154"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_97a6000b-e222-4ea3-90d8-088983fa43f3"
      decimals="0"
      id="F_a2f3cafd-ba8a-41c2-ab2f-f249a80da45e"
      unitRef="U_shares">7093656</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3"
      decimals="4"
      id="F_cd6c11f9-64db-46aa-b5cf-0ff640edf5c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.1499</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cf65a7a3-2a38-4ea3-ae2b-df2c94585ea3"
      decimals="4"
      id="F_9436f3ff-211f-4df1-9e90-2fa0d0c3b5b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <wve:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0"
      decimals="-5"
      id="F_3133c29d-7a97-4224-836e-44ea96c56ca0"
      unitRef="U_USD">70000000.0</wve:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c9b76942-31ca-4f0f-b2c8-01128371a0f0"
      decimals="-5"
      id="F_ef172ce1-20cd-4666-baeb-d3c1d9ae1fce"
      unitRef="U_USD">65500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding
      contextRef="C_1b4431b2-3b0c-4c57-a400-5e339022d24b"
      decimals="INF"
      id="F_5cb029ae-0d43-4679-a5de-dbb8488b582d"
      unitRef="U_pure">0.1999</wve:PercentageOfOwnershipInterestInOrdinarySharesOutstanding>
    <wve:MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise
      contextRef="C_961bdd6a-40fc-47c3-ab35-05fb69ac44f8"
      decimals="INF"
      id="F_257402f6-7f35-4f61-a824-641d07244041"
      unitRef="U_pure">0.1999</wve:MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_7b3ef020-c56d-44f0-bf1d-a2864004da91">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. NET LOSS PER ORDINARY SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies the two-class method to calculate its basic and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to ordinary shareholders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2022, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7,093,656&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; vested and exercisable Pre-Funded Warrants outstanding to purchase ordinary shares for the exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The Pre-Funded Warrants are included in the weighted-average shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic loss per share is computed by dividing net loss attributable to ordinary shareholders and Pre-Funded Warrant holders by the weighted-average number of ordinary shares and Pre-Funded Warrants outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares, RSUs, and Series A preferred shares, are considered to be ordinary share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following ordinary share equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.963%;"/&gt;
        &lt;td style="width:1.658%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.787999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.658%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.934%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,526,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,584,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;979,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,027,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Series A preferred shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,901,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,901,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, for the periods presented, the two-class method does not impact the net loss per ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not participate in losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1014ad06-e986-48e5-9503-e639ae78d329"
      decimals="0"
      id="F_1c919322-bd2e-4d95-b987-73c491c4d5d7"
      unitRef="U_shares">7093656</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_1014ad06-e986-48e5-9503-e639ae78d329"
      decimals="4"
      id="F_654fe300-237e-49fa-b8f4-9251d5d28300"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_73d2db2b-76d7-4a24-a933-2ecba6ea5ffd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following ordinary share equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.963%;"/&gt;
        &lt;td style="width:1.658%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.787999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.658%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.934%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Options to purchase ordinary shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8,526,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4,584,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;979,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2,027,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Series A preferred shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,901,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,901,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_945817ec-c317-4c4d-a941-a9c2cff299de"
      decimals="INF"
      id="F_598340f5-dcce-4cd7-bb98-315966b09ac2"
      unitRef="U_shares">8526312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_523d0df5-7bb1-4976-bcb4-802b05e28667"
      decimals="INF"
      id="F_fb4e675c-6485-4110-9ed0-7bd9e26d3d8a"
      unitRef="U_shares">4584490</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5e525306-9d10-4441-8453-95cbed2392b8"
      decimals="INF"
      id="F_2ea7c7cf-ff5b-4baf-885a-bef2c133eecd"
      unitRef="U_shares">979850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_01de9b35-d2c7-4f8d-8e10-25a3ffd4f38d"
      decimals="INF"
      id="F_6817708a-9a10-4dd0-8e06-6c10dec83b9a"
      unitRef="U_shares">2027019</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4026c365-b133-428c-860d-0c091ee9904f"
      decimals="INF"
      id="F_716e3a88-b576-4483-9b4a-1388f0b08126"
      unitRef="U_shares">3901348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bf5de431-1632-48b6-aedc-f9c9b3179fc4"
      decimals="INF"
      id="F_8127d533-2f30-400f-94c9-390c36b86906"
      unitRef="U_shares">3901348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_5b5300a8-cbeb-4b11-984b-f51a6f325798">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three and six months ended June 30, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; income tax provision. The Company maintained a full valuation allowance for the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2022 and 2021 in all jurisdictions due to uncertainty regarding future taxable income.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s utilization of its net operating loss carryforwards and general business credit carryforwards in the United States may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. As of June 30, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company is evaluating whether an ownership change occurred during 2022. Should an ownership change have occurred or occur in the future, the Company&#x2019;s ability to utilize its net operating losses and general business credit carryforwards may be limited.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      decimals="INF"
      id="F_82e41168-af16-4225-ac09-456c48921553"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7b1b9ba9-0c6e-49d6-b754-f2f26976e667"
      decimals="INF"
      id="F_06f7c32e-c3b4-4121-82bf-aab1e3026994"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7001869b-47df-4996-89c7-c6dba52a5dea"
      decimals="INF"
      id="F_f12e1e98-bcac-438e-8a2f-4a482075bf5a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6752b2f4-4dd0-440a-be4d-e4f3ef12bef2"
      decimals="INF"
      id="F_6087d0ff-405c-4c6e-8a37-a6d8874a962f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <wve:GeographicDataDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_2840a548-618c-4891-9b6d-bcec0270874d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. GEOGRAPHIC DATA&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Substantially all of the Company&#x2019;s long-lived assets were located in the United States as of June 30, 2022 and December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</wve:GeographicDataDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_3ed69e8c-9c11-438f-9694-12a3b7395698">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. RELATED PARTIES&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had the following related party transaction for the periods presented in the accompanying consolidated financial statements:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2012, the Company entered into a consulting agreement for scientific advisory services with Dr. Gregory L. Verdine, one of the Company&#x2019;s founders and a member of the Company&#x2019;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; days&#x2019; prior written notice. Pursuant to the consulting agreement, the Company pays Dr. Verdine approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand per month, plus reimbursement for certain expenses. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <wve:AgreementTerminationNoticePeriod
      contextRef="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619"
      id="F_2162d753-0af7-49d4-b20d-33480afcc7a6">P14D</wve:AgreementTerminationNoticePeriod>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="C_21718b59-6bd5-4e8e-8a55-c7aa9df13619"
      decimals="-3"
      id="F_d37c123c-2e65-47e6-ba33-6203af9db7f3"
      unitRef="U_USD">13000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_f89f8768-79a1-4893-aa6c-a9a3f0f8678c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.889%;"/&gt;
        &lt;td style="width:2.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.647%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses related to CROs and CMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;11,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_77d87470-9f60-4584-863d-b5b38401f117">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.889%;"/&gt;
        &lt;td style="width:2.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.647%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;6,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses related to CROs and CMOs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;3,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;11,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;14,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/&gt;&#160;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_b69065f9-1dd4-4a07-8dd3-c4f4ff18e76a"
      unitRef="U_USD">6574000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_e0991216-b8aa-46c3-b102-e86e6c7b4007"
      unitRef="U_USD">10181000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_3cf64ad0-b283-4e15-9ccd-6f27b551fdd9"
      unitRef="U_USD">3473000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_a04cfbde-f076-478c-93e3-93c355e0ba1c"
      unitRef="U_USD">3571000</us-gaap:AccruedLiabilitiesCurrent>
    <wve:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_95b3ae12-ac2a-4f33-b400-c9d8abf09bcf"
      unitRef="U_USD">1038000</wve:AccruedExpensesAndOtherCurrentLiabilities>
    <wve:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_0594de7a-cc08-422b-aaac-0ea50257f2a0"
      unitRef="U_USD">1109000</wve:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_c20e87e3-d498-4147-b0a9-71f5f7748d21"
      decimals="-3"
      id="F_b1f47295-0cf8-4b09-982e-91c269c3ff25"
      unitRef="U_USD">11085000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_452c859b-42ad-40fe-8bc7-b21ef73a2d44"
      decimals="-3"
      id="F_afe1e480-a8fe-4565-933e-792ee4635f09"
      unitRef="U_USD">14861000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_58626c81-144d-4d8e-871a-3c563d339b9a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into lease arrangements for its facilities. A summary of the arrangements is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lexington&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 26, 2016, and as amended on December 31, 2016, the Company entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 year and 9-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; lease , which includes two successive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; renewal options&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for its facility in Lexington, Massachusetts (the &#x201c;Lexington Lease&#x201d;), which the Company uses primarily for its current good manufacturing practices (&#x201c;cGMP&#x201d;) manufacturing, as well as for additional laboratory and office space. Throughout the term of the Lexington Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Lexington Lease, the Company had restricted cash of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in a separate bank account as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cambridge&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2015, the Company entered into a lease agreement for an office and laboratory facility in Cambridge, Massachusetts (the &#x201c;Cambridge Lease&#x201d;), which commenced in October 2015 with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; years with a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; renewal &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; the lease.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;  Throughout the term of the Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the Cambridge Lease, the Company had restricted cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in a separate bank account as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, the Company exercised its option under the Cambridge Lease to lease additional office and laboratory space at the adjoining facility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The combined space constitutes the entire building located at 733 Concord Avenue. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease for the additional space commenced on October 1, 2021, with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the &#x201c;Additional Cambridge Lease&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; On the commencement date of the Additional Cambridge Lease, the Company recorded a right-of-use asset and corresponding operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and began recognizing straight-line rent expense under ASC 842. Throughout the term of the Additional Cambridge Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company notified the landlord of its intention to exercise the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; renewal option under the Cambridge Lease to extend the lease term through March 2028 (the &#x201c;Cambridge Lease Extension&#x201d;). In June 2022, the Company calculated an incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and remeasured the right-of-use asset and the lease liabilities related to the Cambridge Lease Extension. As of June 30, 2022, the Company recorded an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of operating right-of-use asset and corresponding operating lease liabilities relating to the Cambridge Lease Extension. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <wve:LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription
      contextRef="C_b12dd15a-4910-42a5-a1bb-da412b6b9efd"
      id="F_1d396df6-786f-47d0-bfee-26105ed2de52">10 year and 9-month lease , which includes two successive five-year renewal options</wve:LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db"
      id="F_11dc2734-5248-4ea3-aa2e-8e4b4116776c">P10Y9M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_e7d9cdad-8ec2-4ea7-a84d-bf715f20d7db"
      id="F_f42a80a3-b501-41ac-8f5d-b3321b3b74ed">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_9c0260b0-d65e-4e5c-ba7f-4ad60a49c91c"
      decimals="-5"
      id="F_47eea367-98ca-429a-b798-ea8858069a69"
      unitRef="U_USD">2700000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_94d9d100-4484-4e3c-afe1-66999eb32fe3"
      decimals="-5"
      id="F_c181bb63-8bc1-4994-88f7-970d3a1f45e2"
      unitRef="U_USD">2700000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_33eafbee-95ba-4008-99b5-86a8a72a242d"
      id="F_a635b5da-20b8-49c9-acef-e1c926703450">P7Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd"
      id="F_0862d0a1-bb5d-4e6c-9722-266b95c6c7ac">five-year renewal option to extend the lease.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_33eafbee-95ba-4008-99b5-86a8a72a242d"
      id="F_78b02981-5077-4283-b406-fb168cd38027">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd"
      id="F_4bf8bf15-1ed9-4a50-9371-a30f389feb6e">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3"
      decimals="-5"
      id="F_7e066c3f-a8cf-4069-8769-6abbfd738b98"
      unitRef="U_USD">1000000.0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_e23b1234-bfa8-4df5-ab78-74d94722218e"
      decimals="-5"
      id="F_ea391a7a-c532-42fd-bca2-c037cc5c3efd"
      unitRef="U_USD">1000000.0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_3d33988f-7cb6-4d1b-9f36-c9ad8c1bb3f2">The lease for the additional space commenced on October 1, 2021, with a term of five years and, for accounting purposes, is considered a separate lease from the Cambridge Lease (the &#x201c;Additional Cambridge Lease&#x201d;).</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1"
      id="F_0da04961-ce67-4ebc-8ab7-a42386104094">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1"
      decimals="-5"
      id="F_194b496e-4758-4268-b9b2-71484c782274"
      unitRef="U_USD">4500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1"
      decimals="-5"
      id="F_20a78be9-9fa9-4b0f-9af3-df376cad8841"
      unitRef="U_USD">4500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3"
      id="F_8634b4ea-be0c-4d30-9067-e97edf3a0d73">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <wve:IncrementalBorrowingRate
      contextRef="C_c7fbf71d-d2b3-4287-b637-63e42c02b4fd"
      decimals="4"
      id="F_e370a311-c340-4996-a203-169257a2a1e3"
      unitRef="U_pure">0.1053</wve:IncrementalBorrowingRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3"
      decimals="-5"
      id="F_5d6457ca-b2ad-41c0-b4c4-8b84e615b296"
      unitRef="U_USD">12000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_dbbfdeb6-e088-4d06-9fb7-d125c6b8fae3"
      decimals="-5"
      id="F_ba226b92-f14a-4ca9-9031-f243c254c0cd"
      unitRef="U_USD">12000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_bc79ed5e-e97e-43dd-86ab-860fc162b811"
      id="F_6f0b7ef6-94fb-4a07-8f78-9218de61eea2">In August 2022, the Company executed the second amendment to the Cambridge Lease with respect to the Cambridge Lease Extension.</us-gaap:LesseeOperatingLeaseOptionToExtend>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#.6-TJ+J!@."JJAWO^QGYXB] 3B<&$"Z >38 ;0;T'INL4/6FG7%-%N>2?&
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M!F50&H?2!(JFJE1Z+^%KEJX)#1Z!]H*2'H&U'*$.3*@[,-H!Y-"0#$KC4)I
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M0ST?*"V+#9N-3:?>=+A-"C0J@](XE"90-%6ETO6):=?'9MUT;*A@XFI59.B
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MKZNJ_?;#><>_K^HOAQB7?P%02P,$%     @ 9CX+5?J3"R)\!P  :R,  !@
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M<UOKHA8&OO$43*.DMW@?>-74 8B.=PW[B9T_^)!G0AHRA,WE6),#D]$'F',
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M%'\V20_1M?RI8N5B= W_K!4RTM,$O*\<0I,?:(/AV]7Y_P!02P,$%     @
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M.XQ8U6C3\+)F0-CU4B;+P, H4(^<N%,X\I[BPRW)@@'-2#)*E^MD.0(@N0*
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M QS?*FH?P(9DO0_WK0&&RG[;UE]%%F-VYEKI&":ZX3,FVR/AYD'/D.JYL3/
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M%!QP"Q^ [S.E:O\+'A#^=LN+_P!02P,$%     @ 9CX+57C@7UQ]!   9PH
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M ?G!XO&'BML.O@MKA2:*-(.=)T-F39[+RJ8Y#; M"HZ%",E>X9'$5J;(?/Z
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MW@N;&V_*<,Z<&D^GUG"9T\\$M&Q [V>&!L_JAAVL?W@,_P-02P,$%     @
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M!?B^LDB!]$('=/_)<?D/4$L#!!0    ( &8^"U70#0F5#0,  $H'   9
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M&GO=).[O6;\1.E0OX4Y_*U$O?1<WD*E*VKK5M:OM0S&M^^.3>_W*7#.]Y-*
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MBZM9 JZ?AOTFV#9.H)T--,_BLJ8/"#HVH/O*VG#<<(#3)VG]!5!+ P04
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M5H'03 JB8#'RSL.S<6+K7<%7!AO=&Q/K9"[EG9U<%2,OL(* 0VXL \7'&L;
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MM.2L:-RC03)5H$&89D$NR"435.0,<YKA(N"V-II\/Y]KHW!C_MB61R-@L%V
M_;.>Z9KF,/)JVTNMP<O>O@F'P8=MZ?PGLF=9Q5U6\3[V;$QUZ4+)[0#N5VQ-
MN0U@F^N&:NBH[(FRSL(H#H=QZJ_[?K:4)4$R''1ESY0..J6#O4IGI52&&% 5
M[M8U:%/MDMGP)+W^41($P6\J]W;[Q]23SDORY]1[8;LOH*W!X]<83%X&/#B-
M7CC<J^%O'?J]8\E>"9^I6C*A"8<%T@<G[[&;:H[99F)D[4ZJN31X[KEAB3<3
M*%N [Q=2FJ>)/?RZNR[[!5!+ P04    " !F/@M5M("%6W8$  #Y'0  &0
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MZ-]G6::>OA0%;%ZO>/H?4$L#!!0    ( &8^"U6^'G"P5@P  &F8   9
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M-!]*"U T66VUT45O8W2IU594>%&R.;IB/$H;W6-J>&NYJ;.JC7M"]\^-ZT-
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M9([6%35T.5=R3Y2U1C3[XK1QWLB&"7N,&Z-PE:&?67[ 3'DOM29K4.2CRIC
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M-6$245AIJ>#L0K=,X0:&VRA>VXZXY$KW5[LL]8P%81ST]Q7G:K<Q MW43O\
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MAFB&/S!!JGCFK'0>:O8'W:X%G /*I95 ]'=FJ#2*^#HW04.Q%@6'@/*,)!+
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 9CX+50A@\:!B P  +A<   \
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MR&PGD-,&!__5@]PG(/=W"+D6R0,"\F"7D)D'V2<@^V$A[TN.>-42U*L'])T
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M02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M (6N*0M84A:PI"EE3%+*F_TG6#ZV7?_T/L%V36JKFX,^Z'ZVS+U!+
M 0(4 Q0    ( &8^"U4'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 9CX+5?!G5DKN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M9CX+59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !F/@M52,B0S^L%  #!'P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M9CX+5=-2:65-!@  @!L  !@              ("!+@X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &8^"U7_-^I_P@(  )P(   8
M          " @;$4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !F/@M5FYC NQ@&  "0'@  &               @(&I%P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 9CX+51XF 6>F$   H=@
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M965T.2YX;6Q02P$"% ,4    " !F/@M5X&?"<Y@'  #($P  &0
M    @($S3P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M &8^"U6?=H7[@!(  ,=%   9              " @0)7  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 9CX+57C@7UQ]!   9PH  !D
M             ("!N6D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !F/@M5Q#7"B?P$  "$#   &0              @(%M;@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &8^"U4Q@/@XN ,
M +$(   9              " @:!S  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 9CX+55&_S\M6 @  (04  !D              ("!
MCW<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !F/@M5
M<GL1)D\#   X!P  &0              @($<>@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( &8^"U5R/?L)S@(  %(&   9
M      " @:)]  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 9CX+5;9"[Y']!0  L!$  !D              ("!IX   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !F/@M5YQ*<A&T(  #P&
M&0              @(';A@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( &8^"U70#0F5#0,  $H'   9              " @7^/  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 9CX+56(KO/<<
M P  G@8  !D              ("!PY(  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !F/@M5T(=,%JX"   S!@  &0
M@($6E@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &8^
M"U7Z<;.OG (  /<&   9              " @?N8  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 9CX+5;2 A5MV!   ^1T  !D
M         ("!SIL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !F/@M5N:25I?P"  #@"0  &0              @(%[H   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &8^"U4+8OR!YP<  &I1
M   9              " @:ZC  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 9CX+5;X><+!6#   :9@  !D              ("!S*L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !F/@M5 E*&
M;84'  #9)@  &0              @(%9N   >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( &8^"U7S><R??P(  #H%   9
M  " @17   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M9CX+54RM>7M8 P  @ T  !D              ("!R\(  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !F/@M5'=J3AH<"  #!!P  &0
M            @(%:Q@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( &8^"U4-=_NP@0(  + %   9              " @1C)  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 9CX+5<NL(X:T @
MC <  !D              ("!T,L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !F/@M5GII.LJ &  "L+P  &0              @(&[
MS@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &8^"U7I
M4XM%-@,  $H3   -              "  9+5  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ 9CX+59>*NQS     $P(   L              ( !\]@  %]R
M96QS+RYR96QS4$L! A0#%     @ 9CX+50A@\:!B P  +A<   \
M     ( !W-D  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &8^"U6,WU^M
M;@$  -T4   :              "  6O=  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( &8^"U4&5T)WCP$  ' 5   3
M  "  1'?  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     J "H 70L  -'@
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>133</ContextCount>
  <ElementCount>194</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Unaudited Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets</Role>
      <ShortName>Unaudited Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Unaudited Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Unaudited Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit</Role>
      <ShortName>Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Unaudited Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Unaudited Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Net Loss Per Ordinary Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare</Role>
      <ShortName>Net Loss Per Ordinary Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Geographic Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData</Role>
      <ShortName>Geographic Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Net Loss Per Ordinary Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables</Role>
      <ShortName>Net Loss Per Ordinary Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - The Company - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail</Role>
      <ShortName>The Company - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Shareholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Shareholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Net Loss Per Ordinary Share (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Ordinary Share (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail</Role>
      <ShortName>Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Related Parties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail</Role>
      <ShortName>Related Parties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="wve-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="wve-20220630.htm">wve-20220630.htm</File>
    <File>wve-20220630.xsd</File>
    <File>wve-20220630_cal.xml</File>
    <File>wve-20220630_def.xml</File>
    <File>wve-20220630_lab.xml</File>
    <File>wve-20220630_pre.xml</File>
    <File>wve-ex10_1.htm</File>
    <File>wve-ex31_1.htm</File>
    <File>wve-ex31_2.htm</File>
    <File>wve-ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img55497064_0.jpg</File>
    <File>img55497064_1.jpg</File>
    <File>img55497064_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="383">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "wve-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 133,
   "dts": {
    "calculationLink": {
     "local": [
      "wve-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "wve-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "wve-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "wve-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wve-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "wve-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 318,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 7
   },
   "keyCustom": 29,
   "keyStandard": 165,
   "memberCustom": 18,
   "memberStandard": 13,
   "nsprefix": "wve",
   "nsuri": "http://www.wavelifesciences.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Share-Based Compensation",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Collaboration Agreements",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Shareholders' Equity",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Net Loss Per Ordinary Share",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare",
     "shortName": "Net Loss Per Ordinary Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Income Taxes",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wve:GeographicDataDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Geographic Data",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData",
     "shortName": "Geographic Data",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wve:GeographicDataDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Related Parties",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Leases",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Unaudited Consolidated Balance Sheets",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
     "shortName": "Unaudited Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Net Loss Per Ordinary Share (Tables)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables",
     "shortName": "Net Loss Per Ordinary Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - The Company - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail",
     "shortName": "The Company - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_796c0529-ff6d-4304-8565-b6a278d71641",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c168803d-75ea-450b-8676-2d3cdeeebce0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_7001869b-47df-4996-89c7-c6dba52a5dea",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "wve:FairValueAssetsLevel1ToLevel2TransferAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_7001869b-47df-4996-89c7-c6dba52a5dea",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "wve:FairValueAssetsLevel1ToLevel2TransferAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_66fb8ad3-5567-4c36-8044-b37768f732bc",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_9dc48f65-6d35-4fbe-879e-ed161cf3817c",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_57758a2d-e69c-4d16-9b5f-18555ad23a37",
      "decimals": "-5",
      "lang": null,
      "name": "wve:FundReceivableForResearchAndPreclinicalActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Shareholders' Equity - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
     "shortName": "Shareholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_1014ad06-e986-48e5-9503-e639ae78d329",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Net Loss Per Ordinary Share (Additional Information) (Details)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
     "shortName": "Net Loss Per Ordinary Share (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_1014ad06-e986-48e5-9503-e639ae78d329",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Unaudited Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_945817ec-c317-4c4d-a941-a9c2cff299de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
     "shortName": "Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_945817ec-c317-4c4d-a941-a9c2cff299de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_7001869b-47df-4996-89c7-c6dba52a5dea",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_21718b59-6bd5-4e8e-8a55-c7aa9df13619",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wve:AgreementTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Related Parties - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail",
     "shortName": "Related Parties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_21718b59-6bd5-4e8e-8a55-c7aa9df13619",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "wve:AgreementTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_c20e87e3-d498-4147-b0a9-71f5f7748d21",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:LesseeOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:LesseeOperatingLeaseDescription",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_486a8fa5-30ae-4027-9f84-10bb3ca49ea1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_7001869b-47df-4996-89c7-c6dba52a5dea",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Unaudited Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_7001869b-47df-4996-89c7-c6dba52a5dea",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_ed04036d-ee72-4713-80e6-728911c04be0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit",
     "shortName": "Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_25c8d8eb-2dcd-4e58-b29e-a48f2a155cda",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Unaudited Consolidated Statements of Cash Flows",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
     "shortName": "Unaudited Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - The Company",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Significant Accounting Policies",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Fair Value Measurements",
     "role": "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "wve-20220630.htm",
      "contextRef": "C_bc79ed5e-e97e-43dd-86ab-860fc162b811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r82",
      "r83",
      "r164",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r163",
      "r171",
      "r205",
      "r207",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r376",
      "r379",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r163",
      "r171",
      "r205",
      "r207",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r376",
      "r379",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r133",
      "r148",
      "r149",
      "r191",
      "r193",
      "r334",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r133",
      "r148",
      "r149",
      "r191",
      "r193",
      "r334",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r163",
      "r171",
      "r195",
      "r205",
      "r207",
      "r233",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r376",
      "r379",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r163",
      "r171",
      "r195",
      "r205",
      "r207",
      "r233",
      "r234",
      "r235",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r376",
      "r379",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r82",
      "r83",
      "r164",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r93",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r93",
      "r98",
      "r146",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r191",
      "r194",
      "r378",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r191",
      "r194",
      "r378",
      "r403",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r93",
      "r98",
      "r146",
      "r206",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses related to CROs and CMOs",
        "totalLabel": "Accrued Liabilities, Current, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r40",
      "r41",
      "r42",
      "r364",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r271",
      "r308",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r244",
      "r245",
      "r246",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In-Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r162",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of pre-funded warrants , net of offering costs."
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r79",
      "r122",
      "r125",
      "r131",
      "r139",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r267",
      "r272",
      "r291",
      "r317",
      "r319",
      "r349",
      "r363"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r79",
      "r139",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r267",
      "r272",
      "r291",
      "r317",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r79",
      "r139",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r267",
      "r272",
      "r291",
      "r317"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Long-term assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Data"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r11",
      "r73"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash equivalents and short-term investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r68",
      "r73",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r292"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r77",
      "r79",
      "r101",
      "r102",
      "r103",
      "r105",
      "r107",
      "r115",
      "r116",
      "r117",
      "r139",
      "r151",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r169",
      "r170",
      "r174",
      "r178",
      "r184",
      "r291",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant Exercise Price Per Share",
        "verboseLabel": "Pre-funded warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Purchase price of pre-funded warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Pre-funded warrant outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reason for issuing warrant or right.",
        "label": "Warrant or Right, Reason for Issuance, Description",
        "terseLabel": "Warrant or Right, Original issuance date, description"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Ordinary shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Ordinary shares, no par value; 86,724,658 and 59,841,116 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r356",
      "r370"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r118",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r188",
      "r189",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Collaboration and license agreement, deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r188",
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred revenue",
        "verboseLabel": "Collaboration and license agreement, deferred revenue current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r188",
      "r189",
      "r192"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r71",
      "r143"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r238",
      "r239",
      "r241",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r99",
      "r101",
      "r105",
      "r106",
      "r107",
      "r111",
      "r112",
      "r279",
      "r280",
      "r357",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to ordinary shareholders basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r101",
      "r105",
      "r106",
      "r107",
      "r111",
      "r112",
      "r279",
      "r280",
      "r357",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to ordinary shareholders diluted.",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of foreign exchange rates on cash, cash equivalents and restricted cash",
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based compensation expense not yet recognized",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options [Member]",
        "verboseLabel": "Options to Purchase Ordinary Shares [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r114",
      "r140",
      "r184",
      "r186",
      "r244",
      "r245",
      "r246",
      "r253",
      "r254",
      "r278",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r308",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r281",
      "r282",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Company's Financial Assets Measurement at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r282",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r165",
      "r196",
      "r197",
      "r202",
      "r204",
      "r282",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Inputs Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r202",
      "r204",
      "r282",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Fair Value Inputs Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r282",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value Inputs Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurements1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r285",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value Measurements Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r122",
      "r124",
      "r127",
      "r130",
      "r132",
      "r347",
      "r353",
      "r358",
      "r373"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r250",
      "r251",
      "r252",
      "r255",
      "r257",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r96",
      "r97",
      "r121",
      "r249",
      "r256",
      "r258",
      "r374"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "negatedTerseLabel": "Income tax benefit (provision)",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r70",
      "r332"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Dividend income and interest income, net",
        "totalLabel": "Investment Income, Interest and Dividend, Total"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Description of additional lease space"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to extend the lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease option to extend description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r79",
      "r126",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r268",
      "r272",
      "r273",
      "r291",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r79",
      "r139",
      "r291",
      "r319",
      "r350",
      "r366"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, Series A preferred shares and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Series A preferred shares and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r79",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r268",
      "r272",
      "r273",
      "r291",
      "r317",
      "r318",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r14",
      "r15",
      "r79",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r268",
      "r272",
      "r273",
      "r291",
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r46",
      "r51",
      "r54",
      "r72",
      "r79",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r104",
      "r122",
      "r124",
      "r127",
      "r130",
      "r132",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r280",
      "r291",
      "r354",
      "r368"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r124",
      "r127",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r12",
      "r348",
      "r362"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r49",
      "r50",
      "r52",
      "r55",
      "r184",
      "r293",
      "r298",
      "r299",
      "r355",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "verboseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of short-term investments",
        "terseLabel": "Purchase of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r141",
      "r142"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of ordinary shares, net of offering costs",
        "verboseLabel": "Proceeds from issuance of ordinary shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance pre-funded warrants, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from the maturity of short-term investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Short-Term Investments, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r243"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.",
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Consulting service expenses",
        "totalLabel": "Professional and Contract Services Expense, Total"
       }
      }
     },
     "localname": "ProfessionalAndContractServicesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r46",
      "r51",
      "r67",
      "r79",
      "r88",
      "r96",
      "r97",
      "r122",
      "r124",
      "r127",
      "r130",
      "r132",
      "r139",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r266",
      "r269",
      "r270",
      "r274",
      "r275",
      "r280",
      "r291",
      "r358"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r144",
      "r319",
      "r359",
      "r367"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r203",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r203",
      "r311",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r203",
      "r311",
      "r314",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r312",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r248",
      "r333",
      "r418"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r73",
      "r75",
      "r405"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r386",
      "r396",
      "r404",
      "r406"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs [Member]",
        "verboseLabel": "RSUs to Employees [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r186",
      "r319",
      "r365",
      "r383",
      "r385"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r140",
      "r244",
      "r245",
      "r246",
      "r253",
      "r254",
      "r278",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r119",
      "r120",
      "r123",
      "r128",
      "r129",
      "r133",
      "r134",
      "r136",
      "r190",
      "r191",
      "r334"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "verboseLabel": "Collaboration revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Increase in operating lease right-of-use assets and lease liabilities related to lease extension"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r16",
      "r17",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Shares [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement By Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Ordinary shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Ordinary shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted to employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "verboseLabel": "Vesting percentage."
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Contractual life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r26",
      "r351",
      "r352",
      "r361"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r76",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r77",
      "r79",
      "r101",
      "r102",
      "r103",
      "r105",
      "r107",
      "r115",
      "r116",
      "r117",
      "r139",
      "r151",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r169",
      "r170",
      "r174",
      "r178",
      "r184",
      "r291",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Series A Preferred Shares [Member]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureNetLossPerOrdinaryShareAntiDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerOrdinaryShareDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r49",
      "r50",
      "r51",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r114",
      "r140",
      "r184",
      "r186",
      "r244",
      "r245",
      "r246",
      "r253",
      "r254",
      "r278",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r308",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Additional Paid-In-Capital [Member]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r114",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of ordinary shares under ESPP, shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of ordinary shares, shares",
        "verboseLabel": "Shares issued under equity agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r184",
      "r186",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Option exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of ordinary shares under the ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares",
        "verboseLabel": "Equity investment aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r79",
      "r137",
      "r139",
      "r291",
      "r319"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r170",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r300",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r300",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r300",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r151",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, Ending balance",
        "periodStartLabel": "Temporary equity, Beginning balance",
        "terseLabel": "Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at June 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheets",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Series A preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Series A preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, Ending balance, shares",
        "periodStartLabel": "Temporary equity, Beginning balance, shares",
        "terseLabel": "Series A preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedBalanceSheetsParenthetical",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r100",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r99",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic.",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "wve_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_AgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination notice period.",
        "label": "Agreement Termination Notice Period",
        "terseLabel": "Consulting agreement termination notice period"
       }
      }
     },
     "localname": "AgreementTerminationNoticePeriod",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "wve_AmortizationOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of right-of-use assets.",
        "label": "Amortization Of Right Of Use Assets",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfRightOfUseAssets",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_AtTheMarketEquityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity program.",
        "label": "At The Market Equity Program [Member]",
        "terseLabel": "At-The-Market Equity Program [Member]"
       }
      }
     },
     "localname": "AtTheMarketEquityProgramMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge, Massachusetts.",
        "label": "Cambridge Massachusetts [Member]",
        "terseLabel": "Cambridge, Massachusetts [Member]"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CategoryOneProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category one programs.",
        "label": "Category One Programs [Member]",
        "terseLabel": "Category One Programs [Member]"
       }
      }
     },
     "localname": "CategoryOneProgramsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CategoryTwoProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category two programs.",
        "label": "Category Two Programs [Member]",
        "terseLabel": "Category Two Programs [Member]"
       }
      }
     },
     "localname": "CategoryTwoProgramsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CollaborationAgreementCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement commencement date.",
        "label": "Collaboration Agreement Commencement Date",
        "terseLabel": "Collaboration agreement commencement date"
       }
      }
     },
     "localname": "CollaborationAgreementCommencementDate",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "wve_CollaborationAgreementCommittedCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement committed cash.",
        "label": "Collaboration Agreement Committed Cash",
        "terseLabel": "Collaboration agreement, committed cash"
       }
      }
     },
     "localname": "CollaborationAgreementCommittedCash",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement upfront payment.",
        "label": "Collaboration Agreement Upfront Payment",
        "terseLabel": "Upfront payment under collaboration agreement"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_CollaborationAndLicenseAgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement date.",
        "label": "Collaboration And License Agreement Date",
        "terseLabel": "Collaboration and License Agreement Date"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementDate",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "wve_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CollaborationAndLicenseAgreementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement month and year.",
        "label": "Collaboration And License Agreement Month And Year",
        "terseLabel": "Collaboration and license agreement month and year"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMonthAndYear",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "wve_CollaborationAndLicenseAgreementResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement research term.",
        "label": "Collaboration And License Agreement Research Term",
        "terseLabel": "Research term under collaboration and license agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementResearchTerm",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "wve_CollaborationAndSharePurchaseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Share Purchase Agreements [Abstract]",
        "label": "Collaboration And Share Purchase Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndSharePurchaseAgreementsAbstract",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wve_CollaborationAndSharePurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and share purchase agreements.",
        "label": "Collaboration And Share Purchase Agreements [Member]",
        "terseLabel": "Collaboration and Share Purchase Agreements [Member]"
       }
      }
     },
     "localname": "CollaborationAndSharePurchaseAgreementsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_CollaborationBudgetedResearchAndPreclinicalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "collaboration-budgeted research and preclinical expenses.",
        "label": "Collaboration Budgeted Research And Preclinical Expenses",
        "terseLabel": "Collaboration-budgeted research and preclinical expenses"
       }
      }
     },
     "localname": "CollaborationBudgetedResearchAndPreclinicalExpenses",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement [Member]",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_EmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee share purchase plan.",
        "label": "Employee Share Purchase Plan [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeSharePurchasePlanMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_EquityInvestmentAgreementOfficialClosureDateMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investment agreement official closure date month and year.",
        "label": "Equity Investment Agreement Official Closure Date Month And Year",
        "terseLabel": "Equity investment agreement official closure month and year"
       }
      }
     },
     "localname": "EquityInvestmentAgreementOfficialClosureDateMonthAndYear",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "wve_EquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity/",
        "label": "Equity [Line Items]",
        "terseLabel": "Equity [Line Items]"
       }
      }
     },
     "localname": "EquityLineItems",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "wve_EquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity.",
        "label": "Equity [Table]",
        "terseLabel": "Equity [Table]"
       }
      }
     },
     "localname": "EquityTable",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "wve_FairValueAssetsLevel1ToLevel2TransferAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assets level1 to level2 transfer amount.",
        "label": "Fair Value Assets Level1 To Level2 Transfer Amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransferAmount",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_FairValueAssetsLevel2ToLevel1TransferAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assets level2 to level1 transfer amount.",
        "label": "Fair Value Assets Level2 To Level1 Transfer Amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransferAmount",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_FundReceivableForResearchAndPreclinicalActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund receivable for research and preclinical activities.",
        "label": "Fund Receivable For Research And Preclinical Activities",
        "terseLabel": "Fund receivable for research and preclinical activities"
       }
      }
     },
     "localname": "FundReceivableForResearchAndPreclinicalActivities",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_GeographicDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographic data.",
        "label": "Geographic Data [Abstract]"
       }
      }
     },
     "localname": "GeographicDataAbstract",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "xbrltype": "stringItemType"
    },
    "wve_GeographicDataDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographic Data Disclosure [Text Block]",
        "label": "Geographic Data Disclosure [Text Block]",
        "terseLabel": "Geographic Data"
       }
      }
     },
     "localname": "GeographicDataDisclosureTextBlock",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureGeographicData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "wve_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from sale of ordinary shares"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in Operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_IncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental borrowing rate.",
        "label": "Incremental borrowing rate"
       }
      }
     },
     "localname": "IncrementalBorrowingRate",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "wve_June2022OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "June 2022 Offering.",
        "label": "June 2022 Offering [Member]"
       }
      }
     },
     "localname": "June2022OfferingMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee leasing arrangements operating leases renewal term description.",
        "label": "Lessee Leasing Arrangements Operating Leases Renewal Term Description",
        "terseLabel": "Renewal options"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "wve_LexingtonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexington Massachusetts.",
        "label": "Lexington Massachusetts [Member]",
        "terseLabel": "Lexington, Massachusetts [Member]"
       }
      }
     },
     "localname": "LexingtonMassachusettsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_MaximumTargetsForPreclinicalPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum targets for preclinical programs.",
        "label": "Maximum Targets For Preclinical Programs",
        "terseLabel": "Maximum targets for preclinical programs"
       }
      }
     },
     "localname": "MaximumTargetsForPreclinicalPrograms",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "wve_MaximumTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum termination notice period.",
        "label": "Maximum Termination Notice Period",
        "terseLabel": "Collaboration agreement termination period"
       }
      }
     },
     "localname": "MaximumTerminationNoticePeriod",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "wve_MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of combined voting power of securities outstanding immediate effect of exercise.",
        "label": "Minimum percentage of combined voting power of securities outstanding immediate effect of exercise"
       }
      }
     },
     "localname": "MinimumPercentageOfCombinedVotingPowerOfSecuritiesOutstandingImmediateEffectOfExercise",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "wve_OfferingCostsInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs in accounts payable",
        "label": "Offering costs in accounts payable",
        "terseLabel": "Offering costs in accounts payable at period end"
       }
      }
     },
     "localname": "OfferingCostsInAccountsPayable",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_StatementUnauditedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "wve_OptionToReachMaximumTargetsForPreclinicalPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to reach maximum targets for preclinical programs.",
        "label": "Option To Reach Maximum Targets For Preclinical Programs",
        "terseLabel": "Option to reach maximum targets for preclinical programs"
       }
      }
     },
     "localname": "OptionToReachMaximumTargetsForPreclinicalPrograms",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "wve_PercentageOfGlobalCostsAndPotentialProfitsSharingRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of global costs and potential profits sharing ratio.",
        "label": "Percentage Of Global Costs And Potential Profits Sharing Ratio",
        "terseLabel": "Percentage of global costs and potential profits sharing ratio"
       }
      }
     },
     "localname": "PercentageOfGlobalCostsAndPotentialProfitsSharingRatio",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "wve_PercentageOfOwnershipInterestInOrdinarySharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership interest in ordinary shares outstanding.",
        "label": "Percentage of ownership interest in ordinary shares outstanding"
       }
      }
     },
     "localname": "PercentageOfOwnershipInterestInOrdinarySharesOutstanding",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "wve_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-based RSUs [Member]"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer Inc. [Member]"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrants.",
        "label": "Pre Funded Warrants (Member)"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureNetLossPerOrdinaryShareAdditionalInformationDetails",
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_ResearchLicenseAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research, license and option agreement.",
        "label": "Research License And Option Agreement [Member]",
        "terseLabel": "Research, License and Option Agreement [Member]"
       }
      }
     },
     "localname": "ResearchLicenseAndOptionAgreementMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash.",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsMeasurementAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_ScientificAdvisorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific Advisor [Member]",
        "label": "Scientific Advisor [Member]",
        "terseLabel": "Scientific Advisor [Member]"
       }
      }
     },
     "localname": "ScientificAdvisorMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_SharePurchasePriceAtEqualToFairMarketValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase price at equal to fair market value percentage.",
        "label": "Share Purchase Price At Equal To Fair Market Value Percentage",
        "terseLabel": "Share purchase price at equal to fair market value percentage"
       }
      }
     },
     "localname": "SharePurchasePriceAtEqualToFairMarketValuePercentage",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "wve_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares restricted stock award vested.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Vested",
        "terseLabel": "Vesting of RSUs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/StatementUnauditedConsolidatedStatementsOfSeriesAPreferredSharesAndShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "wve_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda pharmaceutical company limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda [Member]"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_TimeBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time-based restricted stock units.",
        "label": "Time Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs [Member]"
       }
      }
     },
     "localname": "TimeBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_TwoThousandNineteenEmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee share purchase plan.",
        "label": "Two Thousand Nineteen Employee Share Purchase Plan [Member]",
        "terseLabel": "2019 ESPP [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeSharePurchasePlanMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_TwoThousandTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 equity incentive plan.",
        "label": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "wve_UpFrontConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front consideration received.",
        "label": "Up Front Consideration Received",
        "terseLabel": "Up-front consideration received"
       }
      }
     },
     "localname": "UpFrontConsiderationReceived",
     "nsuri": "http://www.wavelifesciences.com/20220630",
     "presentation": [
      "http://www.wavelifesciences.com/20220630/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.6(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r419": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r422": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r423": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r424": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0000950170-22-016653-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-016653-xbrl.zip
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M?A,^S4(R=T&Z3S&^>.!!6C(>"!55QTKF1$%^RSOP8!BA5H8U>$!Y:?X['FA
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MG9I$\<I*B;9!+RK9I[L*'G*SZRCB+@_M4P7E2=S/=<H<]3Z.2+(C+N,(;#T
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M=OJ=@^ )M<%XHLXU?DX:(2_WM:]-8S8@&0].4Y1#C 9RZI)"0 @I3 [=16_
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M\V:# DE>JNG^*3?5$%-M>K$ !@^LG.P*KX#B;H-_^ 7?D,B43/A]]_9C--\
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MV?/ 'O?XCI=XP*1_86E'?N1$U79KZ7-[$<(%U 5;O(J)A<LE!%XOWS$Z9I^
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M]3\ <L0-2N,>  -:X-M-&M3W2X?V[MA_JLK_N5B2<RIL;U62;7U\0#;7"1%
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MV:'P";%ABLKUM&"(#>2.%:7QWKT=.K(]:AMK/-\<W=E!"L2]*/37YLO/\ G
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MT4]SK$=CNSC0(<>S?Q+2./15 <&U1G.]<M.^TG!YX\3#V\2:9\>^8GVL1I(
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MY0[YWS),P0\ L-8G$FN+#EL&OY;]+7?B1KC>HNS35_1</3D$0M,LN=\" %0
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MC*M::'+ :^B5L*3'4R=/GB,DA/Q50^FCJPB3[,^5Q%RTK=L3J),OZHG##O'
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MP/2DZSF(--[!RG0*V3&3]_\ID\10U5:!S+)9U;5$*C\=;DA\_/F$=<2![P%
M9.->MR!3"+8I!_P ?0\X45LPW*JF*INU:[_<TG?+N-:FJGD?14?SA5=KTVGI
MQN[LP& XI"E-+M[=OG>Q$MCVM\W:ODRN>IEGT>CB)OH5*O26?.V4"6DT/;4F
MOZLT#JD]$;[G-9!@@;4W1IC;,M0?\]5F%N#AI_:O&+I7NNL+',\.*\'IY*U?
M)C&IGMU("L8N_-Z_8[HH\TAKSQ!=_^%7N%9"+5M[ LKI1X=72JI"(!-O4AN
MV$T63C\8-71!6#E/O^Q VO!+%(MM7=C.^2"O!IQ-DJ%2_9?EJ7+@$-G3D'*'
ML3ST1?VB4QTIZ3<93[B$+ZJ2P+8QT!@-&%9_#*XMA&"0^!N0C^1E2*07R<MA
M8OJ?S61F5)$^TFCO!:298AHLI&EY:D-U2%GDG,59QQ958<>=8?&3J)5^K;JH
MMD7W-H@BJE_ "SJ"MUI\594SX"+&\2G"#>X)MJ?68S6>M?=57#B(IG3'-:\^
MZU9<4+Z]$Y1/\>69=GW.WSK/[R<Q\_5D(1\"C/EID!%/Z)%#4TPT[QG3+?F<
M'SO2S@06+>UZ4.2S)!>?=.0EW.L[6GCG_;?-!R[Z>8+^P^0E:]@VM]2OOO3N
MVGI EN_,"]*L[\F_-VI0[QY-+VNY7&=<]?SX!XGW:7).IO9)L<,\BFZ54G=Y
M$V%.0OF5CL-3)-F>R<?(=<[@ K+D+Y.R,^/<-#U<DYC#/&E\Z.117&5IE939
M6:'- (^Y4FO>9!T&X^E7=$36/;/OL:T?*'4T1-;L'\GZ^:V98,JL5SW5W]?N
M*=AZ?XT=LV$Z=8")M6Y, 6-:/^)-9U?R,OW)-RA>.-',^*4U7JJ[W*^C2+QL
MU8V3M+=H8&)9S[!;@$<W$/_O;MRI"5JV>5Y89;%6)P/#4%7KR6K97<Q$DP=[
M%N;WPPVBTAG?28C:H+=_$=]4-OH!80_\OG1E788./>0W4\47H/';;,WIW-9(
MO\R<&[,7SO)S<_S[V!:,Z<<I:/2IFR](R#[/56*57/)G2P05$?0?:6RW9#95
MI31?[KP6-'Z3QF4\.\L=76M!,T"^!>(?-:88U!BG%15\]1-^\9LN_&)0%&\F
MTPG'GF=@H%"65)<N[H(_:4@,J9AV:MCYTG!)F;\8(U]KB48*3+YB+P#ER9</
M#'KAT2@E7I=6?]OPW7U*)4%VNW\X>&UWBKHAN "1CM2'_[+1(:ROI5H8A\S6
M)K<21_#H2<6T?1!$GZ.?FUBMS0H"%?@*-35_[H>>7)*-3+TZ%]*!IDH$X$_/
MC9)?7C1J]%1C\(Z^BQ+$^9:UT]&-(#&_SX:E=]O,\PR"=I6&[]2.]&)V@&5/
M.SU'6"7=^[UD7^O6._U3T83!P/X:;;OS)1T0'+'RI*/-OL68@_V7.PV]1TR=
M#5.=&)"V1&*S[,MMH-^$X7C/L"B5S&_](_*P2#T*'5M]F8#PMM-QC8\!OZ.E
M >$F(9"TD((U2;SE@\7.>JOJX%T.+KUP_)_1/9=TT[-GLQDF]I+:R9S)]3FK
M)G_W]_)'V;^X8;S^Z&(H"X*,QM$MN4>-8*H7/&EOL$C4UI%UP_C,=8G%5X^C
M_T_6W/@<']#(1[6IMC7,,OPC\_D[!F?NN!/6]^&ILHI"PQ_[TM7VUMM$8;.+
MB@HZVY.6H2?]!/9R='F")97+MC8#E6(<V/B!$<'/H,B;V_:%"OT95M%I#^($
MOD$1W0A/2;UI7W2X]W671XINR@K5W$Y3ZZ1%6[CO@F$Q@;(#0ZS9!S=VVF-Z
MCEG-/M;I(M5IK>UEU@= ZNYL#PL>Y;"BJ$F=CQ^2ZG+WUJ/72$#,DN^8T6N\
M;I3-IN@L7'VLY6##M8Y]+ES,R;=(0LE@'TYT@.-(%BVYIDM3X+4;<&EOV299
M6)'<R#A]RO@819-E6YKCEWB$G?=%DW#C(HO1Q3U_ET\[N/>)#5V+[R2WL7Z$
MA_[@_^P*5%YL+K>T_1J3 #);6^5J6V %T1QTE3*S[MUMO=)]@PC:\'HSK3SB
MG"O9T'EE$',4:MO%LXDRL(]A7SW9S>G5K;/*ZI.OMPJ'Y2.2-IH[:SK&G4#L
MY5-CN;<^.E$@ 2,^:8%2;NWM $>!C$;O)ZQ6("+/QK[)G?U"O<TLUA2%OBP7
MBQJC?&D8GD6/VGC]Y4(_6=Y"/5YD\C%U<YH^/*R#_M#;/7J.4&GNI2+0/UDP
M3\T1Q"@7,V ?0-7ZS5\(R\%;5WF=YK4=-*:'':C2ECU6]\TH5X&]L?\E3HY,
M,QHD5IVRY,^;2,V!R6:.Q/CFQ4>P\%;Q 7 8";XEG&DI^>\YX#J'O&\>806@
MTJ/7F,S(F+->ZLG*FP= 9]!?Y*VNK"S <]- (?)CB(YVX+,_K[-DD'.YAR@:
M@PV'+Z39B$0PR0/ N+GJ:$J*\@$0B[KPPC\UPKJRS4/R_<4BV\#'7D2$]_QQ
M+?CL0CDD83->_$BNX!4^W==95!T"<[9!,_0FK;2WX;?F2+Y9]_8UI#J![:FM
M%_666'[$=1[HE/D!(/P+/[5T-KUPZ6 N#@K]8)4E$Y!WDRU]:D2= ^LWK(53
M>G]PWUDO')9QSGM5BU>N#MMLJC*!Q70C0<_G;YS\;_=_GU>2?FF^H X7?X>>
M#<L.7(>-5LJ?@BQHVM-I$ >W^+L&*X\B2=^GV:!&^=#&;_!/Y6-1EW_!5FF2
M=:H %Y0,<F)+W)5FH;"QGA.W3 %"@IUHK(GO<N!7_*3SNR]K=<']QOGLNWG7
M1Y#Q % Z>@2K_V TP'^U'RY+^L^ROVDTYW]Z*I8 ]0V]9Y,\S%F)HC<8(ZL/
M>$1FH$J F\6>;'PW]1?!3>UA#JZ7L5AIRTCK)K%*<*8![.1'[6&M24%!;T6B
M<H3GB4NK$^FX>"C_@0GA#NZZ:/IK2T&/8+- MK/C)L*87T]W&YR\<43RB:NH
M2]B<6V+I+(2%'M_NFG^<P<HF<I7D,)G<KZF^+;CR0S<CPQM3/\5C0_;H!E !
ML,0-^+I&+ZYFTWJIUVG\<'Q=]_22C,^$R&3)<)%A*?TG[?!?]&OU;</1GA ]
MZO=$RMQFK[_@W+[HK2R@<F_=4#_>!!79$@AY+1((8PA=H(KVE;U@MZ-',V_B
M-ELT4<UA+/U+[C1*)>L5>(?*,VP.#A-F>MWY3C4WYQ#A_LE27W?$-S?8Z6]!
M$A%]-M3;:4K;6Q4V>4$\_#&7A=>\":A16[G$P^FH=R#V9V4Z?%\.U"U+X ^
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MO(&=4F/>*0JNB%-F6KB3%YS?82K8;(T3=SY8 C>F[6:S++$XC3<YM3+=/H*
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M7#AB(],X:S_JSVSL<B4L:B8@P0',@*>3ABQ6K4Q0\7<9>F?]MXRFDE7&E??
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M0D*K&)5>TD3**:H+H[OSJ/_D&2ZQF?/P0VC?D?W'@#W]EY#]#NP/7%" G)
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M5 QN-G?V8RNJFC?B]:)[QN+E+V]!Z3,'?_O-"TNXFP/IM["?D05??P<7?O'
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M+IU]44[Q:+S0_F@':C?TJ!OICR(HVIYQS/3)L"\=LS Q;[/RKA;JD[CYTF_
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ML'U8ZH"URD]K(Y%Z%C3X-CTH'0<\H3Y\)OL9W/PM&!O(KWV !2%#03.N2CA
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MJ77=XW"BR/8&@T1&AR5/GO#9Q,M\\.J6"ZPAQ8:$W1_7:YI"&T76+/O<5G$
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MR7#[MD[4ZC=*"+]85-6,4[#A0\\4WCKMG+6*,UN?W^UW^<Z^WO?7!=?QW]6
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MI\#EP.QZ2P%M0]CMN'EOI)A9Y_]C[RV@ZER6-N%-2" 0W()O@@02-+@30O
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M'054]@/O3ZN;.JK&;*J\F2N:+54/>?>B;+&I@3FM;(3,1:DS)@\T.-9T?2X
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MD[IUA%D_Z$WTN^'W1+Q[ME2<2A\&27ZB:3$#,"W%3A\#_^!U68[S16><5[V
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MPEP:-;QY?*;!0-+7GJ!%$DL("A BS AAA)G[-/NF?2;0 >[8R=,;0.\%\0U
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M1\,_+M;-71B,(%WTJ= WXLQ[BORW=B,7W'0.**"8()PWFP':#/0.G8^S;)N
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M@^:QVG"*S%:0[Q!HYR/Q]]Q3 /D2ZCFE7)F9<'C!3%B<'"9N2).3@+^SQI7
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MA^6UCIG=#1D<N-JUQ^/FVY6V->M>H;6%! W&&=-3DJZT&O3IHFN%-P"#\,R
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M26?C> 0D(&S2VDV$GZ3<9[_TP\HVG$C!QRR:3V>ED$..<\FJ20EH M03LDH
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M$26$2!NP@"_5ZFI$!NE1_9SK$$(RS([04^;V>+$.:;E-T;0OPM[GV#]JC\I
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M]6[\")R=-0K:$5$Z0%E1F[BKU&.M=8_X]9^_[3]J$-0RC\\P]OO"N5KOG#W
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M.AQNJ!<<HE-'4"ZJZZ(36YHA\2)"9//M2P[<3L0-FHUI.<HX&M?0W^KP#&\
M$>#3E+ALF)E\"BX#7/^/EVC_QC'^(?\74$L#!!0    ( &8^"U4GK[/-L-@
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M7(;$F[S9P(+M:[0T6QZF,.LMZ$FXST;MM1]_KZCBDE]U&5[%M@"5<I_X"S:
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MOK!PZ!9F];N5 !:F@Y):(\9I4U(HP)(PTP)K\2<3KMJ/3@A$F5M#7P<99^R
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MU](_[,6-#O;=(;O+-RF\4%%X,]=5UV,GU7++%ZPMXK^Q QVL0CPQ?FTJRL6
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MV1?MSQ<Y$#3NT=:N3D0O3^4H.FV*+"!5(DN &%Y^ 85FCE7N*2C$ZKP,G11
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M]6.Q&PNK[G(<G]4;W,EI@L5<],=5SM!^F'DZM!_!_ <]VSM.#!0V^EZ^EWQ
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M-E*[;#H?>S44A-O;3)NKZA#OJ:3G)Y*"AL5'./#<LCUC-=@($9S6OS@COB
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MT(4!V5;>U^S)[XF$%S(I"[[$AX$CWU4,]5Q7[@6 3\4FAA9\[U2:)+,[6_4
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MX_U+RB5C9+L].=G@J6SC*\SLWW]4^,M"5T@1:OS#N_;^.^4_?.7@OU-P\,C
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M,EKE==#HXDI:0EWU*/G;D$O\M/2"?"J&O\UB2&7$LTWU,3=%8;K:V('R89[
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MT7CR.GN&(^&2/:RRFJO817N]3B[,7%DOK;8.]6'@#X>W<'X)97&O(0C)W5]
M ,RN#0FA,.>L!_-#]O1HKN0=:2TR<TS$YG*Z%Z^\C]RY(<9V)#X&1JC3#@*D
MPVH,OM[,X@G9WR^,SS[T8"%1__IC_OW_5</S_PV!U/5_Q7'H"R"]Z04 > '
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M]+A>D2Y1S&5B"Z$WB^6@M'5)[R%R6.</&ZL]?37&5+Z[WVP=85\"'/O*F9W
MZK4]))Q<2VG&&_*A.Z?5Q0?SI.2/IPUNWNW'NL,'>N;OC_0DBPL.,V +.)\9
MI>C 5DRTJM1V;K\:4U[S:<./CG6BUM.V-.AS=U_[A"<_U#L#*^.:_^M[C"&*
MGNP@!,(8\59"L0;/"5 I#>^^^6^LT6[$"?'LI;_L<8%AR>Y7T;M>R#292BNQ
M8T:@,*7.3EK%"P!HE]Z7FK#]+W=&#!0WNZ/+Y.W.L9+78I=@)<,#G7*9)&,:
MTYDBZ-I<8&U^[721_BBDID4"_J?;B@SPP_*8EN\<,.&S<$8=1?.C5<R_0)DY
MI4'C+0$(^^\5.G MZ(/P";2>I>AJ25G>S;F9.0S6H]60U<JX+H;VG>823O2T
M+Z9PISMDG#8A)69FZ9HY@^<E=^Z(MV#G:@O#278&.=ED/WQ.CI[_%$)&YE?0
M72TBEG;O*?7^V#8?W W3V[X<(]&9MISCD-97+#:9<'8E&LC>T 9ZPZ:.^I$)
M+]#W8]FHF+OGYW#7B5,,7?A! @@NP5J_\2'RD$P7WHA*,6>#]),?FU-<;H<:
MQ2NF1@<$XDXR]MLA2KFN2?1_D $WI77^'MA?*W.);XA34V()-J!;+(ET<EK;
MRJPH+IB)4G@?B"-'1DZGKRA\EN^>I4[[+:DI6R,G^ISJXAUFCQE2EL*%U2<9
M+#PI*4OWLWFTK4[GBNV]_]CIQ -OYGVLL[^-"KFV*D1+6RLLR6T)#>L>1X<?
MB%+W1Q*G5S'>,'4P,5=MWBX^1V")4Y5+A5^5*U96M"][EOW+UX=!2MEDKV7M
MVL&ASP1\T;O9R9(MZ_95>$-%=JGWJE'.@9:,,74/I5C7T/SD?7K9Y*]U>'ZU
M2YZ#1^7LTG.!D#]M28/G 6.^$D5"Q\O;3<;+:'S1FPU@QD6W)XX(Z'-@UJ)I
MCZC\M4I;IRAU5 $9)0VSTK8>TFS&2!RSR*8C<M.8A5>2>D1/ &>4MHJR?+CO
M"/<[1+WAM&UL==,[J$HT+]9WH@':T(30;%BDH^\_U(9-51TV[8HZAFV?,8=P
MT3<3%RE>_:QGMQ!'74OSVQAIHDB,;7HD)8?^/77CE0T$N:X'XMB>+ALH?CO?
M5VG7Q>VB:/U]'>VQRTS%,P&496<W+'Y\$R#3TB%D>BLD@CHE_K'D!6"E=TBS
M6/ZU6(42(=%:"35N-3VX(/M0C14TL!/PFSH7L1XU77#;/3W6<"%0:NWKVO0W
M>$VA__E_B""KMRNEE2\ <,<0BBF[BMN3U/JXR\F'YL:D[J-$:;0DX42_ZKN(
M^+/'5M<1G,9-@6#F()WAXUOXK6GW?:^G+H%1P7WZG:N<<=1;BZVA'8!BUW F
MI45TCG1>AJ>GN=+P )]@3.FB5_:J#G3M;PI3M3+96HI.T*>2[>1\6%Q.:P]P
MX..8T:1;5 S7@W&VY\^4%X"ZD 8*0WR[%C!\D'(;]_,UN(Q%=77>,W!4JJK)
M\%PXPQ3CP$-4+G/N D;U176&JW)#U_K<2K$@_O=B=3*CD5\G)?YD;)M<&E,Y
M@Z8@&&3ER'0D3U78\UEPS44_063<"WZ;WB9+>\&SJIC5:D7\EUJJMBC[NM#%
M\YB7W8:T_[V$/7'@:].A-0E?:4)#_W+U]&.%S-IO&AS1(XV;$ACC2(_V->*8
MN7EVU_?74< R@X*?J,/>/VJ"2'']"*0,Z(M69Y=? #QW]P&8 WS@6TZN5NG[
M85L8]=]I^  6!%9F\?7S.E2-2YH7!Q.Q"]BR0)V^U=DSV'-=W#=@(-Q/Y57E
M'UP8 *9@(>G@)U*YX)QP)[4$9\:.U]0_V3S@0/\!Z.[9_X@XPQ,!WQDD])3)
MM!$^04COI0;./PY!(CA=UYY<GGOZS7>,);C<]_+UB%DI"V3-%V1XC#*IUUSG
MD0O=1%.B7+TW)) U8C;P]OM=V:K%,OQ\Y59$=N>)FKW(*CIP[&E.X[T\!G3.
M)2>N2[YGZSP]^-<&YPQ'71Z)V5(S3EO/B?.4[:<@R/]I!0;\NN]A6,,?QI&$
M=Z$E7E$]TW;/U+4UT89#G!63JF:-S$.-YX.,E$&JT[&-PK24U,E34_(YQ>M_
M);1S<C9<!--Q:ETW1MILM!Y0\(V TKT?[=F'+20M!#UYN=9#,]=\S#:9RKQL
MC%,[$[SLUMVV!,VA8KZ_CZE:M\(_,69]MOC*%AIDF#3?YOGVB^KPZASBN4)T
M]7Z1>XJR-5VGJ=#NOG E@CK'F;CHD/^GKUBOV2^ZHO5Z"I_X,H_'1MJ+"7(8
M6GPZ<81]4<483YCJOI[98&^*]<"W1%76&]&VMLKZKX6B2C9ML?KT5LBV^(CE
MI,P7 -X >IMIX23Y@6O*O6KQUXTVI7.,H]WI>KF?.T!FV^VP!$&\,OS0$"(U
MCL:=FL!UXKF)B.ENJ[J+W-!MB@F!YTE0UT3J]C=X"ZD*_"PNP_%TWE6;^ 7@
M4<64<ZV<6T.4@6"26H(H4LAX?HU.V)/%<-2<DS3"_:R+6NQEV,O<#:$FGB'Y
M'*<6.D*X;+@TQ)"8]]<_A(\\; C@L.3$Z[R_2HUFS]V3/O#(0$U5/=L:5_M4
M]HXYN2-@]=N:S?D?8XZO8^M/UO,&\PYU"W6+<I4D0KHNC2EP_.\8^.IW/S"6
MT"ZW,P[LB\.JUD[;P_*7]@*HYJ#]8W0)[J_UI97*D"R92 ;I)7Z=K8I[OM4
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MFDK;U%31:%C;>,;Z"X"@#R<SBC'K\D&E+O(-SX_?R^_7=AE8A8TR<<0D7NW
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MZ3ST5'](;9CG*9] PTK]RTN<7.A0@_5U1%#A&V7TO,JF6-2(&IK=#3$VG='
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M\9O+!81@#/*GWX@H=;2Y#E\>8M3%A50?^FB7,?WE3\A8<LA27X,PT/Y5Y_U
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MQK7'&99K5ZU]UL4VY3]UU"M6OJT<F6:/^D5K3;?*1_:7G1!B-74PN[9U4(T
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M(YX/57:&9O /(9 ="QU+#"PUTIB.3TYI!*A&2I6*&%TZAQ\U%#RY+71]FKO
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MK\[;WCIR=N;M3^S^ O]!+?@NHTPJ\R$TL]'5]8"L&+)BR(IA[8J!9L6P5L7
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MP'9QV/;:+5T3<T-BE3&PU>%_\MTDC%@"Z-/)*#'1.: O\;&.<%P'&ZA=AR7
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M;ZSTZ6DP;?3! MV7_ -UYZ8^CV[XRG,.K]PZ:B870<9+WM6EBFXMM6!%I2T
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MG3:I<,5(:*,:L2=!<;B:QX82HN<F>9'V45IQ:\1NF *Q [Q [)VZ ,3>J6-
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MT:'=#5W4Y2=\SSE:YI:S-,SO*G&8>J')F\0HN"JXT$E((_9R<<[MZ:*.9UM
M%V$>QC$Z]"#%9+.7I3GT15B76=ANUXMXL0U#'FU7LS?S=&9_B>O9GUY+M;>_
M[I[V8G76LG'SIE8TALTBS<(RS_+B[&);,H9LC$Y?WT[E+I3U097U'C(*FKH#
MX)ZJIN;*^.RD)R&J)25%&#1U(2TECTPXJ=AU37V#VK0'8;U<+)]O'I?UTX'?
MOAL([??:NGU;\M-MV);-HWIR7M8M1^ZOSL[">K-[RJ_*F[VMO,6G">_WC 4.
M+IBB)"E3ZN6-!4[J0+76I$KR1H9P&Y_^_B6)W^'G9]\8\8YE1\?7=V(%TL?.
M+#0C-&-/CNHHHZ 9H1DGJ!F+L48H7XBGT#0C4YZ"C9FLSE&;IIJ4N];/<).Z
MO3XUHTVJQE1\4XK&D*HJD;>\D'"6&U5+5>K:!9S[^/2'T(S603-.FN&@&:$9
MH1FA&:$9H1F_[ (N%2KG10^ZQY,RKE#P3!/+T53!-(_.[*.FL4_-:++VE9=$
M,J>AK%,*"D97LMQ*G9VU.I7;^/1WKQEYPQ-HQDDS'#0C-",T(S0C-",TXQ=I
M1J8C9T8.5\GO=MHL(R>LI)J]T)RK7*[O,]ZDWK-/S5C;IT^6<TK).%+9&?+!
M""JE>L]#*"'4V_CTA]",!IIQV@QWR]6QD^HNZAWL_[%[R9(I-..&Y^6WBMA=
MY>MF=K$I>;98OK= -JW.7UYL&V;-EA\OMWW?B_S^E]Y.N>VDPJ[/A0V:VGJ=
M9HV>M,]9HTQ [GO% C/:D4U^J,ALNM5'ED@75C-/7/%P;8OX)L68;_CGY))^
M'EZ<Q[)^5'<Z=O/H8KO9-N!O[')]&7#)3V\K7'8#81]#K$4,-SRG+$@%8\EI
M5H;91R8%9;T*UPH(]O@Y7^O[:Q_WBSZI,?/VQN?"R]L2\FAVFPZB0^Y [B Y
M('>.6NZX4&UT-E 0;B@,#(E<+I(,%R'S;$V5=A]UA(>6.UQ9)X(55)JPH2;B
M2I,N/!%ODL74HH1.UV3='C_GK<@=Y>?>RCEWM[9O";DS'42'W('<07) [ARU
MW E5%.5X)*]9'HXS:_LN%4J!J^1"2CJZ?93 '5KN9!TSC]*08=Z0,BE2R%Z0
M%HG%R*Q/_-I0ZSU^SMO9W9%SS=5<B7=-NH;< :)#[O3I LB=7CT#N7/<<L?Q
MH*+D@AKK#W-5M*78Y \9F:6SQ?,0]3ZJMPXM=X3BD0LO*7DYO.?HR85A5K65
M)4?6OBAUBY_SMG9WA&B!I-XUJ!%RYQ@0_>W2,O0G]*]\8/S;-7XS]?#SRY+=
MN^DI&*%N.=K<@$NZ<PG@"G"%W(!+1N(2P!7@"KD!EXS$)8 KP!5R R[9[TXB
MFE2/IDGUT?9%6<^&3M-U>5&6F\5/9==I^BTZ08^ N/9]7 NL[/0<'8[IS3$
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M5#&"P[ ^H!0+ 2P$ *5CAM*375\,H'3J4(HBNY$Z#AP(#NS)AR/D0"PG *6
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ML=\[46*[>F(YU+NI018(=) %R (YU$$.]6YJD 4"'60!LD .=9!#O9L:9(%
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MZS#C/PA&3G%/Q6JF2A).V6ME$SXK%6T(%(4LI*S(%*Q1PU!AQTHTMAB/8QW
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MG6+8E-P0X_QE66["D&^X.'&,<@L=V/T9^O@D5N^8AK% $\NAWDT-LD"@@RQ
M%LBA+\\AM F.KI$ 1#\:^P.D^@CT$6(/B!XYA!R:.'\C]A'[X _D$'((_('8
M[]C0QQ?[$RC\D86QF*6B8@,G)6-SLF2)6. U!%9*B7$??7\?FC^^*QCX;J@7
MN/=6N<!_K5>;_4PD-W.O,9!\LL#3NZG!L CTJ3)L[Z2)%=K$<JAW4X,L$.@@
M"Y %<JB#'.K=U" +!/I4R6(">W="25$<YU1+\J2RUA2D]51K\$D+:R*KMWUW
M(/;N)@<\N$SP6#OW_EXVV^$NP%6=/7GZ(VX#'+'(0I=RW^8^/L'5.[AAU,Z$
M\ZEW@X-$#N^#\9D;) (2Z<.98\@GM/F-KLP3,F"47@!L]13T(T2C"6S>%Y<\
MJR714"]+BN5$GCE&493VK\FZ$OC5S?N4@J]%<1*B1E+!,PJZ?<E5%".=YM;_
MNGG_\T_E?1OWNSW[S9.RV:X7:5OR[F$G/X=U'C8 K\S<V^P>_/:./?O@AKUB
M+7*9Q; ]0,\HH0<4C#Q 'F ECGQ"/H%7D ?( _ *\@GYU($+P"L=. %Y<' 7
M@%>03\@G\ KRH#MS'U\>@%>03]WF4^\&!XD<W@?C,S=(!"32AS-'W5TWG3[W
MWM/KT?9%6>_NPEN7%V6Y6?Q49F>KS0T;[*;CUS[E ]J(^S,T),.X) -R:'0Y
MU+NI018(=) %R (Y].4YA%:YT9V,@>A'8W^ 5!^!/D+L =$CAY!#$^=OQ#YB
M'_R!'$(.@3\0^QT;^OAB'_R!'$(.@3\0^XC]8^2/K]\0QXU#IO=/^.YI5"F;
M8B3C9!./I%@MY(0S[8M6F47O4Q)7IU&QK'UQ3%---9 J,I,;;H4--@I1@U9&
M7[L&=E<)=^_M0KC395J=EQ]6F\W#LGU4GX5?/OW>B$V+L_;=!^=1<25P?<1M
M5U/>5K#^\= 5DB.$6,@+R(NIQG[OY(OEZ<1RJ'=3@RP0Z""+/LEBJFM1&:MB
M(7L2UJ6VKE2.7$B1?!7&6&-\"FX?UQIB+=H_0O:^%L5=B,?:L]D0X MZ-*?F
MS3YUY'X;TU\7Q?]JEO=7Q??NK?$YYB/I\>FN@4[M;%/CCG-4:#U_\U_[R$A6
M<!FX#%S647J R\!EX+*[25;TN8[N(!EJ9)1>@!KIU#%0(U C4"/'D:R]&QQ<
M!BX#EX'+P&5(5G!9%UX EW7J&' 9N Q<=AS)VKO!P67@,G 9N Q<AF0%EW7A
M!7!9IXX!E_7+95/MF*J::\Z%(2\D(^69I!"J)<-#%J$$)96^VC$5:];,5TTR
MLDPJM>]<JH**=RRU9UBCKG5,/2S;WUJD]ML:I?A<>+.G[BBHDI&W54'60-9
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M/=,UGP+CH-\L0+"'!%16ZD[7XF.-YN%WT4%+RL_DLE1P7#_\_(]$)6F2A0E
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M^>]:\6! \MCI?::ZQGVG%[6VQ-]XW_ENJ/SM#L8?W2$@$R:CG!8%85J!K<H
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MHZ?IAPK_0;_Q[7/3Q[X5+@??!F+*SX&U6[!H',W[ Y->VR77L<JJN$CCD&>
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M8002EH2*Q2!YLX+P1&FBA,A9GHLDCS935@5C,14@>44H"9-)1C@+0Y+H."Y
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M\EQWVD=(=D83SQDYL_TUN)1@>G'!='C_R3-[L)7G9/>V8U+XB_H^A[")_=7
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MGWF;<C7$7X' U;GA@=8=@C8PB_RI'IH6:#N^%[$7]]7LZ9#![)G)L/S Q+8
M$*)0]P-FZ8%A3X-@$M@44-V([EBV;UJVH_L1P\5&$YWY4T^?.N', 2W/,CW^
MPHLUQX9R3)VN8THY3:33I-ERV&YCPV]RP_,@+A"D -RDOM/"QP9B:&T>6QLU
MVNU4H=5I3* P"__(XA31J_:U#)'K, ;&T;?CPY$*Y0KAUT49EU6)L7CX-3P*
M$*SY59P0QB=90"U"@!)3VP:ZIP$89]K%%4\K/GXRLX"2GCTOTJ<!X)$3FCY
MD>WJP8R%7F#ZOAUMI]4<*"%Z?^Y,WW?X>ZVED?XG3FYSSNO]KEU[6>O:DY)T
M]%SN/2-DAC-S33W@[E1WN!_H'H"OSAS+]ES3<(R9LW5G"YT,$9OHML%@=PUK
M"B?"<W33@,,0,&?&V;UV]VCSA]#](/QBQV00@5@6J0M2+Z",@2I?9L)^*4B
MQ2$YSSNJA.2"/%OLQ($U;_A%RR/['.-'96-^%N9<+0DHP! BT:29M9\>Z]B;
M<X0"HCM=/M6S2*\06X'I2L)3^+TP2@E*6AM0[$Y=C&=URG::.7-\$(4@T:83
MK)SF>KH_\RU]:CJ>$TP]RYH>1!1N.&!Q=9^COQ?\ C?K"4TSRV!3S^<SF"&;
M81V/2)^QR-;#R)ZZ 8"YYYB'7U]])7=UD)4YXUUE.X[)#D-F]?DES!R9^C*-
M_XUL"L8N(\9&&X0<0[7W1JK8%]_>:IYCW9I<=5]I,G0'EK+W#F;OD=&/!O_Z
M"4FS4FPG[250/T%+!'8+3;^8WF^\W<(JI">?2HGU7!M$-V>ZSXT 3!3;T&<&
MJ+-H?8!T8T8XM0_A85,!M$%K6^LIQ;?[)D24II550I"60KAJ'UD>S)$OO%NS
M.32*817PL59]U?9S%<!A4(DVH P=<D%.&B',V ?M+;M&D9=+[?!$=31N3PUF
MFV"NVHZ!>8^NSBS#UDUW9DVFS&(FW^+TA\0H\8[/AY;P_UW3_2N0?4V! <.'
M-QJ,;G55&.>.ILOCR?X6@$/BIY\(=I%4K*AR"09[S(^6CSIU/[M-;W>Q8<,]
M%)+:=$'OLX#2KJ?E5&V92>@ZDVD B$AE=<S T'TG<'3/]QSNFA/?FKF'0,27
MLF5\9EFN/[/TR'28[@1@T,P,V]0CR[$#:^($1K 59OKQ]1W6EL%LUR,W9H!G
M6VW]ASP3C;C 7]TM+YY*TW0CPY_R"$Z.$_FZPXRI[D533Y]9IA<"8W'.GLP9
M?FL>6M^/!";<5I=54>Z0W6 C!%4I 034Y@PO&./M8O*'[=EL\H_CP>'!WF?:
M W&'&DMUH@Y;\$E5.:HOT\Y4E:.7*K7U5*0@:0CK7_S3^B>\Q.0E^'^&<1%4
M!7+</^&GR:J(BW]&O:S@L5=.P:(T:PP67KTJ8;K-S@OM7;,Z JX+N4) N><"
MZ<.M4_LE3ED:Q.@+1.@MZU5]Y465E*1N2_CIWK[]D<.XRZEF@-EVK&XU\?!]
MKO=@L%A4XD'M)EP_9JP]9EI6Y5K4;%RPMG%YNW%9LW%:,<^J!#W*\'M&[E=X
MZX\J%<HT@>CZH$4))IDH$21&%29:FF%: ELN.:.KPCPI^/6<YUQX=&%Z_UNQ
M'&1XLH(CA(Y<C&K_ F333$/_7QH+GL1O7:1I!1_:?NI_FE@Y55\0Y46VDHQ&
M,-D$?D%SQX>_@?:0"PT1O_+^)IAC60Y4+Q:QH&-SG?G;^[?M;6;XA7#DV+5%
MV2EKLN;7P>_>,N^.=^=;MFBB=W$JM'^< 6XVHV2/FEY[MQG@D=,](UC? \G<
M]:AWO[ZI+.$V+!.6"HIA<*'DE^**./[*KPJ8:E&,VN(0\*MKEH=ZDF5_BH!$
M<TS*.2OAP:LLN4+[O_A3^N-3&2UHDDJ9/*-(GP4J?GB5/,N+[JS+>8;18O&+
M#B%DW*#>D*_P&>T7\51-?50=2VEUW$VJ0=I5?9[T_<6=9/(=>[EK*_% WL%_
M(WH(ZQ+ [VLY&)#@"^,H N&!=^-S$&]8!Z'.1*@?#"G)R"?6'"'[Q8ME@L$-
M?T5VBLCAV7/Z^Y_R^ ,FS*[JD4-![,.I2I^O>'X5\^N#[?0!M;@G4\Q.+]KY
M#RR0"/]H 5""*FX#EX,:<<E37L:!MN!A'" L8KJ.B->@@E%*!W;(DQ@."GFN
MXHCKI(00HH'B5;95&I<\6R:88%V6"6E[_(JA.)&:'U4/&VM_Q_IBVI>O'[Y]
M!#MP8I\+$8<Q\CSF)19U1/TA@R^*"BMA7M%8/,F6Y#8!>"]1 1#PS%.,H(N\
M4J D161![L%>C2@<MHC_S1I-$KX25HW\3>$CJ!:"$I)AU$/+8(NSM H2GI5Q
MB!'Y:_3G+3%9E0A!DP"5L\ CJ <)*XH.]6@^L()++C,4<M!#*,L352?TY"#!
M:K*3R YY1*I339\Z.7(.AP!^B7>S<:95NH Q4\[#L>*+0_.%W%;RT6X<@+4M
M!205OP.684$<MKKWUT\7K>Z-YVS.<M0R-8Z7_T1Z29)4"4.X#N9 =CC;&(J-
MJ7%<SN%0BCP"?@.K%JHS;+L\%3H<VT5&X\"7$,?A!R6/4SB@>!LIR[D\_MW3
M'4E3"!2']G%X=P$/H>53_[3SS;'VWRM*<LBO.&6BR]1T_&J"5"*&F+,K^;V,
MTB'@ UA/( QQE/8D$^GH6=!888[RQ/N<IZ2[Q $JS U7T,$O8&\3F&$"A@\R
M-4S7C^&87,9!074#L < 1]5;:-2P@3*[#\>)2=O7P@P3<)IEAI6P&)$F'%2F
MH)2%'J\R;&2)*AK\!NQ*."HH7K(HTN6.UP)2F%UKO?[F,%$N?E@4&=B796VX
MO0-B<;1>\3SE- ;.% [R2M0S@A. @O#SYEDC6G4B?"R\8BD*:JIGR^0@O*(9
MH>A9MR[6:,&HV)VV !+'*)1+,!<K^,]J*9>Q\7Q#+?QYA'?D>!I0SB104P8F
M>(K!4,V'%9# *H$AJL8(0S.&/@*[=H79!\"$.Q;)DB(3*\7Z6CJ<7A#?<3'G
MVQ6[,ER"G.X52)E01%3A%9"Y8$V%!6!-(9+,0QXP'!X3=1;PZI708=<*>76_
ME?-+7&^6@R(L:25\ O'"K_)"Y*LN63E'KZV2N0>LO(KFC.0"3,=K=I B)$&,
M B7"H%1:X+>E (;?U7( &*.5H2G'K6-"FM82J.;:1A*Q!#U$*R&-,8M+FU<P
M1Q+*8M\#^)M/]U3*/$O6?#"YF$:6)<"S_Y#2#V^NE,"2]:?PUW_&)>E/.=T4
M0D= PWP=Q@5&8R+HU^7>KY]0S/]&N@2=\@(D71I0*3H0OO%(*S!74)2F0U<F
MR!BD7"UHX*<)7C*2I5505N>HX24<@ A^+T571QTJA+6(JA?I8JU61;(1/79:
M50BM!Y4IL60=GM!E9GQ'3*/?!<<F ;\!!'+C5HJ)#LM$%T /_<.;7W_>.@S;
M6DRCJ%Q\^,A;M]+/(.\0^@GU8,B47Z-PW7%<5V--O"H5)CP1PCC ;VJ($*3Y
MXZFH2GG @*EQ:JT67)#3(>?^2H OB?D&=VN0E1%/8"W2FI'_LR" Z=7H*M&9
M]),.GGYEA,SP0JI5A%D,=9L,!X*37!.'I_]>+4 _D.L!BR&O8 FUBB2-"I04
MM6?.ST) "=1>8,D-)=]=?&U\.F\ >U+$2:0-;&4JQ$X@=H/(\+/\<%&7/TH9
M !TQ##!3@0RS <G2UTM9/ZB-<>T-C()R#C/HQ-?>?&C+*9$P(U<X8-UEQ<0K
MO_Z,B=-QT0K=VF JR!E$N:[2PENU>E$A99]0CN(\1XDBDJ8[^I%0IXJ[=J9S
M=(HY>KB L*@\E?,1:*E( GAN(?5#.'$T*2'H,*%"F&GT".@<JZ[<[%J-7SYI
MR+>@HW,Y2" /HLC%(-&.JQ$&7V<\0< %^Y-$]8)T&_A&*44D'2O<;[T1S_5A
MZJSR(.)-!7B?D!1MDD&\N-2*//CK*_C#9.+,IH;K_-,8_[&\? 705^[\>4T[
M6K5K.<N;<SDO:^K"7S"RW_=U#^X0J%0325/+4*DF+W4(E<Y9ZYP;E@*:;V0(
M2?--7NL2%V10C6(:*HJ$Q*AB+C&\A>FEC2F&NEZ52F_2G,%L@\;*0VS'#I'"
MJM_0:;M**LQB59L\PA6"7M,_^4J+."I9O*[MT[59SK1".#E %>RH B)HO*8?
MC#5<.DP;'E_3SZ1&L4>=B$54F-5W3W>H.#O\S>BZD(Y'"N-EB?"PK!FZTH[;
M23+,(#CJT)WB1IRLX,1:E5\SU&^/9]#91$U\W571F/(B_@!T*NIH2B+, FGU
M"WU=]MN2*1_ ;GH($Z>$5+R%E*,;IU:^P4Q LP-V[$] *JH/@B$:$;UN0M:+
M^ 9959?^H$T+5E8\@D]+60-[^B=8(!C33M>B0R +2&-'NZ/QI288[\[@(V5\
M2:[O#<9I<SM:G_:Z.[)U^,J0?&U.15E [0C("4GB#J/H:.:,[L7S1/'Z3BM&
M>"B6AKN3\)O6,KOBL'/2)<XQ_,:I&D''OA7FI7*S'!;RKK/\S\X1$RD2>QE,
MFZ.?F;@RE/4/L)I$A3MU5<MRX#?!ON23@V^("&<3])2>;S)5><*%%V%7T%!8
MV^A(#,EMNA+7C6M@$];\<IFLZ@#!+L\.1G1"CG< T5^ D(X^H***2WD4\<5-
M7QXZ0M$TW^$^%(<3N:T(<HSU /:'Y+M?<T+NP/P:OEJ?,.QP$R 5P@U$5AJ@
M4[6193F/D$:P[I#SI;CZ6)1,WKF(M'EV+5/68(TP2Q!>BVS;2;9+'1 WUFN?
MP@;.8YR!H?,#%8W]NDMS;;U[%&Z62=8&I81F0O,3-V,*Z;^*2TIVQ*A0)U/R
M.#*E@*6N8M"?>KV<?9/'<]'G>3]P&ZZR/B]FKSH)H DP*<6*C DU$0\]S(%Q
MA B) V(BD'@\H6 )9G5@'+)F2916.0D:(8\W98VP9DA0 N>"7 CR# 1T4?E"
M:I#[^#)G"Q$BZ@X;IU=<N)*%G(0?155.+D4N\DH;*5TG $C9%;!E>T%,)J\L
M,+M%9@Y*BZ06O$KG/W9U9.VBF4&G>%GYP-T))6U0\@<7&H5PF7<]XBUNK?G&
M:Q0544V$:U!=KXEMZF2Q9"7.,: YJ@"D( >@3W<S (3AC)D6;;$E$1RH>>6*
MY3&JJ6W\<XSS:Z>%FA--(,;B?TO$QZ95!<8V855U?Z]Z9J/N-.44:BU*IK@U
M?*G.X2'3ID2JBI9G/AY'07@,$ '!XR6G2CZHY7[2VVC.K69I&]&A?99;VD;!
MA5]&AL";35W+[J#[%Q1H AF,1NQVC!P?B=$_!4.3V8;J;E9'"S]A]P_8 >V2
M)9BR73#2B)O8Z:\L^701-+%3G6Z;7-(IE0&N)I=ISI>LFX$@7$@)QN;JN6\%
M4M=R ]?S 64<$CW7.4P]Y?D5LE*Q*O!*5S/!MY^^=9JL= H0+5892(<E,+J&
M.3XX1@'$![Z,N['AW[NO@V$.K ?C(R<F,-,%F<7MX[]\?]=Y_#=1-:^LZX'@
MI;+::&A>^:W[QKL*>#_%6%U5!)0:%\)Z<)JK]HUW'[NOB,P$T+5U$_Z,Z5ZK
M94&V&<BSF!*6VM5<=.97.QT:XLO+'V<;4@$.<<V$DF^1/\^<\<3R?CK?$A6P
M0#0HSL  N;F'F/@#> 6,M)J3Z#444WEY3L) QVN'Q1F>67QWI^AH>1(F94]_
M&K8L6:-H0\XX)=(151_TD5L(W*7;=&*94\]U9I8]=:;6Y"<@&AT5RSJO#T3G
M)*Q/:U@$!F']?^]UPW"T-XTL_5D(PK>S+(^FE@S9\Y 0&MWTTN= FFD)+(R5
MV#:-Y=HOT&2 H[BO1^PD1(),(:X%83%J> UOG[=WT!7/*9X[2IZSMWGNVZ<O
M=LMP#V2OW]YU0DM=S:%A6-#4D^P:[X15)7+R;]^_-TG>E+[=Y%"#*G*%JL%U
MG(0Z)@7O>%86):%A00UGF#>M>+@71TSQ\+/P\*>);0(32[-#\C"_ 8MA8M-_
M]>+/>+GKXLAN#@9MEI18Q46]V&3%1<^$A*[VYFM[*4;RD3"GNU;TM_=?OWSX
M=&$*<WHW"Z%9-][#/\JG\P,;!;8X.A1%/L\_V!4G_V)=J%E&,R]EJ<Y%AOM1
M+="M32G>W60<4?(!_A@O65WZZHHE%15ZF N]@U*82YYCMD#MU;O,LNT[0!@0
M"[H9[,&O'[^T^>OKC]=]4V3&<^- 7[5I-97,<*C=F6UB,-TRBHNX=6 VH5GT
M\X-"%7#X$SGJ@SG#"_5-,GL0@ HFB[M1NGO<N6+1!G;K&JN-?ZN3MS!J;F6U
M<<).LE&<IMD59BY@I9$-K%DC@G UE9PMV@H76$PZ%Q=?;GVW<V6OJ.A2E,CV
MD$D(2*S&,R<(@3Q:Q#?:99+Y5&&E"BE:(8X0):7 I*5#3J"GO!"Y>^=$:";G
M&L<3(P@JO'.4<]'>C<.]#21M<"Z854[$VY@@)J\+TJ%!NQ6NQ_FGP!Q+D-(I
MN@Z/.(BB<FGK7%I3Y=*^6$+WKL(;PX#;A]>VN'\8'F7V6XF#7Z23NJ<72AYU
MF\#MP]E[]ALEYIX;)>:.&R53RVAOE-B&NE&BDOF?$ ([_5)"+*= WKY+EC<A
M6(I5=M,%U^*6;?$R'_37:Q5<?\H4K4^\RBGK4E$9J4Q?#K$F/F6PG%'")_E&
MGHC^,H(VQ!2Y,VS)T8W!U>85E1:A7 JYNCJT(%+9NQE$Z]FP,.6(YR)#'A.#
M1 ;R1K6CHJX)6><=S_D-ZQB=OSIO+9'H5LC^O/M:Z/2%P/<_+3((VN?%[#4S
M,?F$NKB\G6G_??%6["C\$+/%8\R,KH/)B0P\";\(Y=-0#2/A]8BQP=>2,S&V
M/ :2+FNG1.0-+?F23H5XIY/[\>5KZ^A9OYY/&%05LNPH-6XLJ:I^2=Z(!7QV
M7HR:FQ5A7.354M;7QZ8S]61V5$!20O:0^8JRX2N7:5>E3$_\Y?/;OW_3X925
M6+ER[<:<\"2-1/$4H6>.-#@S88:7!L*1%F:5GX"1#M2%ORT36(J?Z9W*+5_F
MF'1D^G^QVH)WXD-4/*&MM5"PB)="K)49^N]:UQ^F4V(Y"7+2986X05B??M$U
MKHRI\!UY$]_.="EE_Y)A9H4.LK9[_4C+_#]$B+9)/=)D;YG:L;W,DM6O7]IS
MWN1\Y=S/LV(9XS!14G7+CKW]]DLG.PI(42P8+0=^T5Q)^#.FC+*FIUU2-Y_V
MXXPN4>6B/D)-*9Z&RRS&^I_4R7E]JS9#SSY""5N2<XTH@<02\6/!W:)X5%M0
MRN=TF066055(A2,X!,XGSFKJ#H(8^M*F=HK,[6Y%L6XII_4[).@POL)=I.=$
MI>"Z_P+&8J@88=8T+X;UT,(.P_?*Q5:[V"SE8E,6[DLGRR_S.)'ESU'O3=.L
MHJ;D#$ONQ"2TJB4U)98UA[+T,D,!L2'TQ.T/!J)/W"GQQ56-S"]X?M5<XQ(W
M1T<B"Y[J%#8:D93O;W[]\O.VPM,5^2BX28Z"53VJRRIM A#(QGHP@DR\@"80
MZ"\">KK7]:2(QR4@SO)45IL,Y><P43C$VP#P"3E^F\'+TTO9*H+NJ8FB/W55
MI!S;I8J\; (G[%*V,36\8\,T4.0:38O4/U%WGX)C<.3FFDB"JN.&XF]=/5$6
MG:^U-DFWQH#8[NE*5PL!OS&9N!!7%COE-#=EO<J[4'D71Y9W\77-&FMDSS6V
M6Q!B"\6@N)F#MVN82/AM4RUP<<M">V,:VN)RI*5_M1J5]URSZQ\ZG1^Z]0_M
MYH<_8WE:NI<GZLICZ%=<ZZB+@@1<PVLC55$K\MJ;M0$T4A%J04C?%>)P5!=*
MMIV?6DF[MEB&#>=7FC?1WBS_"J0TS9]!)Y>5F6/1RZ*^5POSSM*FNT6CW..G
M9"E(6AXHE:%8$MY(IL''^W(BE1[3.SWFCG"-M2=<8^T(U]BS3@$PV_8.&*YY
MRG6_X"%0**M0]LA0]D)V':@19PV'\#<"L#IJ/"C)5  SS. #:5;*ME-H?Y"_
M B]S<U:AGZM.A**6F+4CO6MR+'D>9U*-IFHT-S'V@J%[Y%@ 2WA!M3< @ !5
MA2@=NO9<ZRNE%#-91$26UX&GJD5G25T;IK[LNUY6'?^$98.[9LM8^^]N@>?.
M#>&FV Z6&:]5DC6Z"5J-6FNLN2),/B?A@:K=:9W<L :^<Q[PF/(-+1H0/[FU
M)6N6E<K,[@5K*=GUG!D 7:>P<(^+GBZ2M4*4$3$V<! %==!'D6),.HH31L9"
M0B72*2FV=4Y_BGY?[XG1>'-EW8[: PXR H>$YS6>\"M9-FS=5(&!"WRE8>TU
M08&CNWM$K?30IQE^#B-1494TI::Q9^"^66%)=0P?78HR\"$K6=W7N1%]-$D4
MXT45B2O(92?&T+K419GDL?9^#Z6OXR3I5 T1:<)U33"Y)BIR@D$16MQRSHJF
MKN&&OTI)L7XPF9)BSR#%1-4)?B7X"/G19PD3;E[AW]AT:JS5#Q=>!Y%\3V\O
ML@*K#,(L0MD7A><R[QYO+&!J_VJL_4(MJVIA]*93O@*]"&D][L\B]1Y+$V!/
M!RQ1RNLH8<%%012VMH1SJ;S17'+J!R@"9:*$&=82P@J&F:@V0;U/A3<5_H8A
M2 R%AT"MF#I?-I59<%KHP+YMQ.T!,9U_15<@*!:8\UK@M33M7O;N2._:E8UG
M0?,3O-F!]>FQ<R$2K.U@1+.# 461=1"EY#I/F-^(25^<%U$&:0T5U#V@)ZGM
M@D=6]%(MYB)7J-$4=D(1(F-;Q[.!HHW0NP3L@F-K7]#DDPC!"Z42E<QJ/XIE
M!45%/!JX6^YV([C<1)77N_Q0]<5.#]JB[A%;=_S16 7 +OOJMFF/HO[F32FP
ME>(%G;*B5#@%5R&F_ 5D#.6UQ(4H.7C-Q&T8L1!262CC05I(< *R)0?$93Y/
MA%%'N4_WIY*ZF7("87-;A<V/Q]U\&HFQ]A!3'2DQ]K<V'[8M+[V9&6N/L*)N
M6[ML?]&.?24Y9-@<NQ*EB$H)!94DE';>1^_:(LN7\[CH%/7Z]NE+)\>K_ND"
MRW5@-9'Z=Z.M-H2=LKUZP,0E2ED79"Z+=77-=1RQ<Z]VO7%3MPI9G[?[_F<7
MZ=?GE>R;MTC1K0O,=$HE[LO:7M.-VG9P3?.W*,Z+4L=AI4_CMW>=8J;?FWY.
M="+H8.&Q$PWBZL+SHNC,>NO2SN%I:[R+XX>%U!.^68I&Y(FCSV75?7E'$9KZ
MVC6U+LLWZMB\D6/\O/.47Y=KQUP:(9T$U!CKW=$LQ=7@*B?%M^ZE*FY7BP7H
MG4)9=3'X!9:7QJP7J84*^M0=\62+8ATV.([ [J)VK*Q8+;!!,!8,'!'UA5D)
M\F")"FLGG!!56"*?,K0[A2_K6]>CYEA@"4].R9=<;W,K*56GF?*:8Y_$">UP
MGWGB_MQ=%Y?N\VKVJM1M%X*VJ"H<I3_3+/@SQ-JL:QLF"P.3+=WGY3YP\X99
MDGJL76SF7>OUW\-5"H,%K2SZ\C_ZEW<=R,4<9Y(Z-1MWR^"W)2/0*)9%K65&
M=/T\"9\2+T5T_=$P.U$X5'AFJ(\O9O6),]21M/ :9>.)&A0YJ).R&PY8IECK
M@PXCEU6 -X3]7 XG3Z*Z17&X,X5)^-_>__[^[7<=P*')PF?]N2%!6K/P.5*1
MD/H\;M^3 /4#?:L2_@#L'GA)@LX8N6K+;KVZS9L-&RPXTC9X<-2N6I2.OQ1%
M=['?4DI):?%"M))JF/7CUP\MJVY<D=BQ.WON2(P&?DD"-8]O?%GRA0\*7W.Y
MI\VL%C[EKN-++DYJ,!NDVG#]"7_CNJC;[Q'#-V1=GZ:D?MTUFLJ&K]6#J5N5
M4EGJC4N-M<L0VQWAM!?L3]J05A8K@?9R+@:LPC=$98!\#%3R;^>E6US6GH*>
M=7==66FP8WS7);+AKZTE2&4*-X9 BY_+&V1)0N6UF_+I;?MTY+D_XZ6&Y:D$
MG],WP[KZ%I@JJ&/*AD2B=89LNE. I)5MZCJ3HL>Q![$0:&S!.PR&'<6RCM51
MYB TT&$QTORJ;&PLY/QVQ%JCT-ZOU5L4(\&0G4<;.Q/D9-T5:X-@VAN,U@,$
MY!G:7@A:W4>D5E-?3F#:%<B,+/]Y)'S\37DNV4@X%56E<&"]$UX &XO"^IC]
M7"!("_DGSI8F2JIG!2*C2+ZHKYZN;2:I8HV!WFY>TTVIZ1XE'Z!B\/$..&[?
M:-T%.-*:&)0X1=#?YF$)Z:F$WT&O)3T:0-=C2!N*6Z=@6G.,&*J);?@;\<S/
M5G6[[H_O@)DS(9D6$@+1.I!2IV:UNS&Z&U#'8OX)73Q:%K'H["!<%QDBM/:O
M"K0+6/ES0SB20QWC)W6HBI87BL:'#,4CJ\F&)51L$3M-AJ+39-.-4/8>>7,!
MI-,_O/GUYZW&)UME#W_N5/O8ZS;N^"WKIB2[VYK(";"<=YVUU %3.A"(-=^(
M6I([6F(VTUEO9RH[^K8"(%GI*"QX6M>.!9M%!#R:+IF81XV3S()5*9NG8)6*
M !W/G/0!DJ9*%+QDQ- ]&Z(Z3Z5T+K[?)V;HCCJ*F2AFO%8 N:.2D;5.17<V
MZB$CB E@:W39BW<77^LVKZ(!-4P@**5A+6LG_W\491&97XUQ0?ZYK!"N \PZ
M(>N@+J<L!Y;" KV(-2:CXR'DZ"9IN]WF=>U<TD;C/* @!?Q9=@V 4=MH#(R_
MYJ6AJ ,5 +Z\Q,R;;G2#6!BC.]C:*$;OEN!9(C )(GRQ<5$FE6P+1>\U3B76
MW+CN!$!)AQ&QC\8_Y39-HX &<I>Z"3_-'HG-_/#IG4[RB68O_"=4ZA9.0IT
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MF/6!\/>YA;7/5YA;RJ^?#K8&2/.G:".>HI]7U'58XJ5R<A=+#2?&9!S1MCO
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MV^U'G2ZE;I?(VR43=;M$=5%X:3E_=QK8SJ2774X0%+X8B1MI&/X:=1TA(ZG
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MR I @WE5\%+.XW=^ Y\K\1-KOQP)?R4 41!4BTHX24(>Q4%,GM/7GN>,W>9
M:9^K;KX[S0(=LHM8+HQMDTDL=O.<3HQVV!&^(Q@.%NNV\+ 6[UZRE?@&K+4Q
M&E\[TP[R['G!YZM,&)C6J0'%Z3'J/T3 !+10BLLBL\#9%]K0PQGU&DX6G!^M
MJ"+D"8PGP,E"I713)47.A.\A2Y0DL%.@HU9>\P14/N'Z(+\)J8 B! &Z9B$G
M*P.VP(< -XMEK>7"@ M&>O45N4!\X>  53HH!>M><WJB*H2:SJY8G) C))!&
M4EX;20!?&2CK.&I*<(D:>5H",XHIC+4/\/D04T6DEH\#\X1(F6DY T'3_!X&
M1B(@;\'".3Z=<EH2!P(*Q((]$0\+XN  8A/$Q##Z';$K4 ]QNM+' P?R3P"_
MSJL9NAK0Q+@$!94TV["F^4A#.P,_=]UL>JUD=S9,3+26G'+9.*YT';7R#%3.
M].1TR=,3$7]/RS@A%H YUQ:L5L!R*'<B;0U8:9 (J[8 <8&1R0B/73[J'#HX
MN'42,XF'F*Z+[3-:&2*F#\\T21K"^H(36=L^TL#)I,TC!A0V6"XM-,G5]54S
MY%41,^5WV[7$ZA_A#5!X9[20*$[(D5O,>1))ZT^\#YL*,Q*1U%3[!;9!^Z;;
M%]^^UN-R[=O[MZC@%A43XK'1G3M6)+(?$E"C))R0HZ1%$L /%G!21)@V76V2
M9J>]231IC3^,)PE-&_0G/"PDT?\"'ZS2-K(3+\1U*OPOZ3RH8E,PEZS>5,,9
M29DK95\]2R[TGH?0AB5%5N]'*/* *)Y581S^2JCOPA38= *\MD U,KHF\J:9
MT9TB62<"P#!ZO;7447/J_L;);(#W?__]K?:FL8/J'S?FCX9^!)@>JG*5V#2@
M$; )($YWEW'GX72GM<RN'\RYH$@]3?)X Q'B%(\&GIEV*G'W&,('V4)$!^CG
MF'0%.IM!RVO^:JW;<=_HJQ?U5SM&7"WPZR<9P/N<ZV*V]7,UI\G<JK$F/%X(
M9YF69.DE<-J_*A!UE$N),VS&PW0!_<\TNX9C *"?822$MB-O!F="$Z -D68<
M,)KTRU#^9II6Y,A<@O;1G"'3T/^GB9RL.,MES.0=#_C"AQG9YJAE71"75W%6
M%0#D-?E$RL0MIY7"H((W6\X4YQ$T\^[YZS-;;F:)')9UU@[[PP_2]SE9([O(
M/^I*R A5L@R/5O=8X^XV F74? 3,/1%R0PZBZ#@0$\$,YT?,4;^CO<$KI&#(
MX=,^3[+KG\6M4AXDE 74CI ))G2:7"&,X\@I$B$DP5J.()<*:6:4,I-V77'"
M^4*+65O$6+MW-')$S[S%?"4<&KTNSL0;&3-K:T/%Q_ XK>W*QFX(Y;R1LION
ME=<=+ZO2_HY=^_M<8XO=<>/4^D\*KX-X H0N,-]K6X9V<'Y- 6IX>C>/^:M&
M4]IDMWMK3@.4S_>0<QV9-6[DW/<YWQ!G<5TZXE9=:B. 8EOW@(,FEK7"RX0<
M#4KA\D6ZH^P1,@9)NJ%L;&@S8TTX"2^JRZHH <4W S^O'7L#GSIBL[7<<<-Q
M"F1#=*5IAQY=Z'OHJF_]$CD1;A&ERJ=\0)]R"+0E$ZCC5:E-/0FY>"0[.X9I
M, 7YB0*,QXJ?(0>.-.%_8DDBK!48Q\=:):O6>=-X7@3S7L]Y2EX;..O7697(
M6"T*P4N1N!H# @>DE^*QD%.# 1KWC! ">&3:;Y$\$\:O7Q6PQ451>W!6Y $C
MGYKP%F6WF]_(TB*3E_)P8?+B,VNNKQ2M<2W,@%F/&;Q5,E+=],10R4@J&>D9
MDI'NG\?Z%B,*OX"-]7292,,@\D$;JG0+'VD"ZHIJ@7E!_^;"-T61G B>()_5
M%2##V1$CP%'*(;FOV_>,655F=<U-G U6OS+.Z7$]8:NL*F'X&QZ>BT^9!M%/
MOD >\&7!SPJ^9*A>U)0@0T>,_6JS_1(F-PO]XJQ^?T<3)O$YUQI[,^\G6M6.
M2J1R3N.),[OS&>.N)YRQ;;@_/LQA)C,9N_=8]_HPM_2Z$GC2TU97WGTX\-GK
M8WN'8\ 7J:2LJ+^3^D!K_/U?7[FO7J:F]3U[-]8TZ\L>/I\1LZ%!/OXD?(MO
MM(_"^_U^S?O=KR+G]VKC.+B3\0+\K?!O$!)8X5\O\,]2^'?D^(>1# 5U1PEU
M2I"^./65(#TE06HJ07J4@E39#(,0M@KJ>@%US^<S&YSL>I8PW^-W^$V<:N4\
MJPJ6AL7.'F#/R6>#V]U^(9,,#MX7FBQC.K(< S0#BX[=47<][7NX_1->N\-X
M>E6("QCMM3@97(_7"JT\@#\/ML\/1$/5X/:'=N'6;IA]WX,>=;9\9._:0W.-
M:DM[^+:TKC=R9X_L2ZOXL4^=9A6**13KWQ[TB&L4BATMBDWLT73J*A0;%#_>
MVB_]QVWS_[^]JVUN&S?^[_^? I/>=9*.+.O!#['3WHSCA]9SR<5GYYJ^\T D
M)*&A2!U(VE8__7]W 9"4+=N)(]F4M)UISK8H$MP?=A?8_>WBF</&2P3HR^[*
M;7.B>>S*GS\ZS2N9)\I_J6WF,@F:%Q_/OOCH;#>V][86;L*66H7JONQ@9\/.
MIA[27R9!L[-Y=F>SM;7+GF:9/0TGGU=[FTMG#&%)5&]2:87"">A56(.L5ZAP
M^<3-ZY'G-GL[NXUVFP/OZZA-=1<XNY"7QV#YQ,TNY+E=2+O;V'G++N3EM8E3
MKRNV)SVFYKW8T!5/.(&W$.HF&,IXH 1VE*(NG \<*'/K)"<.FR_C>F->8;]O
M+Y"M.T[+!,DBJI9YW3*OO&_G[<N&XI]0N%PGU)<Q>L\.CQT>.SQV>&OI\-J=
M%CN\-7-XG*Y>R=  IJM#%1@Z_E@O/@S R8<ZK(WF&RZ=ML:=9F<;K7&8Y-@/
M?;F62#6RPC6I4OL.<'FIM8#8PFYCJ_7$SFC/K>6\Z.)2;O:G[$_KJ6#L3]F?
M_O(:D-S9?B)SGOWI$JG[@T$,^"^>OL0G6,WC)+WE/4CO*?/-7HQC>NPHO4]%
MU[F#6:1_/E3OQV;P=YS!/JO_GVU#\-/.V^9N]01J&_\:&PT2@]&(T)[=BD?T
MX5GK49+:<]9W]YIM_[T&GB*?XI'+>&9QJ[E7O2&=5+S1D_BT(!F-59S:LZW5
M#?ZL^!3BYY\2[0>GQ':W^?8I4^)MN]F9-26D^&GJL.QJN%4& 8@S2X51@=)7
MZ)3F,R&6^'C3Q5KETZ+K"%OEE[7*L_J_.!7L;#=W[JH@_ #O$@Q!1:OZ9%0D
M,WL$]S@WP1!4*[66-S'9!AXI[AZ%!]VG#;I[JWIW>]-KF8HT[Z7JSQRN SU/
MDRBDQ,=/K<IH9CX-KTIE9)\[-FA<L@G]%9,H8WSP*A_HS5/_.[W/ U._U=RZ
M._/OF^+K-]78K]TCWI.BQ)C]VLOZM?A;*\#)Y?RTLUO=292^Z,Z"$Y^-]X;;
M!DJ%J>B;9$1_I0'@P\6G?E_A0*LWPEV'T6A<T"EZ+Y68$(9D)G:#8EW8&4CQ
M)*=W^B*-D> N5]F6\,S^3K?UG3.[W2WWUD^8V?=.59RAAO9?$M9W0[4!=_L*
M7T<'"+X0[C(P<K3V^ZA;9W/-U]O 2!'R<Y2Y4;2R9IV<FTY^410>"C+4#ORS
MCJVFZ#B :9_">^F^#L! ^S!22N2M)([A2[ATO-;9D%0DB0<)(@6*HR0L'<G0
MA^I*10DM%JM:BQ_A=S0FFV(9B>"?'\\$##3OPU763I27-\5);D#]S"@Q"O1;
MP?<S'>@Q+%5!I65&]RK&=PV&8.I=KE"E=9^>"E;A6NW?FD&AOO* .8P1R_VM
MYG9W]^=W=Z95J--Q)"?[_4C=?,.4^F\.*_#^Q$N=O@:37YKL'4V<#<![E.YC
MY Z_.W.:E?A5![6L\VY*HH4X=4RB(ZE^UT,>$'!5;KO;G9W.SLYNI]WNOFUU
M?P:9_?4O-[B:>>?G0V4B3(]JN>3[ZI?J](>?PSRP2A+ RV"&4&1&RPB\[Y6,
M<AN>Q(_!H]&EH/"A#JEB$[0=]$RCW2W$M ER<O^R^K#ZK*3ZD!Y,^3)X:J$^
M5;\&"T=XVR"Y4N!F0&P#Y7C,,KR"!2MXJS#4Z"OA>V[)B&J%FCGC=N\$:UDM
M9@%KV:*UK*\C=<LC"3D>PW: $I>I75L.HJ0''Q@UR".9):!C<J!@'^B6D5Y5
M;WNV?F*\2R.-8[VJ">ZL5XO6*[>HPU#'30:#5N.[ZH#K.B-Q.Z5CV%EI#/JK
MB4)/ABEC7NO5!$W6ED5KRTA^53!6[$\ST$$U@^LB';B1HL E1D7BY HU"U7I
MWD '"",#?1LUQ-GYZ<7'!EU IX-F>J3_YS=;T^$."DFF/L>+7T=WAVZ05;$>
M4X55<?&J"-LBB9IR1ST".98]'=GP83:$EQ@,IT.(<"U^/BF"BX<?/['NU 1;
MUIUGU1U4BBA2H#PVYF"Y&^/$@%^*=.(W3JG&_!8FQ63P9ZY3BE(0&209C2-*
MME#H?-;=6+/J@3QKUJ(U*U7JJW4J/5*P:B1BC GJ6^&&6Q%T#CS4!$G6E$5K
M"NR(QDD<>J:%'L%C,V)6X*^'G_Y]>K31WO,1/7BQ4(U@RY58I]7+4WCG%!0&
ME8V5IA:@LM(L/%J78HF@3FT<H9?K*+RUVTF$Y1TU,#J7&=W+,V69X+ LN\?K
M-._1GR>2DSIS9\N4A<;+!%:W?8LZ,BQZ5(WE0-DJW0W9AU?;E]&UG*3O7HE-
M+O^<1_DG,[8<8VLD)\1V,EIA>CE48/S RQH!OV*1%^SI=)KFRB709#SQ+ECV
MDBL*^0=13K0Z,"4B3C(1Z9%VO/^^U)'" G6X0J4-MQ>\P7!G'F%92RK["G:3
M[A&X[D5N5G59' PE[!?C@6)6[\K/Q_<JD'FJ_ R+\Y&"T:;"Z/2KC67G,$D-
M[IPL]2]-DT!3D0G-3OS2;3:%R0=5"A+Y1?<8O!P$AE?"7'547Z<2=N83L2*)
M(ICKIII'SH;:A+#H-#0,W*_=>NPL\A-R@+_&R75L:8=&P>]8.XD/Q\*:D:4@
MPD<C6UZ)K>_S+(<+P8<CMQ7\<T;Z23O(HABT8"O>EH=5M\PSI>]-,O@-)^J>
M'*L\@X6T3^XUQ2?XY-8X3(5!^^"W+8$R5## $-?F(S0@&(E-3%JQ'4RBY)7Y
M:J_,4?](*6!3VO#^S\5.4ZOKCGURA_?L^9?3K#'Z9!:%[$%UI'R@U>5Q@D-#
MGLQ8CVFB5P--O&6NQ<1AQ7P.Q82%1@_</:G44!IP3[ >!DD%Z3V^W%(XG4Y1
MU0!X]'%N8!7+FE,/9%ESGD-ST'FACMQ*L'N_E.9(P70%<;,S&JPNM8"3U671
MZG(]5!3;D#:I<8U>P^T^X3ZP 4Q@!0;K..I<;C"-/M3P:UBI')W:BMHMWF?Y
M5842(R>XLRK7=&Z1%^D MX8*+RB_G1A6NWI,"U:[Y_)2L.M"QB06@Q*G*PN2
M$46:*K%&HZXTW)"=5<U19:U9M-90GX*>Y4!BVSC+5K&I0](A1U9YB*O"RE(+
M,%E9GL/%/)6?PDI2"Q!929YM'68W0'8I5LEP):.1,@%L7?3_[/:F[-E133)/
M!1H:I4=JN,X[E-KRS!9JX=-W>Z-[5W5T19']LSU-U0Q?Q[I:C[G$NKIX_C^U
MII)!H,89M1VX5WD:GJ#I0AFH:12](*515'U646[24EO$9C/25RK.D46"'74F
M#:]]H6VF=>M[#X0168>7:XZQ#K^4OX4'CZ5UGGW8W[EX"&A'JH*<= 5;8:$F
M5[HGH*.U)4'^"RH&C0M\^>GL&B$Z;,6Y9-57MOD:&HB9EV_X?K%!)/6(5\8U
MF4FLJ<^AJ:K?Q\9YKES.4;94,(QA<(."[^'\<H7M80L<6%5J 26KRK.HREW&
M)E6<&DIRV98+V"'!AUAPC>H6C,X7%GHUO;4DSB?^0+1/FSDC!W<[\49=A@<5
M]N.B2R9F:6#K;6>OO5/\;W?=N,*G*#I0#UJQE%2VV5R="K6NRJ'+?#_[*I?.
M]7S2\$U<-BE\9IJ/:,5DF;:XM9@B(_N&&Y8*E,FO\-B)DB:U+1.)A.MV/8Y?
M'(,)-V*@8N3P*M=+&&^!-=(P;LKH>I:@8]N&#T?BJ4N<S1D78J!=4U.<QD7?
MN,:]^SC<@KE-6\..,<F*&U9W8GF  [6\8'^C.QLYXOWVD(YMROU<];0)JX^>
M.Q4F]+BR?VRO^LP(]I174D?$ED:%(QHQ29B>B,)LBH,@H*;+@VA"#&L:0JRF
MY(9G9632SI5**[T^3',"R[]O-48+W_TO-JB]JJHUD_U_5($/0IC6./GOX. G
M'\R!$G8 )T\%Q04I*D%_4P8IYD,5(]X6ZJ$:-8@. 9,WBIKB2S&Y@MP818>D
M#"5I\(2FF,ZH7]6-:_V1 O0VX$&#09W'YUD[GZ2IICGH*+1RXIP SFY'Q;!T
M#=1H]X?#*>=Q,#"*7$=3?)Z*G'A5,%*G4T+QI'O?J82:GH,FX1A=]W!R43$=
MV8C#"U4/=!_V<\;%3_$KR348FW2HQ[;-B;+$+=OM6%L[2*W*ATD$+Y"6&JRC
M/$.;X(,V5NH(DO6=R#*!883V_8H:'IA ?7@,V$BGYC*$ <)B$)39KG8I F3W
MB&XDU0& 0I<RH#>J-&VW+33A_F@6G1"*CZT5\C.GX89ZE42(NA>_&Y1_!6RY
M&>/9 ;9\R?E]E)+10='3MI(2S:C5$Y@K[&E-P6K:)X-U'&)C:.IY;7M/3[\%
M#N>KZT)#L))/@4MR8RN@0O!/M$$'R6._>M0(N_B?>$]@*Z+3-/>QN6MW\(%O
M6!\D>126;A&;UA.*=X1,*\7VWKL9LV.!QF[MUR[]F8KNO)!3\^FZHT:EK1@
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M:7$-/GC&O3]D(=S6GG=?S9)0%5CQ9=N=W#_XT%9959Y*%&;;A2OQU7H)W/,
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M3ZCW44@IUFC.76)F6%P>FKBY6M[HBY,*_8T'@"O V&43?JCH6&+06D2W3J7
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MP<QFRU[EM8'$35GPJ#]ZR1,:U82[R.BXZ+42K^%+(N&/+W_X'U!+ P04
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M+3A]G,3>]_X/GJ3"9T<1A.'"NZ81B7Q*0F^T?NB_O7[D'WF=,/2&DDIX0Q#
MGR X6O89(H+S< UC+NBY\"<P)3?,5^Q=-%)XY@\\/&+\L772;I^V-E2Y+>2[
MYKI94W[4/#YIGAX?S470\' T(J&>;?"0=?/Y7OOG4]7Z^.SLK*6^W3055-<0
MNSUN_?[Y9J1P-G&$8I0:-#Y]YWE+<7 6PA#&GGR]'_:SG9 G".D8A$]1=V Y
MJG(8VA].VZV8S%G$IHN6)&T-\<_748SC*U7C/B))0&,(NDPJ!0WP\^"2A/+A
MHPE +)!Q]?P)A_%%X_E)BFS9L138/P_M+E[,X*(AZ'060J-E!>;F6S$8#V;
ME6J)3H2-IC,.$X@$FM@-$Z\@@^K/<DQ 72(FUR%[?F59['7[UK"W'O.:4/Y?
M$B;P&8A\KS@:)=,IX0MD#,>%1 NQ<5\=(5!]4VT[\::'030$/^$<??8E$53T
M("8T+)&4!4[>1:>VN#J^SQ,(KN8S5&^0VCZ()\"[R!]R?4/) PUI3&&+U9C"
M2,*VV,D3LT]"/PF5Z<LY.M,:YC%$ 03K/J0\W\_'2QXU7':XGV&2<'_-'_YW
MC\7L)+EJT1)2FK*W)O(P7=./.9M>-!+1?"1D]C4ERB\L\I?RW8B3;1LBA)@3
M/_Z-QI-N(F(V!;XF7J1)&0^ 7S0PFGH&&6.HT K?)0)Y9C/)#PF7@^,(<-2N
M4<S\/R8L1-;%U9\)0M+)($531YS=_-%%>V,)^KY;LB /(71K-IA+QUR 3\YV
M<L['%SF\3R24GKX3=PGG"W39RH77#*YV'+."J!6>8O]SRQE&;_'B%KUGC$,I
MAW$FG>P7J ]0,S>#<<>41:IMO?0RXQ\+W6<]-33?XC03X+'CD(PG!AF(96=+
M%8OI)D/7,9LXFE62&#W>8)P/JDPR&-\+4+2U06INBC5473,WV@DP]E8<WQ(:
M]*,NF=$8V:\+RD,BU#N8SAC'%&K99!W>=*8RNNO$,:</22PCO#MV2VHUYL:)
M2M9^BU(4UR&71K6C">/Q'?!I/WH"$:OJA1:=<] .T6U=JQ76$\='TM!A^7XR
ME:S!JMJ1KE#V(Q]3;EFGQ(!W,+XC\]J@-XLT"@L,N_&BZY!- HTAFBRGOBP/
M:;-3C<=R';:YD]Z)(&N(U2B6E##7N<,*UZGCN,RL-6>6W;53U\&:.>:A+#)'
M$%P1'B%DD7+4/1A3G]8'<&E,<<MAAN'RJO)>M_$LA9>RR%UL/U; %K(LH%"N
MCS.>71:1B 1"4G#&1#PH3"M.U I""\)8K#]12RAJ^<3(G8;D <(RUVN!:>.%
M BT,4VJ[HU$8L^8/C)[,+I1RKBTSV#55^ZX]U<A;/M&RG-/8!MLZ;[G+;::-
M#7]BMG2C]R9&M-8D7RAR>VR5.NF]9A98+5X/TK)=2&(!@O$4XL:DL;\LE3.#
M[S2SXX]-5BWRW+,!K050)0L36C#%-#9&)J\HKQ^+G-86&#^@LJZ%5+T?ZZIF
M'KV7T]EPL]HJN=[1ZIK:\5_5*L%YGJQ2+ZXEB\6!J1&I!4A5RKI:8!4ZL.$:
M"BJW>I^03V"+_<+H.]W"'==;; LE1%:LH+QDFJ/]I816L@UM530GS="UM:OK
M)>JSWW"Y>;JU6\B]P?=N;JNN<,[#=I%Z8ZW;.5B_ZO $40+72*N;ZZ[F?IC(
MPVIRX/!?D%X2=GT_G284V0UFTJ+ []*RJ@E(G.E8=JA7/D$'<1MQ+IOVHQ@X
M?H(:W*-/-$!CJ@_P['#IP*Z_76LWC1*4TM9P+V',^$HS4"E 7,W1 A _C3!W
MZN.C52 A[8*%H1+P4EZU$=+&"ZP/N>3L$0#L5$:!/70'(5/UJHT:U03JFPYW
MP=IT#7U&1<=8E-==HT3I8[2<T?W%'2>1P#E$HHD"]6Z%+?A?LO0\>SN+7-\A
M9^AH$-+*9"XAPB!2NP6PZ21"(R_Q*Z+B),1A[013&E','XD\I+[K)YP?SBH3
MIE+] HJ:8#8,!C5Z4!<5?F?O_[HJ\<Y)_[X2Y&7ZJ996TOL#<I.<?+]Z3W86
MO\KFY?UUL%P*"P"T4^4.R]DV-I@LFP!V&<YM;X%YHPQ."\.$T@J@-W?<>X)X
MNR?:=.N[P5N>4]^TL[-N491JYBU5%-#8*GF^03Z47S9]_8=9LW1-FE1@I?NM
M+3!>FOEH 911V5+<JM-?"5&M:_C;^XELYR]HF)*96\[D5!Q<+NXQ#.U'RTE;
M1J;R0KC<D[:W9*$0W;&._V=".>3N0M/5J-S,Z'(DLKHGJ50BG/D @9KB^T(D
M\C8<==G2>MM8?8IU*(2=Q?F]Q?OL!ZF6M\ I0ZGY7*[9]F#YBN^7^0XF/A,2
M/<(03>)J/ 9?G^SJ1V(34*1'HB9"K0))JUPX%=6JY/M"_Y*RIA%JUF!<[F"<
M/AK\%L[E-\(QY*K+X6AGW8I6)6M29SW,K3P_P=?.E/&8_E\]8##>V4-;>P$<
MZ&8^DSCA-%ZH#19A"/Y2.FH#99QS(\')WT9W@-%I'5]-SDB_;"[O 6;6/E4/
MJ3OD Z8O%0L/%#!Q-0?N4P%!;>1@WYZ6WPS&Z=:#Z$5\;3CH43%C@H2_<I;,
M5)E6^,MJ)03;8F5MCDV_S$X[H:J)8/X^(1PN<:34ICN(A'KN[O);385QJ 7+
M,+SVFG!HL:/PAJ+3=)VC+I(PM(E]W[4^]CL$']"?/(2@NWG@&Q!$=G_T1@@?
M:EKU.E@.JGJ[I<YF$__YUJ2Q<RI^(XB/]728+Y%#SO'3[2$/S<V;9]^8F I/
M?VUS\IK6_@RJ$AI_HCT$E*G1U+1&\3(7NSUPII5)E43JW;;J5(S!]O?QF'9@
MXRQ5A14Q+;P*';@S>@7I@]GHZ3JP<^]&V>J=?M!*Z2S=+?/^10K-)37OR(0[
M)E'@ULU,0M>!'9/8K#GFZ?ZZ@66++5TA++7=LAZ<<4G;-;\*_FA#5!W&WH\@
MF:P=95@S('! ?2JM_!BI4Y4>+0@@NPRA191I8GN,],L&Y2.AI;, QH6ZO59:
M#C!FXRX:P^J^5F2&Q"Z8S*I.;V8GR\8N)$\5;C<RH[6S_=B@6*[%9$3J!*3=
MLK<AG!TR)Z#H*]>&@+3$3L#:*T%7U+@UG2M@*M61S;%6Z=8)4934B@V1%_?R
M2OE"I:KN7O)0A=J)D2FJSU9Q)_HNW#K_\)Z_.FR[CK]D></E%KJN;*^_Y4Y+
MK-G1[=P:1B7LJ<"K"+#3VY4K =YF0BGH*86NOEGT/6_&+@"IO2);U]Z9*]3-
MP9C36SUV70%1"9'5:T/S#$,+I)3,K4E0'0)\SQ^&M^X<J]Q$GMF].IV%; $P
M!'7W99U_._=0$>P3[D)W?3]#9>AJ"<!4Q0_:"_[W!?R'%Z;+35)?-RZE<V*$
M2G^U)J?]:RV5F:O]_JJ9,6WA=+CZ7/YYP.3RTU]02P,$%     @ 9CX+55B!
M L-I'0  %O\! !0   !W=F4M,C R,C V,S!?9&5F+GAM;.U=6W/;.)9^GU^A
M];[,U*[C2SH]G52GI^1;QEN.Y9+E[IFG%$Q"%C<4J09(V]I?OP!(2J0$@" %
M$H#BAT[;%@#A?#@X.#<<_/J/UWDX>(8(!W'T^>#DW?'! $9>[ ?1T^>#A_O#
MX?WY]?7!/W[[RZ__<7@XN+BZOAW<PI?!T$N"9W@18"^,<8K@X*_W7_\V^-?9
M^&9P$T3?'P&&@XO82^<P2@:'@UF2+#X=';V\O+SSIT&$XS!-R!?B=UX\/QH<
M'N;#GR,(Z-\'%R"!@T^GQZ>GA\>_')X<3TY//OWT\=.'C^]^.7G_X;^.CS\=
M'Y>ZQ8LE"IYFR>"OWM\&M!?Y[BB"8;@<7 41B+P A(/[XDO_>W =>>\&PS <
MC&DO/!A##-$S]-]E8X:$@D]A0<8K#CYA;P;GX";VV/0^'Y3H>7U$X;L8/1V=
M'A^_/UKU$K:@OQT6S0[IGPY/3@_?G[Q[Q?[!@*Q&A-EW*WQ)T9Q^ZB>K#N7&
M'XZR#U=-MX9^><_:GGS\^/&(?;IJB@->0S+HR=&_OM[<,T@.R6(F!&!X\-M?
M!H,,.8 \%(=P#*>#_,>'\?7V[((H.?*#^5'>Y@B$(?EJ-L(,P:F0_H(DBMT'
MBMI_EGHFRP7\?("#^2*$!T<[SXG\#".Z-0Y]. 5IF+2<H7"<[N8;ST$0[3[=
MRC"Z9\L&/YS#^2-$;:?*&T/S/&=D..2EC_!P!4S+V4I&$LVYF/#F;-F6!,\P
M#*80>P$1VC 3IU3^'?_\_O@H :]Q%,^71XR(^X3(5"J.'R*0^D$"_?.8"N+
M)W_W5Y_BT?0>H@#BX1TA#2)$/IL!1'Z/LA]F<>B3X^+RSS1(EA=P&GC!QJYX
M>:9R+9L$H[J/K^X:OC'YYYLZ(>< SZ["^ 770+/KL%V3O3[AKT" ?@=A"K]"
M0']G,[I/YW. EF1B\7P!HB5>';=#C&&"2VV'R6J$432&7HH0T3'.  [P!4Q
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M* 1YK!MHU(4Y*GR@ )WU8%1SD#M%8^5CLQ65^MTB]J)7H)!%.BRE76U[U$5
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MR*@%]IT%IWV0O\(^#6+GSD+5901]54"F)CSM+'CM@]8;8FH5"W86"N6TV\:
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MIFBVP#D(0^B?+0OT\X;"<NL[CFH+$)>O$'E!_N+*ZL/5/$^:D%\[EBU$CR'
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MG2WY TA,^RZ_T1H =V;D'9X7U^4@8/PI)8+3T,0Q!!%=?V(73B%"T&?3D>Y
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M!:T1ZR_(].\O&Y;S*;+\^Z7U\NS1C2B@Q-/-_3)>O[VL<ULLY@]XJ=1"7FM
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MK\\T"@YV?Q]CV30QABK<>_JYQE@$.8Y248>NSW/#LRY>]>?JJW[]O@FY<O?
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M1S9_<<H4=SL/OV=4T;? TG?CIA#T1DZNX<AHL)-+_J81P6,&9[.$&=/.Z)A
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M.EY)3QE9"U$R@F2LK<]6"=&C AE30PH!8)A4PUH\(@AI,<^5YXX$N]F'KM9
M?')S";MJ2"-;&*X)*I*2[83%O.*UE4LV2K>$I_%H;]C203X._N1)SOD9^;(=
MFI_*=3MK_TX3!_CK>44/#CL[PO6>+]O%3LP-ON!-POQ:_JZ'8U(AAW)Z]GV4
M;66=356=[[?@NILO>6[3[-4+"42\W<3))P U[V6BD\4[1>J7)XFS".#E-H-B
M*"\PRM>_+AJ'UX'%(OG$P 8@:J+.2LOZR>YZ%F5L&#1KSH!P;H"#*ZTMZ$!P
M?(:U^VJ8U>P1C5-T)("^3SBB A6AS\4LH(]:"#<R8',-8!L6I-GU7R8^FG5X
M:.Y*);D*[KP2\:-AAW3]3A:]8<F+%X6_"Z]YE%+5+^!7=Q0\T+Y2_%)J">1%
MK_K*,^K8$'&@C,[60AV_7&F@F()5(8:5^/(Q?5O#F#Y(V/?2?A$]DL@8@%^L
M^,KR2\H%UOESY@&,]FTD48GI7/3X+[T,T+E.60(!Y7@O"4SI-%Z>;L%U4 BP
M-308-2^0_TAO8H"MLQJ*,-Z"2=^07 \Z)A?HD1P5EB^'CP9QPX069-$^/@O^
M9RM,J) U[<?T[!%\C[,"N7 1CUCD6ID/SZH6,P*G-$,SA'^-NB#16G1A3V'1
MB':]\LDPZ,MR84_(OYU@7>U'S$^#Q+[N'Q$Z\_WM>LLOERN\#/UPE+MX$#[D
MK2&(%8C@=C-P2NX(*A64:H?D-ID!ODW%[T$?ADK-E&*P8V:9Z+B=?:W<5FQX
M]6]<J024&V-M92F7<Q4&8:J2G3#AB>=72#F=PN[^&F+BAK262RMI+3!I"<PM
MO<CY.9@OX=7PR"4W6%S1I^1S'&40-/0+]GHQ=BWAN>6@BFLB%L,B6=QX#8.R
M$[2CPQ[W(I 2_\5XQ1V(Y(A(# G%GC%B@[++\Y>C7X3*I;+79@A@,<H[PJ(K
MA#T0S^VVWN>JK9?]ST\<1XXI/VE1@:H?'*$@JM2.^MKY'\[0S3.\Y KR>;%R
MV6)F7_E"JC=P?1O9U!2#$-CUR(,74@7PTMN$F4?Z I<79!'0!1584!X/L7Q0
MUE2P\B;F1D0I'XB_$MA7 V>VH;X&XJ9DJLFYV5":IZQ@/*,Z>39(V_>P&4I[
M"W@(S$X%XH0W .2:"*M5"(/DY-F#*!N:&>*(CY8,M;3P60[B=%63UJS&FEGD
MA]19*>7?I:@89"3OJHG;GJ;5!A;'L(LN\'H3)UZRXTK"H)4RGNBC"\$.@!RW
MQ$DBL7#&K9HQ-(=U42(?0>!HJ0+$,Q<@),O'QF8A#-:9%"+@T7)(JHQ="\9$
MD([5*BB2J8<D]C$.4J@4"AC5L)3SY<\,=+!?!H.D+*#F!6TXBZ?+;02>F3<Q
M"LO%!*]XO*3'%+ZI#V$RQ\(TT?$KR0);DK =">4N!MC-51QA'N;5*Q4N9NBA
M0$P$C4USSF2\Z3*W@K=^3L+@!7_V4OHZKK8ISH;R(DC2)ZA$W)+E?4A.I/='
MDBPS8-O3,R CY1(9^N\Q9F$6'A"M"<3FI=5[RK2:T&M]J+6(K&9EUM$H(J[M
M%2@#*JW7\.BRQ-CUQHMV?TB5L*SRRG"C=8:44C'UI9I@1+)J7.2)"V<#V12M
M9%Y,@5];QFA;V2J]U^SNT!+P)E0AXW)=R.5ZKB_76!7@1U^EH?;32 O$;K+Y
MLI*3N>/_.\C%^R7RMD$()@=F 0O7RJT+=K!CXTU\8/Y:TM>D('_"TT]WZ%?Q
MWU$>41W Q$"8XPH9X-0K#,L\M#7=>#9]%0-S)I4($VZ&5?#X)IZNW\,TPTPG
ME95^KB%HN%>6:%'#AP4@!RA;\1H#(W^PP9AK^WSY0+!5"^[Y8.C7+*%"W-(C
M*9[B<\/GF[+,K/0VXL+#IR1.!ZC=E?($.AZ3CF7A\:]Z$883ZL2<3GC27 K.
M-#XO^!<Z,\M@;TJ"[#!XTCP3OE3R9T3PZ %YJN&\C0)W,!P#I,/W&"=H]B[T
M&5"=C-&":+!A@Z'%"$I,'(QQ/-P1'6.SKX"QUA!G(A@L O@@7L\F. RSPPQS
MU['+#)$X>N'05CQO:[IS%]N,DQD'$]Z"=]*!+W)PY^/8KL:A?(NR^NPHKL0G
M?X6#+<$" *%)XDM-(A\S-O<R1(E)H+D .T#-XEZ:6Z60UNC")F130W"U:*2R
M7A(<HD4\3EN,5+;6"[R&5^)UN@E3WR,0F'Y#_Z671B1)(DZ3Q=XC1G72+)#Q
M9Y^#VHM4/:KUR-T8^GT^P;U,>:67KDBA\BIUU.(2*HRHND9O8SKRQ!D5'RK/
M;Z3$^.DY83ZCJ4]?E9Z,/-B/ZN4P54/D78\B\?5-=N:NQW$0"W-HT=SW6@0V
M]MDM)=A8Q6U:4+>^;89ECG3EZU@8JJ'-GMI'FRW+MQ C1269A*/JL7_K%7 F
M$V\WB8#1X^_%$;!1$M<1)WB"&,GBNK7(!PN4G3W(,%E6EG* FE4R_C8G+$,;
M1RA>-1Q+Q,P-JZPY C.YDE#VI03\J1A*_J^X4 (9!&--J&=54;W?<. ]T'VQ
M]GR\S:"\MPC(N0O7X"<>H((M&\-V>5=+C) 2#V7Z,G0)B1&.E,5J&5O.ZJ;,
MJB]8)7PDBS;',E2QG?K7)0N_+E%!X%]*6(E*J>SC8Y[4^&;,B=SP,83=2^*E
M:1[F/4]8MNTCO>GBZ"9.X-&E5]\BOH^CW"G:YPN+<:CRRA.13] \"5]"B);(
M@^'!>'Z"@C$"#4;@GI@8Y\,P\"\9%S]2>,4LRL(@)%O(LGN"<$WNI?/6N'^-
M.94V*HB?6*I8;8LETH&;$<K-/23Q,LSN#HEP4-3.&A[8"?R5; ->#"#AYLR*
M>0D<*U ;)R:$5]6B7YGJ0-85U!XL:^QG4YPG&?ZKV#;>B"S<(=YX04KX&6TB
M]0TQ\Y+UZ41F([M[F:_?<>*'*69:<)&=)7Y-]P[L+J.L/-32T! 6 XYG/QB%
M;YU,(L<8S\0P"JMB"[.QE,0[11*I,*XDY^6-+%ZDN=5.22LI3'E_"ZGZG?BK
M7:]W7+%)Y@1YU8393R,\XT_;S88PQJAJZ*6K&Q*_79-!,)95TASL#8@C27V4
MF\H&>^6L)(7'H( 8H!N50<$N@>,PHI+TFBG+%A^5!V\'3S%H@:R,CD?Z?D!)
MD:.#"YKCEN[0%>[H==P,I3NLG[-ZG:7<>B? 70:18!AJ<UH!'U;@K@MMWN).
MM,=K[M315H\J[*%BF)&0@K4X'W=#I&DUU!._&R.[:&C>B%NV(*+C,J:"9<_]
MQVA8A_^G:ERP]5F]IR><O%+Y)^UO!!%$.<8QISKQV1/CQ"U>VV ]IRK'#=,X
MI,C9RQ] J2%.KA!AO^44+=1G'W#^%6._AH]Q3/L6%/UQGL/A>*C;Y,?1^^$\
MBXJC_9U[LG2I/==7[^F2L68JM\@]SG2%&7@ 2:DP0U]C:ZE 12CI*P4JCI%)
MQ6S94$LB'TBI)3%&#(#> 7#]#@95' "F$?ADM[+84340<- 0:X/7 ,G9()@.
M4N8#G>J1A&/&6;M8/E)9N;C#RBVK*Q<[6CEP ?.0I*MMD@-K\$@>]J/(B92V
MM2'2E*4M-ATAU\(Z?_+K#YA]*N>B)*#:PEG*\$N<[.81IK?@2^*M!P%9XD01
MI8HD6>N 40,Q0KX"'FH@9((7 %+;",IC%""^C>CMEM[A5TQ^Z%>-3@&UXD1/
M$".+?A@3N:L_/^HQ44SYG/"(+!EN138;ZY?^$;,E[WH6&<H'0GRD'"= ;%/>
M1$(RY /:L5(M$@^<[4^[]7/<"PY=$$*<T@0G2\:9)US'C9+#8U[:AS7+D<GZ
MG12))D9EP<>G+Q:EHQ'Y:STR,FJ\&%(<G@)AS<:Y&7$)*N\QYR[D2Q'PI> I
MR3(N-"F6@D%:(X\MQ2L;W1)VZ&P-D3J_"[VH4F.TEUM"I0Q;6U-=]1A8(AIN
MJ+K+R,(?\MJH1\%-94]V^$8VZQ1MGU/F7,VN7^G_+&B?V7O8#[(P)XD8301$
M)\\!:9@\^A4HVHS3HEIK@E=0OO@5\X"^>TSWV,)[[V-'+)&U',LX( M$-_M*
MF.,]!S:GU$]J 8X/GETL#Q7E_,D#TQ?]%_J,9+L'2C*;10$$WV_6/=&6RKCG
M@"J7>MS$M1'#,1\;EF,=)<-$Q^N3X%..<H+8."=Y8L/Q\JL>ST.8MI\3SE$V
M4Q%3=&AY(;5LE:"(!,G<%78LO)1K0W->-ISDU.=.6C[!J+%%@,!6E# _3+@M
M9<+K@XL8T)M2CUS$75M/BA^4WQ\YOQ%^@0 <:<YAK-E&U[+SY<@!'\WB#4\[
M0OY-7UD7Z%A.2^HS55*9I75!MO &FJIJ7>Q*OPSI,VVHN'6QJ_PZHE_4XDJ0
MRB+$38MP CZPD5>AL.0H&!NS++?K'QR7F%MI2K@AI4H2Q\.5H7*Y;ZUR>1O$
M)9T$A@2'!4[6/9EA=!!#0(%@M 3Y[=B7Q\=TKK*V Y?F:P+C'!^G!R"9)NHN
ML&1#_83!N;I9A3Z4.N@9MU<0XP5$;8;L#3?YRI=1F @H5=NUS@_!(><8!;<1
MY9?-/&5BX&+E15J$\MYU5(X&H-WRPA!E3?K%S0B4"66F0I3/Z%S-F.YC)_%W
M#D*;K4%/[@M><)K'GPFO$B[%GOD>\;<D-_BSQO2WJ(;7^)4M$RE6:(  O1/$
M9V'1I$WE+_IZPG]@G[]Z9%C(.Q8""T\F^X,RQ.@ >-8X+0>G"799:#,NQFGD
M:Y;X)4ZH("$G0/_8,@?1XH,?1S[>9*=\X45WV&9J+?)9$-!E2B_I'^?)(GZ+
M\B6,&YNQ-?DP^L2YH!>E6\*,,E+:X@%,ZM0;&SJ:?"W J]AB>3*LRD.7]HY9
MJ=V1#6R8VD[E:RCA=F?U#=6AN6-&E*!TR(;&@9*)PTP>>5$R'5_=>[MFLR'H
M[AZ_L5]2+8==.CIFSI"%(FK:J5DH32=M?RJ.V(8'9D;OY8"ET!/OI?KZE'YT
MO?$.56QX,6F!R9_.MMDJ3L+?<:#=I$,/XGK1ZH$J/"U6R[RIL6,FRCBIE5 H
M'2.-'1PS4ZTCTW21F-HZO"YDE8+_VGH)%;3)[A%OXB2K7AR&9@[%UDHY:B8X
MG"]B+D PE\42)UR[JPJR>W1U?=RI\LJN*28RZ%]AM<6D#K:4>';%AF\_W)I.
MSK]!0Y3QM3  LD82XQQ<I?N(3&VD'"\ ?3G7<<2F):!6\@AKG+SBX"9.;K89
MU:(D?*B.];V)3(?I^_C!X_=%"V-%0\>37^ UO9V]9,=-JW16\X1=%%PZEQJC
MCIV.71TQJ&"-T&EQ8!"(1E Y,;5QK=J+XRV<YW6<"*V.W];),5.Z&L)IHU[<
MW&,BWTA)-C-;+HR-77^3%HQP[5=IZ>.8)1F^9%9URBT<RM/<O@N!YLE&>+39
M]7D)TF2RNXR#TK7;L8OC]>=Q\[FHV:3B&)HZ5!2$_>WZ'=1_MK^9=U%<H,K.
MKZH)G3NZEKJ3%R\2R3]@HX])&,BHC0>(FXBD"TY8K*CL);]/6MC &Z_MH<=P
M?:&HP?E,WC:)[/J6KE42ED_ 94YZZ<V72HA>@SFHM9=3+Y0:;B3]2R!<8]I/
MEDRNNZ2Z])K.@]P@ZDU.MFNR[QMUU7T=!49"4_%BJ6#0CQ!G  QT<&<U])N8
MT>Q,6+[.]S>:&;JZEU8JN0>74*J 7G0_A]GJ<IMF5$))<D.308K9AX1S>?-I
M[1%RL4W#B*I7>OFRU,2UQ*(KE'8G<6;;C835'J[-+93Z?*DXE:HFB<:&SD^+
MC#Z'V0FP(2'IF>^Y]EZ3<,LTO+>E!HXG^S,&EQ;=UJ]TE[_@LN]1*0_/*OKJ
MF-F+@,/;"@*>9O1&U:G!ZF^.OT>AL,R7JM]8F.$NXS1+V=H^*V[CQA""?A2G
M(\"V2*ZNWQ70S_G!UCXBQ<\3\+AR*?@Z"JJ*C;&1ZVV@,=T^X@B_>0220+I:
M>Y4NSGT\#3)=L].R8U>';I)'D#%TOI'\!X=ZR),?TM4)EZ$_"U[#-$[T$:>&
M9M.Y91KDBWHKQ]/NED)J$EV[]YZ$X&>6^%R[F"I1NU<\<4/K8-(W=6T6&@RK
MN6/X[$"C.+SMYLLE!O,/D_)NHPHJ1_72:V[MW-0@4A<>Z.P\\M_AQNS1TK6<
M@-QU0T5QCW#!ZH;^6\U>8FSH7%.O&J7DWGC$/@Y?32%B7?HY/!UW^)WN]BR.
M/GLI?5566WI+R_(EU;/1U-:EK(4WPG2M^""V4!-U Z^BWG6]5T>'WR<WT<-U
MJIKH]9^HI;EKV4T?;-AN<G1MZ]T_%T''4_?>KJ4,Z3Q6',KT(0F9GZ_!SM*E
MGVMK<3G"CMOHN'M,:S,V-W<N"]R$1-@:]1) \;O#R_G)QY%'W_ O4;K!/E4F
M<:"_C(T-)_?N/R1XXX4R,J7;FU_N,YWC+0NU-II/F]J[-B+I:B?G!OA<8;GT
M"($+MUI&66M<ZD?2Y5G#+_"5"M@0CQC.FJFA:XM97:BI_#2=DU,/T^QXA,P=
M73.W?4ZILD\?.R56R621,C9V*"M39=&'4+@7.I]/)'[V"-/B(4@NSL"42:61
M)%Z&W-E#!:Y',%M41>C#J+@,WA(E:A9O<;GT394S8\-I7.)L"YD#Z.JM'*ZY
MQ-^2N%Q1P&/06T <.G:;6GQFM?*+[O.T=IH04S++B7F#9?Y0&U/:3I.,V0PS
M<&I32:UV ;1W<7T50!-P[C'W?)C^=IG@(,S@3P9'H*FY:T=(/\/YQ4Y/P/0<
M6QS.[8.^C),UG#H&$5"I*O,E"DVFRNX]W6]XLRN[P<'9I=]D+J<Z?J4)XZA+
M+]=?C-Z2%9@MR-I:Q4D&414*GJSVNW7N[9K-XEN\8B5H$J8+(1:&GU7O]%U3
M3.F0]*<90"@\QK4P0-UJ[$G"M:;85"I0B_GR*8G3O7&,&DBY],@PG;T&"5'Y
MR;VTN\1I2I?+(P +*%X+D9"=-M@NN_5T&<7*'S?N'_Z%JE.&(#Y3.^?V9#5V
MVR3/U5M-^3&G>P3 )V&1]W[2E;ZNXX[Q)L%^R,&7-=]$_=WUXUR7(@H)5T"!
MEO]!:7D;@59 K]JK,-W$J4?HC;K=T!X0)DT_1QC1RUCX7V-]7N:8XSOWLXE(
M&O$?$#K.&D-NU(93.;47V^ %9TP/8@8HGCCLTRY@_)=)UHV'MQN)R=RN#S$)
M_5UCF)NQL<L<P2V<'!D8=!,G^N76!QH<1,#Y%P/(@H7W+G;0!8[P,FQ -Z@U
M=?BUF*.7(?:3BSA)XC?N#J@)AJ9V+H/ 2Q%""<#T9/22]L@BAF33SU[R&\XD
MZI!PB%39.H2&0Y:9YK"7';A[KZF<HHZ($DWM7:LN(OUJ$<]\*C30#6:JW*A5
M7SKWGMX7:T=VT3:?IC& VRP.P3"N]'1X87S9T/,.#I(H#0,AC_*WM>P#:VOK
MD(7%6[Q8Q=O4BX+%&]WUNWF$96T2N)'I],S1I'MUG@IFQ,4N_^/?0OHAZ.NT
M8S@))EV[6T_7F2NM(2:3B"5AR$W98H7YVR]@#'FP@7Z/-;=V?TGK"FD6*88M
MR;G[])]*;#9_:>X,]EI-LPDFQO+8@T5\_9[A2!NNT-[+-5O%SFA.AM4VG%"V
MHSFBI]YJ6L'AEUZ2[" NG^'JJ#7J%S&O4*_C:F\B+B-&95BBC+[6I2QK&[D6
M.O,,Q0'\B&9X[\%'<1V54JN&(G$56QZR3AV=6VHAXR&148YZ&VVIB7/I0MH?
M^6-Z"ZEG]%^8*1Q2A/1/5X=N4WR[FF37Q@Y3$8QT5G)C(^=G0;@_>:4(.C&X
MQ>O9MDUM75_QM3CY^SC#'>U;G3M/CLENW+A_1[;K+9/>."IOO-XD>$5W/GW_
M^*UD1B_KW-GUM]$$99FY,K=V;3E8+K&?S9?7[_X*Y!+P.\PCUQYD][-R?D,O
MO/?;0"#LL"DU)7,:&KN.0R@<(%U*=$RA.L<CSJBBB0,9 JW<1E>8+J[>]=C>
MR_5E)94TH772.S6.F()B2N!JZC"5L(4\3.C+9@G6=>'=:8Q3,/1Q?5*T]7D[
M!"ETZNC:95?*;FZ(6M<V=)E@L Q_QPE]. Q9!.6?76M5K%I+HQI5:N%ZQ^\+
M^SQ%D&>C6[EKO'^GCLY%D6NZU"_T7:,2TQM=?/H6>)'!@*)MZOQ-U\+C[8FF
M-P&S9LV,T'3:C8U=*X?!_VS%QJ:[/@@8_(M''NC%?QN)\G,"-<$,O+(W$><9
M 7>Z;!?-SZYO,C5/EPH3G[T,DOUV+-:?$.SS#$%V364=[K?#R4T$*6#^%N$D
M784;:4>]C>8)52,!VJ I=:</'8>L_\<VPN<?S\\ET*%>\M&WF@!^(+NO0QY<
MTU0JM]K.]9W(T$_S\)+"$*F]^TR-7:.?Q5%<=O\WY!$9&[O^$F5$STZ.K>(+
M")6E46,;=@37=H4"W84%^#95+S6U=:Z(Z)VS'5T)>W1WO[7;#.L0KW./L_ER
MX;T?:)M723A77!3C8N-CW:V':^G_P(\VX2^5OP8X:XXK*S682BBI4D;L-MIL
M.]=KW(N ZTVG!UIMPM9O[.'Z#M2KB@W>R*8.KIFI!1IY^MBB!O;V(^'\0G_$
M+R%8,:(,X)?U5WBYC>OSTW#YWL0)#E\B?C+\DJTI"MC?"'=9Y,:.0Z_YPT=R
M+9QIW1NS3(9-FMV*73JZ=KWO4W1A:K43:HY"%8"OU:M8;3P9CV(4E+(6<V^A
MUM1Z0'?WYCU]NAL][P;[G;&]ZXVGA7]1'[2+7=%&.%IF;UX2L/]AP!E1T%Z]
MWL8XKI=.'L.[)@BF>BN'S[\ G=N=G3\OPHS4GO[J[\YC=TUE/32%93IW<OT8
M%[JQ6:*L-7*]U_/"C8;C*T[O<_7T7K]O0GZK\[Q3X]TP!''W^K>N]$2NRA5P
M$$T>Q_VIN!; RK%-YC= V]"Y5_L51UO,P3OKH1$<W!-6/4TAF2TPJ T'D'%_
MMTJU1DPZC+9TAD7LY@5>4H4GSXD'6#+*6"S<;>PI8UDYE%TJO3$/!/?)&6YE
M6\.Y!+O(P?VOO,QK,5QUZC"%/#6U9$%CKEJUH>N7M4]@,W]!ZL*#.+AJ"#4/
MJS;IR^/-8 J>8CJ"T3M,?W-NZGI:84(:8ZW4%JXWL*XJ2@NH:5L?U]950F\U
M3\*KUA3 !M]VMYY3\6(HQ;AN(WK V0D0$<2-WHNFCE-ACL=*,&#)W)DNO"[!
M' !8M@G$KW#3=R+_2C]9V Q//.@ T\!_N:?3R3".]BPIN#\%A^Q^#J-PO5VK
M<5GT9#Y#ZL9/,:@H#_%;N8Z3<A_=KM<X"/,W#)*3>.V*ZI+8&>4K.%+&3/K!
MB$_ 0B6E'9V#2M?&]3/7KS1$XRTY%&W7)J3P)6*)=5$F#'+L#--WCG+3G&?<
MJ>?1&'_Z&7VF\<S=Q-N$/5('H)RU]IVPLUDZ=/6Z6F,B06^JSBUE]>HNCT]?
MS#;LQ@ZN-:V.(6U=VKN&QBU#GVGCAC00QGMT=:[$"[!O5C?<A#E3;C,5,8\'
MI#%\PW/S26EH/LU7C2>8]'5I-%"9VO5@SJ$R-'5X*4B$O4?L^:O/WCMH40LO
M>8%TASA1X,EE?<KJU; W 8=&:Z$EZFO:EGYTK2'4,A0:HC^-C5UJ_0?LI EO
M'I@>QZ>$YPXN(246I?P4IH\XPF\>@83B*YSZ2;BIEB_I3\VU=K9GI>6)E5=F
M*D:XWK>"88<N#N\V)LO@9 ,IU&#CT/GB=&VF(J\I-5K.&X4VM>%DM!Q][&LS
M3&SWWJY?HSRHSE3K5&W@^F[:/J?X'UN T7G%NK*6C0U=1\=(,SZO[:9W9M%]
M :(PYL&.Z2+./*+^#L71[^/L%YP]8C]^B<+?]<*HM<&<GTHMF$0WU.-:ARG8
ME_9*\VWNX5I%-,VK42-LZ^1\P^7UG*Y &X]9N';#)VKLX!S3J [##M(G.-2B
M!IRCME[.Y8Q+#!,AMU& W_\3&PQ#E4:NW[*.D$830C!2%3DZH3 2KTC&L\\K
M0;WMK5V+/C474M-%96[M/GZS'N9NP$ H#O&^E33VH^FR'HK,$>JX1=O:3\6
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MZM($Z:A7(0X8OA3KF%Z_^5$>@. &)JM++_+SB% _G9-F(& ,U(5QAJ7)G.M
MVTY3&].HO:YMSLK#VJJH;[4HZ1Y=X!J,G*&]"CI.:^F16)-;(V&$0"$]</Y'
MV1P3/%RF /H8_UR;EB;MX"T#,1*9)+6A(C]*_$:C""=Z)+")'YY&BN9!<C%2
MX/^T2%X^!" D].._$'0)LN@?/RZ3%P GSVD&/7\;/$0Z$8A^>[?__8>^R:D
MG*$1*=0TONZ=F GZJ0#_W$WD+2C4-+\?#!MT3H8)XJ\ IQ]Q0&JV&XR\&[1?
MO>@?P(,WZ).40V"[Y< D%OC($5EOVSN9,^CAQ+:GS>HYB2BD-;_OG9Q"DCV"
M18BE0)S=>RL:VU&;#40<UJS@NK3C2(+ )?;?PLUE$K!IY?<:B/1+Q&,0GV4!
M>/L_8,,DMMVN=_)*#6*W2=D2A]ET( QOP@AI/.@'%PED(]AL-9BP^8\<Z;X
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M%R]10VN01,397;K;H#=>",DS4=^0QHG^3436^;'LS"WUNPF)]B:WBX'=25N
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M53G$'.[#-1I9X<=3,(M%]4CWC,]1H"9AJHJ XUB#(X!0[+X0XK=G:/8!VPN
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MAT2)LG3-[PSPE90D.'@/4\,(L]=DMDSRU(N#V2L2'9MI#/ %@6QS2QXB"%\
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M\8CP873OB>060-J&MR7(S([#2G<SD:K5PE64M,5J;LLJF,MO,.:$9QQFLKX
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MD[5G@IW,!9VM3^O)E\(;Y]P*INTQ#TY,N!.6AZ\YQ:<^_O,?E6;YXL/I;*=
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MB*(P"31\DZ-*^=?CGX,PH-6?&N-\[DC)B7FA'\G^BR@L,LF:4@=S(T5).2H
MSJYFT1+1LY27%_:LT)&#;V74*P(57S<&O7E(!KZ^HB(=R\+>,_D,3]%^<&G=
MB_S@Z<AM_.B',"6TCV K-K1&1 0T6GJJ)9"4[9-M>"(YOEI?&1NCIAW5UP(H
M?2SN1W==2?M#W"BMM#2QF<#.)XKV#N3<JO5RN2 UAT1J6H=$:FY8$"@-XA)$
M#I[32$O9NG%C[\A5F0L%.8S+<@/0_::@CLM@%+(*BDA+6ZI2OU1*Y7(9?XQR
M&6D,7@;B$@J, 5&AJDCM_%![ B+"DP[T,+*F.PZ%U&(W3WL]00?G3GP,4%F;
MN[7, %II8)F<'TI?&7$A<LCLN<>]*&--,SOWI&4TT_$D:84H7JT6G5423989
M8 6\!2D^)%)\=DBD^ OW36;;2J/*)1TN4D_V\VP>9NJ)UL+07H(<+)<GDI#K
M=?8>:TT-HQ)SZ5YD)(LTJ'63JS?3":IH7-6/15*,8N]_>MR-Q"9EJ];^.FVD
ME38RW>M4>G!\=+UQ>'2!]B1N4Q'Q?757$,"[F%3\>H]3/@+)IE*.;EF=,MJ>
M8&=H$ :>6$2J)#J&HB1>C-B>"[2+HKO:M*G0'D7I(5 JHPQ@UA;0A.4PLNOA
M$*E'!1M+KR'<M0HP%DM>B0CC%7%*V197YXH."FD*1*BE8E1B?_H7;EDV\]DC
M&7@A?'?/)C!998+K,F;%(>ICZ:N/GXOOZ^(O;L;&?A0TR:4'DIG2GV<@V<T$
MACD7A'W?"?M!Q<]]$MYW)O))SZ/,P41K:T6/=<_MR"6F>W+K_M- -J<R5X+:
MFH* #C:28,@RMRLW(-8Q<&@0DR]0FX%SH-,C83A3KE?I!+OT;)NCO?\:@^R5
M7Y[:Y A'RZ^3/;_($KO7E^Z^=;2)NI1+SQCL*C)KBSDN.D@ECXY\MVJCIU0X
MP'1TY(UJ<T[1ORW9)7!%+A->N*^]Z!B%OA06TJWB=5T+B;89[=6YXS +N0_(
M!O"8R:29!I_&F+3U[%IT)&J<IA/$7R<.TE3B@MK)M/V#1!UU%2 D[Q^Q8(ZF
MX*756<?=J0&*#/N]YX:7A\0-N\QF ;-.K]V$'UO9[.YBTUX>Z1^0O666FE%=
M26]+6T6/T2BL+;&6 D@4&!"';DMCJ31R)@R80+)0;A>$C<?P+H,DG$WXP'ZU
M/8]TL%H>\>$I>_0V.W2&[+-)*=J5_*I\YCK&F%7D.A:YCD6NX^N!K)!.]T4Z
M[1Z2='I/E_'/>10Z#&F !TE#Z<]:J/!C-SJF63VB5NR#FNMXEDI;4!F+I82X
MLA1/!=7I-3I_9<PQ:E+'0"12$T':L0301#^VWD0!\C*FBCU21R=/R)%<-O$"
M3M-AX6@$"G@0HGXLP\V94+9R7 @3#[%U""/?9RJU2P?;:V%+E\!04U7!N?ZJ
MKI]I6%)*=\:E=,SR"$XAV@5DN&\RX%];/$)7FBMP-)6-F16AG<I?6J:Q49#R
M[61ZD^G-%AMM8<NX]<UU, HBO"]$N'=(1/@2J RH1SD-#KO6_L@'%B7().C3
M>OF;M%=15N_A+A)"^)HM'7!9%$!GTZ(+4OKRQA1(O8S88@X@1J I.Z8U9KU[
M,[&3*8V>7?CA]IVL7!T660G11($A!#DU, XSSZQVWL=B T98 L714>YPU,W$
MPJ7, 6)=TD\BX>S#"8*',?LF\E$DGXLB!U)C!?0[IJ1Y$R:ES9AX1$*<Y[+8
MF^%3A\G41!&JQ*)GK@;G*BN4>RXW"<Z28G&V:#[)9"P?$ZU5] :*CU&.4?R,
M$A:3&0+2Y91.&I3S5&96O*KLK!N'A&5\R\P8QY0"'N5(+1<@0T^ $%LAUCF(
MA_&7^=]9BUW)D]?%^8#>/\(@F/,4$?7L9:/XG9Z!;U+7U0)H(*CKZ^2]>*PC
M9DR,$GG@E,RL\?'&L7?,*JF9Q(Z8)7_\J/_O(-Z\._0N7GE8I=?_OQVU5N;3
M]EO?46@6MM_"]IMKV^_.$/\\=@3K_=&[_#KL=5'DT/*9K.&@:AC1D0=RBHXI
M-7:#@+T?W%^QMDFGW[VYO>^V=P.DSSK5NPW1R[OKT]^O^Y])JU8CE[?]2X N
MN?W6[]V7R,W-92E+ WOG*9,#W_S7)&.4=)E-YVC.DHH1*!<VCP(>5,V918[
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M'TY'GK7X^+</I]/ L3_^%U!+ P04    " !F/@M54FSH]#P(  !63   #@
M '=V92UE>#,Q7S$N:'1M[5QM<]LV$O[>7X%))ZT](\F292<UY?-,G+@SGNFE
MK9.;ZU>06(HX@P0+@))UO_YV >K%EF3+%]>5928SDDDML(LEG@>["TBGF<O5
MV7?L- ,N\)V=.ND4G%W\T>[W.KW3@W") @>UQ&FLQ<1+ELRZB8)_O'%PX]JR
M$%"XJ-OIOAVDNG!M*_\+40^O2S?(N1G*HNUT&84;2A;0SD .,Q>AGN/0).6Y
M5)/HJ\S!LL\P9E<ZY\6T=:R=TWG=@=?)E1P6D8+4#=Z<G5(74Y/&F730MB5/
M("H-M,>&E\MFW:L4-8ZE<%F42M=.4!*'1VH.J-79#]_WWG4'IP?E5KG"4"]W
M?1'SY'IH=%4('(;2)C+#F.]U6_[__F#I7F]_L-Y]XV!HK)5X&G]>W&0REHZ%
MZ>9]^VU>[1T^N5L35 SF.?Q::)-S]32>_7AQ]?7RY\N/'[Y>_OKY"_O7YT\7
M5^S+Q4>Z9/WNX;9Z>Q6>M]W7ERWV&Z\4.^^P<ZT*W6+_['SJX.OYAQ9+P#B9
M3IC+N(N>Q.L[2:)"CM8Z0TA;*CZ)4@4W&SCB/Y4ECT\U^F9MZ[AQ S_<-@XL
MMU',+5#;E<Z9V][O]/O]MR][BM[RZ,R=LO"N\UY]E))['+SDMS=GO<YTUB\\
MX]LVO"QO(N!9QD? #(PDC$$@MJ5EOU?H #!JPJZ@U,8Q7;"?42GK==N_,YVR
M?U.;7V0*[$LBH4A0U2].= 8S4D#_U*__+R+>-8AX 8@XW#U$G./4$33C\PF[
M+O18@1A"*P##!#@(C3T5VC%JQ67!>#%A5>%,!3A*CC,0NR*<<);CE9%<L90G
M>,LPG6.0Z'206Q(H +%DN9F02,ZO ?4N]&GQGD!C4*6B@9,.$DBD2:H<Q3P4
MT;5@&#HMR9BMZ&7>?@P&ZDYH +FT"O,A60S96+H,!VA+2+R!U&^)IFF!PQQA
M,\'BR:(;!JR!^RN#>_\5P1U8*@L$%&%S#J 68AW%\6.S\+DL4C+)2>Q'%HFJ
M!/:)(%U 2PL!+FE)Q1%9H@>B#:7F^*^A9^^H1DN%I(Y;)%$I%$#0:T2F5V>]
M/0FW&4N5'MLI(Q@82NL,1T6<;@:[T<K6 K#MU)@E:QMLOSIL'^T>MK_> L(/
MW]\<=GLG UO#MTYG:>W3:2KQ<L_N>YA<,F[  Q(!)F,%!!P&Z+I829M1"Q++
M<>FGY9^NT5&)TK;"=J3?:!6061J=@,#;ENTA$ 4@L@/:+FZ2C!=#8!]PO;VJ
M%$KT^KS=.]Z#8$7O6(2K<"FI=E,$1J#^&2W*"T01@$NV;*PHO:4H144TSKOT
M@1*4(T0/,T*-4 +>+3PV)/'B2>+HZ/U)[Z1W=-SKONN?O"?"X/L[1Q@"+$X*
MA(T/FQ_&=(LB^H17=O,F%%K'P&::0K"N*X,=X*H\DM:O]2@%A>^'JFWS*&$Q
MTC"@N =\':W/0=NJHQ#Z4&+$@+98K:3@SAL:6RDD-Y(&($-.X6.?@GJJ+,7Y
MGB*M3PI\9* MH$$.(Q%J5.+TD$FE. 4T."QOQ#Q?P!8A^UA,FO"O&$@0GR*V
M![%!M: AE-=$*/&N$\K&2_@2KVR^^&],+TA)(RF(-;C5!:<HAUMD'*HA$)5P
M(Z:P1J*1/)9*N@GE%ZO4$LEY!O#@#OQT2W2A!N&#J9MZ0&5E2B07Z_.A)-%&
M> -\-6((!:8Y"CD&/X&2R(M$JL(%'D&2DR7&,PV3;,=\WQHF27:/26#$5>77
M;X(9I"DD3HX0('9%SC]/=38(2,+EZCJ 9PYLB,&$#=6&6%=NO0F;A$Q\)@U4
M2DD?KC2R>%JD\618NP+M&?C.&_1OQ1S=&O2+W4-_C:ME?-+.0YW>^T\66>!'
M^YBX@=(,G225(?PMQ/2W^LNU=7B'#I)@+S;!+OX,FX5L;QT%I<@AN)C?$:^M
M31 ??J>$-E&*:F;2?C HXW:6^U 8X#D'A(^/O!/JV&7"E+P&56^;W)%O?8-?
M-F68ADYV@T[J8NAQ4PR=%T/]"8$9 [7FJS$%!XN,,%^8"=*/R':6"AAS\W@E
MI-/&SC(,?P/[S'/I',!]P4^L,8DA 2'10M_+'A('QAJ68AE\IV+*E.C@STKB
M #RU547B=U?VFZKG=LS?K0DN=K#J2=N05"Z0B'NJ^-/>@3_6(^OL8%9]' ._
MIG _I.L^X/>%!G^P8;HE^2CLUX7"L-^R8C'G AM:F*WEZWFBKD]@&\2Z-LA3
M/NFPF''8*D>$H)?\:.K(:>7NK5_N&\AOQ<3<&LCO8%V2TH;4X%+:0@""CP 0
MPOY$4(WU5@C 93'2:@04A1=\6!]L,G70 'FI] 3PTW&F0YC ;S$)(G]%7C('
M[<8TT5F#R>:P]S=,@D]43HH8_OM0#1$=K-=KL</NX=.<J'^>L]U_NQ/9RC/@
MSM?35ZP6O')Z$./R!,9;B',;R<V+MY%.=(7$)&] #(*N(^_F6A['JGAI(;*A
MQDZL@\I0FYFJHOI^6 BCJ70MA%)B=B#>]_V^<_333V_]*78GUL@<=HY[AP_(
MG'@;%T3P#W/7L.D4"(Y>-ND!K(S1 ^T8(X3KR+^VZ<;J!SVB3";AJIXT.!7)
MMG5S>/K4'S&)NZ^.*,XGBU_W6#D5_K+G%_RX]8_P&;]C\K?XOZ:@F4N.NS@>
MY@\5;/VSV79X'=B#M=^Z6H6[AE\;<#;DV/A_9PBP(;\&?#L+OL;_#?G=2WX&
MK"2/^>+TQTQ"RBYN(*GH; W[-6S&-4S8(/'%(['Q?\.$]SW%O=_"B5ZNE@EP
M_SX&Q'<JH&Y]L?I%_)K3,VV./+,OLMD26?(A!)BW>>K 1%R-^<3ZQ?+T(/PJ
MV.F!_SVQ_P%02P,$%     @ 9CX+54'D*#,R"   64X   X   !W=F4M97@S
M,5\R+FAT;>U<;6_;.!+^?K^"Z*)["6 [EIVT&]D7H-M-@>#VNKMI%W=?*7%D
M\T*)6I*RX_OU-T/*+XF=QD&+7<51 B21/.0,AWP>S@REC*<N5Q=_8^,I<(&_
MV=A)I^#B\C_=8=0;C$_")0J<U!+C1(N%ERR9=0L%_WCEX-9U92&@<'&_UW\]
MRG3ANE;^#^((KTLWRKF9R*+K=!F'&TH6T)V"G$Q='/6BL] DX[E4B_BSS,&R
MCS!GUSKGQ;)UHIW3>=V!U\F5G!2Q@LR-7EV,J8NE2?.I=-"U)4\A+@UTYX:7
MVV9]42EJG$OAIG$F73=%21P>J3FA5A???Q>]Z8_&)V6C7&&HE_N^2'AZ,S&Z
M*@0.0VD3FTG"C_H=_WT\VKH7'8\>=M\\&)IH);Z-/R]OIS*1CH7EYGW[=5Z-
M!M_<K2DJ!O-G^+70)N?JVWCV_>7UYZL/5^_??;[ZY>,G]OO'GRZOV:?+]W3)
MAOW&>GL7GIONZZL.^R<:ROZE#2\Z+ 7C9+9@;LI=?,_/0LX>]+20ME1\$6<*
M;C>]_&:WD_];65*SM,,WZUK'C1MY5W;1 [F-$VZ!VNYT_'I$P]YP.'S]O&?B
MCD=7[I2%=YWWZI.4?,'!6WY[=1'UEE.],<=W;7A>WL1US:9\!LS 3,(<!"YH
M:=EO%3H C%JP:RBU<4P7[ ,J95&_^QO3&?LWM?E99L ^I1**%%7][$1OM$("
M^J?^V2+BD!$Q.#Q$_(A+1]"*SQ?LIM!S!6("G0 ,$^ @-/94:,>H%9<%X\6"
M584S%> H.:Y [(IPPEF.5T9RQ3*>XBW#=(ZQD--!;DN@ ,22Y69!(CF_ =2[
MT:?%>P*-096*!DXZ2""5)JUR%/-01->"8>BT=,IL13_6[>=@H.Z$!I!+JS#L
ME\6$S:6;X@!M":DWD/HMT30M<)@S;"98LMATPXBU<']A<!^^(+@#RV2!@")L
MK@'40:RC.'YL-CZ7148F.8G]R")5E< ^$:0;:.D@P"5MJ3@B2_1 M*'4&O\U
M].P]U6BID-1QAR0JA0((>HW(].JLMR?E=LHRI>=VR0@&)M(ZC%4=XW0SV(U6
M=C: ;9?&;%G;8OO%8?OT\+#]^0X0OO_N=M"/SD>VAF^=P]'>I[-,XN61/?8P
MN6+<@ <D DPFF/8A<!B@ZQ(E[91:D%B.6S]M_W2-CDJ5MA6V(_U&JX#,TN@4
M!-ZV[ B!* "1'=!V>9M.>3$!]@[WV^M*H40TY-WH[ B"%=&9"%?A4E*)H@B,
M0/TSVI0WB"( EVS96U%V1U&&BFB<]^D#)2A'B!]GA!JA!+P[>&Q)XMF3Q.GI
MV_/H/#H]B_IOAN=OB3#X\<$1A@"+BP)AX\/FQS'=H8@^Y97=OPF%U@FPE:80
MK.O*8 >X*\^D]7L]2D'A^Z$2TSI*V(PT#"CN 5]'ZVO0=NHHA#Z4&#&@+58K
M*;CSAB96"LF-I '(D%/XV*>@GBI+<;ZG2.N3 A\9: MHD,-(A!J5N#QD6BE.
M 0T.RQNQSA>P1<@^-I,F_"L!$L19Q/8@]J@6M(3RD@@E.71"V7L+W^*5_3?_
MO>D%*6DF!;$&M[K@%.5PBXQ#-02B$F[$$M9(-)(G4DFWH/QBEUHB.<\ 'MR!
MG^Z(;M0@?#!U6P^HK$R)Y&)]/I2FV@AO@*]&3*# -$<AQ^ G4!)YD4A5N, C
M2'*RQ'BF99)FK/?&,$EZ>$P",ZXJOW\3S"#+('5RA@"Q.W+^=:JS1T 2+G?7
M 3QS8$,,)FRH-B2Z<@^;L$_(Q%?20*64[/%*(TN611I/AK4KT)Z1[[Q%?R/6
M:&/0+PX/_36NMO%))P]U>N\_V62!O]NGQ V49N@TK0SA;R.FO]-?KJW#._2\
M!/9B4^SBCW!8R(X>HJ ,.00W\WOBM;4IXL.?E- A2E&M3#H.!DVY7>4^% 9X
MS@'AXR/OA#IV63 E;T#5QR;WY#M?X9=]&::ED\.@D[H8>M860]?%4/^$P(J!
M.NO=F(*#3498;\P$Z2=D.UL%C+5YO!+2:6-7&8:_@7WFN70.X$O!3Z(QB2$!
M(=%"W\L1$@?&&I9B&?Q-Q90ET<$?E<0!>&JKBM2?KARW5<]FK-_&!!<'6/6D
M8T@J%TC$/57\Z>S /]8CZ^Q@57V< [^A<#^DZS[@]X4&_V##\DCR2=BO"X7A
MO&7'9LX%-K2PVLL?YHFZ/H%M$.O:($_YI,-BQF&K'!&"7O*CJ2.GG:>W?KMO
M(=^(A=D8R!]@79+2ALS@5MI! (*/ !#"_HF@&NN=$(#+8J;5#"@*+_BD?K#)
MU$$#Y*72"\!/YU,=P@1^ATD0^3ORDC5H]Z:)W@.8;)]I_HI%\!.5DV*&7^^J
M":*#15&'#?J#;_/@^)_S'LA?[D2V\WT1Y^OI.W8+7CD]2G![ N,MQ+6-Y.;%
MNT@GND)BDK<@1D'7J7=S+8]C5;RT$-M08R?6066HS2Q547T_;(3Q4KH60BFQ
M>GG&]_VV=_K##Z_]&R]./" SZ)U%@T=DSKV-&R+XA[EOV'()!$=OF_0(5N;H
M@6Z"$<)-[']VZ<;NB9Y1)I-R52^:L)C(O(>6\7+BG[".!_VW9_WUU^"E,<>/
MB\V7'G:NC79"&TY3?\FLU4RV<ATZO40GT;,)SVQ&FP[1$WNR\<;2+K0>/DWW
MG_-KIRVKMJQZD+/6=.;<9LU&KKF6RULN/R!6: RNVED[("Y_/Y60L0^K@N(O
MX6RS)?:7LT1;FF]GHYV-YTG?1[^&9[R1N;<X_/A+=(F_J:3>^..+%_IOK%I7
M-,D5TU5D4?()!/KK\LR!B;F:\X7U,<;X)/QCN/&)_Y=R_P=02P,$%     @
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M5.]"CCOV'<J_ %!+ 0(4 Q0    ( &8^"U5R?29AK+(  .6[   1
M      "  0    !I;6<U-30Y-S V-%\P+FIP9U!+ 0(4 Q0    ( &8^"U7B
MBF%Y3I,  +O.   1              "  =NR  !I;6<U-30Y-S V-%\Q+FIP
M9U!+ 0(4 Q0    ( &8^"U4GK[/-L-@  ,W]   1              "  5A&
M 0!I;6<U-30Y-S V-%\R+FIP9U!+ 0(4 Q0    ( &8^"U4=%8%!!XP! !P<
M'@ 0              "  3<? @!W=F4M,C R,C V,S N:'1M4$L! A0#%
M  @ 9CX+59#X9#<:#0  -8   !               ( !;*L# '=V92TR,#(R
M,#8S,"YX<V102P$"% ,4    " !F/@M5RXH!4MD*   CC   %
M    @ &TN , =W9E+3(P,C(P-C,P7V-A;"YX;6Q02P$"% ,4    " !F/@M5
M6($"PVD=   6_P$ %               @ &_PP, =W9E+3(P,C(P-C,P7V1E
M9BYX;6Q02P$"% ,4    " !F/@M5M>?K\;%?   7A 0 %
M@ %:X0, =W9E+3(P,C(P-C,P7VQA8BYX;6Q02P$"% ,4    " !F/@M5&0TV
MNMDK  "%/@, %               @ $]000 =W9E+3(P,C(P-C,P7W!R92YX
M;6Q02P$"% ,4    " !F/@M5'9,7N*@8  !$(@$ #@              @ %(
M;00 =W9E+65X,3!?,2YH=&U02P$"% ,4    " !F/@M54FSH]#P(  !63
M#@              @ $<A@0 =W9E+65X,S%?,2YH=&U02P$"% ,4    " !F
M/@M50>0H,S((  !93@  #@              @ &$C@0 =W9E+65X,S%?,BYH
M=&U02P$"% ,4    " !F/@M5<N$V2*D$  !*.0  #               @ 'B
EE@0 =W9E+65X,S(N:'1M4$L%!@     -  T +P,  +6;!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
